Wednesday 24 September |
Time |
ROOM A |
ROOM B |
ROOM C |
ROOM D |
BOARDROOM 949 |
09:30 |
|
|
|
|
09:30-14:00
Added to your list of favorites
Deleted from your list of favorites
|
|
14:00 |
|
|
|
14:00-17:30
Added to your list of favorites
Deleted from your list of favorites
D10
EANS ESSFN EUROPEAN DIPLOMA OF RADIOSURGERY
Basics of Radiosurgery
EANS ESSFN EUROPEAN DIPLOMA OF RADIOSURGERY
Basics of Radiosurgery
14:00 - 14:15
Introduction.
Jean RÉGIS (PROFESSEUR) (Keynote Speaker, Marseille, France)
14:15 - 14:40
History of Radiosurgery.
Jean RÉGIS (PROFESSEUR) (Keynote Speaker, Marseille, France)
14:40 - 15:05
Basic of Radiobiology applied to SRS.
Michele LONGHI (Neurosurgeon) (Keynote Speaker, Verona, Italy)
15:05 - 15:30
Histological changes.
Kita SALLABANDA (Medical Direcor) (Keynote Speaker, Madrid, Spain)
15:30 - 15:40
Break.
15:40 - 16:00
Imaging and quality control.
Jean RÉGIS (PROFESSEUR) (Keynote Speaker, Marseille, France)
16:00 - 16:20
Dose delivery & quality control.
Pierre DUTHIL (Keynote Speaker, Toulouse, France)
16:20 - 16:40
Organ at risk dose threshold in SRS : Principle, level of evidence.
Selcuk PEKER (Neurosurgeon) (Keynote Speaker, Istanbul, Turkey)
16:40 - 17:10
Conformity, selectivity, gradient indexes small beam measurement in functional SRS.
Ian PADDICK (Consultant Physicist) (Keynote Speaker, London, United Kingdom)
17:10 - 17:25
BED: definition, clinical applications.
Ian PADDICK (Consultant Physicist) (Keynote Speaker, London, United Kingdom)
|
|
|
15:30 - 16:00 |
COFFEE BREAK
|
|
16:00 |
|
|
|
14:00-17:30
Added to your list of favorites
Deleted from your list of favorites
D10
EANS ESSFN EUROPEAN DIPLOMA OF RADIOSURGERY
Basics of Radiosurgery
EANS ESSFN EUROPEAN DIPLOMA OF RADIOSURGERY
Basics of Radiosurgery
14:00 - 14:15
Introduction.
Jean RÉGIS (PROFESSEUR) (Keynote Speaker, Marseille, France)
14:15 - 14:40
History of Radiosurgery.
Jean RÉGIS (PROFESSEUR) (Keynote Speaker, Marseille, France)
14:40 - 15:05
Basic of Radiobiology applied to SRS.
Michele LONGHI (Neurosurgeon) (Keynote Speaker, Verona, Italy)
15:05 - 15:30
Histological changes.
Kita SALLABANDA (Medical Direcor) (Keynote Speaker, Madrid, Spain)
15:30 - 15:40
Break.
15:40 - 16:00
Imaging and quality control.
Jean RÉGIS (PROFESSEUR) (Keynote Speaker, Marseille, France)
16:00 - 16:20
Dose delivery & quality control.
Pierre DUTHIL (Keynote Speaker, Toulouse, France)
16:20 - 16:40
Organ at risk dose threshold in SRS : Principle, level of evidence.
Selcuk PEKER (Neurosurgeon) (Keynote Speaker, Istanbul, Turkey)
16:40 - 17:10
Conformity, selectivity, gradient indexes small beam measurement in functional SRS.
Ian PADDICK (Consultant Physicist) (Keynote Speaker, London, United Kingdom)
17:10 - 17:25
BED: definition, clinical applications.
Ian PADDICK (Consultant Physicist) (Keynote Speaker, London, United Kingdom)
|
|
17:00 |
|
|
|
|
18:30 |
18:30-19:00
Added to your list of favorites
Deleted from your list of favorites
A14
WELCOME ADDRESS
WELCOME ADDRESS
18:30 - 18:40
Welcome addresses.
Lorand ERÖSS (Keynote Speaker, Budapest, Hungary), Rick SCHUURMAN (neurosurgeon) (Keynote Speaker, Amsterdam, The Netherlands)
18:40 - 19:00
Hungarians contribution in functional Neurosurgery.
Marwan HARIZ (neurosurgeon) (Faculty, Umeå, Sweden)
|
|
|
|
|
Thursday 25 September |
Time |
ROOM A |
ROOM B |
ROOM C |
ROOM D |
BOARDROOM 949 |
|
07:00 |
|
|
|
|
|
|
08:30 |
08:30-10:00
Added to your list of favorites
Deleted from your list of favorites
A21
PLENARY SESSION 1 - OPENING & SPECIAL LECTURES
PLENARY SESSION 1 - OPENING & SPECIAL LECTURES
Chairpersons:
Lorand ERÖSS (Chairperson, Budapest, Hungary), Rick SCHUURMAN (neurosurgeon) (Chairperson, Amsterdam, The Netherlands), István VALÁLIK (head of department) (Chairperson, Budapest, Hungary)
08:30 - 08:40
Opening.
Rick SCHUURMAN (neurosurgeon) (Keynote Speaker, Amsterdam, The Netherlands)
08:40 - 09:10
Brain Networks in our lives.
Laszlo BARABASI-ALBERT (Keynote Speaker, Hungary)
09:10 - 09:15
Orbituary Tippu Azziz.
Alex GREEN (Consultant Neurosurgeon) (Keynote Speaker, Oxford, United Kingdom)
09:15 - 09:40
Limbic DBS for pain.
Alex GREEN (Consultant Neurosurgeon) (Keynote Speaker, Oxford, United Kingdom)
09:40 - 10:00
BEST OF 23-25 Pain Surgery.
Patrick MERTENS (Head of the department) (Keynote Speaker, LYON, France)
|
|
|
|
|
|
10:00 - 10:30 |
COFFEE BREAK - FLASH POSTERS SESSION 1 - EXHIBITION
|
|
10:30 |
10:30-12:00
Added to your list of favorites
Deleted from your list of favorites
A23
PLENARY SESSION 2
PLENARY SESSION 2
Chairpersons:
Stéphan CHABARDES (head of the department) (Chairperson, GRENOBLE, France), Brigitte GATTERBAUER (Gamma Knife) (Chairperson, Vienna, Austria), Matilda NAESSTROM (MD, PhD) (Chairperson, Umeå, Sweden)
10:30 - 10:50
BEST OF 23-25 Movement disorders & Psychiatry.
Marwan HARIZ (neurosurgeon) (Keynote Speaker, Umeå, Sweden)
10:50 - 11:20
Sensing and adaptive DBS.
Martjin BEUDEL (neurologist) (Keynote Speaker, Amsterdam, The Netherlands)
11:20 - 11:50
Conceptual revolution in radiosurgery.
Jean RÉGIS (PROFESSEUR) (Keynote Speaker, Marseille, France)
11:50 - 12:00
#46380 - PL01 A human brain network for chronic pain alleviation by bilateral anterior cingulotomy.
PL01 A human brain network for chronic pain alleviation by bilateral anterior cingulotomy.
Background: Stereotactic dorsal anterior cingulotomy is an established neurosurgical intervention for intractable cancer and non-cancer pain. However, the mechanism by which cingulotomy modulates pain networks for therapeutic effect remains unknown.
Methods: This international, multicentre study used stereotactic lesions and patient-derived high angular resolution diffusion imaging (HARDI) and tractography from 26 patients to identify brain connectivity associated with pain alleviation following bilateral anterior cingulotomy. Discovery cohort data (n=14) was used to identify a structural connectivity network disrupted by lesions associated with changes in patient-reported visual analogue scale (VAS) pain scores and morphine equivalent daily dose (MEDD). This network was used to predict ideal lesion locations in an external validation cohort (n=12) using reverse probabilistic tractography. Dominance analyses were performed to identify the contributions of neurotransmitter systems to the topography of our identified pain alleviation network.
Results: Chronic pain aetiologies were diverse and were most commonly cancer pain (n=19/26) or neuropathic pain (n=4 peripheral; n=2 central). Pain significantly reduced post-cingulotomy as measured by median decrease in both VAS (50.0% (IQR=70.0-20.0%); P<0.0001) and MEDD (61.1% (IQR=84.3-17.6%); P<0.05). 65.1% patients had a good outcome, defined as ≥30% reduction in VAS. Structural connectivity significantly associated with pain alleviation converged onto a brain network previously implicated in chronic pain maintenance and involving the orbitofrontal cortex, dorsolateral prefrontal cortex, insula, anterior and mediodorsal thalamus, amygdala, striatum, periaqueductal gray, and ventral tegmental area (PFWE<0.05). The Euclidean distance between ideal lesions predicted by connectivity with this network and actual lesions made across the external validation cohort was reliably associated with patient outcome (Spearman’s ρ=-0.43; P<0.01), suggesting that this approach could be used for prospective lesion targeting. Pain alleviation network topography was characterised by opioidergic, histaminergic, and cannabinoidergic neurotransmitter systems (R2adj=0.42), each of which have significant roles in canonical pain processing. Moreover, a functional pain alleviation network derived from 1000 healthy controls using lesion network mapping converged onto the same brain regions.
Discussion: We identify the first brain network associated with post-cingulotomy pain alleviation with direct implications for lesion targeting. The overlap of this network with pain-relevant brain regions and neurotransmitter systems provides further insight into the mechanisms underlying chronic pain maintenance. Future neurosurgical interventions for chronic pain should likely aim to modulate this identified network.
Valentina LIND (London, United Kingdom), Jai SIDPRA, Patrick MURPHY, Segev GABAY, Assaf BERGER, Frederic L.w.v.j. SCHAPER, Nanditha RAJAMANI, Rowena EASON, Aswin CHARI, Clemens NEUDORFER, Mark RICHARDSON, Christian LAMBERT, Himanshu TYAGI, Marie T. KRÜGER, Ludvic ZRINZO, Jonathan MARTIN, Michael D. FOX, Andreas HORN, Ido STRAUSS, Harith AKRAM
|
|
|
|
|
|
12:00 |
|
|
|
|
|
13:30 |
13:30-15:00
Added to your list of favorites
Deleted from your list of favorites
A27
PARALLEL SESSION 1
Movement Disorders 1
PARALLEL SESSION 1
Movement Disorders 1
Chairpersons:
Harith AKRAM (Associate Professor) (Chairperson, London, United Kingdom), Halász LÁSZLÓ (consultant) (Chairperson, Budapest, Hungary), Cristina TORRES DÍAZ (Staff Neurosurgeon) (Chairperson, Madrid, Spain)
13:30 - 13:40
#46294 - OP048 Impact of automatic segmentation and directional leads on outcomes of deep brain stimulation for Parkinson’s disease: A Cohort Study.
OP048 Impact of automatic segmentation and directional leads on outcomes of deep brain stimulation for Parkinson’s disease: A Cohort Study.
Background and objectives: Deep brain stimulation (DBS) surgical workflow has changed drastically since the inception of the technique, especially with technological advancements. This study aimed at evaluating clinical outcomes after the introduction of automatic segmentation and directional leads.
Methods: This is a retrospective cohort study, including patients operated on at the study center between 2014 and 2023. Primary outcomes included MDS UPDRS part III improvement and LEDD intake improvement at 12 months compared to pre-operative baseline. Multivariable analysis and propensity score matching followed by a linear regression were used to study the outcomes of interest.
Results: Of 279 patients screened, 210 were included. At 12 months, mean motor improvement was 41.5%, and LEDD reduction was 45.5%. Propensity score–matched analysis (n = 171) showed significantly greater MDS-UPDRS III improvement in patients treated with both directional leads and automatic segmentation software (p = 0.019), with a trend toward LEDD reduction (p = 0.075). Inverse treatment probability weighting confirmed both associations (p = 0.018 and p = 0.038). Despite worse baseline severity, patients who benefited from both techniques showed superior motor improvement (p = 0.036) and LEDD reduction (p = 0.003) compared to patients who benefited from none.
Conclusion: Our DBS workflow for PD patients proved to be a significant improvement overtime. Use of automatic segmentation per-operatively for trajectory optimization and of directional leads routinely might have a significant impact on patient motor outcome and LEDD decrease.
Mazen KALLEL, Emmanuel DE SCHLICHTING (Grenoble), Valerie FRAIX, Anna CASTRIOTO, Elena MORO, Stephan CHABARDES
13:40 - 13:50
#46356 - OP049 Stimulation induced side effects in the posterior subthalamic area: a novel patient generated atlas.
OP049 Stimulation induced side effects in the posterior subthalamic area: a novel patient generated atlas.
Background: Essential tremor (ET) is the most prevalent adult movement disorder, often impairing fine motor skills and reducing quality of life. Deep brain stimulation (DBS) targeting the ventral intermediate nucleus (Vim) has been the established treatment for pharmacologically refractory cases. In recent years many centers instead opt to use the caudal zona incerta (cZi) and posterior subthalamic area (PSA). Despite clinical success, the anatomical substrates underlying effect and stimulation-induced side effects remain poorly understood. Previous studies using volumes of tissue activated (VTA), have shed some light on the subject. Recent methodologies using probabilistic stimulation maps (PSMs), where patient VTA are transformed to a common space for voxel-vise group analysis, have generated new opportunities for further investigating the area.
Aim: This study aims to use a pre-build group-specific template to use PSM and investigate the relationship between stimulation-induced side effects and anatomical structures in the PSA.
Method: We previously developed a refined method by creating a group-specific MRI template of 77 ET patients. Clinical data, including stimulation settings and side-effect profiles, were combined with finite element electric field simulations to estimate tissue activation volumes (VTA). Probabilistic stimulation maps (PSMs) were generated by transforming individual electric fields into a common neuroanatomical space, enabling voxel-wise statistical analyses of side-effect occurrence.
Result: Results demonstrate that certain side effect such as paresthesia and dizziness are generally found in the entire investigated region, with paresthesia as the most frequent and diffusely distributed. Other side effects were associated with specific clusters within the PSA and some did not yield any clusters at all due to scattering and low occurrence.
Conclusion: Anatomical mapping of stimulation-induced side effects could possibly define "hot spots" and "no-go" areas within the PSA. However, anatomical variability and low occurrence rates of side effects in this material limit definitive conclusions. Paresthesia was found in almost the whole area, perhaps due to it being a side-effect occurring in all patients at low amplitude and thereby not clearly positioned spatially in combination with having very small VTAs for comparison. In our opinion paresthesia are common and most often transient symptoms during electrode testing, existing in almost all DBS-patients, and this material suggests it will not impact the final result of the treatment. This study suggests the importance of cohort-specific templates and advanced simulation techniques in refining DBS targeting and programming. Possible future improvements include integrating connectivity analyses and patient-specific factors to optimize electrode placement strategies.
Erik ÖSTERLUND (Stockholm, Sweden), Teresa NORDIN, Dorian VOGEL, Patric BLOMSTEDT, Karin WÅRDELL, Anders FYTAGORIDIS
13:50 - 14:00
#46359 - OP050 Tractography vs. canonical targeting for tremor control- randomized controlled trial -preliminary results in 75 patients (The TRACT Trial).
OP050 Tractography vs. canonical targeting for tremor control- randomized controlled trial -preliminary results in 75 patients (The TRACT Trial).
Background: Tremor is a highly disabling symptom in both Essential tremor (ET) and Parkinson’s disease (PD). Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS) and Deep Brain stimulation (DBS) are the most common neuromodulation techniques for ventral intermediate nucleus of the thalamus (VIM) modulation. Since direct VIM visualization is challenging, indirect targeting is the most common approach for VIM targeting based on structural landmarks. However, it is correlated with suboptimal tremor control up to 20%, inconsistency of the treatment’s outcome, especially regarding the long-term effect, and side effects such as ataxia, sensory or motor deficits, and dysarthria. We previously presented a novel tractography-based targeting approach with promising results. MRgFUS is a non-invasive technique that enables optimizing targeting in real-time based on clinical evaluation and may be utilized for comparing clinical results between different targeting approaches without compromising the treatment outcome.
Aim: Explore the clinical efficacy of our Tractography-based targeting with respect to canonical targeting in a prospective randomized controlled trial.
Methods: The trial was approved by the local ethics committee (Helsinki). ET patients who underwent unilateral MRgFUS thalamotomy were randomized for Tractography-based targeting or Canonical targeting. Both the evaluating neurologist and the patients were blinded to the targeting approach. The other targeting approach was delivered in case of failure to reach 100% Tremor reduction. Every patient has a postoperative follow-up with an MRI at 1 day, 1 week, 1, 3, 6 months, and 1 year. The primary outcome was tremor control and adverse events. The secondary outcomes were treatment time, sonication number, and final lesion distance from the original targeting point.
Results: We present preliminary results from 75 patients (38 Tractography and 37 Canonical) with statistically significant superiority for tractography-based targeting.
Conclusion:
In this very first RCT neuromodulation targeting trial, we demonstrate tractography-based targeting clear superiority to the traditional canonical targeting approach, leading to better tremor control and QoL improvement. In addition, this specific target may improve outcomes as a secondary target after canonical targeting.
Lev-Tov LIOR (Haifa, Israel), Shalem NOAM, Sinai ALON, Erikh ILANA, Sederova INNA, Nassar MARIA, Katson MARK, Eran AYELET, Schlesinger ILANA
14:00 - 14:10
#48018 - OP051 The Efficacy Of Double Targeting DBS With VIM And PSA For Treatment Of Head Tremor Cases.
OP051 The Efficacy Of Double Targeting DBS With VIM And PSA For Treatment Of Head Tremor Cases.
Introduction: Tremor is a common symptom in movement disorders appearing sometimes in isolation and sometimes in combination with other symptoms. Head tremor is a rare variant with an uncertain pathophysiology which may occur isolated or in combination. When sufficient relief cannot be achieved with pharmacological treatment, Deep Brain Stimulation (DBS) has proven effective for ET (Essential Tremor) and Parkinson’s Disease (PD) tremor. VIM (Ventrointeromedial Nucleus) of thalamus has been the main target for tremor DBS surgery but unfortunately, there is a scarcity of data regarding the effect of VIM-DBS on rare tremor syndromes, for some conditions limited to a few case reports and sometimes with conflicting results.
PSA (Posterior Subthalamic Area), a newer (but already known from lesioning era) target for DBS surgery lies in the lower proximity of VIM, it is possible to align the electrode to place electrode contacts in both targets. Double targeting of the VIM+PSA is a rather recent practice, allowing us to stimulate both nuclei simultaneously or separately, which represent a personalized and effective strategy for managing complex tremor cases. This study aims to evaluate clinical effectiveness of a double targeting of VIM+PSA in patients with head tremor.
Methods: Between 2019 and 2024, 32 patients with head tremor, treated by the senior author and DBS electrodes were implanted bilaterally using the double targeting technique and had more than 12-month follow-up are included in the present study. Patients are classified according to etiology and affected body sites. Patients’ demographic characteristics, clinical aspects are provided with their tremor scores and relevant symptoms are shown in Table 1.
Results: 21 of 32 patients (%65.6) who underwent double targeted DBS surgery recovered with remarkable improvement of tremor symptoms with TRS score of 0. 8 patients (%25) had clinical improvement equal or more than %50; while less than 50% improvement was seen in 3 patients (9.3%), all of whom had some improvement compared to preoperatively. No surgical complications or clinical worsening were observed. The outcomes are presented in Table 1 , with the items selected in accordance with their specific condition.
Conclusions: In the current study, double targeting of VIM+PSA provided a very satisfying degree of tremor reduction in several head tremor syndromes. This method offers tailored stimulation strategies and expands the therapeutic window during programming. Our results support the use of this technique particularly in cases where conventional targeting may fall short. Further studies are needed to decide on the relative effectiveness of the two targets in relation to combined targeting, as well as on the role of DBS in various rare tremor conditions.
Ismail SIMSEK, Halit Anil ERAY, Atilla YILMAZ (Istanbul, Turkey)
14:10 - 14:20
#48029 - OP052 RebrAIn AI Algorithm for pre-operative targeting of the VIM correlates lesion location with the occurrence of a gait disorder.
OP052 RebrAIn AI Algorithm for pre-operative targeting of the VIM correlates lesion location with the occurrence of a gait disorder.
Background:
MR Guided Focused Ultrasound (MRgFUS) is an incisionless and efficacious treatment for medication resistant ET and tremor dominant PD. Initial pre-operative targeting of the VIM often relies on generalized stereotactic coordinates, resulting in the need for significant awake testing during sonication to find the optimal targeting location. Despite the attention paid to targeting, gait disturbance remains a complication in a significant number of patients, most of which is transient. Although the occurrence of this complication is not solely related to the location of the lesion, several centers have shown that a deep lesion correlates with a higher frequency of gait disorder. While studies have previously described using DTI imaging for better preoperative targeting, no standard algorithm exists to create patient-specific targets. We present here the RebrAIn AI algorithm that allows accurate prediction of the lesion target in MRgFUS patients and its correlation with imbalance.
Objective:
To demonstrate the efficacy of the RebrAIn AI algorithm in predicting VIM lesion sites in patients with significant tremor improvement following MRgFUS sonication and its interest to correlate with gait disturbances.
Methods:
A retrospective analysis was performed of 161 ET and tremor dominant PD patients treated at a single center with MRgFUS of the VIM. Patients were excluded that were missing pre or post-op tremor scores or gait analysis. Following chart review, anonymized MRI images of 50 patients were analyzed using a targeting algorithm. Two studies were carried out: a Z-axis correlation between the location of the RebrAIn prediction and the lower pole of the lesion, followed by a multi-direction analysis of the relationship between lesion position and the occurrence of gait disorders.
Results:
Analysis of the correlation between the distance from the RebrAIn target to the inferior pole of the lesion on the Z axis and the occurrence of a gait disorder shows that the deeper the lesion, the greater the risk, with a correlation coefficient of 0.36 (Figure 1).
Multiaxis analysis of the directions shows that the deeper and more lateral the lesion, the greater the risk of gait disturbance (Figure 2). The maximal correlation value is 0.36 and it is achieved at direction (0.45 , 0 , -0.89).
Conclusion:
The RebrAIn algorithm is effective in correlating the occurrence of gait disturbance after MRgFUS of the VIM in tremor. This study confirms that an inferior and lateral location of the lesion generates an increased risk of gait disturbance.
Jacob A ALDERETE, Lisette TORRES, Kathryn CROSS, Martin DOMINGUEZ, Nejib ZEMZEMI, Emmanuel CUNY, Ausaf BARI (Los-Angeles, USA)
14:20 - 14:25
#46191 - OP053 Spatiotemporal evolution of sweet spots for motor improvement in Parkinson’s disease patients undergoing STN-DBS.
OP053 Spatiotemporal evolution of sweet spots for motor improvement in Parkinson’s disease patients undergoing STN-DBS.
Introduction: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective treatment for motor symptoms in Parkinson’s disease (PD). However, the optimal stimulation sites - so-called “sweet spots” - that correlate with the best motor outcomes remain incompletely defined. Identifying these regions can help refine targeting and improve clinical results.
Objective: To investigate sweet spots associated with motor improvement in PD patients treated with STN-DBS and examine their structural connectivity profiles.
Materials and Methods: Forty patients with Parkinson’s disease who underwent STN-DBS were included. Motor outcome was measured by the change in UPDRS III score (OFF medication) from baseline. Imaging data included preoperative 3T MRI (FSPGR BRAVO, SWAN, T2) and postoperative CT, which were coregistered for 3D reconstruction of electrodes using the Lead-DBS toolbox (Horn & Kühn, 2017). Volumes of tissue activated (VTAs) were calculated at two time points: 6 months and 36 months postoperatively. Sweet and sour spots were identified using Sweetspot explorer in the Lead group (Treu et al., 2020). Connectivity analysis was performed using the PPMI 85 normative connectome (Ewert et al., 2017).
Results: Sweet spots for motor improvement were primarily located in the superior-lateral STN and adjacent white matter above the STN. A right–left asymmetry was observed, with sweet spots in the right STN located more superiorly, particularly in the Forel H2 field. Connectivity analysis showed a weak but significant correlation between motor improvement and connectivity to the right precentral and supplementary motor areas (R = 0.28, p = 0.0048). At 36 months, sweet spots shifted ventrally, from white matter to the superior part of the motor STN. Moreover, there was no significant correlation between motor improvement and connectivity to hyperdirect pathway at that point.
Conclusion: Motor improvement in STN-DBS is associated with stimulation of superior-lateral STN regions and overlying white matter. The right–left asymmetry and longitudinal ventral shift in sweet spot location may reflect underlying anatomical or adaptive changes over time. These findings support the importance of individualized targeting and connectivity-based approaches to optimize long-term DBS outcomes.
Svetlana ASRIYANTS (Moscow, Russia), Anna GAMALEYA, Anna PODDUBSKAYA, Alexey TOMSKIY
14:25 - 14:30
#46237 - OP054 Imaging matters: a universal sweet spot for image-guided programming of deep brain stimulation for Parkinson’s disease.
OP054 Imaging matters: a universal sweet spot for image-guided programming of deep brain stimulation for Parkinson’s disease.
Introduction: The cardinal motor symptoms of Parkinson’s disease tremor, bradykinesia, and rigidity improve substantially with deep brain stimulation of the subthalamic nucleus (STN-DBS). Fine-tuning and optimizing the stimulation parameters can be complicated and take up to 12 months. The volume of activated tissue (VTA) is a model-based visualization of the tissue that is activated by the DBS. This activated volume is influenced by the location of the active DBS contact and the stimulation parameters. Sweet spot-based programming hypothesizes that stimulation of the region of overlap in VTAs between patients that have good clinical effects will lead to good clinical effect in new patients. The aim of this study is to identify sweet spots in the STN based on our DBS-cohort.
Methods: We retrospectively analyzed data from 101 patients who had bilateral STN-DBS between March 2018 and January 2022. We collected motor improvement (difference between pre- and post-operative UPDRS-III OFF medication), pre-operative MRI-scan, post-operative CT scan and the DBS programming settings at one year follow-up. We performed a number of pre-processing steps in Brainlab Elements software: 1) Registering the MRI to the CT scan, 2) manual segmentation of the STN in the T2 sequence, 3) detecting the DBS electrode location and orientation, 4) simulate the VTA based on the collected DBS settings. Analysis consisted of the following steps: 1) linear registration to a common space (MNI-152), 2) calculating an average STN in common space, 3) linear registration of patients STNs and VTAs to average STN template, 4) linking motor improvement scores to the VTA volumes, 5) applying voxel-based statistics.
Results: Median age was 63 years with a median disease duration of 108 months. Median motor improvement at one year follow-up after DBS surgery was 50%. We found sweet spots for the motor symptoms: bradykinesia, rigidity, and tremor. Figure 1 illustrates a substantial overlap between the sweets spots for the three cardinal motor symptoms.
Discussion & conclusion: The overlap in the sweet spots suggest that activation of this overlapping region alleviates the three motor symptoms at the same time. We aim to verify that programming based on sweet spots leads to the same motor results as the current time-consuming clinical practice. This technical approach assumes that current spread is isotropic and that the brain consists of homogeneous tissue. Future research should incorporate anisotropic conductivity and directional properties of neural pathways to enhance physiological accuracy of the models.
Eva Marike DE RONDE (Nijmegen, The Netherlands), Anne RIJPMA, Ronald BARTELS, Rianne ESSELINK, Saman VINKE
14:30 - 14:35
#46244 - OP055 Imaging strategy for individual targeting of the ventral intermediate nucleus of the thalamus for essential tremor.
OP055 Imaging strategy for individual targeting of the ventral intermediate nucleus of the thalamus for essential tremor.
Introduction:
High-intensity Magnetic Resonance-guided Focused Ultrasound (MRgFUS) targeting the ventral intermediate nucleus (VIM) of the thalamus is an effective, incisionless treatment for essential tremor (ET). However, individual results could be variable with potential side effects. Outcome is strongly influenced by the accuracy of individual anatomical targeting. Since the VIM is not directly visualized on standard brain MRI, current targeting strategies rely on indirect methods such as atlas-based coordinates and anatomical landmarks. Sometimes these approaches fail to capture inter-individual anatomical variability reducing treatment efficacy [1,2]. Advanced imaging techniques, including diffusion sequences and White Matter nulled MPRAGE (WMnMPRAGE) have been proposed for improved VIM visualization and adjacent tracts such as the dentato-rubro-thalamic (DRT), a well-known component of tremor circuitry [3].
Methods:
We hypothesize that the hypo-intense region observed on WMnMPRAGE corresponds to the DRT's termination within the VIM, that could represent the optimal lesion placement. To test this, we acquired WMnMPRAGE, T1-weighted, and diffusion-weighted MRI data from 10 ET patients undergoing MRgFUS. A common template space was created and extraction of the dentato-rubro-thalamic (DRT) tract was performed using tckedit in MRtrix, with specific regions of interest (ROIs) defined to guide the probabilistic tractography. The inclusion ROIs were the contralateral dentate nucleus and the superior cerebellar peduncle, the ipsilateral red nucleus, thalamus, and primary motor cortex. To enhance the specificity of the tract reconstruction, the ipsilateral cerebellum was excluded.
Results:
A consistent hypo-intense region was identified in the posterolateral and ventral thalamus across patients, aligning spatially with the DRT's projection zone within the VIM (Figure). As the DRT remains myelinated until it reaches the thalamus, this hypo-intensity likely marks the bundle's terminal portion and does not represent the entire VIM. This region may correspond to the previously optimal target associated with the maximal improved tremor control.
Conclusion:
The recurrent hypo-intensity observed on WMnMPRAGE, especially when combined with tractography, appears to represent a critical anatomical landmark linking the DRT and the VIM. This method holds promise as a patient-specific imaging approach for surgical planning, potentially improving the precision, safety, and efficacy of MRgFUS in the treatment of essential tremor.
References:
1. Lehman, Vance T et al. “MRI and tractography techniques to localize the ventral intermediate nucleus and dentatorubrothalamic tract for deep brain stimulation and MR-guided focused ultrasound: a narrative review and update.” Neurosurgical focus vol. 49,1 (2020): E8. doi:10.3171/2020.4.FOCUS20170
2. Jameel, Ayesha et al. “The evolution of ventral intermediate nucleus targeting in MRI-guided focused ultrasound thalamotomy for essential tremor: an international multi-center evaluation.” Frontiers in neurology vol. 15 1345873. 26 Mar. 2024, doi:10.3389/fneur.2024.1345873
3. Su, Jason H et al. “Improved Vim targeting for focused ultrasound ablation treatment of essential tremor: A probabilistic and patient-specific approach.” Human brain mapping vol. 41,17 (2020): 4769-4788. doi:10.1002/hbm.25157
Olivia MICHALCZYSZYN (Paris), Nicolas TEMPIER, Eve RIGAULT, Nadya PYATIGORSKAYA, Melanie DIDIER, Eric BARDINET, Elodie HAINQUE, Carine KARACHI
14:35 - 14:40
#46329 - OP056 More caudal stimulation field may result in a better levodopa reduction after STN-DBS in Parkinson’s disease.
OP056 More caudal stimulation field may result in a better levodopa reduction after STN-DBS in Parkinson’s disease.
Background: Deep brain stimulation (DBS) is a well-established treatment for advanced Parkinson’s disease (PD). DBS has been shown to improve patients’ motor symptoms, reduce motor fluctuations as well as reduce levodopa-induced dyskinesia. Subthalamic nucleus (STN) is the most common target in PD-DBS . STN-DBS does not only reduce disease symptoms but also allows reduction of levodopa (LD) medication. The exact mechanism or the optimal stimulated areas, however, are not entirely clear. The traditional STN is target is the posteroventral STN, commonly referred as the ”motor” STN. There are, however, differences in patient’s response to STN-DBS. In some patients a great reduction in levodopa is possible, while in some patients the reduction is modest. Nigrofugal or pre-supplementary fiber connections have been proposed to explain these differences.
Objective: We aim to compare stimulation field models between patients with different LD responses.
Patients and methods: This retrospective study examined 21 patients with advanced Parkinson’s disease implanted with bilateral Boston Vercise Cartesia directional leads. Pre- and postoperative (4-6 months) motor UPDRS-III scores, LD doses, as well as programming parameters were collected from patient files. Automatic anatomical mapping using Brainlab Elements was done for all the patients. Post-op CT scans were fused with the MRI. The location and orientation of leads was automatically identified. Each patients’ individual stimulation parameters were fed into Guide XT in Elements and stimulation field models (SFM) created for each lead. Data was then uploaded to Brainlab Quentry analysis tool. Stimulation field aggregate maps of patients with levodopa reduction greater than 50% or less than 50% were created and compared in the Brainlab reference brain model in Quentry.
Results: Fourteen patients had levodopa-reduction of 50% or more and seven had less than 50%. Good LD-reduction group also had better absolute and relative UPDRS-III reduction (11.5 points / 70% reduction vs. 3.1 points / 40% reduction) when compared to preoperative scores while medicated.
We found that the aggregate maps of SFM’s on both patient groups mostly overlap. However, on coronal plane, the SFM’s of patients with greater LD reduction are located more inferiorly, extending into the substantia nigra.
Disucssion: Our findings indicate that more inferiorly located stimulation field may be linked to more pronounced LD reduction. This supports the hypothesis that the stimulation of nigrofugal tracts, connecting the substantia nigra to caudate nucleus and putamen leads to greater LD-reduction.
Markus POLVIVAARA (Tampere, Finland), Timo MÖTTÖNEN, Kai LEHTIMÄKI, Mika KOSKINEN, Joonas HAAPASALO, Ilona HENRIKSSON
14:40 - 14:45
#47434 - OP057 FAT1-weighted MRI-guided focused ultrasound thalamotomy for essential tremor.
OP057 FAT1-weighted MRI-guided focused ultrasound thalamotomy for essential tremor.
Background and Objective: Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy of the ventral intermediate nucleus (Vim) is an effective therapy for medication-refractory essential tremor (ET). The Vim is not readily visualized on conventional MRI, and targeting is routinely performed indirectly, with atlas coordinates. Inaccurate targeting due to inter-individual anatomical variability can result in side effects and reduced efficacy. FAT1-weighted MRI is a high-resolution, high-fidelity modality that combines fractional anisotropy mapping and anatomical T1 sequences, and allows direct visualization of the Vim. Here, we assessed the outcomes of ET patients treated with a novel FAT1-weighted MRgFUS thalamotomy technique.
Methods: Targeting was performed through direct visualization of the Vim on FAT1-weighted MRI sequence. Clinical, technical and imaging data were collected prospectively at baseline, 6 and 12-months follow-up.
Results: The first 14 consecutive ET patients undergoing MRgFUS at our centre were assessed. Their mean age was 73.6 years, and disease duration was 31.8 years. There were significant improvements in treated hand tremor score (60%), disability score (71%) and quality of life (72%) and no clinically relevant side effects at 12 months. A mean of 6.9 sonications were performed, and the mean time from first to last sonication was 34.6 minutes. Greater tremor improvement was observed with lesions in the inferior and lateral part of the Vim.
Conclusion: This is the first case series assessing FAT1-guided Vim targeting in MRgFUS thalamotomy. These results demonstrate that this method is safe and clinically effective, with added technical advantages including low sonication numbers and short procedural time.
Marie T. KRUEGER, Harith AKRAM (London, United Kingdom), Valentina LIND, Jonathan HYAM, Indran DAVAGNANAM, Prasad KORLIPARA, Tabish A. SAIFEE, Thomas FOLTYNIE, Ludvic ZRINZO, Patricia LIMOUSIN, San San XU
14:45 - 14:50
#47972 - OP058 Quantitative evaluation of MR distortion correction in stereotactic targeting of the ventral intermediate nucleus.
OP058 Quantitative evaluation of MR distortion correction in stereotactic targeting of the ventral intermediate nucleus.
Introduction:
Magnetic resonance (MR) image distortion represents a critical challenge in stereotactic neurosurgery, particularly in procedures such as deep brain stimulation (DBS), where submillimeter precision is paramount. This study evaluates the spatial impact of MR distortion correction—using the BrainLabTM Elements (BrainLab, Inc., Munich, Germany) software—on the stereotactic targeting of the ventral intermediate nucleus (Vim) in a cohort of 20 patients (40 targets).
Materials and Methods:
The study included twenty patients who underwent brain MR imaging for headaches and had no other known diseases or pathologies identified. Both distortion corrected and uncorrected stereotactic coordinates were extracted for left and right Vim targets using the Schaltenbrand atlas. The Euclidean distance between the uncorrected and corrected coordinates was calculated for each target. Additionally, absolute differences in X, Y, and Z axes were computed. Statistical comparisons, visualizations, and threshold-based analyses were performed to quantify the spatial and clinical relevance of distortion correction.
Results:
The Euclidean distance between corrected and uncorrected coordinates showed significant displacements, with a mean shift of 1.21 mm (range=0.5-2.04 mm, SD=0.46) for right and 1.16 mm (range=0.59-1.92 mm, SD=0.37) for left targets (p < 0.000001 for both). These shifts were clinically meaningful, as 60% of right and 65% of left targets exhibited displacements exceeding 1.0 mm. Axis-specific analysis revealed that the Z-axis was most affected, with a median shift of 0.85 mm, compared to 0.50 mm for Y and 0.20 mm for X. Symmetry analysis demonstrated no significant difference between hemispheres (p = 0.756). No significant correlation was found between age and shift magnitude (p > 0.38).
Discussion:
MR distortion correction resulted in significant spatial shifts in stereotactic coordinates for Vim DBS targeting, with median displacements slightly exceeding 1 mm and over 60% of targets exceeding the clinically relevant 1 mm threshold. The most pronounced and consistent shifts were observed along the Z-axis, consistent with established patterns of MR distortion. There was no significant hemispheric asymmetry or association with patient age, underscoring the necessity for universal distortion correction to ensure optimal electrode placement accuracy in procedures demanding submillimetric precision.
Conclusion:
This study demonstrates that stereotactic coordinates generated with distortion correction differ significantly from those obtained without correction. However, it should be noted that the accuracy of the BrainLab™ Elements distortion correction algorithm was not independently validated, and the analysis was based on MR images from individuals without movement disorders rather than DBS candidates. Therefore, definitive conclusions regarding the clinical impact of distortion correction require further investigation, particularly with postoperative lead localization data in actual DBS patients. Nevertheless, the substantial spatial discrepancies observed highlight the need to critically assess the role of distortion correction in stereotactic planning workflows.
Ali Haluk DUZKALIR (Istanbul, Turkey), Dogu Cihan YILDIRIM, Selcuk PEKER
14:50 - 14:55
#48015 - OP059 Is It Possible to Have Best of Both Worlds? Asymmetric Deep Brain Stimulation Targeting in Parkinson’s Disease: Clinical Outcomes of STN-GPi Combination.
OP059 Is It Possible to Have Best of Both Worlds? Asymmetric Deep Brain Stimulation Targeting in Parkinson’s Disease: Clinical Outcomes of STN-GPi Combination.
Background:
Deep brain stimulation (DBS) is a well-established treatment for motor complications in Parkinson’s disease (PD), particularly when medical therapy becomes insufficient. The two most commonly used targets are the subthalamic nucleus (STN) and the globus pallidus internus (GPi), each with distinct advantages. STN stimulation enables effective tremor suppression and allows for significant reduction in levodopa dosage but may exacerbate dyskinesia in certain patients. In contrast, GPi stimulation is superior in suppressing levodopa-induced dyskinesia, though it is often less effective in reducing medication dosage.
Only a few reports have suggested that combining both targets asymmetrically—STN on one hemisphere and GPi on the other—may leverage the strengths of each target in select patient groups. However, these approaches offer potential advantages in terms of individualized DBS planning. We aimed to assess the clinical impact of this asymmetric targeting strategy in a series of PD patients with tremor dominant phenotype and prominent levodopa-induced dyskinesia.
Methods:
We retrospectively analyzed 10 patients who underwent asymmetric DBS surgery in 2024–2025 at our center. Most of the patients presented with a tremor-dominant phenotype and significant preoperative levodopa-induced dyskinesia. DBS leads were placed unilaterally in the STN and contralaterally in the GPi according to the sides where the disease started and dyskinesia was seen. Demographic data including age, sex, disease duration, and symptomatology were collected. Patients were evaluated pre- and postoperatively using levodopa equivalent daily dose (LEDD), tremor sub-scores from UPDRS III, and Abnormal Involuntary Movement Scale (AIMS).
Results:
Mean LEDD was reduced by 50% (from 1122.9 to 606.6), mean tremor scores improved by 90% (4.7 to 0.4), and mean dyskinesia scores decreased by 95% (10.5 to 0.5). Total suppression of tremor was achieved in 7 patients, while a significant decrease in tremor scores was achieved in 3 patients. No major surgical complications were observed. There was no significant association between demographic variables and clinical outcome. Our findings are consistent with those reported by Zhang et al. (2020) and Zeng et al. (2023), who described symptom-oriented asymmetric DBS approaches.
Conclusion:
Asymmetric DBS targeting may represent a personalized and effective strategy for managing complex PD cases, particularly in patients with tremor-dominant profiles and prominent dyskinesia. Notably, dyskinesia suppression was observed bilaterally despite unilateral GPi stimulation, suggesting that bilateral clinical effects may result from the widespread connectivity of the GPi. Future studies incorporating advanced neuroanatomical and functional imaging techniques are warranted to elucidate the mechanisms underlying this observation.
Ismail SIMSEK, Halit Anil ERAY, Atilla YILMAZ (Istanbul, Turkey)
14:55 - 15:00
#48034 - OP060 Supplementary Rescue GPi Leads for Parkinson Disease with Suboptimal Response to Previous STN DBS Surgery: A Retrospective Study.
OP060 Supplementary Rescue GPi Leads for Parkinson Disease with Suboptimal Response to Previous STN DBS Surgery: A Retrospective Study.
Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as tremor, rigidity, and bradykinesia. Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) is an established therapy; however, in certain patients, stimulation-induced dyskinesia or suboptimal response may occur. Rescue implantation of electrodes in the globus pallidus internus (GPi) offers an alternative approach to address persistent dyskinesia and limited therapeutic benefit from STN DBS.
Materials and Methods
This retrospective study evaluated four patients (n=4) with PD who had previously undergone STN DBS and presented with persistent dyskinesia or insufficient symptom control. All patients underwent rescue GPi DBS implantation. Clinical parameters including Unified Parkinson Disease Rating Scale (UPDRS), Abnormal Involuntary Movement Scale (AIMS), and Overall Severity Index (OSI) scores were assessed pre- and postoperatively. Imaging data were reviewed to confirm electrode locations, and stereotactic planning was conducted using CT-MRI fusion techniques.
Results
All patients experienced significant resolution of dyskinesia following rescue GPi DBS without surgical complications. In three patients (%75), dual stimulation from both STN and GPi improved symptom control. For 2 patients who received bilateral rescue GPi electrodes, after GPi stimulation was added to STN stimulation, dyskinesia symptoms diminished dramatically without previous benefits from STN stimulation were lost. For the patient (%25) with severe side effects from dual STN electrodes, GPi-only stimulation provided substantial relief. AIMS and OSI scores decreased to zero in all patients (%100) postoperatively, indicating marked improvement in dyskinesia and motor symptoms.
Discussion
GPi DBS appears to provide superior control of dyskinesia in patients with prior suboptimal STN stimulation. This approach allows for reduction or cessation of STN stimulation, preserving tremor and bradykinesia relief while resolving dyskinesia. Dual-target stimulation or shifting stimulation entirely to GPi based on patient-specific profiles offers a personalized treatment strategy for complex DBS cases.
Conclusions
Rescue GPi DBS is a viable and effective strategy for patients with Parkinson’s disease who experience suboptimal outcomes or dyskinesia from STN DBS. Supplementary GPi stimulation enhances symptom control and expands the therapeutic window when STN-related side effects limit efficacy.
Halit Anil ERAY, Ismail SIMSEK, Atilla YILMAZ (Istanbul, Turkey)
|
13:30-15:00
Added to your list of favorites
Deleted from your list of favorites
B27
PARALLEL SESSION 2
Pain 1 - Modulation
PARALLEL SESSION 2
Pain 1 - Modulation
Chairpersons:
László ENTZ (Attending Neurosurgeon) (Chairperson, Budapest, Hungary), Denys FONTAINE (Neurosurgeon) (Chairperson, NICE, France), Artur VETKAS (Neurosurgeon) (Chairperson, Stockholm, Sweden)
13:30 - 15:00
#46200 - OP120 Where are effective electrodes localized in motor cortex stimulation? a large multicenter study.
OP120 Where are effective electrodes localized in motor cortex stimulation? a large multicenter study.
Objective: Motor cortex stimulation (MCS) has been used for over 30 years to treat refractory chronic neuropathic pain. However, its efficacy remains controversial, its mechanisms of action unclear and the optimal electrode placement is debated[1]. Our aim was to analyze a large series of patients to identify optimal lead localization.
Methods: We analyzed retrospectively 98 patients treated with MCS for chronic neuropathic refractory pain across eight French, German and Brazilian centers. Postoperative CTs were normalized in the MNI template using ANTs to calculate the coordinates of the active contacts. These coordinates were mapped onto several MNI space-registered atlases[2,3]. The electrode-pial distance was computed. Patients were categorized in non-responders (NR - all stimulation settings failed to relieve the pain) and responders (R). The latter were divided into certain-responders (CR - the analgesic effect stopped when the IPG was turned off) and probable-responders (PR). Logistic regression was used to compare patient characteristics, stimulation parameters, electrode coordinates and atlas values.
Results: Statistical tests revealed a significantly greater electrode-pial distance in NR vs. R (5.73 vs 4.94mm, p<.022). The stimulation frequency and intensity were lower in R. Leads located inferiorly and on the right hemisphere were associated with higher response rates. While effective electrodes were often localized on the premotor histo-functional areas, the difference was not significant. Electrodes were effective regardless of motor cortex somatotopy. Pain relief was associated with stimulation of 90-100mm long streamlines.
Conclusion: These results challenge traditional MCS assumptions. Precise targeting of somatotopic motor regions may not be critical for pain relief. Instead, duro-pial distance could predict MCS response. The association with medium length streamlines suggests MCS modulates distant pain centers. This study highlights the need for a more nuanced approach to MCS, moving away from motor somatotopy and integrating connectivity analyses to refine electrode placement and optimize clinical outcomes.
1. Lefaucheur, J.-P. Cortical neurostimulation for neuropathic pain: state of the art and perspectives. Pain (2016).
2. Glasser, M. F. et al. A multi-modal parcellation of human cerebral cortex. Nature (2016).
3. Bajada, C. J. Fiber length profiling: A novel approach to structural brain organization. NeuroImage (2019).
Fig. 1 Lead localization in face(green), upper_limb(red) and lower_limb(blue) in responders
Fig. 2 A.Odds Ratio of response as a function of fiber length distribution B.Effective(red) and ineffective(blue) leads on short fibers (first row) and medium fibers (second row) pial surfaces in responders
Petru ISAN (Nice), Patrick MERTENS, François VASSAL, Joachim KRAUSS, Sylvain FOWO, Roland PEYRON, Jean Jacques LEMAIRE, Clement HAMANI, Erich Talamoni FONOFF, Yann SENOVA, Mounia BOUIH, Isabelle FAILLENOT, Yann SEZNEC, Jerome COSTE, Saryyeva ASSEL, Genevieve DEMARQUAY, Adèle JACQUES, Fabien ALMAIRAC, Denys FONTAINE
13:30 - 15:00
#45843 - OP121 Trigeminal tract deep brain stimulation for trigeminal neuralgia secondary to a pontine lesion can produce reversible facial analgesia.
OP121 Trigeminal tract deep brain stimulation for trigeminal neuralgia secondary to a pontine lesion can produce reversible facial analgesia.
Background: Trigeminal neuralgia (TN) consists of unilateral paroxysmal attacks of facial pain triggered by touch, speech or eating. It is usually caused by a neurovascular conflict and is often treated with microvascular decompression or ablative procedures. In some patients, TN is secondary to a brainstem lesion that can be isolated or in the setting of multiple sclerosis. In such cases, pain tends to be more refractory to conventional therapies, presumably because the pain generator is located proximal to the nerve which all interventions target. We are currently conducting a phase 1 trial of a new treatment paradigm: deep brain stimulation (DBS) of the trigeminal tract proximal to the pontine lesion (NCT05451251).
Objective: Assess the impact of trigeminal tract stimulation on facial sensory thresholds.
Methods: We report the results of the first patient enrolled in our DBS-TN trial, a 68-year-old male with TN secondary to a solitary pontine lesion who had 2 microvascular decompressions and 4 ablative procedures. A posterior fossa trajectory was used to implant a DBS electrode within the trigeminal tract proximal to his pontine lesion. Quantitative Sensory Testing (QST) performed per the German Research Network on Neuropathic Pain protocol was conducted preoperatively, postoperatively, and while stimulating the trigeminal tract at 130 Hz and 1200 Hz using an external stimulator connected to an externalized lead extension. Sensory thresholds for the mandibular branch affected by TN were compared between all conditions using a two-tailed paired t-test.
Results: Lead insertion into the trigeminal tract did not produce facial numbness or related side effects. Stimulation at 130 Hz produced facial hypoesthesia with statistically significant changes in the thresholds for cold detection, cold-induced pain, warm detection, heat-induced pain, thermal sensory limens, mechanical pain sensitivity, mechanical detection, and wind-up ratio. Stimulation at 1200 Hz produced less profound changes, but also altered thresholds for warm detection, mechanical detection, mechanical pain, mechanical pain sensitivity, and wind-up ratio. These alterations occurred only during stimulation and resolved upon its interruption, demonstrating stimulation-induced and frequency-dependent modulation of thermal and mechanical sensory thresholds.
Conclusion: DBS of the trigeminal tract can modulate facial sensory thresholds in a patient with TN secondary to a solitary pontine lesion and produce reversible facial hypoesthesia. This feature could potentially be used to interrupt triggers that generate pain attacks and abort attacks once they occur. Our trial is ongoing to confirm these findings over the long term and in a larger cohort of patients.
Mélodie GRONDIN-LAVIGNE (Sherbrooke, Canada), Oriane HERVIAULT, Sarra BLAGUI, William LEDUC, Mattieu VINCENOT, Guillaume LÉONARD, Christian IORIO-MORIN
13:30 - 15:00
#47651 - OP122 Clinical Decision-Making and SEEG-Guided DBS Implantation in Chronic Refractory Neuropathic Pain.
OP122 Clinical Decision-Making and SEEG-Guided DBS Implantation in Chronic Refractory Neuropathic Pain.
Background: Chronic neuropathic pain affects nearly 20% of adults, profoundly diminishing quality of life and contributing to chronic disability, depression, and anxiety. Conventional deep brain stimulation (DBS) targets, such as the ventrocaudal thalamus (Vc; VPL/VPM) and periaqueductal/periventricular gray (PAG/PVG), focus on sensory-discriminative circuits but provide sustained relief in only about one-third of patients. These approaches frequently overlook the affective and cognitive dimensions of pain (e.g., rumination, catastrophizing), which amplify suffering and drive opioid dependence. Moreover, fixed open-loop DBS cannot adapt to dynamic pain states, leading to habituation and reduced long-term efficacy. An unmet need exists for adaptive, closed-loop neuromodulation that integrates individualized targeting with intracranial biomarker detection to dynamically modulate various dimensions of pain. To address this gap, we present a case report and a stereoelectroencephalography (SEEG)–driven protocol for individualized DBS target selection.
Methods: A 74-year-old woman with a 12-year history of severe atypical right facial neuropathic pain (VAS 10/10), refractory to pharmacotherapy, nerve blocks, microvascular decompression, and Gamma Knife radiosurgery, underwent SEEG. Thirteen depth electrodes targeted sensory (Vc), affective (anterior insula [AINS], anterior cingulate cortex), cognitive-limbic (orbitofrontal cortex, ventral striatum/anterior limb of internal capsule [VS/ALIC]), and reward-related (ventral tegmental area) regions. Over 10 days, the patient underwent 134 randomized, blinded trials of bipolar stimulation at low and high frequencies with interspersed washout periods. Patient-reported outcomes included VAS, McGill Pain Questionnaire affective subscore (MPQ), and Pain Catastrophizing Scale (PCS). Clinical responses, SEEG biomarkers, and tractography guided final DBS target selection.
Results: Stimulation of conventional sensory targets (VPM, PVG) provided minimal analgesia (<10% VAS reduction). In contrast, stimulation of affective targets resulted in subtantial pain relief: continuous AINS stimulation reduced VAS from 10 to 5, and VS/ALIC stimulation reduced VAS scores from 10 to between 2–4. These findings were confirmed in double-blind sham-controlled trials. Subsequently, permanent bilateral DBS electrodes (Medtronic Percept, SenSight leads; 4 leads, 2 IPGs) were implanted in AINS and VS/ALIC. At two-month follow-up, ongoing clinical programming reduced average VAS scores to approximately 4–5/10, alleviating subjective affective distress and enhancing functional capacity.
Conclusion: This case highlights the necessity and effectiveness of addressing affective and cognitive dimensions in refractory neuropathic pain through individualized neuromodulation strategies. SEEG-guided parameter testing identified non-traditional DBS targets (bilateral VS/ALIC and AINS) that provided substantial symptomatic relief compared to classical sensory targets. Incorporating intracranial biomarker-informed mapping into DBS decision-making can overcome limitations of generalized approaches, supporting personalized management of complex chronic pain syndromes.
Artur VETKAS (Stockholm, Sweden), Skelin IVAN, Srdjan SUMARAC, Luka MILOSEVIC, Taufik VALIANTE, Kalia SUNEIL, Hodaie MOJGAN
13:30 - 15:00
#46243 - OP123 Safety and feasibility of deep brain stimulation of the anterior cingulate and thalamus in chronic refractory neuropathic pain: a pilot and randomized study.
OP123 Safety and feasibility of deep brain stimulation of the anterior cingulate and thalamus in chronic refractory neuropathic pain: a pilot and randomized study.
Background: Deep Brain Stimulation (DBS) of the anterior cingulum has been recently proposed to treat refractory chronic pain but its safety and its efficacy have not been evaluated in controlled conditions. Our objective was to evaluate the respective feasibility and safety of sensory thalamus (Thal-DBS) combined with anterior cingulate (ACC-DBS) DBS in patients suffering from chronic neuropathic pain.
Methods: We conducted a bicentric study (clinicaltrials.gov NCT03399942) in patients suffering from medically-refractory chronic unilateral neuropathic pain surgically implanted with both unilateral Thal-DBS and bilateral ACC-DBS, to evaluate successively: Thal-DBS only; combined Thal-DBS and ACC-DBS; ACC-DBS “on” and “off” stimulation periods in randomized cross-over double-blinded conditions; and a 1-year open phase. Safety and efficacy were evaluated by repeated neurological examination, psychiatric assessment, comprehensive assessment of cognitive and affective functioning. Changes on pain intensity (Visual Analogic Scale) and quality of life (EQ-5D scale) were used to evaluate DBS efficacy.
Results: All the patients (2 women, 6 men, mean age 52,1) completed the study. Adverse events were: epileptic seizure (2), transient motor or attention (2), persistent gait disturbances (1), sleep disturbances (1). No patient displayed significant cognitive or affective change. Compared to baseline, the quality of life (EQ-5D utility score) was significantly improved during the ACC-DBS “On” stimulation period (p=0,039) and at the end of the study (p=0,034).
Conclusion: This pilot study confirmed the safety of anterior cingulate DBS alone or in combination with thalamic stimulation and suggested that it might improve quality of life of patients with chronic refractory neuropathic pain.
Denys FONTAINE (NICE), Aurelie LEPLUS, Anne DONNET, Anne BALOSSIER, Bruno GIORDANA, Petru ISAN, Jean REGIS, Michel LANTERI-MINET
13:30 - 15:00
#46234 - OP124 High cervical high frequency spinal cord stimulation for the treatment of facial neuropathic pain.
OP124 High cervical high frequency spinal cord stimulation for the treatment of facial neuropathic pain.
Objective
To describe the technique and first results of high cervical spinal cord stimulation (hcSCS) with high frequency (10 kHz) as treatment in drug-resistant neuropathic facial pain
Materials and Methods
As an off-label treatment, 12 individuals (5 male/7 female) with trigeminal neuropathy had hcSCS electrode placement (with tip C1/2) mainly in general anesthesia, only 4 cases in local anesthesia. After successful test stimulation with an external impulse generator (IPG), 8 patients received a rechargeable internalized pectoral or abdominal IPG. The tunneling of the electrode cable to the IPG implantation site was done under general anesthesia. The follow up period was at least 4 month.
Results
In all but one patient with a cervical stenosis and need for a microsurgical placement, the implantation of the epidural electrodes were achieved without any technical problem via upper thoracic interlaminar window using a Touhy canula . There was one intermittent neurological deterioration in a patient with multiple sclerosis (temporary hand numbness). No surgical site infection occurred. 8 of the 12 patients had a relief of their facial pain of at least 50%. In the 4 cases without pain amelioration, the electrodes were removed in local anesthesia.
Conclusions
The hcSCS procedure may be a treatment option in desperate cases of therapy resistant trigeminal neuropathy for it seems feasible and safe. It is an off label use. Clinical studies should be conducted in more patients and with long term follow up.
Martin GLASER (Mainz, Germany), Axel NEULEN
13:30 - 15:00
#46272 - OP125 Tractography in combination with fMRI as a tool to optimize DBS targeting within the ventral posteromedial nucleus and ventral posterolateral nucleus for chronic neuropathic pain.
OP125 Tractography in combination with fMRI as a tool to optimize DBS targeting within the ventral posteromedial nucleus and ventral posterolateral nucleus for chronic neuropathic pain.
Background:
Chronic neuropathic pain is a symptom associated with high individual and social burden. Treatment of these patients can be complex with several conservative and invasive therapy options. Thalamic deep brain stimulation can be a last resort treatment option for patients with chronic neuropathic pain, if no other therapy has been proven to be effective. There is a considerable variability within different centres regarding targeted structures, the most common being the ventral posteromedial nucleus and ventral posterolateral nucleus (Vpm/Vpl). This study aims to analyse preoperative tractography in combination with fMRI results as potential planning tools for individualized targeting.
Methods:
Five patients with chronic neuropathic pain could be included in this study with diverse peripheral or central lesions. All patients received preoperative fMRI imaging to identify the secondary somatosensory cortex (S2). Subsequently, stereotactic surgery was performed to implant unilateral DBS electrodes targeting Vpm/Vpl. Clinical outcome was measured using the visual analogue scale (VAS), all patients had regular follow-up visits up to 30 months postoperatively.
The electrodes and the active contacts were reconstructed using leadDBS. We simulated the activated tissue surrounding the electrodes (VTA) at different follow-up time points. Probabilistic tractography was performed to identified the tracts connecting M1, S1 and S2 to Vpm/Vpl. Finally, we calculated the overlap between each VTA and the identified tracts, and correlated the results to the clinical outcome of each patient.
Results:
Three out of five patients were classified as responders, demonstrating a reduction in pain intensity of more than 50% on the VAS under chronic thalamic stimulation in the Vpm/Vpl. No complications were reported during the follow-up period.
In the cohort of five patients there was no consistent activation pattern in fMRI as response to the sensory task and all BOLD responses were shifted relative to the expected S2 area. Structural connectivity could be demonstrated between the primary motor (M1), the primary somatosensory (S1) and the secondary somatosensory (S2) cortex as well as the functional areas exhibited during fMRI to the Vpm/Vpl with no clear correlation to the clinical outcome.
Conclusions:
DBS was well tolerated in this cohort, with no procedure-related complications. Based on this small cohort, thalamic DBS could be a potentially safe and in some cases possibly effective method to treat chronic, therapy-refractory neuropathic pain. Extensive variability of activation patterns in the fMRI during sensory task could indicate functional neuroplastic changes, which could also complicate the interpretation of structural connectivity.
Rabea SCHMAHL (Cologne, Germany), Ricardo LOUÇÃO, Petra HEIDEN, Fátima Ximena CID RODRÍGUEZ, Veerle VISSER-VANDEWALLE, Pablo ANDRADE
13:30 - 15:00
#47652 - OP126 Electrophysiological Biomarkers and State-Dependent Target Identification Using SEEG for DBS in Neuropathic Pain.
OP126 Electrophysiological Biomarkers and State-Dependent Target Identification Using SEEG for DBS in Neuropathic Pain.
Background: Chronic refractory neuropathic pain imposes a heavy clinical burden, yet conventional deep brain stimulation (DBS) protocols concentrate on sensory-discriminative circuits and neglect cross-diagnostic affective and cognitive aspects of pain. Adaptive, closed-loop DBS, where stimulation parameters adjust in real time based on neural biomarkers offers a multidimensional, state-dependent modulation paradigm, which may overcome the limitations of fixed, open-loop systems. Here, we demonstrate in an N-of-1 study how acute stereoelectroencephalography (SEEG) can identify pain-state–specific electrophysiological signatures and guide affective-target selection for chronic, closed-loop DBS.
Methods: A 74-year-old woman with intractable facial neuropathic pain (VAS 10/10), unresponsive to medications, nerve blocks, and surgical interventions, underwent a 10-day inpatient SEEG trial. Thirteen depth electrodes were stereotactically placed in sensory (ventral posteromedial [VPM] thalamus), affective (anterior insula [AINS], ventral striatum/anterior limb of internal capsule [VS/ALIC], centromedian-parafascicular nucleus), cognitive (orbitofrontal cortex), and reward-related (ventral tegmental area [VTA]) regions. Continuous local field potentials (LFPs) were recorded alongside 264 patient-reported assessments: McGill Pain Questionnaire affective subscore (MPQ), Pain Catastrophizing Scale (PCS), and Visual Analog Scale (VAS). Natural pain fluctuations, 134 randomized bipolar stimulation trials (low vs. high frequency), and double-blind sham runs were interleaved with washout intervals. Electrophysiological features, including spectral power (delta to high-gamma), coherence, and phase-amplitude coupling, were extracted. Semi-supervised k-means clustering categorized high- versus low-pain states, and logistic regression models predicted binarized affective thresholds, quantified by area under the ROC curve (AUC) and odds ratios (OR).
Results: Despite persistently elevated VAS scores (mean 9.6 ± 1.5) failing to track subjective fluctuations, MPQ and PCS scores exhibited dynamic variability correlating with distinct LFP biomarkers. Delta and theta band power in AINS and VS/ALIC were associated with heightened affective pain. High-gamma activity in AINS was also linked to pain-state transitions. An optimized logistic model classified pain states with high accuracy. Phase-amplitude coupling and network connectivity analyses elucidated dynamic interactions between affective and sensory circuits. Sequential stimulation mapping confirmed significant analgesia at VS/ALIC (VAS 10→2) and AINS (VAS 10→5), whereas VTA stimulation aggravated pain.
Conclusion: Acute SEEG monitoring identified precise electrophysiological biomarkers of affective pain, facilitating informed target selection with potential for chronic closed-loop DBS. The anterior insula and VS/ALIC emerged as optimal loci for modulating affective pain dimensions. These findings provide a framework for biomarker-guided, adaptive neuromodulation strategies tailored to individual pain profiles, representing a significant advance in treating refractory neuropathic pain.
Artur VETKAS (Stockholm, Sweden), Skelin IVAN, Srdjan SUMARAC, Luka MILOSEVIC, Kalia SUNEIL, Hodaie MOJGAN, Taufik VALIANTE
13:30 - 15:00
#45262 - OP127 The Impact of Deep Brain Stimulation on Back Pain and Adult Spinal Deformities Associated with Parkinson's Disease.
OP127 The Impact of Deep Brain Stimulation on Back Pain and Adult Spinal Deformities Associated with Parkinson's Disease.
Background: Parkinson's disease is the second most common neurodegenerative disorder worldwide after Alzheimer's dementia. In Germany, approximately 400,000 people are affected. Back pain and spinal deformities are common comorbidities in patients with Parkinson's disease. Deep brain stimulation (DBS) is well established as a core component in the treatment of Parkinson's disease concerning the neurological cardinal symptoms. However, the value of DBS as a treatment option for chronic back pain and spinal deformities in Parkinson's disease is unclear, except for a few reports. The research question of the present study is the effect of DBS on back pain and spinal deformities associated with Parkinson's disease.
Methods: In a prospective observational study, the Oswestry Disability Index (ODI) was used to quantify back pain in 52 Parkinson's patients treated with DBS, one week pre-operatively and twelve months post-operatively. Additionally, biplanar full-body X-rays were taken to assess the sagittal balance. Positive approvals from the responsible ethics committee and the Federal Office for Radiation Protection have been obtained.
Results: Of the patients studied, 42% reported a pre-operative ODI > 20%, indicating at least moderate disability due to back pain. The median ODI in this patient group was 36%. One year after the intervention, the median ODI in this patient group was 27%, indicating a clinically significant improvement (p=0.003). A deviation in sagittal vertical axis (SVA) was diagnosed pre-operatively in 50% of the patients. Of these patients, 42% exhibited normal SVA one year post-operatively.
Conclusions: This study is the first to examine the effect of DBS on Parkinson's-associated chronic back pain and adult spinal deformities in a large sample of patients with Parkinson's disease. DBS appears to be a promising therapeutic approach in treating these comorbidities of Parkinson's disease. However, the pathophysiology of Parkinson's-associated back pain remains unclear and should be investigated in subsequent exploratory studies.
Philipp SPINDLER (Berlin, Germany), Yasmin ALZOOBI, Gerd-Helge SCHNEIDER, Peter VAJKOCZY, Nils HECHT
13:30 - 15:00
#46242 - OP128 Decreasing the risk of lead migration in occipital nerve stimulation for cluster headache by using ANKERSTIM ™ leads.
OP128 Decreasing the risk of lead migration in occipital nerve stimulation for cluster headache by using ANKERSTIM ™ leads.
Objective: Our aim was to assess the effectiveness and migration rate of occipital nerve stimulation (ONS) utilizing a newly developed anchoring lead (ANKERSTIM™, Medtronic) in patients treated by ONS for refractory chronic cluster headache (rCCH).
Methods: We included 38 rCCH patients (16 women, mean age 43 years) in a prospective multicenter ONS registry from 2019 to 2023, including 33 patients implanted with the ANKERSTIM™ leads and 5 with other leads. The effectiveness of ONS was evaluated by the frequency of CCH attacks, abortive and preventive medication use, quality of life (EuroQol 5 Dimensions scale), the functional (Headache Impact Test-6) and emotional (Hospital Anxiety and Depression Scale) impacts. Complications were monitored, focusing on electrode migration, device malfunction, infections, and local pain.
Results: After a mean follow-up of 20.3 months post-ONS, patients with Ankerstim implants reported a 66.6% reduction in attack frequency (P = 0.0022) and a significant improvement in their quality of life. During the follow-up period, 11 patients in the ANKERSTIM™ group experienced device-related complications, including infection (6.1%), lead migration (6.1%), hardware dysfunction (12.1%), and pain at the lead insertion site (12.1%). The migration rate was 40% in the patients implanted with other electrodes.
Conclusion: ONS using ANKERSTIM™ leads showed comparable efficacy, while also presenting a lower risk of migration, compared to ONS using other leads reported in our study and previous studies
Samia MESSAOUDI, Aurelie LEPLUS, Anne DONNET, Jean REGIS, Sylvie RAOUL, Emile SIMON, Denis SINARDET, Sophie COLNAT-COULBOIS, Jimmy VOIRIN, Michel LANTERI-MINET, Denys FONTAINE (NICE)
13:30 - 15:00
#46245 - OP129 Poor effectiveness of occipital nerve stimulation to treat refractory neuropathic facial pain: a case series.
OP129 Poor effectiveness of occipital nerve stimulation to treat refractory neuropathic facial pain: a case series.
Context. Neuropathic facial pain (NFP) that remains refractory to optimal pharmacological management poses a significant burden on patients and a challenge to pain specialists. Recent clinical evidence indicates that peripheral nerve stimulation (PNS) exhibits therapeutic potential in managing occipital and facial neuropathic pain. This study aims to evaluate the effectiveness of occipital nerve stimulation (ONS) specifically in the treatment of NFP.
Methods. We conducted a retrospective analysis of prospectively enrolled patients with refractory NFP unresponsive to optimal specific medical therapy and, in some instances, motor cortex stimulation. These patients were treated under a compassionate use framework for unilateral NFP using ONS. Each patient underwent an initial ONS trial lasting a minimum of two weeks. If they experienced an improvement in their NFP exceeding 40%, they proceeded to definitive implantation one month later.
Results. 13 patients were included in the study, with a mean age of 66 years and a male-to-female ratio of 1.2:1. The average duration from NFP onset to ONS surgery was 9.6 years. During the trial period, only 6 patients (46%) experienced significant improvement and proceeded to implantation. However, 3 of these patients (23%) did not report any benefit one-month post-implantation, motivating hardware removal. Additionally, in 2 patients (15%), the initial improvement did not translate into long-term relief. Ultimately, only 1 patient (8%) reported sustained long-term improvement in NFP. Notably, this patient had previously experienced a 10-year benefit from motor cortex stimulation prior to undergoing ONS.
Conclusion. In light of our results, the limited and inconsistent improvements observed in a minority of patients suggest that ONS may not be a reliable surgical treatment option for neuropathic facial pain.
Malheiro SOFIA, Nathan BEUCLER, Aurelie LEPLUS, Michel LANTERI-MINET, Denys FONTAINE (NICE)
13:30 - 15:00
#46361 - OP130 Treatment of lower extremity and axial pain with spinal cord stimulation: long-term experiences in Pécs.
OP130 Treatment of lower extremity and axial pain with spinal cord stimulation: long-term experiences in Pécs.
INTRODUCTION
Spinal cord stimulation (SCS) is an evidence-based therapeutic modality for chronic pain syndromes that do not respond to conservative therapy. One of the most common surgical indications is failed back surgery syndrome (FBSS).
OBJECTIVES
We performed a long-term follow-up of patients operated for FBSS with spinal cord stimulation, separately investigating changes in lower extremity and axial pain, as well as their quality of life before and after surgery.
MATERIAL AND METHOD
Spinal cord stimulation was used to treat 158 patients with chronic pain between 2003 and 2024. The spinal pain syndromes were FBSS (n=64) and degenerative scoliosis (n=10). Patients who had undergone surgery an average of 6.1 (±3.4) years prior were selected for long-term follow-up (FBSS: n=16, degenerative scoliosis: n=4, total 20 patients, mean age: 66.4 years, range 43-82 years, female:male=16:4). Face-to-face and telephone assessments were performed preoperatively and at the final follow-up with the following tests: pain intensity was analysed with the Visual Analogue Scale and quality of life with the Oswestry Disability Questionnaire. Lower limb and axial pain were assessed separately.
RESULTS
Of 61 patients with chronic spinal pain syndrome, 20 were eligible for long-term (6-year) follow-up. Visual Analogue Scale scores and Oswestry Disability Index values demonstrated significant improvement in both lower extremity and low back pain, as well as in quality of life, compared to preoperative data (p<0.05). Lower extremity pain improved from 9.6 preoperatively to 2.4 immediately postoperatively and 3.4 after 6 years of long-term follow-up according to VAS. Axial VAS scores improved from 9.2 preoperatively to 3.9 immediately postoperatively and 4.8 after long-term follow-up. ODI improved from 86% preoperatively, to 34% immediately postoperatively, to 43% after long-term follow-up.
CONCLUSIONS
Our results suggest that spinal cord stimulation can be successfully used in the long term for the relief of lower extremity and axial pain of FBSS and degenerative scoliosis origin. Consistent with previous findings in the literature, our patients showed a more significant improvement in lower extremity pain than axial pain.
Eszter BACSA (Pécs, Hungary), Máté NAGY, Annamária JUHÁSZ, Zsuzsanna ASCHERMANN, Márton KOVÁCS, Márk HARMAT, Norbert KOVÁCS, Balázs BERTA, Attila SCHWARCZ, István BALÁS
13:30 - 15:00
#46371 - OP131 Management of patients with immunosuppression that require implantation of neuromodulating devices.
OP131 Management of patients with immunosuppression that require implantation of neuromodulating devices.
There is little literature about the management of patients that have or undergo immunosuppression due to other conditions like cancer, various types of treatments, or severe rheumatological disease. These patients usually take immunosuppressive drugs or undergo treatments like chemotherapy or radiation, that modulate the immunological capability of preventing infections post implantation. These are usually patients that require pain pumps or neurostimulators.
We present our protocol that includes preparation of the patient with skin, urinary, rectal, nasal and blood cultures. Assessment of white blood cell count and the use of immuno stimulating drugs prior to the procedure, according to the directions of the attending oncologist or other physician and with the contribution of a haematologist, we prepare these patients monitoring their lab work for at least a week. During the procedure meticulous skin preparation especially at the area of the pocket is made and in every incision Vancomycin powder is applied. Sutures are removed at least 15 days post procedural and anti microbial drugs are administered for at least 15 days. Special care is taken, when there are ongoing treatments like chemotherapy or immunosuppressive drugs, in order to arrange the procedure at least a week after the last immunosuppressive treatment.
With this protocol, we have implanted 11 pumps and 6 neurostimulators, with only one post procedural infection.
We think that following such a protocol can provide safer conditions for applying neuromodulating devices for the treatment of pain in this particular patient category. In such patients of course large cohort studies are required to establish long-term safety.
Dimitrios PEIOS (Thessaloniki, Greece), Athanasia TSAROUCHA, Christina BLE, Ilias KOPATZIDIS, Kyriakidou AIKATERINI
13:30 - 15:00
#46373 - OP132 Relief of degenerative scoliosis-induced back and lower extremity pain with spinal cord stimulation in polymorbid patients.
OP132 Relief of degenerative scoliosis-induced back and lower extremity pain with spinal cord stimulation in polymorbid patients.
INTRODUCTION
Degenerative scoliosis, which is not relieved by conservative treatment, is mainly treated by direct spinal surgery. However, conventional direct spinal surgery under general anesthesia may be associated with an increased risk of morbidity and increased surgical complications. The relatively minimally invasive spinal cord stimulation analgesia method, which can be performed under local anesthesia, percutaneously and with less surgical stress, may offer an alternative and long-term analgesic therapy in such cases.
MATERIAL AND METHOD
In our institute, we planned direct spinal surgery for six patients with degenerative scoliosis suffering from intolerable back pain and lower limb pain. However, the presence of polymorbidity, we chose the lower risk spinal cord stimulation surgery as the first therapeutic option (10 women, mean age 69 ± 11 years). Patients completed a self-administered test battery before and after surgery (Oswestry Disability Questionnaire - ODI, Visual Analogue Scale - VAS; measuring back and lower limb pain separately). Questions on analgesic intake habits and satisfaction with therapeutic effect were also assessed. Average follow-up was 5,1±1,6 years.
RESULTS
ODI decreased from preoperative average of 88 ± 8% to 37 ± 14% postoperatively, VAS (back) from 87 ± 16 mm to 47 ± 15 mm, VAS (lower limb) from 90 ± 17 mm to 7 ± 16 mm separately. Fifty percentage of patients did not require analgesic medication after stimulation, while the other 50% had reduced medication. All patients were satisfied with the results of spinal cord stimulation.
CONCLUSIONS
Our results show that spinal cord stimulation resulted in significant improvements in quality of life (ODI) and pain reductions in during the 5 years follow-up. In our opinion, spinal cord stimulation is an alternative to direct spinal surgery for the relief of back and lower extremity pain caused by degenerative scoliosis in polymorbid patients at high surgical risk.
Máté NAGY (Pecs, Hungary), Annamária JUHÁSZ, Zsuzsanna ASCHERMANN, Márton KOVÁCS, Márk HARMAT, Norbert KOVÁCS, Eszter BACSA, Balázs BERTA, Attila SCHWARCZ, István BALÁS
|
13:30-15:00
Added to your list of favorites
Deleted from your list of favorites
C27
PARALLEL SESSION 3
Psychiatry
PARALLEL SESSION 3
Psychiatry
Chairpersons:
Anders J. FYTAGORIDIS (anders.fytagoridis@regionstockholm.se) (Chairperson, Stockholm, Sweden), Miroslav GALANDA (Chairperson, Banska Bystrica, Slovakia), Ludvic ZRINZO (Professor of Neurosurgery) (Chairperson, London, UK, United Kingdom)
13:30 - 13:40
#47656 - OP141 Long-term Neurosurgical Outcomes in Obsessive-compulsive Disorder: An International Retrospective Observational Study.
OP141 Long-term Neurosurgical Outcomes in Obsessive-compulsive Disorder: An International Retrospective Observational Study.
Introduction
Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterised by persistent obsessions, with or without compulsions. Deep brain stimulation (DBS) and stereotactic lesioning are emerging neurosurgical interventions for patients with OCD. While numerous trials have demonstrated the short-term efficacy and safety, further understanding of their long-term outcomes is needed to decrease the access burden. This study aims to describe the long-term efficacy and safety of neurosurgical interventions for OCD and to identify predictors of clinical outcomes.
Methods
This international retrospective study included severe, treatment-refractory OCD patients from 11 institutes who underwent neurosurgical interventions and had a minimum of three years post-operative follow-up. Patient demographics and clinical characteristics were collected. Clinical outcomes related to obsessive-compulsive symptoms and quality of life (QoL) were assessed using the Yale-Brown Obsessive-Compulsive Scale (Y- BOCS) and OCD-modified Eastern Cooperative Oncology Group (ECOG) performance status scale. Response status was classified as complete responders (Y-BOCS reduction 35%), partial responders (25-34%), and non-responders (⋜ 25%). Least Absolute Shrinkage and Selection Operator (LASSO) regression was used to identify clinical outcome predictors.
Results
Of the 291 patients screened, 51 met the eligibility criteria, including 34 DBS and 17 stereotactic lesioning (primarily cingulotomy, with 6 treated using Gamma knife and 11 with radiofrequency ablation) patients. The majority of exclusions were due to a lack of prior cognitive-based therapy or insufficient Y-BOCS follow-up data. The average follow-up duration was 7.0 years (standard deviation [SD] = 2.5; range: 3 - 11 years). The mean improvement in Y-BOCS was 17.8 (SD = 9.3), representing a 53.3% improvement (Figure 1A). Significant improvements in QoL were observed, as assessed by the OCD-modified ECOG scale (preoperative vs. last follow-up: V = 231, p < 0.001; Figure 1B). A moderate positive correlation was found between OCD symptom reduction and QoL improvement (Spearman’s rho = 0.52, p < 0.001). However, no statistically significant difference was observed between responder and non-responder cohorts (p = 0.08). No statistically significant difference was observed between DBS and lesioning cohorts (baseline: p = 0.853; Y-BOCS follow-up: p = 0.172). Common adverse effects included hypomania (9.8%), insomnia (9.8%), memory impairment (7.84%), and weight gain (7.84%).
Several predictors were associated with greater OCD symptom relief at one year after surgery, including specific OCD symptom dimensions – repeating (coefficient [coef] = 0.368), aggressiveness (coef = 0.236), symmetry/exactness (coef = 0.205), checking (coef = 0.130), male sex (coef = 0.171), dual DBS targets of ventral capsule and subthalamic nucleus (coef = 0.125), comorbid major depressive disorder (coef = 0.044), and illness duration (coef = 0.001). However, illness duration (coef = 0.021) and dual DBS targets of nucleus accumbens and anterior limb of the internal capsule (coef = -0.400) were associated with OCD symptom fluctuation during the follow-ups.
Conclusion
This is the first international cooperative study to investigate the long-term neurosurgical outcomes in OCD patients. Our findings detail both clinical and functional outcomes over an extended follow-up period and identify several predictors of short-term symptom improvement and long-term symptom variability. Despite the inherent limitations of a retrospective design, this study contributes important clinical evidence regarding the efficacy and safety of neurosurgical interventions and provided clinical evidence guiding future candidate selection.
Yihui CHENG (London, United Kingdom), Paul TURNER, Matilda NAESSTRÖM, Patric BLOMSTEDT, Viktoria JOHANSSON, Wei WANG, Botao XIONG, Eda GÜNGÖR, Veerle VISSER-VANDEWALLE, Pablo ANDRADE, Daniel HUYS, Jens KUHN, Shyam Sundar ARUMUGHAM, Dwarakanath SRINIVAS, Juan A. BARCIA, Rebeca L. LEÓN, Jason SHEEHAN, Bomin SUN, Kuanghao YE, Yijie LAI, Mohamed A. ABDELNAIM, Berthold LANGGUTH, Kostiantyn KOSTIUK, Victoria PIPIA, Alik WIDGE, Marwan HARIZ, Ludvic ZRINZO, Eileen M. JOYCE, Himanshu TYAGI, Harith AKRAM
13:40 - 13:50
#48019 - OP142 Deep brain stimulation in the inferior thalamic peduncle for major depression disorder and obsessive-compulsive disorder: long time follow-up.
OP142 Deep brain stimulation in the inferior thalamic peduncle for major depression disorder and obsessive-compulsive disorder: long time follow-up.
DBS has been proposed as research and compassionate treatment since 2005. The targets involved by stereotactic technic included: Anterior Limb of the Internal Capsule (ALIC), Nucleus Accumbens (NA), Bed Nucleus of the Stria Terminalis (BNST), Subthalamic Nucleus (SN), Mesencephalic Forebrain Bundle (MFB) and Inferior Thalamic Peduncle (ITP). In previous publications, we have reported the effect of DBS in ITP. Since 2005, a small number of publications has been reported. However, the outcome of stimulation in this target could show us important information. The aim of this revision is analyzing the short and late effect of this treatment.
Material and Methods: A series of cases with patients with OCD implanted from 2005 to 2023 is showed. Inclusion criteria all over patients were diagnosed and evaluated by an expert psychiatrist. Inclusion criteria were major 18 years-old, time with OCD diagnosis at least of 5 years, Yale-Brown Obsessive Compulsive Scale score (Y-BOCS) at least 28, under pharmacotherapy with re-uptake serotonin inhibitors, neuroleptics, benzodiazepines and neuromodulators of mood, at least 6 months with cognitive behavioral therapy, absence of neurological disorder, sign of inform consent and follow-up at least one year.
Y-BOCS were performed preoperative base line, at least 3-months, 6-months follow-up. DBS system (Medtronic or St. Jude) was implanted by stereotactic frame (Zamorano-Dujkovniv or Leksell). Target coordinates were X= 3-4 mm lateral to wall of third ventricle, Y= 3-4 mm posterior to fornix column and Z=anterior commissure – posterior commissure level. Electric stimulation parameters were defined according to clinical responses but initially 2.0 volts of amplitude, 450 microseconds of wide pulse, 130 Hertz of frequency, in bipolar and continuous mode. Side effects were evaluated in two aspects, by surgical procedure and by DBS.
Results: 13 patients have been implanted, 5F/8M, range of age 21-65 y, 3MDD/10OCD, Follow-up 12-228 months, average of improvement 51% in OCD and 62% in MDD, 3 explanted, 4 depleted, 2 lost, 1 dead. Side effects as transitory anxiety in 3 subjects.
Conclusions: ITP is an option for treatment of the OCD and MDD. Average of responders 55% and average of reduction of symptoms 45%. Random, doble blind clinical trials is needed. Extended limbic and parlimbic network are involved in the clinical effects. Probably some patients could be explanted without relapse. Ethic assay is mandatory
Fiacro JIMENEZ (Mexico, Mexico), Humberto NICOLINI, Fabian PIEDIMONTE, Rafael SALIN
13:50 - 14:00
#46050 - OP143 An evolutionary view on the prefrontal cortex connectome and psychopathological networks: Tract tracing and imaging studies linking two distant anthropoid species.
OP143 An evolutionary view on the prefrontal cortex connectome and psychopathological networks: Tract tracing and imaging studies linking two distant anthropoid species.
Introduction: The brain is the most complex organ and evolution encompasses various steps of refinements. It is therefore conceivable to look for anatomical resemblances in nonhuman primates (NHP) which have a common ancestor with humans (Figure 1a). The common marmoset (callithrix jacchus) is a new world primate species which has been used to model human brain development. A recent addition to the view on psychopathologies in humans is the definition of disease related (sub-) networks which allow to disentangle phenotypical and taxonomical aspects in the explanation of distinct disease features. For obsessive-compulsive disorder (OCD) (and major depressive disorder (MDD)1), advanced neuroimaging has facilitated the definition of such subnetworks 2,3. The target regions of primarily descending pathways (projection pathways) are realized as deep seated network hubs 1, as such facilitating a therapeutic access to larger parts of psychopathological networks in humans via Deep Brain Stimulation (DBS).
Tractographic approaches are required to reveal connections of cerebral brain regions in humans and diffusion tensor magnetic resonance imaging-based fiber tractography (DTI-FT) is employed in vivo since long range anterograde tract tracing (aTT) is invasive and therefore not feasible. However, because of the indirect nature of such connectomic network description it appears justified to search for the constituents of these networks in other less developed NHP species, thereby relying on classical tract tracing experiments to understand how well human DTI-FT might depict the network anatomy 4 (Figure1a).
Methods: We have here used prefrontal viral (adeno associated virus = AAV) injections in the common marmoset (n=52, left, prefrontal locations) to analyse its complex PFC connectome and to compare these results with a rendition of the human PFC connectome (HCP, n=1000), based on DTI-FT (Figure1 b-c).
Results: Comparison of AAVaTT (marmoset) with DTI (humans) is possible and allows for a connectomic distinction of evolutionary steps of PFC development. vlPFC and dmPFC/dlPFC appear to change their role over the course of evolution (Figure1 d-e). Network effects of OCD and Treatment resistant depression serve as validation of our principle approach (Figure 1 f-g) . On the one hand marmoset’s PFC hard-wiring - as detailed with AAVaTT - might serve as the blueprint for more qualitative human DTI-FT and anatomically derived descriptions of the PFC connectome. On the other hand, distinct inter-species quantitative detailing might explain functional differences and even more so with respect to human specific psychopathologies.
Conclusion: To our knowledge, there has so far been no attempt to directly and holistically compare the PFC connectivity of human and marmoset in species specific common spaces, at the same time detailing fiber anatomical routes, cortico-cortical and cortico-subcortical connections and their quantitative contributions to our current sub-network descriptions for psychiatric diseases.
References
1. Coenen, V. A. et al. Neuroimage Clin 25, 102165 (2020).
2. Li, B. J., Friston, K., Mody, M. et al. Wiley Online Library 24, 1004–1019 (2018).
3. Shephard, E. et al. Mol Psychiatr 1–22 (2021) doi:10.1038/s41380-020-01007-8.
4. Coenen, V. A. et al. Brain Stimul (2023) doi:10.1016/j.brs.2023.03.012.
Volker Arnd COENEN (Freiburg, Germany), Alexander RAU, Akiya WATAKABE, Henrik SKIBBE, Juan Carlos BALDERMANN, Manuel CZORNIK, Doll MEYER-DOLL, Thomas Eduard SCHLAEPFER, Horst URBACH, Bastian SAJONZ, Mate DÖBRÖSSY, Marco REISERT
14:00 - 14:10
#46311 - OP144 The Neurocircuitry of Body Dysmorphic Disorder: A Systematic Review, Meta-Analysis of Imaging and Neurophysiological Studies, and Proposal of An Updated Model.
OP144 The Neurocircuitry of Body Dysmorphic Disorder: A Systematic Review, Meta-Analysis of Imaging and Neurophysiological Studies, and Proposal of An Updated Model.
Introduction
Body Dysmorphic disorder (BDD) is a severe psychiatric disorder characterised by excessive preoccupation and obsessive concerns with perceived flaws in appearance, leading to compulsive behaviours. This often underdiagnosed disorder carries a high incidence of suicidal attempts. Recent advancements in neurosurgical interventions for obsessive-compulsive disorder (OCD), which shares a taxonomical spectrum with BDD, underscore the potential for cross-applicable intervention approaches. However, further understanding of BDD neurobiology is required to explore the implications of these interventions. This review aims to synthesise the latest findings of the neurobiology of BDD and propose an updated BDD neurocircuitry model.
Methods
A systematic search of four electronic databases and in-text references identified 38 peer-reviewed original articles following PRISMA guidance, and the protocol was registered on PROSPERO (CRD42024553665). A qualitative thematic analysis on morphometric MRI, electroencephalography (EEG), and neurochemical findings in BDD was conducted, and an activation likelihood estimation (ALE) meta-analysis was performed in a subgroup of functional magnetic resonance imaging (fMRI) articles to quantify brain activation patterns.
Results
Brain regions on MRI with significant morphometric divergence in subjects with BDD were predominantly located in primary and secondary visual processing areas, temporal-limbic, and frontal-striatal networks, despite overall heterogeneous findings. The electroencephalography (EEG) studies suggested early visual processing and attentional abnormalities. The ALE analysis revealed a general hyperactivation over the frontotemporal region and hypoactivation over parieto-occipital regions in BDD participants. While BDD shared a similar connectivity pattern in frontostriatal and arbitration networks with OCD, it was further characterised by a bottom-up and top-down interaction between the ventral visual stream (responsible for visual detail processing) and temporal-limbic network (associated with anxiety mediation) compared to anorexia nervosa. Neurotransmitters such as serotonin, dopamine, and oxytocin are shown to play a key role in the pathophysiology of BDD, suggesting a complex interplay of neural circuits and neurotransmitters underlying the disorder. Based on these findings, we have expanded and detailed current neurobiology model of BDD, comprising large neural networks involving visual, limbic, and frontostriatal system dysfunction. We further described the relationship between the visual, limbic, and frontostriatal systems and the interplay between them, how this was correlated with the clinical symptoms of BDD, and potential therapeutic interventions (Figure 1A). BDD is a complex disorder involving cognitive and emotional dysfunction (Figure 1B).
Conclusion
This comprehensive review of up-to-date neurobiological studies of BDD reveals differences in brain structure and functionality compared to healthy controls. The proposed neurocircuitry model expands on the previous understanding of BDD neurobiology and elucidates the interconnection between the visual processing, temporal-limbic, and frontostriatal networks and their clinical implications. It further describes the detailed connectivity and activation abnormalities in BDD neurocircuitry. This review provides theoretical support for future neuromodulation target identification.
Yihui CHENG (London, United Kingdom), Emalee BURROWS, Ludvic ZRINZO, Harith AKRAM, Trevor W. ROBBINS, Himanshu TYAGI
14:10 - 14:20
#47980 - OP145 Immediate and sustained reduction of drug craving and use with focused ultrasound neuromodulation of nucleus accumbens in patients with severe drug addiction.
OP145 Immediate and sustained reduction of drug craving and use with focused ultrasound neuromodulation of nucleus accumbens in patients with severe drug addiction.
Introduction
Substance use disorder (SUD) addiction is a global health care challenge. High relapse rates and mortality associated with SUD and opioid use disorder (OUD) highlight the limitations of the current medical and behavioral treatments, and novel treatment strategies are needed. The nucleus accumbens (NAc) is a critical region in the addiction and reward neurocircuitry implicated in drug craving, relapse, and use. We initiated the first-in-human FDA-approved study to investigate the safety, feasibility, and efficacy of focused ultrasound (FUS) neuromodulation targeting the bilateral NAc in participants with severe OUD and co-occurring SUDs.
Methods
In this open-label study, participants with severe OUD/SUD and multiple overdoses received up to 20 minutes of NAc FUS neuromodulation (220-kHz ExAblate Type 2, Insightec). Individual targeting of the NAc was done with high-resolution MRI and tractography. Outcome measures included clinical safety and tolerability (assessment of adverse events), MRI imaging, craving, and drug use (cue-induced craving, urine toxicology) at day 1, 7, 30, 60, 90 (primary endpoint) post-FUS, and an extended follow-up 180 days post-FUS.
Results
14 participants received FUS neuromodulation, 9 of whom completed the primary 90-day endpoint (5 completed the 180-day extended follow-up). NAc FUS neuromodulation was safe and well-tolerated in all 14 participants, with no device or procedure-related SAE or MR imaging abnormalities. FUS neuromodulation acutely reduced cravings for opioids in all 14 participants (pre-FUS: 6.6 ±3.7, 24 hours post-FUS: 0.7±1.1 [Mean±StDev]; mean reduction 89%) and all other substances (highest non-opioid substance craving pre-FUS: 7.8±2.8, 24 hours post-FUS: 1.1±1.5; mean reduction 86%). Opioid craving reduction was sustained throughout the primary 90-day endpoint (0.6±1.0; mean reduction 92%) as well as the extended 180-day post-FUS follow-up (0.7±1.3; mean reduction 89%). Cravings for non-opioid substances revealed similar reductions (Day 90: 1.1±1.9, Day 180: 1.1±2.2; mean reduction 86%). Relative to pre-FUS substance use patterns, which included multiple episodes of drug use per week, reductions in substance use were noted across nearly all participants, where 6 of the 9 participants were completely abstinent throughout the Day 90 endpoint. All participants who completed the extended 180-day follow-up (n=5) were abstinent throughout the course of the trial.
Conclusion
FUS neuromodulation of the NAc is a novel approach for the treatment of OUD/SUD addiction. The procedure was safe and well-tolerated, with immediate and sustained reduction of drug craving and drug use. A larger, randomized, placebo-controlled trial is underway to further evaluate the safety and efficacy of FUS neuromodulation for drug addiction.
Ali REZAI, Ali REZAI (Morgantown, USA), Manish RANJAN, Pierre-Francois D’HAESE, Aniruddha BHAGWAT, Thompson-Lake DAISY, Jeffrey CARPENTER, Berry JAMES, Victor FINOMORE, Sally HODDER, Farmer DANIEL, James MAHONEY
14:20 - 14:30
#48620 - OP146 Cortico-cortical evoked potentials reveal an effective connectome of the human subgenual cingulate cortex.
OP146 Cortico-cortical evoked potentials reveal an effective connectome of the human subgenual cingulate cortex.
Akash Mishra1,2, Ashesh D Mehta1,2, Stephan Bickel1,2,3
1 The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA
2 Departments of Neurosurgery and Neurology, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
3Center for Biomedical Imaging and Neuromodulation, Nathan Kline Institute, Orangeburg, NY, USA
Introduction
The subgenual cingulate cortex (SCC) is hypothesized to have a critical role in major depressive disorder (MDD) due to its extensive white matter connections and high functional connectivity with brain regions that are implicated in MDD. However, the strength and directionality of these connections within the human brain remain inadequately characterized, which obscures the specific role of the human SCC. SCC cortico-cortical evoked potentials (CCEPs) offer a unique opportunity to delineate these directional relationships (the “effective connectome”), which may elucidate the SCC as a therapeutic target for treating patients with MDD.
Methods
Eleven patients with intracranial electrodes for the identification of epileptic foci were recruited. Pre-operative Beck Depression Inventory (BDI) scores were collected. SCC CCEPs (40-100 pulses) were applied, and evoked activity was simultaneously recorded from all other gray matter contacts. Direct effective connectivity from the SCC was quantified by calculating the root mean square (RMS) of the evoked signal within a 500ms window. Network-level (i.e. relay) relationships were investigated using Granger causality.
Results
SCC CCEP-evoked responses were assessed in 3269 cortical contacts. Evoked responses (FDR-corrected p<0.05) were observed in contacts within the medial and lateral orbitofrontal cortex (OFC), rostral anterior cingulate cortex, and superior frontal cortices. No other cortical regions demonstrated significant responses. Participants demonstrated a range of depression symptom severity (median BDI: 17; no or mild symptoms: 4 participants; moderate symptoms: 4; severe symptoms: 3). The connectivity from the SCC to the OFC (p=0.01) and INS (p=0.03) was positively correlated with depression symptom severity. Further assessment of the evoked responses between brain regions revealed that activity in the OFC predicted activity in the other identified cortical areas (FDR-corrected p<0.05).
Conclusion
SCC CCEPs were used to construct an effective connectome that describes directional relationships from the OFC to cortical regions that are implicated in MDD. Select connections within this connectome correlated with increased depression severity. Hence, this connectome is congruent with and extends observations from prior studies. Interestingly, the OFC may play a significant role in mediating brain activity between the SCC and the broader depression network. Therefore, the therapeutic mechanisms underlying SCC neuromodulation may involve both direct effects of the SCC and OFC-mediated effects. Future studies should leverage SCC CCEPs to refine targeting for neuromodulation therapies and to assess if this effective connectome can serve as a longitudinal measure of network and therapeutic response.
Akash MISHRA (Manhasset, USA)
14:30 - 14:35
#46346 - OP147 Action-related networks in the pathophysiology and treatment of Gilles de la Tourette Syndrome.
OP147 Action-related networks in the pathophysiology and treatment of Gilles de la Tourette Syndrome.
Background: Gilles de la Tourette Syndrome (GTS) is a neurological disorder characterized by persistent motor and vocal tics. While deep brain stimulation (DBS) has emerged as a potential treatment for severe, medication-refractory cases, the optimal brain networks for targeting remain poorly defined. Understanding the connectivity profiles underlying successful treatment and symptom onset may help refine therapeutic strategies.
Methods: This study examined data from two independent DBS patient cohorts (N = 37 and N = 10) and a separate lesion cohort (N = 22) in which brain injuries were associated with the onset of tics. We employed a normative functional connectome derived from resting-state fMRI data of 1,000 healthy individuals to map the connectivity of DBS electrode sites and lesion locations. The aim was to identify common functional networks associated with both tic suppression and induction.
Results: Greater clinical improvement in DBS-treated patients was significantly associated with increased functional connectivity between stimulation sites and action-related networks—specifically, the cingulo-opercular network (p< 0.001) and the somato-cognitive action network (p= 0.002). Connectivity patterns matching these networks were identified as optimal for thalamic DBS targeting. These findings were confirmed in an independent DBS cohort of 10 patients, reinforcing the relevance of these networks across samples. Furthermore, brain lesions linked to tic emergence demonstrated connectivity to the same functional networks, suggesting a shared pathophysiological basis between lesion-induced and idiopathic tics.
Conclusions: The results underscore a critical role for the cingulo-opercular and somato-cognitive action networks in both the emergence and treatment of tics in GTS. Mapping therapeutic and pathological sites to normative functional connectivity patterns offers a robust framework for identifying clinically relevant networks. These insights could guide future interventions and contribute to more precise, individualized approaches in neuromodulation therapies for GTS
Juan BALDERMANN, Pablo ANDRADE (Cologne, Germany), Petra HEIDEN, Andreas HORN, Jens KUHN, Veerle VISSER-VANDEWALLE, Michael BARBE
14:35 - 14:40
#46355 - OP148 Deep brain stimulation in the bed nucleus of stria terminalis – long term effects on patients with obsessive-compulsive disorder.
OP148 Deep brain stimulation in the bed nucleus of stria terminalis – long term effects on patients with obsessive-compulsive disorder.
Introduction: Deep Brain Stimulation (DBS) has demonstrated effects in the treatment of severe and treatment-resistant obsessive-compulsive disorder (OCD). Significant symptom reduction has been reported in the literature, not only regarding obsessions and compulsions but also concomitant depressive symptoms. However, long-term data are scarce, and while some studies report a sustained improvement over time, others demonstrate a loss of effect.
Here, we present the 5-year outcome in patients treated with DBS targeting the bed nucleus of stria terminalis (BNST) for OCD.
Methods: Eleven patients with severe OCD were included in a longitudinal, non-randomized study evaluating DBS in the BNST. Patients were assessed at baseline before surgery and at annual intervals afterwards. Symptom severity was evaluated using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) (n= 10) and the Montgomery – Asberg Depression Rating scale (MADRS) (n=11). The main outcome measures were changes in Y-BOCS and MADRS scores from baseline to the 5-year follow -up.
Results: At baseline, the mean Y-BOCS score was 32.7, (standard deviation [SD] 3.0) and the MADRS score was 29.4 (SD 4.5). At the one-year follow-up, YBOCS scores were reduced to 20 (SD 4.8) and for MADRS 21 (SD 5.8). Further improvement was observed at the five-year follow-up, with Y-BOCS scores decreased to 14.0 (SD 6.5), and MADRS scores to 11.09 (SD 6.9).
Conclusions: BNST DBS provided significant long-term improvement. Obsessive-compulsive symptoms were reduced by 57% and depressive symptoms by 62% from pre-surgery until the 5-year follow-up. Thus, the beneficial effect from DBS seems to maintain long-term.
Marianne JAKOBSSON (Umeå, Sweden), Matilda NAESSTRÖM, Patric BLOMSTEDT, Viktoria JOHANSSON
14:40 - 14:45
#46110 - OP149 Real-world data on Deep Brain Stimulation for obsessive compulsive disorder: leveraging a global device registry to examine safety outcomes and success metrics.
OP149 Real-world data on Deep Brain Stimulation for obsessive compulsive disorder: leveraging a global device registry to examine safety outcomes and success metrics.
Severe treatment-refractory obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder involving repetitive thoughts and behaviors that interfere with daily life, which can be unmanageable with psychotherapy and medication alone1.Deep Brain Stimulation (DBS) for treatment-refractory OCD in has been a treatment option in Europe and the United States since 20092,3. Research over the past 2.5 decades has demonstrated the safety and efficacy of DBS for treatment-refractory OCD3-10. Scientific guidelines support DBS for severe treatment-refractory OCD, stating that the potential benefits outweigh the potential risks11,12. The objective of this analysis is to contribute to scientific knowledge by reviewing safety and efficacy outcomes of DBS for OCD from a global, real-world device registry.
The Product Surveillance Registry (PSR) is a registry that enrolls patients undergoing DBS. Patients are consented and followed prospectively from implant through therapy life cycle. This analysis includes 57 enrolled patients with OCD enrolled in the PSR from July 2012 through January 2025. To determine efficacy, we calculated the mean change in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) from baseline to 6/12 month follow up. To determine safety, we reviewed serious adverse events (SAEs) and device events.
The mean (SD) follow-up duration was 46.8 (32.7) months. During this time, 13 SAEs occurred in 11 (19.30%) patients (Table 1). A total of 138 neurostimulators, 113 leads and 106 extensions were recorded. Fourteen device events occurred in 10 (17.54%) patients (Table 2). Nine components (3 extension, 2 lead, and 4 neurostimulators) had a product performance event which resulted in clinical actions. More than fifty percent (23/53- 53.5%) of the therapy-naïve patients had Y-BOCS data at both baseline and 6/12 months. A significant mean reduction of 10.48 points was observed between the two timepoints (p<0.001), with 47.8% and 13.0% of the patients achieving a full or partial response.
Our research demonstrates that DBS for treatment-resistant OCD is an effective therapy in a real-world population, with 60.9% of patients reporting a full or partial response to treatment at 6/12 months, and 63.6% at 36 months. The SAEs and device events reported in our cohort suggest that DBS has an acceptable safety profile for this hard-to-treat population.
Stephane PALFI (PARIS), Bart NUTTIN, Chris BERVOETS
14:45 - 14:50
#45490 - OP150 Preliminary results of a Phase II/III study of bilateral capsulotomy with magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment of refractory obsessive-compulsive disorder (OCD).
OP150 Preliminary results of a Phase II/III study of bilateral capsulotomy with magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment of refractory obsessive-compulsive disorder (OCD).
Introduction: Ablative neurosurgery is currently an accepted treatment option for patients who have reached the limits of conventional psychotherapeutic and pharmacological care. MRgFUS represents an alternative to currently available ablative procedures. There is already evidence that the use of MRgFUS in patients with refractory OCD could be very useful.
Objective and method:
This Phase II trial aims to evaluate the preliminary efficacy and monitor the medium- to long-term safety of this technology in selected patients with treatment-resistant OCD symptoms, in order to determine the optimal dose and establish clinical response criteria that justify advancing to larger Phase III trials.
Follow-up will be conducted at 7 days, 1, 6, and 12 months post-treatment to assess both symptom reduction and the medium- and long-term safety of the procedure. Patients must have a minimum score of 28 on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Follow-up will include a psychiatric evaluation, functional MRI, and neuropsychological testing.
Results:
Currently we have included 3 patients who have been treated with 4 lesions at the level of the internal capsule (2 in each hemisphere). All patients showed objective improvement in the first month's follow-up, also presenting changes at the level of functional resonance, which was maintained and increased over time, with no impact on neuropsychological tests.
Rebeca CONDE (Valencia, Spain), Antonio GUTIERREZ, Guillem LERA, Andres LOZANO
|
|
|
|
15:00 - 15:30 |
COFFEE BREAK - FLASH POSTERS SESSION 2 - EXHIBITION
|
|
15:30 |
15:30-16:30
Added to your list of favorites
Deleted from your list of favorites
A28
PARALLEL SESSION 4
Movement Disorders 2
PARALLEL SESSION 4
Movement Disorders 2
Chairpersons:
Katsuo KIMURA (Associate Professor) (Chairperson, Yokohama, Japan), Ioannis PANOURIAS (DOCTOR) (Chairperson, ATHENS, Greece), Lennart Henning STIEGLITZ (Head of functional neurosurgery division) (Chairperson, Zurich, Switzerland)
15:30 - 15:40
#46182 - OP061 Neurophysiological Fingerprint of Movement in Essential Tremor Patients with Deep Brain Stimulation.
OP061 Neurophysiological Fingerprint of Movement in Essential Tremor Patients with Deep Brain Stimulation.
Background: Essential Tremor (ET) is defined by shaking of the limbs (tremor) during movement. Deep brain stimulation (DBS) of the thalamus and tractus dentatorubrothalamicus is highly effective but has side effects, including dysarthria, gait impairment and habituation to stimulation. On average, patients experience tremor only 20% of the day. Ideally, stimulation is switched on during movement only, using closed-loop, or adaptive, DBS. These moments may be detected from a decrease in power in the beta frequency range (13-35 Hz) in either subcortical (local field potentials, LFPs) or cortical (electroencephalography, EEG) recordings (1,2). Movement-related beta desynchronization as a potential biomarker for closed-loop DBS has thus far not been studied in detail using a fully implantable DBS system in ET patients.
Objective: To examine whether LFP recordings from the thalamus and EEG from the primary motor cortex can be used to detect movement onset, with stimulation OFF and ON.
Methods: Ten ET patients with DBS (Medtronic© Percept™ PC) were included; eight with bilateral and two with unilateral electrodes. Simultaneous LFPs and EEG signals were recorded (3), and synchronised to an iPad that was used to present and record finger taps during a cued movement task. Patients performed 36 trials with stimulation OFF and ON, for each hand separately. Data was analysed in MATLAB using Fieldtrip functions. After low-pass (120 Hz) and Notch (50 Hz) filtering, ECG artefacts were removed with an in-house developed method (4). For the EEG, channels C3 and C4 (located over the primary motor cortex) were selected. Time series were epoched in 36 non-overlapping trials. After time-frequency analysis (1s Hanning taper, 25 ms timesteps), a random-effects analysis was performed using SPM12 (cluster-defining threshold p<0.001 (uncorrected), significant clusters p<0.05 (FWE-corrected)).
Results: For the LFPs, significant beta desynchronization was observed in the OFF-stimulation condition (Figure 1). For the EEG, significant beta desynchronization was observed in both stimulation conditions (Figure 2). In the OFF-stimulation condition, there was no significant difference in beta desynchronization amplitude between LFP and EEG signals. ON stimulation significantly less beta-desynchronisation was observed in the LFP signals compared to EEG (Figure 3).
Conclusions: Thalamic LFPs register reliable movement-related beta-desynchronisation only with stimulation OFF. EEG recordings from electrodes overlying the primary motor cortex register reliable movement-related beta-desynchronisation in OFF and ON-stimulation conditions. This suggests that EEG is more suitable for implementing movement-driven closed-loop algorithms potentially via subdural ECoG electrodes.
References:
1. He et al. 2021 doi: https://doi.org/10.1002/mds.28513
2. Opri et al. 2020 doi: https://doi.org/10.1126/scitranslmed.aay7680
3. Buijink et al. 2022 doi: https://doi.org/10.1016/j.cnp.2022.03.002
4. Stam et al. 2022 doi: https://doi.org/10.1016/j.clinph.2022.11.011
Dewi BOESSEN, Anouk BOOGAARD, Bernadette VAN WIJK, Rob DE BIE, Edwin BLOK, Maarten BOT, Rick SCHUURMAN, Fleur VAN ROOTSELAAR, Martijn BEUDEL, Arthur BUIJINK (Amsterdam, The Netherlands)
15:40 - 15:50
#46226 - OP062 Optimization of Adaptive Deep Brain Stimulation Settings in Patients with Parkinson’s Disease.
OP062 Optimization of Adaptive Deep Brain Stimulation Settings in Patients with Parkinson’s Disease.
Objective: To evaluate the specific programming parameters of adaptive deep brain stimulation (aDBS) in Parkinson’s disease(PD) and identify the most effective settings for optimizing therapeutic outcomes.
Background: In patients with PD, characteristic beta-band local field potentials (LFPs) are observed in the cortical and basal ganglia motor-related regions, fluctuating in accordance with motor symptom variations. aDBS, which modulates stimulation automatically based on these fluctuations, has been clinically implemented. However, compared to conventional DBS, aDBS requires multiple programming parameters, increasing the complexity of the settings. Additionally, some patients do not achieve sufficient clinical benefits. This study aimed to analyze the specific parameters used in aDBS programming and determine which settings are most effective.
Methods: We analyzed 40 electrodes in 20 patients with advanced PD who underwent DBS using the Medtronic Percept PC/RC system and had been followed for at least six months after aDBS implementation. We examined the selection process for beta-band LFPs used in aDBS, including the timing of measurement, choice of treatment mode, upper and lower threshold settings, stimulation range, temporary suspension values, transition time adjustments, and long-term variations in stimulation parameters.
Results: Beta-band LFPs corresponding to motor symptom fluctuations were successfully recorded in all patients and utilized for aDBS programming. All LFPs were collected within one month postoperatively. Dual-threshold settings were applied in all cases. Upper and lower thresholds were determined using the streaming function in five cases, while clinical symptoms guided threshold selection in 15 cases. In 10 cases, transition time was shortened from the initial setting. Within six months, 17 cases required adjustments to the LFP fluctuation range, and 20 cases required modifications to the stimulation range.
Conclusion: Effective utilization of aDBS requires meticulous programming and frequent parameter adjustments. Continuous optimization of stimulation settings is essential to maximizing therapeutic benefits.
Katsuo KIMURA (Yokohama, Japan), Katsuya ABE, Ryosuke TAKAGI, Higashijima TAKEFUMI, Takayama YUTARO, Kawasaki TAKASHI, Ueda NAOHISA, Taknaka FUMIAKI
15:50 - 16:00
#48621 - OP063 Subthalamic nucleus encoding steers adaptive therapies for gait in Parkinson’s disease.
OP063 Subthalamic nucleus encoding steers adaptive therapies for gait in Parkinson’s disease.
Valeria de Seta1,2, Stefano Scafa1,2,3, Ruijia Wang2,4, Paula Sánchez López2,4, Camille Varescon1,2,
Ettore Accolla7, Benoit Wicki8, Cécile Hübsch9, Mayte Castro Jiménez9, Julien F. Bally9,
Gregoire Courtine1,2,4,5, Jocelyne Bloch1,2,4,5,* and Eduardo M. Moraud1,2,*
1 Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
2 .NeuroRestore, Lausanne University Hospital (CHUV) and Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
3 Institute of Digital Technologies for Personalized Healthcare (MeDiTech), University of Southern Switzerland (SUPSI), Viganello, Switzerland
4 Neuro-X Institute, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
5 Department of Neurosurgery, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
6 Department of Neurology, Hôpitaux Universitaires de Genève (HUG), Geneva, Switzerland
7 Department of Neurology, Hôpital Fribourgeois and Fribourg University, Fribourg, Switzerland
8 Department of Neurology, Hôpital du Valais, Sion, Switzerland
9 Department of Neurology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
* contributed equally to this work
Advanced Parkinson’s disease (PD) leads to a spectrum of locomotor deficits, including heterogeneous gait abnormalities, lack of balance, and freezing of gait, that remain inadequately managed by standard treatments. In particular, deep brain stimulation (DBS), which is delivered continuously with parameters optimised for cardinal symptoms, displays variable –and sometimes detrimental— efficacy for gait. Instead, locomotor impairments commonly emerge in an activity-dependent manner, such as during physically or cognitively demanding tasks, or when multi-tasking. Continuous DBS protocols are thus suboptimal to address the episodic and context-dependent nature of locomotor deficits. Here, we present preliminary results from the ADAP-GAIT clinical trial (NCT06791902), in which we evaluate the safety and preliminary efficacy of activity-dependent aDBS therapies that dynamically adjust stimulation in real time to better address gait impairments. We enrolled three participants with advanced PD, chronically implanted with a Percept PC (Medtronic, USA) in the subthalamic nucleus (STN), and exhibiting disabling gait disorders. For each participant, we leveraged a neural decoding pipeline to identify personalised STN neural signatures that capture the encoding of locomotor activities across fluctuating L-DOPA states and changing DBS amplitudes. We mapped how changes in DBS amplitudes influence cardinal versus locomotor deficits and identified optimal stimulation parameters to address each set of impairments. We then leveraged neural biomarkers to automatically adapt the delivery of DBS in real-time, based on the ongoing locomotor activity. In all participants, activity-dependent aDBS increased gait fluidity, normalised kinematic and electromyographic patterns and reduced FOG. Participant’s subjective reports confirmed these quantifications. These findings demonstrate the feasibility and therapeutic potential of activity-dependent adaptive DBS. Ongoing recruitment will assess the generalizability of these results in a larger cohort.
Eduardo MARTIN MORAUD (Lausanne, Switzerland)
16:00 - 16:10
#45438 - OP064 Deep brain computer interfacing for sensory encoding: a novel application of DBS electrodes.
OP064 Deep brain computer interfacing for sensory encoding: a novel application of DBS electrodes.
Deep Brain Stimulation (DBS) primarily functions through neuromodulation to alleviate symptoms in movement disorders and pain syndromes. We investigated a novel application of DBS electrodes as a platform for sensory encoding by repurposing unused contacts to deliver encoded information via localized paresthesias.
Ten participants aged 60-79 scheduled for DBS implantation were recruited. Experiments were conducted 1-4 days post-surgery during lead externalization. Each participant underwent a personalized calibration process to establish individual perceptual channels with distinguishable intensity levels. The calibration comprised three stages: 1) exploration of contact-by-contact mapping to elicit localized paresthesias, 2) establishment of intensity ranges for each channel, and 3) verification of intensity level discrimination.
Eight participants subsequently performed behavioral tasks to assess their ability to use the computer-brain interface: distinguishing rhythmic patterns (slow vs. fast), interpreting abstract symbols (letters), and decoding simulated object properties (size and rigidity).
We successfully established stable sensory channels with reliable discrimination between intensity levels in all participants (ROC AUC=0.982). Paresthesias were primarily localized to upper extremities with some sensations in trunk, face, and lower extremities. Modulation of pulse width and stimulation frequency effectively altered perceived intensity while maintaining spatial consistency, whereas cathodic current variations showed no significant effect. In the behavioral tasks, 6/8 participants distinguished rhythmic cues (1.5Hz vs 3Hz) with 80.2 % accuracy 5/6 participants recognized symbolic cues with 65.6% accuracy, and 5/7 participants identified object size feedback with 80.2% accuracy. All successful performances showed medium to large effect sizes and were statistically significant compared to chance levels after FDR correction.
This proof-of-concept study demonstrates that DBS electrodes can serve dual functions, not only modulating neural activity but also transmitting interpretable sensory information directly to the brain. This "DBS+" approach expands potential therapeutic applications without requiring additional hardware implantation, potentially enhancing treatment options for patients with movement disorders or sensory deficits. Future applications may include providing rhythmic cues for freezing of gait in Parkinson disease and sensory feedback for prosthetic devices.
Bastian E.a. SAJONZ (Freiburg, Germany), László HALÁSZ, Saman HAGH-GOOIE, Gijs VAN ELSWIJK, Joana PEREIRA, Emília TÓTH, Gertrúd TAMÁS, Anita KAMONDI, Loránd ERŐSS, Volker A. COENEN, Bálint VÁRKÚTI
16:10 - 16:20
#46225 - OP065 DBS-enabled neurofeedback control over subthalamic beta oscillations in Parkinson patients.
OP065 DBS-enabled neurofeedback control over subthalamic beta oscillations in Parkinson patients.
Background: Technological advances in deep brain stimulation (DBS) have enabled simultaneous therapeutic stimulation and real-time streaming of neural activity. In Parkinson’s disease (PD), pathological beta-band oscillations in the subthalamic nucleus (STN) are linked to motor dysfunction. Prior studies have shown that patients can volitionally suppress beta activity via neurofeedback. However, it remains uncertain whether this reflects true modulation capability or a by-product of general cognitive effort, and whether patients can achieve bidirectional control—both upregulation and downregulation—of beta oscillations.
Objective: To demonstrate the capacity of PD patients to exert bidirectional neurofeedback control over subthalamic beta oscillations using DBS-enabled recording.
Methods: Two previously published datasets were combined to strengthen statistical power. In Cohort 1, patients underwent neurofeedback with externalised DBS leads following surgical implantation. In Cohort 2, patients used a fully implanted, streaming-capable DBS system. In both cohorts, participants were instructed to modulate their STN beta activity either up or down during neurofeedback sessions. A linear mixed-effects model (LMEM) was employed to analyse intra-individual changes in beta peak power across time and direction of modulation.
Results: Across both cohorts, patients demonstrated significant bidirectional modulation of STN beta oscillations. The ability to volitionally regulate beta activity improved over time (p < 0.01), indicating a learning effect. Notably, participants achieved a robust downregulation of beta power by approximately 22% relative to rest (p < 0.0001), underscoring the clinical relevance of neurofeedback-guided suppression of pathological oscillations.
Conclusion: This study provides the first conclusive evidence for bidirectional, volitional control of STN beta activity in PD patients through DBS-guided neurofeedback. The use of both externalised and fully implanted DBS systems affirms the generalisability of the findings. These results bridge a critical gap in the field, previously limited by underpowered designs, and support the potential of closed-loop neurofeedback interventions as adjunctive therapies in DBS-treated populations.
Oliver BICHSEL, Markus OERTEL (Zürich, Switzerland), Lennart STIEGLITZ
16:20 - 16:25
#46236 - OP066 The feasibility of the time-frequency analysis of cortical and subthalamic nucleus during limb movements in Parkinson’s disease patients.
OP066 The feasibility of the time-frequency analysis of cortical and subthalamic nucleus during limb movements in Parkinson’s disease patients.
Rationale:
Excessive beta-band oscillations in the basal ganglia have been implicated in the pathophysiology of Parkinson’s disease (PD). In addition, high-gamma oscillations have been associated with motor function in PD, although their characteristics remain poorly understood. This study aimed to evaluate the feasibility of investigating high-gamma oscillations using time-frequency analysis of cortical and subthalamic nucleus (STN) activity during contralateral upper limb movements in a patient with PD.
Methods:
Intraoperative local field potentials (LFPs) were recorded from the motor cortex and STN during deep brain stimulation (DBS) surgery. An accelerometer was placed on the patient’s arm to monitor movement. After implanting a strip electrode over the motor cortex and a DBS lead in STN, intraoperative CT was performed to confirm electrode placement. The patient was then instructed to perform 30 repetitions of simple contralateral limb flexion and extension while LFPs were recorded. Offline, wavelet transform-based time-frequency analysis was conducted, focusing on the high-gamma band (70–110 Hz). Trials were averaged and aligned to movement onset (defined as 0 seconds based on accelerometer signal change). The baseline period was set from –600 ms to –200 ms, and significant high-gamma activity was defined as a z-score exceeding 3 for at least 50 ms.
Results:
Significant high-gamma activity was observed in both the motor cortex and STN during contralateral upper limb movements in the PD patient.
Conclusion:
This study demonstrates the feasibility of using time-frequency analysis to detect high-gamma activity in both the cortex and STN during contralateral upper limb movement in a PD patient undergoing DBS surgery. Further studies are needed to validate these findings and assess their generalizability.
Kazuki SAKAKURA, Jay SHILS, Nathan PERTSCH, Sepehr SANI (Chicago, USA)
16:25 - 16:30
#46264 - OP067 Subthalamic stimulation reduces high beta – high gamma phase-amplitude hyperdirect coupling in Parkinson’s disease.
OP067 Subthalamic stimulation reduces high beta – high gamma phase-amplitude hyperdirect coupling in Parkinson’s disease.
Introduction
Subthalamic stimulation (STN-DBS) in Parkinson’s disease may operate along the hyperdirect pathway by suppressing the high beta connectivity between the STN and motor cortical areas and promoting high gamma motor cortical processing. In this study, we examined how subthalamic beta activity shapes the pattern of cortically generated gamma rhythm and how STN-DBS influences this coupling.
Methods
Thirty-eight patients with akinetic-rigid Parkinson’s disease treated with bilateral STN-DBS were recruited. First, four levels of contralateral stimulation were selected with improving bradykinesia based on kinematic testing (0: DBS OFF, 1-3). A 64-channel electroencephalogram was recorded at rest, and while patients drew self-paced and traced spirals with their more affected hand on a digital tablet five times at the four selected stimulation levels. After using a beamformer inverse solution dynamic imaging for coherent sources, we analyzed time-resolved inter-regional phase-amplitude coupling (irPAC) between the following subthalamic beta and cortical (primary, supplementary motor, dorsal and ventral premotor cortex) gamma frequency band pairs: subthalamic low beta (SLB; 13-20 Hz) – cortical low gamma (CLG; 31-60 Hz), subthalamic low beta – cortical high gamma (CHG; 61-100 Hz), subthalamic high beta (SHB; 21-30 Hz) – cortical low gamma, and subthalamic high beta – cortical high gamma. Drawing speed was assessed as tangential velocity and its stimulation-induced improvement as slope was correlated with the stimulation-induced changes in irPAC values in the two spiral drawing tasks.
Results
The irPAC value during the resting state was significantly higher than during the two movement tasks (p<0.001), whereas it did not differ during the two motor tasks (p=0.76). The calculated irPAC values did not differ between the four subthalamic-cortical pathways (p=0.08). The irPAC value was higher in the pairs of the high beta band than that of low beta band (p<0.001). However, no significant difference was found between the SLB-CLG vs. SLB-CHG (p=0.42) and the SHB-CLG vs. SHB-CHG (p=0.99). When adjusting the stimulation level, only subthalamic high beta–cortical high gamma irPAC decreased on the fourth stimulation level (p<0.001), and its stimulation-induced decrease along the STN - M1 and STN - dorsal premotor cortex hyperdirect pathways correlated significantly with the increase in spiral drawing speed.
Conclusion
Pathological subthalamic high beta activity abnormally drives high gamma motor cortical processing in Parkinson’s disease, and it is suppressed by subthalamic stimulation. Stimulation-induced decrease in phase-amplitude coupling along the hyperdirect pathways comprising the primary motor and the dorsal premotor cortex correlates with the improvement of bradykinesia during spiral drawing.
Disclosure
The authors declare nothing to disclose.
Ádám József BERKI (Budapest, Hungary), Hao DING, Marcell PALOTAI, László HALÁSZ, Loránd ERŐSS, Gábor FEKETE, László BOGNÁR, Péter BARSI, Andrea KELEMEN, Borbála JÁVOR-DURAY, Éva PICHNER, Muthuraman MUTHURAMAN, Gertrúd TAMÁS
|
15:30-16:30
Added to your list of favorites
Deleted from your list of favorites
B28
PARALLEL SESSION 5
Pain 2
PARALLEL SESSION 5
Pain 2
Chairpersons:
Istvan BALAS (Neurosurgeon) (Chairperson, Pécs, Hungary), Mojgan HODAIE (Attending Neurosurgeon) (Chairperson, Toronto, Canada, Canada), Roman LISCAK (head) (Chairperson, PRAGUE, Czech Republic)
15:30 - 15:40
#47989 - OP133 Percutaneous Spinothalamic Radiofrequency Cordotomy for Intractable Cancer Pain: A Large Cohort From a Single Institution Experience.
OP133 Percutaneous Spinothalamic Radiofrequency Cordotomy for Intractable Cancer Pain: A Large Cohort From a Single Institution Experience.
Abstract
Background and Objectives:
Percutaneous cervical cordotomy (PCC) is used to provide pain palliation to oncological patients suffering from unilateral intractable cancer-related pain below the C4 dermatome. We present our experience utilizing O-arm intraoperative imaging for PCC in a large cohort of patients.
Methods: A retrospective analysis was conducted of all patients who underwent PCC between March 2016 and April 2025 at our institution. Data were collected for up to 12 months after the procedure, including demographic and clinical information. The difference in pain before and after the procedure was calculated using the visual analog scale (VAS) score.
Results: A total of 114 patients (62 males) underwent 120 PCC procedures. The average age of patients was 62.9 (range 22-88, median 65, SD ± 12.5) years. Most cases (86%) were performed in an awake state or under minimal sedation, while 15 cases (14%) were performed under deep sedation or general anesthesia using intraoperative monitoring (IOM).
In 95% of cases (114 out of 120), there was a significant reduction in pain immediately following the procedure with an average score decreased by an average of 8.5 points (from 9.3 points before the operation to 0.8 points postoperatively). In only 1 case, an immediate failure was observed, with no pain relief following surgery. Five patients experienced only mild to moderate postoperative improvement. The median hospitalization time was 2 days.
The average survival time was 4.6 months (ranging from 0.9 to 46.97, with a median of 2.9 months). Only eight patients survived beyond the first year. At one month post-operative, 79 patients were available for follow-up, and 72% of them (57 patients) reported complete pain relief. Three months postoperatively, 31 patients were available for follow-up, and 61% (19 patients) reported complete pain relief. Six months postoperatively, 13 patients were available for follow-up, and 85% (11 patients) reported complete pain relief.
Three patients (2.5%) developed ipsilateral hemiparesis; two of them improved spontaneously within one month of rehabilitation, nearly regaining their baseline function. The most common complication was mirror pain, which developed in 34 cases (28%). Nineteen cases were rated as mild were well-managed with pain relievers; fifteen cases were rated as severe.
Conclusion: PCC is safe and effective in managing intractable oncological pain; however, the average survival time after PCC is typically only several months, indicating a lack of awareness of the procedure among pain specialists and late referrals. We suggest that PCC should be considered earlier in the course of treatment of cancer patients suffering from pain that is refractory to medications.
Segev GABAY (Tel-Aviv, Israel), Kempfner ADI, Strauss IDO STRAUSS
15:40 - 15:50
#47402 - OP134 Stereotactic Spinothalamic Mesencephalic Tractotomy for the treatment of Cancer Pain in the Neuromodulation era: Advocacy for the renaissance of a forgotten surgery.
OP134 Stereotactic Spinothalamic Mesencephalic Tractotomy for the treatment of Cancer Pain in the Neuromodulation era: Advocacy for the renaissance of a forgotten surgery.
Background : The radiofrequency unilateral interruption of the spinothalamic tract at the level of the superior colliculi in the mesencephalon is one of the more ancient functional neurosurgery operation. Based on the literature review our aim is to consider the potential role of this old intervention in the modern neurosurgical armamentarium against cancer pain taking into account the evolution of the operative technique and the emergence of alternative approaches.
Material and Method : We reviewed the literature in order to analyse the anatomical targeting of the spinothalamic tract, the technical strategies, the efficacy on pain, the morbi-mortality the comparison of the safety efficacy ratio with other surgical technics depending on the indications. Among 19 published series only 4 are reporting only cancer pain patients. Two of these 4 series are reporting an anterior approach.
Results : At the level of the superior colliculi the spinothalamic tract location is quite stable. With the anterior approach, a trajectory parallel to the quadrigeminal plate and a target at 7-8 mm from the midline the rate of permanent oculomotor palsy is very low. In patients operated under local anaesthesia with electrical stimulation of the target area painful paraesthesia due to injury of the medial lemniscus are very rare (min 0 max 6%). The rate of patient with analgesia of the painful area pain relive and stop and stop of pain-drug in these conditions is around 80% (min 75%-max 86%) in cancer patients. Early pain recurrences appearing within a month are due to insufficient coagulation. When morphine pump is not an option this intervention can transform the comfort of the last days of patients with unilateral drug-resistant pain of the upper part of the body.
Conclusion : Although very ancient the Stereotactic Spinothalamic Mesencephalic Tractotomy (SSMT) by radiofrequency (RF) is turning out to offer a very good safety efficacy for lateralized cancer pain at the upper part of the body in drug-resistant patients with a modest life expectancy.
We recommend the young generation of neurosurgeon involved in pain surgery to learn this remarkably effective intervention.
Jean REGIS (Marseille), Anne BALOSSIER
15:50 - 16:00
#45819 - OP135 Impact of biological effective dose variability in stereotactic radiosurgery for trigeminal neuralgia.
OP135 Impact of biological effective dose variability in stereotactic radiosurgery for trigeminal neuralgia.
Biological Effective Dose (BED)-based planning has emerged as a promising method for predicting tissue response in high-precision radiosurgical treatments. Given that dose rate significantly influences tissue responses, the condition of radiation sources at treatment should be considered alongside patient-specific factors for individualized therapy. Additionally, BED can aid in developing optimized treatment protocols to enhance patient outcomes.
To investigate factors influencing treatment outcomes, a cohort of 191 patients diagnosed with idiopathic, type 1 trigeminal neuralgia (TN) receiving first-line stereotactic radiosurgery (SRS) was analysed. All treatment plans targeted the trigeminal nerve in the prepontine cistern with a maximum dose of 80 Gy delivered at the 100% isodose using different GammaKnife units over time. Follow-up data were retrospectively collected from a prospectively maintained database.
Median follow-up was 46 months (range: 12–266 months). Pain relief was achieved in 90.1% (n = 172) of patients. Of those, 172 patients, 51.2% (n = 88) experienced relapse. Kaplan-Meier analysis estimated median relapse-free duration as 73 months, with 32.1% of patients remaining relapse-free at 10 years. Medication status was documented for 186 patients, with 38.7% (n = 72) discontinuing medication completely, and another 36.6% (n = 68) reducing dosage by their latest follow-up.
Univariate Cox regression showed that each millimetre increase in shot distance from the root entry zone (REZ) increased relapse hazard by 16.3% (95% CI: 2.4%–32.2%, p = 0.020), while each 10% increase in BED delivered to the REZ decreased relapse hazard by 4% (95% CI: 1.4%–6.4%, p = 0.003). Univariate logistic regression indicated each additional millimetre distal to the REZ reduced odds of medication-free status by 21.5% (95% CI: 2%–37.2%, p = 0.032). Multivariate logistic regression demonstrated maximum BED applied to the nerve positively predicted new numbness (p = 0.046), adjusted for pre-treatment pain duration (p = 0.016), beam blocking status (p = 0.960), and patient age (p = 0.053).
Despite identical maximum physical doses administered, differences in maximum BED successfully predicted the risk of new numbness, highlighting the superiority of BED over physical dose in predicting tissue response. Increasing BED to the REZ improves pain control, whereas higher maximum nerve BED increases the risk of, even though it is generally well-tolerated, facial numbness. Optimizing REZ dose while minimizing the maximum BED to the nerve may enhance clinical outcomes.
Alperen SOZER (Ankara, Turkey), Julian CAHILL, Matthias RADATZ, Dev BHATTACHARYYA
16:00 - 16:05
#46357 - OP136 Efficacy and safety of repeat Gamma Knife Radiosurgery for recurrent trigeminal neuralgia.
OP136 Efficacy and safety of repeat Gamma Knife Radiosurgery for recurrent trigeminal neuralgia.
Introduction
Trigeminal Neuralgia (TN) is a condition causing acute attacks of pain over the areas of distribution of trigeminal branches. Gamma Knife radiosurgery (GKRS) is a mainstay of the treatment algorithm, and its efficacy and safety have been widely shown. However, a non-negligible number of patients may experience recurrence of pain after initial relief. Data on radiosurgical retreatments are still limited, and factors that may influence response to treatment and adverse effects are not well described.
Methods
We retrospectively reviewed patients who were retreated at our institution with GKRS for recurrent TN from January 2004 to December 2021. Both the first and the second GKRS treatment were performed using the Gamma Knife Perfexion or Icon model with the stereotactic head G-frame and with a 4 mm collimator shot positioned on the cisternal segment of the trigeminal nerve.
The median prescription dose at the first GKRS was 80 Gy, whereas a median prescription dose of 76 Gy was delivered at the second radiosurgery.
Results
We retrieved data from 31 patients with a mean age, at the time of the second treatment, of 64 years old; 16 patients (51.6%) were females.
All patients except for one (96.8%) showed pain response after the first GKRS treatment, with Barrow Neurological Institute (BNI) pain scale grade I-IIIb. Two patients (6.5%) experienced BNI facial numbness scale grade IV hypoesthesia. Pain recurrence was observed after a mean of 28 months. All patients underwent a second GKRS, and all except for one (a different non responder compared to the first GKRS) had pain response with BNI pain scale I-IIIB (96.8%). However, after retreatment 8 patients (25.8%) reported BNI facial numbness scale grade 4 hypoesthesia. No patient experiences anesthesia dolorosa. After a minimum follow-up of 24 months, 61.7% of patients had controlled pain (BNI pain scale grade I-IIIb).
Conclusions
GKRS retreatment may be a feasible therapy for TN recurrency, albeit with a higher occurrence of bothersome facial hypoesthesia, compared to primary treatments. In our series, no patient displayed anesthesia dolorosa.
Edoardo POMPEO (Milano, Italy), Luigi ALBANO, Lina Raffaella BARZAGHI, Elena BARRILE, Alfio SPINA, Pietro MORTINI
16:05 - 16:10
#46135 - OP137 Our experience of anterior cingulotomy for intractable pain.
OP137 Our experience of anterior cingulotomy for intractable pain.
Introduction. Recent researches suggest that the anterior cingulate cortex and midcingulate cortex may play distinct roles in pain, emotion and memory regulation. DBS has become widely utilized not only for movement disorders but also in the treatment of some psychiatric disturbances, notably incredible chronic pain. Stereotactic bilateral anterior cingulotomy, including lesions in the anterior and midcingulate cortex, is one of the methods used for treating intractable pain syndrome of different ethologies. The aim of the study is to evaluate the effectiveness and safety of anterior cingulotomy for intractable pain.
Material and methods. At the Romodanov Neurosurgery Institute, 9 patients with incredible chronic pain underwent stereotactic bilateral radiofrequency (RF) anterior cingulotomy. All patients were male. The mean age at surgery was 38.6 years (range 21-72 years). One patient had thalamic pain due to a low grade thalamic glioma, which course a severe contralatarel pain syndrome. The other eight patients had neuropathic pain resulting from direct nerve trauma; among them, four cases were related to mine blast injuries sustained in combat.
Operations were performed using a CRW Stereotactic frame following MRI-CT fusion. Surgery was performed under general anesthesia with intravenous sedation. Lesioning was conducted using a RF monopolar electrode with a diameter of 2.1 mm and a 3.0 mm bar tip. The areas for cingulate lesioning were identified bilaterally through direct targeting. The initial target was located 1.5 mm above the lower border of the cingulate gyrus, 6.5 mm lateral to the midline, and 20.5 mm posterior to the tip of the frontal horn. The lesion was made at 75°C for 60 seconds, then electrode was withdrawn to 2 mm above the target, and an additional lesion was made at the same temperature and duration. Three lesions were simultaneously performed bilaterally in the anterior cingulate gyrus, followed by two lesions targeted 5 mm anterior to the previous ones.
Pain assessment was conducted using the 10-point Visual Analogue Scale (VAS) prior to surgery, at one and four weeks postoperatively in all cases, and at one year in 5 (56%) following treatment.
Results. A significant reduction in pain syndrome was achieved in all cases immediately and four weeks after surgery with a 92% improvement on the VAS. At one-year follow-up, the VAS score showed an 82% improvement; only one patient experienced a partial recurrence of pain. There were no any operative complications, postoperative neurological and mood complications after operation.
Discussion. Despite the study's limited sample size our results indicate that stereotactic RF bilateral anterior cingulotomy is a reliable and safe approach for managing incredible chronic pain of different aetiology.
Kostiantyn KOSTIUK (KYIV, Ukraine), Yuri MEDVEDEV, Andrii LISIANYI, Valerii CHEBURAKHIN, Vladyslav BUNYAKIN, Sergii DICHKO
16:10 - 16:15
#48063 - OP138 Superior visibility using an endoscope and exoscope in microvascular decompression for trigeminal neuralgia.
OP138 Superior visibility using an endoscope and exoscope in microvascular decompression for trigeminal neuralgia.
Introduction:
Trigeminal neuralgia is a disabling disease, which affects a significant proportion of the population (Incindece 5.5/100.000). The symptomatic treatment of the disease ranges from medical therapy (especially AED's and TCA's) to neurosurgical interventions such as percutaneous balloon compression, glycerol or RFT or even stereotactic radiosurgery. The only causative treatment of the disease is microvascular decompression through a retrosigmoid craniotomy.
The classic approach utilises a microscope to visualise the neuro-vascular conflict in the prepontine cistern. However using a microscope allows great manoeuvrability and visualisation of the anatomical structures along the surgical corridor, it does not allow to visualise any structures behind an other one. Also using the microscope the surgical ergonomy is highly dependent on the positioning of the patient and the optimal distance from the surgical field.
Methods:
Here we present our multicenter experience with neuroendoscopic and exoscopic operations with a retrosigmoid craniotomy. The exoscope is a new device to allow microscope like magnification without the optical tubing of the microscope. Which was used especially during the craniotomy phase of the operation. The endoscope (4mm straight or 30 degree optic) was used typically during the decompression phase of the operation.
Results:
Exoscope is typically used during the first phase of the operation, which allows a more convenient operation posture for the surgeon and also microscope like magnification of the surgical field. However the exoscope also lacks the ability to "look behind" the structures. The endoscope gives in every single case added information about the anatomical situation and allows a better overview of the neuro-anatomical situation, especially in cases with narrow cisterns or complex neuromuscular conflict.
We used both the endoscope assisted technique and also the endoscope controlled technique without the use of the microscope if the anatomical situation did require better intracisternal visualisation.
Conclusion:
There is abundant experience how to use the microscope during MVD procedures. Anyhow sometimes the microscope does not allow to overview the whole surgical field, especially in cases with narrow cistern or complex neuro-vascular conflict. In these cases the use of the neuroendoscope as an endoscope assisted technique may provide valuable information about the real situation, showing explicitly the neuro-vascular anatomy of the cerebellopontine cistern. The complete decompression of the initial segment of the trigeminal nerve with the dorsal root entry zone is crucial for the optimal outcome, therefore optimal visualisation is crucial for the best outcome.
The exoscope is clearly adding to the comfort of the surgeon however the added benefit is limited due to the use of the same surgical corridor as the microscope.
In summary in our hands the use of the endoscope in MVD operations's is the future and further training is necessary for the surgeons who are not familiar using an endoscope assisted technique.
László ENTZ (Budapest, Hungary), Loránd ERŐSS, Robert REISCH
16:15 - 16:20
#47694 - OP139 Vagoglossopharyngeal neuralgia: a single-center experience and comparative study with trigeminal neuralgia.
OP139 Vagoglossopharyngeal neuralgia: a single-center experience and comparative study with trigeminal neuralgia.
Objective: There remains limited data on the long-term outcome of microvascular decompression (MVD) for refractory vagoglossopharyngeal neuralgia (VGN). There are no prospective or comparative studies. Here, we evaluate the effectiveness, safety, and long-term outcome of MVD in a consecutive series of patients with medically refractory VGN and compare these results with matched patients undergoing MVD for trigeminal neuralgia (TN).
Methods: Overall, 11 patients with VGN underwent MVD, and these were matched by age and sex with patients with TN. Data included demographic features, pain characteristics, intraoperative findings, and clinical outcomes. Pain relief was assessed using the modified Barrow Neurological Institute (BNI) pain scale for both VGN and TN, with scores I-III defined as a good outcome.
Results: At the time of the surgery, the mean age of patients with VGN was 58 years (range, 44-68), with a mean pain duration of 4,5 years. Intraoperatively, all patients had an arterial compression, most commonly from the posterior inferior cerebellar artery (10/11), followed by the vertebral artery (5/11). Arachnoid adhesions were present in both VGN and TN groups. Inclusively, two patients with VGN presented with concomitant TN, in which the cause was compression from the superior cerebellar artery. Immediate pain relief occurred in 10/11 patients, with good outcomes maintained in 9/11 patients at a mean follow-up of 56 months. Recurrence occurred in 3 patients in VGN, and in 2 patients with TN. One patient with recurrent VGN underwent successful posterior fossa re-rexploration 11 years after the index surgery. No significant differences in pain outcomes were found between patients with VGN and TN, and there was no difference in the rate of complications.
Conclusion: MVD is an effective and safe procedure for VGN, leading to satisfactory pain relief with comparable outcomes in relation to MVD for TN. Besides the classical neurovascular conflict, arachnoid adhesions are a shared feature in both neuralgias, outstanding their importance in the pathophysiology of both cranial neuralgias.
Filipe WOLFF FERNANDES (Hannover, Germany), Ariyan PIRAYESH, Joachim Kurt KRAUSS
16:20 - 16:25
#47693 - OP140 How to deal with the superior petrosal vein during microvascular decompression for trigeminal neuralgia?
OP140 How to deal with the superior petrosal vein during microvascular decompression for trigeminal neuralgia?
Objective: The superior petrosal vein (SPV) is a common obstacle, obstructing the operative field during microvascular decompression (MVD) for trigeminal neuralgia (TN), and its management intraoperatively remains controversial. Here, we evaluate the safety of a specific rationale for dividing the SPV technique MVD for TN.
Methods: We retrospectively analysed 217 patients who underwent first-time MVD for medically refractory TN. When a SPV was found obstructing the operative field, it was coagulated at the distal end of its main trunk near the entry site into the superior petrosal sinus, maintaining cross flow between the venous contributories. This technique was applied in 171 patients (79%) (group I), but not in the other 46 (21%) (group II). Data included demographics, clinical data, intraoperative findings, and postoperative complications were assessed and compared between both two groups. The defined primary outcome was the occurrence of venous-related complications.
Results: The total cohort included 122 women (56%) and 95 men (44%), with a mean age of 60 years at surgery and a mean duration of pain of 79 months. In 216 out of 217 patients, the pain improved, and 213 were pain-free. Operative findings included an arterial conflict in 187 patients (86%), a venous conflict in 91 patients (42%), and arachnoid adhesions in 149 patients (68%). Three patients in the SPV-division group had a possibly venous-related complication: 1) asymptomatic small cerebellar hemorrhage, which was managed conservatively, 2) transient mild ataxia associated with a small infarct in the dorsolateral pons, and 3) transient mild ataxia due to an intracerebellar hemorrhage. There was no statistical difference in the overall complication rate between the groups.
Conclusions: This study suggests that our approach of dividing the SPV at its main trunk while maintaining venous cross flow through its contributory veins is a safe strategy during MVD for TN. This approach improves visualization of the operative field without significantly increasing the risk of the dreaded venous-related complications, as previously reported in the literature.
Filipe WOLFF FERNANDES (Hannover, Germany), Joachim Kurt KRAUSS
|
15:30-16:30
Added to your list of favorites
Deleted from your list of favorites
C28
PARALLEL SESSION 6
Epilepsy Surgery 1
PARALLEL SESSION 6
Epilepsy Surgery 1
Chairpersons:
Robert GROSS (Neurosurgeon, MD/PhD Dir, eNTICE Chair, SOM Faculty) (Chairperson, Atlanta, USA), Anna KELEMEN (Head of epilepsy department) (Chairperson, Budapest, Hungary), Dirk VAN ROOST (Consultant) (Chairperson, Ghent, Belgium)
15:30 - 15:40
#46106 - OP020 Robot-assisted MRI-guided laser therapy for temporo-parieto-occipital disconnection: initial series.
OP020 Robot-assisted MRI-guided laser therapy for temporo-parieto-occipital disconnection: initial series.
Introduction:
Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy (MRIgLITT) has shown safety and efficacy in disconnecting brain tissue, particularly in procedures like corpus callosotomy and hemispherotomy. Recently, we expanded its application to temporo-parieto-occipital (TPO) disconnection for refractory epilepsy in the posterior quadrant.
Methods:
We developed a TPO disconnection approach using 4–6 laser fibers (10 mm) to disconnect the parietal lobe from the postcentral sulcus to the splenium and ventricular atrium, along with two additional fibers to isolate the temporal lobe by ablating mesial structures and the temporal boundaries with the inferior insula. The study was approved by the Research and Ethics Committee. Using the Medtronic Visualase system and the Neuromate robotic arm, we performed ablations in a room-to-room intraoperative 1.5T Philips MRI suite. After confirming anatomical feasibility in a cadaveric model, we proceeded with clinical cases, prospectively collecting all surgical and clinical data.
Results:
We performed MRIgLITT TPO disconnections on six patients (three males, three females) aged 4–14 years (mean: 7 years). All had favorable outcomes: five achieved Engel IA/ILAE 1 status, and one achieved Engel IB/ILAE 2 status at maximum follow-up. One patient developed postoperative brain edema requiring decompressive craniectomy, leading us to adopt a staged approach for the two last cases.
Conclusion:
MRIgLITT-based TPO disconnection is a feasible and effective approach, with favorable seizure outcomes over a three-year follow-up. The primary complication was postoperative brain edema necessitating decompressive craniectomy. To mitigate this risk, a staged surgical approach is recommended for patients without porencephalic cysts or brain atrophy.
Santiago CANDELA-CANTÓ (Barcelona, Spain), Jordi MUCHART, Laia BANYULS, Alia RAMÍREZ, Cecilia FLORES, Anna WINTER, Diego CULEBRAS, Mariana ALAMAR, Victoria BECERRA, Carlos VALENCIA, Jana DOMÍNGUEZ, Javier APARICIO, Jordi RUMIÀ, José HINOJOSA
15:40 - 15:50
#46159 - OP021 Stereoelectroencephalography-guided radiofrequency-thermocoagulation - diagnostic and therapeutic results.
OP021 Stereoelectroencephalography-guided radiofrequency-thermocoagulation - diagnostic and therapeutic results.
Stereoelectroencephalography-guided radiofrequency-thermocoagulation (SEEG- RF-TC) lesions directly through the recording electrodes of SEEG. The published literature shows highly variable results across studies. At the Epilpsy center of Semmelweis University from 01. 01. 2024. to 01. 01. 2025. , from 25 SEEG recordings SEEG-RF-TC was performed in 18 patients (72%).
In this retrospective observational study we aimed to evaluate the diagnostic and therapeutic utility of RFTC at our centre, performed after localization of the epileptogenic zone.
At 3 months post-procedure 56% of patients experienced therapeutic benefit (more than 50% of seizure reduction / responders). Four patients proceeded into surgery despite being a responder. From the remaining 14 patients this effect was maintained at 6 months follow up in 50 % of patients. No patient was seizure free.
Diagnostic yield was noted in 33% of patients that means transient reduction of seizures and interictal discharges up to 4 weeks after the procedure indicating good surgery outcome. Surgery was performed in 22% of patients.
From the 6 MR negative patients 1 patient was operated within 1 month. At 3 months post procedure 50 % were responders, what was maintained at 6 months.
Eighteen % of patients did not benefit from the procedure.
Three patients experienced adverse effect, one patient a seizure during the procedure. In 2 medial temporal lobe patients increased frequency of auras was reported despite decreased habitual seizure count post SEEG-RF-TC. From 9 patients who had postprocedure neuropsychology testing, 2 had worsening in the corresponding functions.
Our results also confirm, that RFTC can be performed routinely and safely in patients with focal epilepsy guided by SEEG. It has a diagnostic yield and is an alternative therapeutic option for patients with refractory focal epilepsy.
.
Anna KELEMEN (Budapest, Hungary), Zsófia JORDÁN, Boglárka HAJNAL, Csaba BORBÉLY, Lóránd ERŐSS, László HALÁSZ, Anna SÁKOVICS, Ákos UJVÁRY
15:50 - 16:00
#46190 - OP021 Clinical Outcomes of Radiofrequency Ablation in Hypothalamic Hamartomas: Analyzing Disconnection and Volume Factors.
OP021 Clinical Outcomes of Radiofrequency Ablation in Hypothalamic Hamartomas: Analyzing Disconnection and Volume Factors.
Objective: Hypothalamic Hamartomas (HH) lead to refractory epilepsy and minimally invasive surgical approaches are standard of care for affected patients. Stereotactic radio-thermocoagulation (SRT) is one of the recognized treatment methods to achieve seizure freedom. This study reports surgical outcome from a single center reporting an ablation technique using fewer trajectories than previously reported and assessed the effect of coagulated volume on long-term seizure freedom.
Methods: Retrospective analysis of all patients that underwent SRT at a single academic center between 2016 and 2024 with a follow-up of ≥12 months. Statistical analysis of outcome dependent on type of hamartoma, seizure type, coagulation volume and epilepsy duration.
Results: 43 patients received SRT, 35 (22 children) had more than 12 months follow-up, with a median of 38 months. 9 patients had 2 and 2 patients had 3 SRTs. 12 months after their last SRT, 60% of patients were seizure free, 88.6% were free of bilateral tonic-clonic seizures (BTCS) and 77.1% free of gelastic seizures (GS) (last follow up 54.3% seizure free; 88.6% free of bilateral tonic clonic seizures; 74.3% free of gelastic seizures). There was a significant reduction of antiseizure medication (ASM) postsurgically with an average number of ASM of 2 prior and 1 after surgery. After 12 months, 14.3% of patients experienced ongoing but mostly mild surgical complications, with hypothalamic dysfunction being the most common. Coagulation volumes were higher in larger HH, but no correlation was observed between coagulated volume and seizure freedom or complication rates.
Discussion: SRT is a minimally invasive method to successfully treat refractory seizures in patients with HH. Disconnection seems to be more important for successful treatment than volume reduction. Even large HH can be treated with smaller coagulation volumes.
Peter Christoph REINACHER (Freiburg im Breisgau, Germany), Julia JACOBS, Mukesch SHAH, Theo DEMERATH, Kathrin WAGNER, Victoria SAN ANTONIO-ARCE, Horst URBACH, Volker Arnd COENEN, Andreas SCHULZE-BONHAGE, Alexandra KLOTZ
16:00 - 16:10
#47615 - OP023 Closed-Loop, Subgaleal Intersectional Short-Pulse Stimulation for the Treatment of Therapy-Resistant Epilepsy in Adults.
OP023 Closed-Loop, Subgaleal Intersectional Short-Pulse Stimulation for the Treatment of Therapy-Resistant Epilepsy in Adults.
Approximately one-third of epilepsy patients do not respond to antiseizure medications (ASMs), are not suitable candidates for curative surgical interventions, or have unsuccessful surgical therapies. Therapies for these patients are limited. The few therapies approved by the US Food and Drug Administration (FDA) include deep brain stimulation (DBS), vagus nerve stimulation (VNS), and responsive neurostimulation (RNS). However, these invasive therapies carry risks and are primarily palliative, reducing but rarely eliminating seizures. In addition, they lack adaptivity and cannot continuously monitor brain activity for extended periods nor provide closed-loop stimulation with spatiotemporal specificity. We sought to develop a minimally invasive, adaptive neuromonitoring tool combining automatic seizure detection and intersectional short-pulse (ISP) stimulation to immediately terminate pathological brain activity. We conducted an inpatient study assessing the safety, feasibility, and effectiveness of ISP stimulation delivered transcranially through subgaleal electrodes in epilepsy patients. We report that ISP stimulation reduced seizure duration by 61%, decreased the incidence of secondary generalization of the seizures, and modulated the spectral power of EEG. Thus, while the precise spatiotemporal targeting of the ISP stimulation enabled enhanced efficacy of seizure suppression, it was achieved without opening the skull. Our strategy offers an improved solution for treating ASM- and surgically-resistant epilepsy patients.
Zoltan CHADAIDE (Szeged, Hungary), Daniel FABO, Miklos SZOBOSZLAY, Livia BARCSAI, Andrea PEJIN, Balint HORVATH, Marton GOROG, Tamas FOLDI, Lili AMBRUZS, Tamas LASZLOVSZKY, Laszlo HALASZ, Marton HUSZAR-KIS, Nora FORGO, Gabor SZILAGYI, Anna KELEMEN, Zsofia JORDAN, Akos UJVARI, Anna SAKOVICS, Anita KAMONDI, Gyorgy BUZSAKI, Lorand EROSS, Antal BERENYI
16:10 - 16:15
#46107 - OP024 MRIgLITT for insular refractory epilepsy in pediatric patients: a single-center series.
OP024 MRIgLITT for insular refractory epilepsy in pediatric patients: a single-center series.
Introduction:
Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy (MRIgLITT) has emerged as a safe and effective treatment for focal epilepsy, particularly in deep-seated lesions such as insular epilepsy.
Methods:
Since 2016, we have prospectively collected data on pediatric patients treated with MRIgLITT in our Epilepsy Surgery Unit. This study presents our experience using MRIgLITT for insular epilepsy.
Results:
We performed nine MRIgLITT procedures in pediatric patients (six girls, three boys) aged 7–17 years (mean: 9 years). Lesions were located in the left insula in five cases and the right in four, including one language-dominant case (age 7). Stereo-electroencephalography (SEEG) was used in three MRI-negative cases to localize the epileptogenic zone. Suspected etiologies included focal cortical dysplasia (n=6) and low-grade tumors (n=3). In two cases, ablation was part of a staged resection.
Brain biopsies, performed in seven cases along the laser trajectory, confirmed two low-grade tumors (pleomorphic xanthoastrocytoma, ganglioglioma) and five focal cortical dysplasias. Biopsy was omitted in two cases due to prior or planned resections. Laser fiber usage varied, with two fibers in three cases, four in one case, and five in another. The mean targeting accuracy during MRIgLITT was 1.21 mm. Two patients developed transient transcortical motor aphasia and contralateral hemiparesis. At follow-up (1 month to 4 years, mean: 1.6 years), six patients were seizure-free, and three showed significant seizure reduction.
Conclusions:
Our findings support MRIgLITT as a safe and effective treatment for insular epilepsy in pediatric patients. The ability to obtain pathology during the same procedure enhances its clinical value. While long-term follow-up is needed, MRIgLITT is emerging as a preferred approach for focal insular epilepsy management.
Santiago CANDELA-CANTÓ (Barcelona, Spain), Jordi MUCHART, Cristina JOU, Mariana ALAMAR, Diego CULEBRAS, Victoria BECERRA, Carlos VALENCIA, Aleix SOLER-GARCIA, Maria Ángeles ESCOBAR, Alia RAMÍREZ, Javier APARICIO, Jordi RUMIÀ, José HINOJOSA
16:15 - 16:20
#46231 - OP025 Peri-insular transventricular limbic lobotomy: an anatomical interpretation of hemispheric disconnection surgery in adult patients.
OP025 Peri-insular transventricular limbic lobotomy: an anatomical interpretation of hemispheric disconnection surgery in adult patients.
Background:
Hemispheric disconnection surgery is an effective surgical treatment for drug-resistant hemispheric epilepsy. Although traditionally performed in pediatric populations, its application in adults remains underrepresented. The procedure includes medial temporal resection with transventricular callosotomy, medial occipital disconnection, and frontobasal disconnection. Despite its proven efficacy, the detailed surgical anatomy underlying hemispheric disconnection has not been fully elucidated.
Objective:
The limbic lobe, comprising the medial aspects of the frontal, parietal, and temporal lobes, lies strategically between the brainstem and neocortical structures. This study aims to reframe the surgical anatomy of hemispheric disconnection in adults using the concept of peri-insular transventricular limbic lobotomy, and to illustrate its clinical utility through representative cases.
Materials and Methods:
Eight adult patients (4 males; mean age 24 years, range 18–32) with intractable hemispheric epilepsy underwent peri-insular transventricular limbic lobotomy. Etiologies included infantile hemiplegia in five cases, and Sturge-Weber syndrome, post-tuberculous meningitis, and schizencephaly in the remaining three.
Results:
One patient required a ventriculoperitoneal shunt for postoperative hydrocephalus. No other major complications were observed. Seizure outcomes were excellent: seven patients remained seizure-free over a follow-up period of 21 years, and one experienced only a single breakthrough seizure. All patients retained independent ambulatory function and were capable of daily activities.
Conclusion:
These results demonstrate that peri-insular transventricular limbic lobotomy is a safe and effective treatment option for adults with hemispheric epilepsy. The term provides an anatomically precise and conceptually coherent framework for understanding what has traditionally been called peri-sylvian hemispherotomy. Broader recognition of this approach may promote its thoughtful application in adult epilepsy surgery.
Chun Kee CHUNG (Seoul, Republic of Korea), Hyun Ah KIM
16:20 - 16:25
#46265 - OP026 Neurocognitive outcome following Selective laser amygdalohypocampectomy.
OP026 Neurocognitive outcome following Selective laser amygdalohypocampectomy.
Background: Selective laser amygdalohypocampectomy (SLAH) is a minimally invasive surgical alternative for patients with drug resistant mesial temporal lobe epilepsy (TLE). This study evaluated the neuropsychological outcomes and patients' satisfaction with life and with the surgery following SLAH.
Methods: Neuropsychological evaluations were conducted pre- and post-surgery to assess visual and verbal memory, naming and verbal fluency. Clinicaly significant change was defined as a pre-to-post change of at least one standard deviation in each test separately. Subjective satisfaction was measured through post-surgery patient-reported outcomes and quality of life surveys. In addition, preoperative fMRI was performed to determine each patient's language lateralization index.
Results: Fifteen patients underwent SLAH for mesial temporal sclerosis (MTS) between 2018-2023. Pre- and post-operative neuropsychological assessments were available for twelve patients (9 left MTS, 3 right MTS). At a mean follow-up of 1.99 years (SD = 1.07) after surgery, neuropsychological outcomes showed that most patients either improved or remained stable in most cognitive domains, including delayed visual memory (10/10), delayed verbal memory (10/12), naming (9/10), and phonemic fluency (11/12). Post-operative cognitive decline was confined to a minority of patients, particularly in semantic fluency (2/10) and delayed verbal recall (2/10). Notably, higher preoperative language lateralization index (which was available in nine patients), indicating stronger left-hemisphere dominance, was significantly associated with greater post-op improvement in delayed visual memory, among L-MTS patients.
Regarding clinical outcomes, good seizure outcome (Engel class I or II) was achieved in 8/12 patients (67%); one patient experienced a worthwhile improvement (IIIA) and three patients (25%) showed no improvement. Subjective satisfaction was generally high, even in patients who did not achieve seizure freedom.
Conclusions: We present our initial results of SLAH demonstrating it is a safe and effective minimally invasive option for patients with MTS, with good post-operative cognitive outcomes.
Amir BANNER (Tel Aviv, Israel), Shani BEN-VALID, Guy GUREVITCH, Lilach GOLDSTEIN, Firas FAHOUM, Amir JANAH, Miri ATIAS, Lottem BERGMAN, Ido STRAUSS
16:25 - 16:30
#46383 - OP027 Connectivity to cortical hypometabolic regions correlates with seizure outcomes after LITT for temporal lobe epilepsy.
OP027 Connectivity to cortical hypometabolic regions correlates with seizure outcomes after LITT for temporal lobe epilepsy.
Introduction:
Laser interstitial thermal therapy (LITT) is a minimally invasive neurosurgical technique increasingly utilized for treating temporal lobe epilepsy (TLE). By targeting the amygdala and hippocampus while minimizing injury to surrounding functional tissue, LITT offers an alternative to open resection. However, post-LITT seizure outcomes vary significantly. Responders—defined as patients who are seizure-free at 1 year (ILAE Class 1)—and non-responders have similar lesion characteristics, suggesting that additional parameters may explain outcome variability. Positron emission tomography (PET) derived regions of cortical hypometabolism, have been shown to have an association with seizure onset and propagation. We aimed to explore whether differences in lesion connectivity characteristics with cortical hypometabolic regions, determined from PET scans, could explain the outcomes of LITT for TLE.
Methods:
We retrospectively studied 14 patients who underwent LITT for drug-resistant TLE. Patients were categorized into responders (ILAE Class 1 at 1 year) and non-responders. Post-operative gadolinium-enhanced MRIs were used to segment LITT lesions (Figure 1A). Preoperative T1-weighted MRI scans were segmented using FreeSurfer (Figure 1B). Lesion characteristics such as volume and percentage overlap with mesial temporal structures were determined and compared between both groups.
Preoperative PET scans were projected onto the FSaverage.symm surface. A laterality index was calculated per vertex by comparing intensity between the ipsilateral (surgical side) and contralateral cortical ribbons, generating ipsilateral cortical hypometabolism masks (Figure 1B). These were warped into standard space for tractography analysis (Figure 1C). Streamlines originating from these hypometabolic masks were tracked, and their projections onto amygdala + hippocampus voxels were quantified, generating amygdala-hippocampal intensity masks (Figure 2).
Two ratios were calculated to evaluate lesion–hypometabolism relationships:
• Voxel overlap ratio: number of high-intensity voxels (indicating strong connectivity to cortical hypometabolic regions) within the amygdala-hippocampal intensity mask that overlapped with the lesion mask, relative to high-intensity voxels outside the overlap (Figure 1C).
• Connectivity ratio: streamlines connecting the lesion mask to hypometabolic cortex, relative to streamlines from the amygdala + hippocampus masks to the same regions (Figure 1D).
Both ratios were compared between responders and non-responders.
Results:
The cohort of 14 patients had a mean epilepsy duration of 15.4 ± 8.9 years and a mean age at surgery of 49.1 ± 14.2 years; 7 patients were classified as responders (Table 1). There were no significant differences in lesion volume or in the percentage overlap with the amygdala, hippocampus, entorhinal cortex, parahippocampal gyrus, or temporal pole between the two groups (Table 2).
In contrast, significant differences emerged in connectivity metrics. Responders demonstrated a significantly higher voxel overlap ratio compared to non-responders (0.82 ± 0.41 vs 0.46 ± 0.29, p = 0.003) (Figure 3). Similarly, responders exhibited a higher connectivity ratio (0.94 ± 0.34) relative to non-responders (0.43 ± 0.18, p = 0.007). These findings suggest that greater lesion engagement with PET-defined hypometabolic cortical regions is associated with improved seizure outcomes following LITT.
Conclusions:
Consistent with prior literature, conventional lesion metrics such as volume and structural overlap with mesial temporal structures did not distinguish responders from non-responders. However, novel metrics capturing disruption of connectivity between the amygdala–hippocampus complex and PET-defined hypometabolic cortex were strongly associated with postoperative seizure freedom. These results highlight the potential utility of integrating PET-guided connectivity analyses into surgical planning to optimize LITT targeting and improve outcomes in temporal lobe epilepsy.
Hargunbir SINGH (Boston, USA), Hargunbir SINGH, Aryan WADHWA, Aaron WARREN, Zoe Angeline DARY, John ROLSTON
|
|
|
|
16:30 |
16:30-18:00
Added to your list of favorites
Deleted from your list of favorites
A29
PARALLEL SESSION 7
Movement Disorders 3
PARALLEL SESSION 7
Movement Disorders 3
Chairpersons:
Selcuk PEKER (Neurosurgeon) (Chairperson, Istanbul, Turkey), Rick SCHUURMAN (neurosurgeon) (Chairperson, Amsterdam, The Netherlands), István VALÁLIK (head of department) (Chairperson, Budapest, Hungary)
16:30 - 16:40
#45608 - OP068 Electrophysiological characterization of the microlesion effect after deep brain stimulation in patients with Parkinson’s disease.
OP068 Electrophysiological characterization of the microlesion effect after deep brain stimulation in patients with Parkinson’s disease.
Introduction: The microlesion effect after STN-DBS for Parkinson’s disease (PD) corresponds to a transient period of motor symptoms improvement after surgery, even with no stimulation being delivered. However, there are no studies probing the electrophysiological properties of this period. Recently available technology allowing continuous recording of neurophysiological activity from DBS electrodes provides an invaluable opportunity to interrogate and physiologically describe this period.
Objective: To characterize the electrophysiological signature of the microlesion effect in PD patients undergoing STN-DBS.
Methods: Using Brainsense technology, we continuously recorded local field potentials (LFPs) from 10 STN-DBS patients (20 hemispheres), from implantation day until stimulation was switched on, four weeks later. Data analysis was performed using the computational toolbox DBScope. Clinical data collected included PD phenotype, disease duration, age-of-onset and changes in MDS-UPDRS-III.
Results: Median disease duration was 11 years; pre-operative MDS-UPDRS-III score was 54.4±13.3 and preoperative LEDD was 1291±418.6 mg. Study population clearly displayed microlesion effect, with significant reductions in MDS-UPDRS-III (-11.5 points, p=0.0098 med-off pre-op vs med-off/stim-off). Average frequency used for chronic sensing was 19.48Hz (beta). Temporal evolution of beta power displayed three clearly distinct periods: early dip, during which beta power decreases sharply to its minimum at 2.8±1.8 days; plateau, during which beta power remains low, lasting 12.7±2.3 days; late recovery, during which signal magnitude stars to slowly rebound. Temporal evolution of beta power was highly correlated across hemispheres. No correlation was found between duration of plateau and clinical variables.
Conclusion: This is the first electrophysiological description of the microlesion effect with real-world, patient-derived data. The temporal window of signal rebound we describe may guide the optimal timing for initiating neurostimulation after surgery. Further analysis on the electrophysiological signatures could potentially instruct adaptive-DBS protocols that entrain the STN physiology to recapitulate and prolong the beneficial clinical state that characterizes the microlesion period.
Manuel J FERREIRA-PINTO (Porto, Portugal), Carolina SOARES, Pedro MELO, Ricardo PERES, Carolina SILVA, Manuel RITO, Paulo AGUIAR, Clara CHAMADOIRA
16:40 - 16:50
#46025 - OP069 Transcriptomic and proteomic signatures of Parkinson’s disease from DBS derived brain samples.
OP069 Transcriptomic and proteomic signatures of Parkinson’s disease from DBS derived brain samples.
The pathophysiologic processes in Parkinson's disease (PD) remain poorly understood, limiting the development of disease-modifying therapies. Human brain tissue samples offer insights into these disease processes. However, collecting such samples presents significant challenges. Fresh brain tissue is difficult to obtain and typically consists mostly of tumor cells. Postmortem samples differ significantly from fresh samples due to rapid changes in protein (Li et al., 2019) and gene expression (Dachet et al., 2021). Moreover, postmortem samples predominantly represent advanced disease stages.
In this study, we applied a method that enables the collection of brain tissue samples during deep brain stimulation (DBS) operation, without additional steps to the surgery (Kangas et al., 2022). We utilized the tissue collected from surgical instruments, namely microelectrodes and guide tubes. Microelectrodes are inserted through the guide tubes, providing region-specific data from the basal ganglia. Conversely, the guide tubes offer hemisphere-specific cross-sectional samples. Our aim was to identify transcriptomic and proteomic differences in these samples based on clinical factors.
The primary study group consisted of 21 patients with PD who underwent bilateral DBS of the subthalamic nucleus between 2018 and 2021 in Oulu University Hospital. Clinical assessments were conducted preoperatively and 12 months postoperatively using the Unified Parkinson’s Disease Rating Scale (UPDRS III) and levodopa equivalent daily dose (LEDD). The study also included samples from six patients with dystonia (two pediatric) who underwent pallidal DBS. RNA sequencing and proteomic analysis using liquid chromatography–mass spectrometry were performed on the samples (42 PD and 10 dystonia samples).
Transcriptomic and proteomic profiles were compared between PD and dystonia patients, and 148 differentially expressed genes (DEG) and 180 differentially expressed proteins (DEP) were found. These differences were associated with processes such as glycolytic pathways, calcium signaling, Rho GTPase signaling and heme metabolism. See Figure 1. Comparisons were also performed based on the clinical features of the PD patients. DEGs were found when patients were grouped based on contralateral UPDRS III score (450), age (223), disease duration (135), disease onset (204), preoperative LEDD (242), and symptom asymmetry (57). DEPs were found based on contralateral UPDRS III (10), age (68), and disease duration (3).
Overall, changes in transcriptome and proteome were found not only between the two movement disorders but also based on the clinical characteristics of PD. The collection of tissue samples using DBS-based method may enable the study of molecular mechanisms underlying neurological diseases and even find novel biomarkers for PD.
Johannes KÄHKÖLÄ (Oulu, Finland), Salla KANGAS, Maija LAHTINEN, Markku VARJOSALO, Antti TUHKALA, Kari SALOKAS, Salla KESKITALO, Reetta HINTTALA, Johanna UUSIMAA, Jani KATISKO
16:50 - 17:00
#45553 - OP070 Segregating structural connections into the subthalamic nucleus and the globus pallidum: an alternative approach to study target-specific effects from stimulation.
OP070 Segregating structural connections into the subthalamic nucleus and the globus pallidum: an alternative approach to study target-specific effects from stimulation.
Introduction: Deep brain stimulation (DBS) is an established surgical treatment for Parkinson’s disease (PD) patients whose motor fluctuations are resistant to pharmacological therapy. The two main surgical targets are the subthalamic nucleus (STN) and the globus pallidum pars interna (GPi). The literature shows that the stimulation of the two targets yields similar improvements in motor outcomes at long-term follow-ups. Nonetheless, different side effects may emerge from the stimulation of the two nuclei and a lesser reduction of levodopa medications is expected from patients undergoing GPi-DBS. Moreover, recent studies have questioned the classical tripartite subdivision of STN and Gpi into distinct anatomo-functional territories: motor, associative and limbic. Instead, a variable degree of overlap exists among the three territories. Based on this assumption, we hypothesize that structural connections are heterogeneously organized within the two target nuclei; hence, the stimulation from the implanted electrode would cover different connections even in the same location with a different clinical effect.
Methods: To prove our hypothesis, FSL probabilistic tractography was performed on 250 subjects from the Human Connectome Project (HCP) to investigate the structural connectivity of STN and GPi with 8 selected anatomic areas. For each HCP subject, the connectivity map of the two masks with each target area was determined by dividing the seed-to-target voxels within the mask by their maximal intensity value. Eight average connectivity maps representing the maximal connectivity of the two masks with the target areas were derived by averaging each map across the HCP subjects. Then, we employed the LeadDBS software to reconstruct VTAs (volumes of tissue activated) of 139 PD patients who underwent DBS at two different institutions: 73 patients who received STN-DBS at the Policlinico Hospital in Milan and 68 patients who had GPi-DBS at the University of California Los Angeles. After co-registration of the 8 connectivity maps with the patient’s T1 MRI sequence, the calculated intersection volume between the patient’s VTA and each connectivity map was compared between STN-DBS and GPi-DBS patients with MACOVA by controlling for VTA volumes. Demographic and clinical data were compared between the two patient groups with MANOVA.
Results: Statistically significant (p<0.001) greater intersection volume resulted with the connectivity maps of the hippocampus and the precentral gyrus for VTAs of STN-DBS patients and with the connectivity map of the cerebellum for VTAs of GPi-DBS patients. No differences were found in any demographic and clinical variables at one-year follow-up.
Conclusion: The heterogeneous organization of the connections inside the two nuclei may explain clinical differences resulting from the stimulation of the two targets despite a similar motor improvement.
Luigi Gianmaria REMORE (Milan, Italy), Evangelia TSOLAKI, Elena PIROLA, Antonella AMPOLLINI, Filippo COGIAMANIAN, Linda BORELLINI, Mailand ENRICO, Giovanni MARFIA, Ausaf BARI, Marco LOCATELLI
17:00 - 17:10
#46097 - OP071 Patient-specific 7 tesla mri connectivity increases effectiveness in deep brain stimulation for parkinson’s disease.
OP071 Patient-specific 7 tesla mri connectivity increases effectiveness in deep brain stimulation for parkinson’s disease.
Although magnetic resonance imaging (MRI) has been used to localize the subthalamic nucleus (STN) for deep brain stimulation (DBS) electrode lead placement in the past 20 years, individual motor improvement following DBS surgery in Parkinson’s disease (PD) remains insufficiently predictable. The effect of DBS relies on modulating brain networks, and this study reports the use of probabilistic tractography and high resolution 7-Tesla (7T) MRI to evaluate patient-specific electrode lead placement directed at the subthalamic motor network. As part of a prospective single center study, motor outcome of the first 102 PD patients undergoing DBS surgery using 7T MRI connectivity analysis (T2-weighted MRI and probabilistic tractography) is reported. For comparison, a control group of 118 PD patients undergoing 7T MRI (target determination based on anatomical landmarks on T2-weighted MRI only)-informed DBS surgery was used. For connectivity analysis, selective visualization of STN motor connectivity was performed before DBS surgery and electrode lead placement was directed at the connectivity-derived motor subdivision of the STN. Here we show significant more motor improvement after DBS compared to the group targeted based on anatomical landmarks on T2-weighted MRI only: 56±15% vs 50±20% (p=0.015), and connectivity analysis showed an increase in response rate (i.e. at least 30% improvement in motor outcome): 96% vs 86% (p=0.008). Moreover, connectivity analysis enabled subthalamic network visualization. In 85 patients (of the 102), both electrode leads were successfully placed in the motor subdivision supported with a high density of surrounding motor connectivity. This sub-analysis, comparing these 85 patients to the group targeted based on anatomical landmarks on T2-weighted MRI only (N=118), showed that electrode leads inside the motor subdivision resulted in the highest motor improvement after DBS: 60±11% vs 50±20% (p<0.001). Our results demonstrate the clinical applicability of 7T MRI probabilistic tractography for visualizing connectivity between the STN and cortical motor areas to enable electrode lead placement directed at the motor subdivision, introducing patient-specific connectivity guided DBS. This proved to be an individual biomarker for implantation location that increased the effectiveness of DBS in patients with PD.
Yarit WIGGERTS (Amsterdam, The Netherlands), Rick SCHUURMAN, Rob DE BIE, Martijn BEUDEL, Wietske VAN DER ZWAAG, Pepijn VAN DEN MUNCKHOF, Maarten BOT
17:10 - 17:20
#46128 - OP072 Evaluating longitudinal functional connectivity differences between DBS ON/OFF states in Essential Tremor.
OP072 Evaluating longitudinal functional connectivity differences between DBS ON/OFF states in Essential Tremor.
Objectives: Deep brain stimulation (DBS) targeting the ventral intermediate (Vim) nucleus of the thalamus is an effective treatment for essential tremor (ET). Yet, it remains unclear which functional connections (FC) are most influential in impacting tremor control and/or concomitant gait ataxia. We studied ET patients undergoing DBS to a major input/output tract of the Vim, the dentato-rubro-thalamic tract (DRTt), using resting state functional MRI (rsfMRI) to evaluate connectivity differences between significant regions.
Methods: We enrolled nineteen ET patients who were undergoing DRTt DBS as part of our NIH R01#NS113893 protocol. Anatomical/functional 1.5T MRIs were acquired pre-operatively and then replicated at two years post-surgery with DBS ON, and then turned OFF to acquire MRIs at 0, 24h, and 72h with DBS OFF. Tremor severity using The Essential Tremor Rating and Assessment Scale (TETRAS) and gait ataxia severity using the Scale for Assessment and Rating of Ataxia (SARA, items 1-3) was scored pre-operatively with DBS ON at optimal stimulation parameters and at each DBS OFF timepoint. Regions of interest (ROI) were pre-defined as the bilateral Vim thalamus, pre-central gyrus, superior and inferior parietal lobules (SPL/IPL), dentate nucleus (DN), and cerebellar nodule. Connection strength between each of the 11 ROIs was measured using z-scores of correlation coefficient differences between DBS ON/OFF and correspondent p-value computed by using Fisher’s method, which represents change on individual level. Effect of DBS treatment at group level was measured by averaging z-scores over all 19 patients between each ROI. Subgroups of patients with higher SARA scores were also compared.
Results: All 19 patients had significant differences in tremor between pre-op/DBS ON/OFF states (p<0.001). Group analysis of all patients revealed that there were both significant increases and decreases in FC with DBS ON relative to pre-op (z-score=3) between cortical ROIs and cerebellum which changed over the 72h OFF period. At 72h OFF, despite tremor and ataxia return to pre-op levels, there was observed to be increased FC relative to pre-op (z=4). Overall, patients with greater pre-operative ataxia had significantly increased functional connectivity between multiple ROIs, including DN and cerebellar nodule, when DBS was ON compared to pre-op (z-score>4), which increased over the next 72h OFF.
Conclusions: Stimulation of the DRTt and concordant improvement of tremor and ataxia resulted in connectivity changes seen in multiple regions outside the motor network thought to be involved with tremor pathology. Such functional engagement of the SPL/IPL in tremor and cerebellum in ataxia, when combined with both structural and electrophysiologic connectivity, may help serve as a biomarker to improve DBS targeting and possibly predict outcome. In all ET patients, FC increases over time as a function of the disease process. DBS decreases FC concomitant with improved tremor, but can either improve or worsen ataxia, possibly based on pre-existing FC. Ataxia is associated with increased FC between cortical ROIs and cerebellum.
Albert FENOY (Great Neck, USA), Z. David CHU, Stephen KRALIK
17:20 - 17:30
#46171 - OP073 Model-based personalization of deep brain stimulation in Parkinson’s disease using Neural Field Theory.
OP073 Model-based personalization of deep brain stimulation in Parkinson’s disease using Neural Field Theory.
Deep Brain Stimulation (DBS) is an established neurosurgical therapy for alleviating motor symptoms in advanced Parkinson’s disease (PD). However, the selection of stimulation parameters currently relies on empirical, trial-and-error approaches, often leading to suboptimal outcomes and prolonged calibration periods. Present attempts at adaptive DBS rely on the detection of specific neural signatures to elicit stimulation, but do not adjust stimulation parameters according to neural activity. This study introduces a computational approach based on Neural Field Theory to derive both effective patient-specific DBS parameters, and DBS waveforms aimed at restoring healthy-like neural activity patterns in PD patients.
We employed a neural field model of the cortico-thalamo-basal ganglia circuit to characterize the neural dynamics of PD patients and simulate their electrophysiological activity. Simultaneous scalp EEG and subthalamic nucleus (STN) local field potential (LFP) recordings were obtained from 13 PD patients implanted with Percept neurostimulators (Medtronic). Data was collected during 70 resting-state sessions (35 eyes-open and 35 eyes-closed), all conducted under medication-off and DBS-off conditions. For each session, we jointly fitted the model to both EEG and LFP data, enabling personalized estimation of the underlying neural mechanisms and their responsiveness to external stimulation.
From the fitted models, we analytically derived DBS stimulation frequencies that selectively suppress pathological beta oscillations in the STN, a hallmark of PD. The resulting frequencies closely matched those empirically selected by clinicians. Furthermore, we computed stimulation waveforms that reshape the STN power spectrum to closely resemble that of healthy individuals. These personalized signals have the potential to more comprehensively normalize brain activity and improve symptom relief beyond traditional stimulation paradigms.
The proposed method enables automatic optimization of DBS parameters, significantly reducing clinician workload and calibration time. Moreover, while further clinical validation and refinement are necessary, this approach holds promise for enhancing therapeutic outcomes by applying stimulation signals that promote healthy neural function in PD patients. Finally, the personalized models serve as generative tools for EEG and LFP data, capable of replicating PD-specific dynamics, and offer a valuable framework for in-silico experimentation and hypothesis testing.
Daniel POLYAKOV (Tel Aviv, Israel), Ron MONTEORIANO, Zoya KATZIR, Firas FAHOUM, Inbal MAIDAN, Ido STRAUSS, Genela MORRIS
17:30 - 17:40
#48033 - OP074 Longitudinal Structural Connectivity Changes Following Thalamotomy in Parkinson’s Disease: A DRTC Tractography Study.
OP074 Longitudinal Structural Connectivity Changes Following Thalamotomy in Parkinson’s Disease: A DRTC Tractography Study.
Background: Parkinson’s Disease (PD) is characterized by progressive motor dysfunctions—tremor, rigidity, bradykinesia—and non‐motor symptoms. Thalamotomy, Subthalamotomy and Pallidotomy targeting nuclei such as VIM, STN or GPi, is an established ablative surgery to alleviate refractory tremor. However, longitudinal white‐matter changes underlying clinical improvement remain poorly understood.
Methods: Twenty PD patients (age 37–82 years) underwent unilateral or bilateral thalamotomy between 2021–2023. Diffusion‐weighted imaging (DWI) was acquired pre‐ and 4 months post‐surgery. After preprocessing with FreeSurfer, FSL, ANTs and AFNI, MRtrix we performed DRTC tractography. FA was sampled along the DRTC length to compare operated vs. non‐operated thalami, and correlate changes with clinical scores (MDS‐UPDRS, quality of life, executive function).
Results: Post‐thalamotomy FA significantly increased in the operated thalamus compared to baseline (p < 0.05). Improvements in tremor, rigidity and bradykinesia-dominant scores paralleled FA normalization.
Conclusion: Thalamotomy induces measurable white‐matter reorganization along the DRTC pathway that correlates with motor and non‐motor improvements in PD. DRTC tractography and FA provide objective biomarkers for monitoring surgical efficacy and guiding target selection.
Mohammad-Hossein H.K. NILI, Shahrzad M. ESFAHAN, Abolhassan Ertiaei ERTIAEI (Tehran, Islamic Republic of Iran), Mohammad SHIRANI, Ehsan REZAYAT, Mohammad-Reza A. DEHAQANI, Abdol-Hossein VAHABIE
17:40 - 17:45
#48023 - OP075 Structural MRI predictors of early clinical response to STN-DBS in Parkinson’s disease: The role of limbic and prefrontal circuits.
OP075 Structural MRI predictors of early clinical response to STN-DBS in Parkinson’s disease: The role of limbic and prefrontal circuits.
Background: Subthalamic nucleus deep brain stimulation (STN-DBS) is effective for treating motor symptoms in advanced Parkinson’s disease (PD), but clinical outcomes vary. This study aimed to identify structural brain volume correlates of early postoperative clinical response, focusing on limbic and prefrontal regions hypothesized to contribute to motor-cognitive integration. We also explored whether postoperative axial symptom emergence could be predicted by anatomical features, and whether systemic laboratory parameters were associated with brain volume changes in PD.
Methods: Sixty PD patients with no cognitive complaints and a Mini-Mental State Examination score ≥27 underwent bilateral STN-DBS. Motor symptoms were assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS) part III preoperatively and approximately one month postoperatively. Patients were grouped by clinical response (≥33% vs. <33% total UPDRS improvement) and by the emergence of postoperative axial symptoms (speech/gait disturbance). Anatomical data were processed with FreeSurfer (v7.3.2), extracting volumes from 68 cortical and 122 subcortical regions including hippocampal, amygdalar, thalamic subfields, and basal ganglia. Volumes were normalized to intracranial volume. Correlation and group analyses were performed in R (v4.4.3), with false discovery rate (FDR) correction (p < 0.05). Associations with preoperative serum creatinine, GFR, glucose, and HbA1c were also explored.
Results: Preoperatively, motor severity significantly correlated with volumes of limbic (pulvinar, entorhinal cortex, parasubiculum) and prefrontal regions (pars orbitalis, frontal pole). Higher preoperative LEDD was associated with reduced left caudate and pars opercularis volumes. Glucose, HbA1c and creatinine levels correlated negatively with amygdalar, hippocampal, orbitofrontal, and basal ganglia volumes. Early postoperative motor improvement correlated positively with volumes of the fimbria, superior frontal gyrus, middle temporal gyrus, insula, thalamic nuclei, parahippocampal gyrus, and amygdala. Improvement in axial subscores was associated with the volumes of the fimbria, pars orbitalis, frontal pole, middle temporal gyrus, insula, and hippocampal tail. Good responders had significantly larger right superior frontal volumes. Postoperative axial symptoms were more frequent in patients with smaller volumes of left superior temporal sulcus.
Conclusion: Our findings suggest that early DBS response depends not only on basal ganglia circuits but also on the integrity of limbic and prefrontal systems. Hippocampal and fimbrial volumes were especially predictive of global and axial outcomes. Superior frontal gyrus volume differentiated good responders, potentially reflecting structural reserve. Postoperative axial symptom development was associated with temporal and hippocampal atrophy, offering a potential imaging marker for motor-cognitive vulnerability. Systemic markers such as HbA1c and creatinine also reflected widespread brain atrophy.These findings support structural MRI as a tool for predicting individualized DBS outcomes and vulnerability to axial decline.
Yavuz SAMANCI (Istanbul, Turkey), Ulas AY, Lara KARSIGIL, Bedia SAMANCI, Gulay KENANGIL, Ali ZIRH
17:45 - 17:50
#47677 - OP076 7 Tesla MRI thalamic motor connectivity as patient-specific target for DBS in essential tremor.
OP076 7 Tesla MRI thalamic motor connectivity as patient-specific target for DBS in essential tremor.
Background
The effect of deep brain stimulation (DBS) in essential tremor (ET) results from modulating the malfunctioning cerebello-thalamic motor network. The anatomical targets for DBS lead placement are the ventral intermediate nucleus (VIM) of the thalamus and the posterior subthalamic area (PSA); situated alongside the course of the dentato-thalamic tract (DTT). However, which target enables highest tremor control and least cerebellar side effects is currently not clear. This study uses patient-specific 7 Tesla (7T) MRI connectivity analysis for cerebello-thalamic motor network visualization and provides a target area that increased effectiveness in DBS for ET.
Methods
Tremor improvement (TETRAS performance subscale 6 months postoperative), cerebellar side effect (SARA) and implantation/stimulation location of 37 ET patients (representing 74 lead placements) are reported. Successful tremor control was considered a score <2. The patient-specific (T2, FGATIR, probabilistic tractography) motor thalamus, sensory thalamus, pre-motor thalamus and the (crossing) DTT was visualized with 7T MRI connectivity analysis. In 25 patients, ‘standard MR-landmarks group’ (May 2019 - January 2024), 7T MRI connectivity analysis was performed postoperative, obtaining insight in DBS location and programming. In 12 patients (from April 2024 onwards) connectivity analysis was performed before surgery; ‘connectivity analysis group’.
Results
Average TETRAS improvement was 50% for the standard MR-landmarks group and 63% for the connectivity analysis group. An optimal stimulation location, showing most tremor control and minimal cerebellar side effects, was identified using 7T MRI connectivity analysis; the overlapping area between the motor thalamus and DTT, consistently located in the lateral rubral wing on FGATIR. This part can be considered the ‘connectivity derived VIM’. In the standard MR-landmarks group, 12 patients showed suboptimal tremor control and connectivity analysis showed active contacts mainly located in the DTT. Selecting a contact located in both motor thalamus and DTT improved tremor control and reduced side effects. Upper limb tremor control was successful in 62% of contralateral assessments in the MR-landmarks group, and in 81% in the connectivity analysis group. For the connectivity analysis group, no cerebellar side effects that led to disabilities in daily living were noted, with an average SARA score of 3.
Conclusion
Our results demonstrate clinical applicability of 7T MRI probabilistic tractography for visualizing connectivity between cerebellum, thalamus and cortical motor areas to enable lead placement directed at the overlapping area of DTT and motor thalamus. This proved to be a patient-specific target area that can further increase effectiveness of DBS in patients with ET.
Sterre JOOR (Amsterdam, The Netherlands), Rob DE BIE, Pepijn VAN DEN MUNCKHOF, Rick SCHUURMAN, Yarit WIGGERTS, Wietske VAN DER ZWAAG, Arthur BUIJINK, Maarten BOT
17:50 - 17:55
#48026 - OP077 Brain network analysis using 7-Tesla MRI and magnetoencephalography for deep brain stimulation.
OP077 Brain network analysis using 7-Tesla MRI and magnetoencephalography for deep brain stimulation.
Background
The effect of deep brain stimulation (DBS) in Parkinson’s disease (PD) relies on the modulation of malfunctioning motor brain networks, by delivering electrical pulses into deeply situated brain nuclei. To further understand and improve DBS effect, more accurate and patient-specific visualization of the motor network is obtained by using both structural 7 Tesla (7T) Magnetic Resonance Imaging (MRI) and functional magnetoencephalography (MEG). In the current study both techniques are combined; 7T MRI visualizes the anatomical connectivity of the subthalamic nucleus (STN), and MEG records the neuromodulatory effects of DBS.
Methods
As part of a prospective single center study, initial results of 7T MRI subthalamic probabilistic tractography (connectivity analysis), MEG analysis and motor outcome of the first 15 PD patients (30 leads) are reported. Before DBS surgery, selective visualization of STN motor connectivity was performed by combining T2 and diffusion weighted 7T MRI, and lead placement was directed at the connectivity-derived motor subdivision. After the 6 months postoperative (MDS-UPDRS III) assessment, MEG recordings were performed for each active DBS contact point selected for chronic stimulation, and during DBS OFF. Neuronal activity for all cortical regions in the Brainnetome Atlas was reconstructed using a beamformer. Average relative power in the cortical motor areas (left and right M1/SMA) between the DBS ON and DBS OFF condition were compared. The result showed the location of the active DBS contact relative to the motor subdivision and the induced change of power in the frequency bands on the cortical (motor) areas.
Results
Here we show significant decreases in the beta frequency band ( t(14)= 2.1, p= .05) in the contralateral cortical motor areas, induced by the active 6 months follow up DBS programming compared to DBS OFF. The relative power in the alpha1 and 2 bands increased due to DBS (t(14)= -2.1, p= .05 and t(14)= -2.5, p= .03). Active DBS contacts were located in the motor subdivision and resulted in 61% MDS-UPDRS III improvement.
Conclusion
Our results demonstrate the feasibility of combining 7T MRI and MEG analyses in DBS; visualizing connectivity between the STN and cortical motor areas together with the modulatory effect on these areas. Stimulation in the motor subdivision reduced pathological beta activity in the cortical motor areas. The combination of these high resolution structural and functional imaging offer insight in the mechanistic effect of DBS and can expectantly be used to further optimize DBS through patient-specific network guided programming.
Lisa VERLAAT (Amsterdam, The Netherlands), Sterre JOOR, Laura HAMMINGA, Michaela GÚČIKOVÁ, Arjan HILLEBRAND, Rick SCHUURMAN, Rob DE BIE, Martijn BEUDEL, Wietske VAN DER ZWAAG, Pepijn VAN DEN MUNCKHOF, Maarten BOT
|
16:30-17:30
Added to your list of favorites
Deleted from your list of favorites
B29
PARALLEL SESSION 8
Spasticity
PARALLEL SESSION 8
Spasticity
Chairpersons:
Felix-Mircea BREHAR (Associated Professor) (Chairperson, Bucharest, Romania), Markia BALAZS (Chairperson, Hungary), Patrick MERTENS (Head of the department) (Chairperson, LYON, France)
16:30 - 16:40
#45891 - OP159 Selective dorsal rhizotomy after baclofen intrathecal pump removal: a single center experience and review of the literature.
OP159 Selective dorsal rhizotomy after baclofen intrathecal pump removal: a single center experience and review of the literature.
PURPOSE
Selective dorsal rhizotomy (SDR) and intrathecal baclofen (ITB) pump placement are two surgical options in children affected by spasticity secondary to cerebral palsy1. The latest literature is enlarging indication for SDR, given the amelioration in residual motor functions and helping everyday patients’ management and care.
In case of ITB failure in non-ambulant patients, SDR represents an alternative to pump reimplantation to reduce spasticity and to facilitate patients’ care.
METHODS
A retrospective single-center study has screened all children diagnosed with spastic tetraparesis who underwent in the last 10 years SDR and had previously ITB pump implanted. A cohort of 6 patients was pooled out. Furthermore, pertinent literature has been reviewed.
RESULTS
Indication for pump removal was pump pocket’s infection, parents’ decision, poor response to ITB.
Patients’ amount of lifetime with the pump implanted has been 6,9 years. It was statistically different the preoperative and postoperative Ashworth score in both procedures (p=0,005 and p=0,02).
CONCLUSIONS
Only 2 studies investigated pediatric population undergone SDR in occurrence of ITB pump removal.
Authors are giving indication to SDR to a larger number of patinets, regardless GMFCS groups and previous ITB pump placement.
In conclusion, SDR represents a valid tool in neurosurgeon’s hand to help ameliorating patients’ long-lasting quality of life, reducing the severity of the spasticity and leading to a better management by caregivers.
Claudio RUGGIERO (Napoli, Italy), Massimiliano PORZIO, Giuseppe MIRONE, Francesco TENGATTINI, Pietro SPENNATO, Giuseppe CINALLI
16:40 - 16:50
#45993 - OP160 Long-term outcome of selective tibial neurotomy for the treatment of the spastic foot.
OP160 Long-term outcome of selective tibial neurotomy for the treatment of the spastic foot.
Objective: To evaluate the long-term effectiveness of selective tibial neurotomy (STN) for the treatment of the spastic foot using a goal-centered approach.
Methods: Between 2011 and 2018, adult patients with a spastic foot (regardless of etiology), who received STN followed by a rehabilitation program were included. The primary outcome was the achievement of individual goals defined preoperatively (T0) and compared at 1-year (T1) and 5-year (T5) follow-up, using the Goal Attainment Scaling methodology (T-score). The secondary outcomes were the presence of spastic deformities (equinus, varus, and claw toes), the modified Ashworth scale (MAS) in the targeted muscles, and the modified Rankin score (mRS) at T0, T1 and T5.
Results: Eighty-eight patients were included. At T5, 88.7% of patients had achieved their goals at least “as expected”. The mean T-score was significantly higher at T1 (62.5 ± 9.5) and T5 (60.6 ± 11.3) than at T0 (37.9 ± 2.8, p< 0.0001), and was not significantly different between T1 and T5 (p = 0.2). Compared to T0, deformities (equinus, varus, and claw toes, p< 0.0001), MAS (p< 0.0001), and the mRS (p< 0.0001) were significantly improved at T1 and T5. Compared to T1, only MAS increased slightly at T5 (p = 0.05) but remained largely below the preoperative value. There was no difference between T1 and T5 regarding other clinical parameters (deformities, walking abilities, mRS).
Conclusion: This study found that STN associated with a postoperative rehabilitation program can enable patients to successfully achieve personal goals that are sustained within a 5-year follow-up period.
Corentin DAULEAC (Lyon), Jacques LUAUTE, Rode GILLES, Marc SINDOU, Patrick MERTENS
16:50 - 17:00
#45988 - OP162 Deep brain stimulation of the medial geniculate body for refractory tinnitus: a feasibility study.
OP162 Deep brain stimulation of the medial geniculate body for refractory tinnitus: a feasibility study.
Background
Tinnitus disorder, can lead to impaired quality of life and psychological suffering, especially when refractory to standard care. Deep brain stimulation (DBS) of the medial geniculate body (MGB) is a potential treatment for severe tinnitus by attenuation of pathological neuronal activity in the central auditory pathway. The aim of this pilot study is to assess the safety and feasibility of bilateral MGB DBS in patients with refractory tinnitus disorder.
Methods
This double-blind 2 × 2 cross-over study was conducted at Maastricht University Medical Centre, Maastricht, the Netherlands. Included patients had treatment refractory, severe and chronic tinnitus without an anatomical cause. Patients with bilateral MGB DBS were randomised to ON-OFF or OFF-ON as stimulation order for two cross-over phases. Primary outcome consisted of safety and feasibility. Secondary outcome on tinnitus severity, psychiatric and cognitive functioning and quality of life was assessed at screening, after both cross-over phases and at one-year follow-up.
Results
Four patients were included. No irreversible stimulation-induced side effects occurred. Surgical-related side effects were transient and resolved within two weeks. All patients experienced DBS as an acceptable treatment. Three of four patients showed improvement of tinnitus on the Tinnitus Functional Index. In the non-responder electrodes had the largest distance from the centre of the MGB.
Conclusions
This study shows that bilateral MGB DBS is safe and feasible for patients with refractory tinnitus. Findings suggest a potential of clinically meaningful reduction in tinnitus burden. However, effectiveness needs to be evaluated in a follow-up study.
Shabnam BABAKRY (Maastricht, The Netherlands), Jana DEVOS, Catharine HELLINGMAN, Linda ACKERMANS, Jasper SMIT, Michelle MOEREL, Carsten LEUE, Annelien DUITS, Yasin TEMEL, Marcus JANSSEN
17:00 - 17:10
#45994 - OP163 Preoperative Disability as a Predictor of Goal Attainment Failure after Selective Tibial Neurotomy and Rehabilitation.
OP163 Preoperative Disability as a Predictor of Goal Attainment Failure after Selective Tibial Neurotomy and Rehabilitation.
Background: Studies assessing the effectiveness of selective tibial neurotomy (STN) assume that the procedure combined with a rehabilitation program, reduces foot spasticity and allows the achievement of personal goals. However, few studies reported failures in goal attainment, or spasticity recurrence, and no predictive factors have been established.
Objectives: To identify predictors associated with the failure to achieve personal goals after STN and rehabilitation program.
Methods: Eighty-eight adult patients with spastic foot, irrespective of the etiology, who underwent STN followed by rehabilitation program were included. Personal goals were assessed using the Goal Attainment Scaling methodology, with T-score calculated up to a 5-year follow-up. Spasticity recurrence was defined as a worsening of spasticity according to the modified Ashworth scale compared to the clinical status one year after STN. Clinical characteristics were analyzed to identify independent predictors, which were then confirmed using a logistic regression model.
Results: At the 5-year follow-up, 10 patients (11.4%) had a T-score< 50. Logistic regression identified the degree of preoperative disability (modified Rankin Scale ≥ 3, p = 0.003) as the only significant predictor of failure to achieve personal goals was. Spasticity-free survival was significantly higher in patients who had achieved their goals at least as expected (p < 0.0005), suggesting a strong relationship between long-term functional gains and the sustained spasticity reduction.
Conclusion: Failure to achieve personal goals after STN and rehabilitation program is rare. However, greater preoperative disability was identified as a predictor of goal attainment failure over time.
Corentin DAULEAC (Lyon), Jacques LUAUTE, Rode GILLES, Patrick MERTENS
17:10 - 17:15
#46281 - OP164 Dentato-rubro-thalamic tract stimulation for post-stroke spasticity: a case report.
OP164 Dentato-rubro-thalamic tract stimulation for post-stroke spasticity: a case report.
Introduction: Post-stroke motor disability remains a major challenge, with limited long-term efficacy of current rehabilitation strategies. This case report explores the potential role of deep brain stimulation (DBS) of the dentato-rubro-thalamic tract (DRTT) in reducing spasticity and improving motor function in a chronic stroke patient.
Methods: A 56-year-old man with spastic hemiplegia and foot dystonia following a right hemispheric ischemic stroke in 2020 was treated with left-sided DRTT- cerebellar DBS after 3 years of unsuccessful botulinum toxin therapy and intensive rehabilitation. Preoperative assessments included Modified Ashworth Scale (MAS), Fugl-Meyer Assessment (FMA), Modified Rankin Scale (mRS), and Chedoke Arm and Hand Activity Inventory (CAHAI). A Medtronic DBS system was implanted targeting the left dentate nucleus.
Results: Initial stimulation (130 Hz, 2.2 mA) combined with 6 weeks of rehabilitation resulted in reduced spasticity (MAS scores improved from 3–4 to 2–3), and gains in FMA (from 18 to 24) and CAHAI (from 44 to 49). Following frequency adjustment to 70 Hz and continued rehabilitation, further improvements were observed: FMA increased to 26, CAHAI to 50, and wrist MAS decreased to 3. Muscle mass gain in the biceps brachii and improved gait were also noted.
Conclusion: DRTT-cerebellar DBS may offer a promising adjunctive therapy for post-stroke spasticity, particularly in cases resistant to conventional treatments. Further studies are needed to evaluate its efficacy and long-term outcomes.
Paweł SOKAL (Bydgoszcz, Poland), Magdalena JABŁOŃSKA, Milena ŚWITOŃSKA
17:15 - 17:20
#45240 - OP165 Anterior Inferior Cerebellar Artery vascular loop in Internal Auditory Canal – Clinical presentation, operative technique and surgical outcomes.
OP165 Anterior Inferior Cerebellar Artery vascular loop in Internal Auditory Canal – Clinical presentation, operative technique and surgical outcomes.
Introduction: Anterior inferior cerebellar artery (AICA) vascular loops extending into internal auditory canal (IAC) are rare source of audio-vestibular symptoms and hemifacial spasms. There has been a controversary surrounding the clinical significance of AICA vascular loops into IAC. Here, we present our experience in 4 patients who presented with symptoms of cranial nerve 7 and 8 compression from AICA vascular loops.
Method: A retrospective analysis of cases performed in last 6 months since starting first post-fellowship faculty position were reviewed and patients were identified with AICA vascular loops extending into IAC. Clinical presentations and surgical outcomes were reviewed. AICA vascular loops were graded based on previously established grades: 1) grade 1 – lying only in cerebellopontine angle but not entering IAC, 2) grade II – entering IAC but less than 50%, 3) grade III – extending more than 50% into the IAC.
Results: 4 patients were identified with AICA vascular loops extending into IAC. 75% were female, aged ranging from 28 – 77yrs. 75% had grade II loops. Most common symptoms were tinnitus and vertigo which were present in all patients, followed by hemifacial spasm (HFS) in 75% and hearing loss in 25%. All patients had failed medical management and referred by our neurology colleagues. All patients underwent endoscopic assisted retrosigmoid craniotomy for microvascular decompression. AICA loops were identified ventral to the 7/8 complex. Arachnoid dissection was performed. Loops were gently retracted out of IAC and secured with Teflon pledges. The loops are tethered through the labyrinthine artery originating at the tip of the loop. The loops tend to recoil back into the IAC and should carefully be monitored with Valsalva maneuvers to ensure they remain in place. All patient noted complete resolution of tinnitus and vertigo, HFS resolved in 1 (33%) and improved in (67%). Most common complication was transient hearing loss (50%). Hearing loss happened in a delayed fashion in 3-4 weeks and started noting improvement over 2 months.
Conclusion: AICA loops extending into IAC are rare causes of audio-vestibular symptoms and HFS. These patients should be carefully evaluated in conjunction with neurology and radiographic findings closely reviewed. Neurophysiological monitoring should be used in all cases. Vascular loops should be carefully handled, making sure not avulse labyrinthine artery originating from the vascular loop. These patients respond very favorably to surgical management.
Salman ALI (Augusta, USA), Fernando VALE
17:20 - 17:25
#46086 - OP161 Surgical Approaches to Spasticity: A 70-Year Bibliometric Analysis of Scientific Trends, Influential Contributors, and Emerging Themes.
OP161 Surgical Approaches to Spasticity: A 70-Year Bibliometric Analysis of Scientific Trends, Influential Contributors, and Emerging Themes.
Spasticity is a complex neurological disorder that arises from upper motor neuron lesions and manifests as involuntary muscle overactivity, leading to impaired motor control, posture, and functional independence. It is commonly associated with cerebral palsy (CP), spinal cord injury (SCI), stroke, multiple sclerosis (MS), and traumatic brain injury (TBI). While conservative treatments such as oral medications, botulinum toxin injections, and physiotherapy remain first-line, a significant subset of patients with refractory or severe spasticity benefit from surgical interventions. These target either neural circuitry (e.g., intrathecal baclofen [ITB], selective dorsal rhizotomy [SDR], spinal cord stimulation [SCS], neurotomy) or secondary soft tissue changes (orthopedic procedures).
This study aimed to analyze the historical evolution, scientific impact, and thematic development of neurosurgical techniques for spasticity through bibliometric analysis. We conducted a structured search of the Scopus database on March 1, 2025, using terms “surg* AND spastic*” and “spinal cord stimulation AND spastic*”, including only articles focused on human subjects and published in English. From 2362 initial records, 1049 documents (1951–2024) were selected, comprising 927 original articles and 110 reviews, involving 3229 unique authors across 318 publication sources. Bibliometric analysis and visualization were performed using Bibliometrix, VOSviewer, and Scimagographica.
Scientific production showed exponential growth, particularly from the 1990s, with a peak in 2023. While the global citation average has declined in recent years—likely due to publication volume increase and citation lag—key studies remain highly influential. Most-cited papers include those by Coffey et al. (1993) and Albright et al. (2003), which established ITB therapy as a cornerstone in diffuse spasticity management. Similarly, literature by Peacock et al. and Park et al. established SDR as a safe and effective option, particularly in pediatric CP.
In the neurosurgical subgroup, SDR was the most reported intervention (n=171, 35.9%), followed by ITB (n=99, 20.8%) and neurotomy (n=67, 14.1%). More recent publications explore nerve transfer techniques (e.g., Zheng et al., NEJM 2022), suggesting future directions toward reconstructive strategies.
Geographically, the United States has historically dominated this field, with 744 publications, followed by China (313), France (258), and the United Kingdom (145). Notably, China has shown a marked increase in output since 2018. Fudan University (Shanghai) was the most prolific institution (83 publications), followed by the University of Lyon and VU Medical Center Amsterdam. Author analysis identified Sindou M (France) as the leading neurosurgical contributor with 42 publications, influential for his work on rhizotomy and neuromodulation. Keenan MA and Miller F led in orthopedic contributions, underscoring the multidisciplinary nature of spasticity surgery.
Keyword co-occurrence and thematic mapping revealed “spasticity” and “cerebral palsy” as central themes. Six keyword clusters were identified: 1) surgical treatment of spasticity, 2) neuromodulation and rehabilitation, 3) peripheral nerve techniques including neurotomy, 4) SDR and intraoperative monitoring, 5) nerve transfer, and 6) spinal cord management with ITB. Emerging topics such as contralateral cervical nerve transfer were categorized as niche, indicating novelty and limited current integration into clinical practice.
Thematic mapping identified “selective neurectomy” and “SDR” as motor themes—both highly developed and central. Conversely, “contralateral seventh cervical nerve transfer” represented a promising but underexplored area. Overall, neurosurgical journals such as Child’s Nervous System, Journal of Neurosurgery, and Neurosurgery featured prominently, demonstrating the high quality and impact of neurosurgical contributions.
This analysis highlights the dynamic and expanding landscape of neurosurgical strategies for spasticity. It underscores the dominance of SDR and ITB over the decades while revealing a growing interest in advanced neuromodulation and nerve reconstructive procedures. The study also emphasizes the crucial role of interdisciplinary collaboration and suggests underutilized research avenues ripe for exploration.
Giorgio MANTOVANI (Ferrara, Italy), Corentin DAULEAC, Patrick MERTENS
|
16:30-17:30
Added to your list of favorites
Deleted from your list of favorites
C29
PARALLEL SESSION 9
Rehabilitation
PARALLEL SESSION 9
Rehabilitation
Chairpersons:
Jocelyne BLOCH (Médecin Cadre) (Chairperson, Lausanne, Switzerland), Marina RAGUZ (M.D. Ph.D. Neurosurgeon) (Chairperson, Zagreb, Croatia)
16:30 - 16:40
#45704 - OP099 Central thalamic deep brain stimulation for persistent minimally conscious state: too little, too late?
OP099 Central thalamic deep brain stimulation for persistent minimally conscious state: too little, too late?
Disorders of consciousness (DOC) such as the unresponsive wakefulness syndrome (UWS, previously named vegetative state) and the minimally conscious state (MCS) are the worst outcomes of acquired brain injury. To explore whether deep brain stimulation (DBS) of the thalamus can improve the level of consciousness in persistently affected patients, we started a N=6 pilot trial in 2017, employing bilateral DBS of the centromedian-parafascicular complex of the thalamus in MCS patients who were >2 years after traumatic brain injury. Because of low prevalence of patients with persistent DOC in the Netherlands, thus far only 4 patients were included. In all 4 patients, low frequency DBS (30 Hz, 450 microseconds) caused direct arousal effects, including wider opening of the eyes, raising of the otherwise flexed head, a more upright posture in the wheelchair and (in most patients) more active visual pursuit. However, no improvement in the level of consciousness was noted (as measured with the Coma Recovery Scale Revised). Furthermore, 3 out of 4 patients died of DOC-related complications (such as recurrent pneumonia) in the first year after DBS. Based on these preliminary findings, we tend to conclude that DBS is not able to improve the level of consciousness in late-stage MCS patients.
Hisse ARNTS, Berno OVERBEEK, Arjan HILLEBRAND, Jan BOOIJ, Rick SCHUURMAN, Willemijn VAN ERP, Jan LAVRIJSEN, Pepijn VAN DEN MUNCKHOF (Amsterdam, The Netherlands)
16:40 - 16:45
#46252 - OP100 Integrating Qualitative and Quantitative MRI Analysis for Optimizing DBS Candidate Selection in Patients with Disorders of Consciousness.
OP100 Integrating Qualitative and Quantitative MRI Analysis for Optimizing DBS Candidate Selection in Patients with Disorders of Consciousness.
Introduction: Disorders of consciousness (DoC) encompass a range of clinical conditions with overlapping presentations, often leading to diagnostic uncertainty. While advanced neuroimaging techniques such as fMRI and PET have improved diagnostic accuracy, they are not routinely accessible. This study aimed to evaluate whether conventional structural MRI, through combined qualitative and quantitative analysis, could support more accurate diagnosis and improve the selection of patients for deep brain stimulation (DBS) as a therapeutic intervention.
Methods: We prospectively included 50 DoC patients who underwent standardized clinical, neurophysiological, and structural MRI evaluation. Patients were classified as DBS candidates or non-candidates based on predefined clinical and neurophysiological criteria. MRI was assessed qualitatively for features such as cortical atrophy, ventricular enlargement, leukoaraiosis, and thalamic or brainstem atrophy. Quantitative volumetric analysis was performed using the FreeSurfer pipeline.
Results: Qualitative indicators such as leukoaraiosis, corpus callosum lesions, thalamic and diffuse cortical atrophy, and ventricular enlargement significantly correlated with DBS candidacy. Quantitative analysis revealed that ventricular volume, total gray matter, CSF, supratentorial volume, and striatal volume were predictive of DBS eligibility. A combined model integrating both qualitative and quantitative parameters showed the highest predictive value.
Conclusion: Structural MRI, when analyzed using a combined qualitative and quantitative approach, provides meaningful diagnostic and prognostic information in DoC. This method may enhance the selection of appropriate candidates for DBS and improve clinical outcomes. Future multicenter research is warranted to validate these findings and establish standardized imaging-based criteria.
Marina RAGUŽ (Zagreb, Croatia), Petar MARČINKOVIĆ, Hana CHUDY, Valentina GALKOWSKI, Maja MAJDAK, Darko CHUDY
16:45 - 16:50
#46257 - OP101 A Human Brain Network Linked to Restoration of Consciousness After Deep Brain Stimulation.
OP101 A Human Brain Network Linked to Restoration of Consciousness After Deep Brain Stimulation.
Disorders of consciousness (DoC) are characterized by severe impairments of arousal and awareness. Deep brain stimulation (DBS) is a potential treatment, but outcomes vary, possibly due to differences in patient characteristics, electrode placement, or the specific brain network engaged. We studied 40 patients with DoC who underwent DBS of the thalamic centromedian-parafascicular complex. Improvements in consciousness were associated with better-preserved gray matter, particularly in the striatum. Electrical field modelling revealed that stimulation was most effective when it extended below the centromedian nucleus, engaging the ventral tegmental tract - a pathway connecting the brainstem and hypothalamus. Additionally, effective DBS sites were connected to a cortical network overlapping brain areas previously linked to impaired consciousness from seizures or stroke. These findings support future trials and help refine DBS targets and patient selection by identifying a therapeutic network for restoring consciousness.
Aaron E.l WARREN, Marina RAGUŽ (Zagreb, Croatia), Darko CHUDY, John D. ROLSTON
16:50 - 16:55
#45432 - OP102 Spinal cord stimulation facilitates motor recovery in spinal cord injury involving the conus medullaris.
OP102 Spinal cord stimulation facilitates motor recovery in spinal cord injury involving the conus medullaris.
Introduction
Emerging research is increasingly supporting the notion that personalized neurorehabilitation can be paired with spinal cord stimulation (SCS) to improve motor recovery in individuals with spinal cord injury (SCI). Currently, no patients with lesions involving the medullary cone have been treated with this approach, probably due to potential peripheral nervous system damage, leaving the open question of whether this population may benefit from SCS.
Methods
A 33-year-old male patient with T11-T12 SCI with medullary cone involvement, unable to walk and stand or voluntary move his legs, was implanted with a commercial SCS within a clinical trial aiming at investigating the effects of SCS combined with locomotor training on the recovery of motor function. The preoperative neurophysiological evaluation showed, in addition to the central nervous system damage, signs of denervation from L4 to S1 nerve roots bilaterally, indicating also a peripheral disorder. After surgery, we characterized our ability to elicit stimulation responses at the level of trunk muscles and hip flexors and extensors muscles, identifying contacts principally activating trunk muscles and hip flexors over hip extensors. Once optimal stimulation programs were identified, the neurorehabilitation protocol integrating SCS into isolated movements and functional tasks started. During 3-month of testing, we determined stimulation protocols for improving isolated movements and integrated them to reinstate independent walking with a walker.
Results
SCS substantially boosted hip flexor, spinal erector and abdominal muscles contraction, improving the patient’s performance in isolated movements. Over 3-month of combining continuous SCS with an intensive rehabilitation, the patient progressed from being unable to walk, to treadmill training with gradually reduced body-weight support and increasing walking speed, up to overground ambulation using a two-wheeled walker. At the time of hospital discharge, the patient managed to cover 58 meters in the 6-minute walking test and completed the 10-meter walking test in 40.29 seconds. Six months after surgery, the patient was able to walk independently for one kilometer with a walker.
SCS can be used to increase muscle strength through stimulation of the spared roots, and can lead to reinstating independent walking, possibly with the help of assistive orthoses/devices. Preoperative neurophysiological examinations are crucial to define whether peripheral damage has followed the lesion, and which muscles were involved or spared.
Conclusions
Our results underscore the potential of SCS combined with neurorehabilitation protocols also for patients with medullary cone lesions and pave the way for new rehabilitation prospects.
Luigi ALBANO (Milan, Italy), Daniele EMEDOLI, Filippo AGNESI, Simone ROMENI, Elena LOSANNO, Laura TONI, Veronica FOSSATI, Chiara CIUCCI, Filippo GASPEROTTI, Leonardo COCIANI, Giovanni ZUCCO, Edoardo POMPEO, Cinzia MURA, Andrea TETTAMANTI, Veronica CASTELNOVO, Jeffrey David PADUL, Carlo MANDELLI, Lina Raffaella BARZAGHI, Federica ALEMANNO, Caravati HEIKE, Carla BUTERA, Ubaldo DEL CARRO, Antonella CASTELLANO, Andrea FALINI, Federica AGOSTA, Massimo FILIPPI, Iannaccone SANDRO, Pietro MORTINI, Silvestro MICERA
16:55 - 17:00
#45434 - OP103 Spinal cord stimulation combined with neurorehabilitation improves motor function and brain functional connectivity in spinal cord injury patients.
OP103 Spinal cord stimulation combined with neurorehabilitation improves motor function and brain functional connectivity in spinal cord injury patients.
Introduction
Electrical spinal cord stimulation (SCS) has emerged as a potential therapy for restoring motor paralysis after spinal cord injury (SCI). Its mechanism of action is based on the recruitment of proprioceptive fibers linked through excitatory synapses to motoneurons at the level of the target root. However, the hypothesis that SCS, aided by motor rehabilitation, may also play a role in neuroplasticity is growing. This study aims to evaluate changes in brain activity during a motor-task using brain functional magnetic resonance imaging (fMRI) in paraplegic SCI patients before and 6-month after SCS implant and neurorehabilitation for restoring motor function.
Methods
Three SCI patients unable to walk and stand, and classified according to the American spinal injury association impairment scale (AIS) as C (motor and sensory incomplete), were implanted with a SCS system within a clinical trial aiming at investigating the effects of SCS combined with locomotor training on the recovery of motor function (clinicaltrials.gov, NCT05926843). Along the protocol, brain fMRI including a motor-task (think about making foot anti-phase movements) was carried out before surgery and 6 months later. Functional connectivity changes over time within subjects were assessed.
Results
All three patients achieved significant motor improvement, progressing from being unable to stand or walk to being able to stand and walk overground independently with the assistance of a walker. Single patient motor-task fMRI comparison between baseline and 6-month follow-up showed widespread increased brain activity of medial sensorimotor areas and supplementary motor areas in all three patients. At correlation analysis, the improvement of motor metrics over time (Medical Research Council muscle power scale, 10 meters walking test and 6 minutes walking test) were related to the increased sensorimotor areas functional activity over time (p<0.01).
Motor-task fMRI showed specific functional activity increase of motor brain networks over time, which was related with improvement in motor performance. These results could confirm the hypothesis of an effect of SCS and locomotor training also on cerebral neuroplasticity.
Conclusions
In SCI patients, SCS combined with neurorehabilitation supports motor improvement and brain functional reorganization, promoting the functional plasticity of brain areas involved in motor processes and executive abilities.
Luigi ALBANO (Milan, Italy), Silvia BASAIA, Elisabetta SARASSO, Andrea GARDONI, Daniele EMEDOLI, Edoardo POMPEO, Federica ALEMANNO, Carlo MANDELLI, Lina Raffaella BARZAGHI, Silvestro MICERA, Sandro IANNACCONE, Antonella CASTELLANO, Andrea FALINI, Pietro MORTINI, Federica AGOSTA, Massimo FILIPPI
17:00 - 17:05
#45140 - OP104 Treatment of Hereditary Spinocerebellar Ataxia with Epidural Spinal Cord Stimulation and Long-term Follow-up.
OP104 Treatment of Hereditary Spinocerebellar Ataxia with Epidural Spinal Cord Stimulation and Long-term Follow-up.
Treatment of Hereditary Spinocerebellar Ataxia with Epidural Spinal Cord Stimulation and Long-term Follow-up
Jian Song*
Central Theater Command General Hospital, Neurosurgery Department
Objective
Hereditary spinocerebellar ataxia (SCA) is a group of neurodegenerative diseases caused by genetic mutations, primarily characterized by damage to the spinal cord and cerebellum. In May 2018, it was included in China’s first batch of rare disease catalogs. Currently, there are no effective treatments to halt or slow the progression of SCA. Millions of families across the nation are suffering from the effects of SCA. The onset of the disease typically occurs between the ages of 20 and 40, often affecting multiple generations within a family. Many patients have been misdiagnosed for extended periods. In October 2019, after ethical review, we pioneered the use of spinal cord stimulation (SCS) for hereditary spinocerebellar ataxia in China. The long-term follow-up efficacy of this patient group has been encouraging. We have accumulated surgical experience with over 10 patients, most of whom have a follow-up period exceeding one year. Our findings indicate that the selection of indications, electrode target positions, and programmable parameters differ significantly from traditional SCS, emphasizing a highly individualized approach. This study aims to summarize the role of epidural spinal cord stimulation technology in the treatment of hereditary spinocerebellar ataxia patients and its long-term follow-up effects.
Methods
Between October 2019 and November 2023, we performed SCS surgery on 10 patients with hereditary spinocerebellar ataxia at the Neurosurgery Department of Central Theater Command General Hospital. Among them, three patients had SCA type 6 (SCA-6), four had type 3, two had type 12, and one had type 7. The main symptoms included cerebellar ataxia, gait disturbance, and balance impairment, with a disease duration of over one year and a clear family history of autosomal dominant inheritance. After approval from the hospital’s new technology review committee and ethical approval, and thorough communication with the patients, we completed the surgeries. The treatment plan for all patients involved SCS surgery, with electrode target settings designed individually based on the patients' symptoms. During surgery, the electrodes were adjusted to the physiological midline under neuroelectrophysiological monitoring.
Results
The surgical procedures were all successful, and postoperative CT three-dimensional reconstruction of the thoracic spine showed satisfactory electrode placement. The devices were activated two weeks post-surgery, and an individualized adjustment plan was implemented, setting different stimulation contacts and parameters on each side. Under stimulation, patients showed improvements in gait stability and balance disturbances compared to preoperative conditions, as evidenced by significant increases in Tinetti gait and balance test scores. In subsequent follow-ups, the stimulation parameters were adjusted according to patient symptoms, complemented by functional rehabilitation training. Overall, satisfactory therapeutic effects were achieved, with notable improvements in gait disturbances and balance impairment. The effective rate one year post-surgery was 50%. For example, one patient’s Barthel index improved from 40 to 80 after seven months of follow-up; another patient’s index increased from 35 to 70 after three months.
Conclusion
Epidural spinal cord stimulation (SCS) has the potential to become an effective treatment for improving symptoms in patients with hereditary spinocerebellar ataxia, reducing disability, delaying disease progression, and helping patients regain hope for life. Current experience in this area is still limited, necessitating further research to elucidate the mechanisms of action and explore optimal electrode implantation sites, target stimulation parameters, stimulation points, and modes to ensure better efficacy.
Jian SONG (WUHAN, China)
17:05 - 17:10
#46347 - OP105 Improvement of upper and lower limb motor function by double electrode epidural spinal cord stimulation in a patient with cervical spinal cord injury.
OP105 Improvement of upper and lower limb motor function by double electrode epidural spinal cord stimulation in a patient with cervical spinal cord injury.
In traumatic spinal cord injury (TSCI), damage of the corticospinal tract leads to a reduction in voluntary movements. Injury of the cervical spine can result in paresis/paralysis of all four limbs. Dorsal epidural spinal cord stimulation (SCS) can be used to activate interneurons in the dorsal horn of the spinal cord, which facilitate spinal motoneurons in the anterior horn. This can promote improvement in voluntary movements. Several studies have previously demonstrated the beneficial effects of SCS in TSCI. In the majority of cases, the aim was to improve lower limb muscle strength. Only a few cases of SCS implantation was done to improve upper limb movements. In this presentation we will present a case where our goal was to improve both upper and lower limb muscle strength. Such a case has not been published before.
The 18-year-old male patient suffered a cervical spine fracture at the level of C.V in August 2023. The injury resulted in an AISA type B TSCI with complete paralysis of the lower limbs. In the upper limbs the muscle sthength was 3/5 in the triceps and 0/5 in the wrists and the hands. Motor function did not improve after complex neurorehabilitation. SCS implantation was performed in September 2024. Artisan surgical electrodes at the level of C.VI-Th.I and Th. X-XI and a Spectra WaveWriter Alpha 32 RC neurostimulator were implanted. The position of the electrodes was confirmed by intraoperative X-Ray and EMG. Tonic stimulation was done during active rehabilitation. Direct posterior horn activation with contour stimulation was performed during the rest period,
After implantation of the stimulator, active neurorehabilitation was done. The strength of the hands and wrists has siginificantly improved: making a fist, griping and finger touch have returned. Voluntary muscle tone of the trunk, abdominal muscles and thighs were increased. The patient regained the ability to grasp, write, brush teeth, self-catheterize, use smart tools, able to sit up in bed with confidence.
Based on the presented case, spinal cord stimulation in cervical spinal cord injury can improve not only upper, but also trunk and lower limb motor function. Contour stimulation with direct posterior horn stimulation can promote spinal neuroplasticity in the long term and may result in better functional improvement than traditional tonus stimulation.
David KIS (Szeged, Hungary), Norbert SZAPPANOS, Balint DANCSO, Zoltan HORVATH, Pal BARZO
17:10 - 17:15
#46312 - OP106 Deep brain stimulation of the cuneiform nucleus to support neurorehabilitative gait training and improve functional recovery in patients with incomplete spinal cord injury.
OP106 Deep brain stimulation of the cuneiform nucleus to support neurorehabilitative gait training and improve functional recovery in patients with incomplete spinal cord injury.
The mesencephalic locomotor region (MLR) indirectly modulates the activity of spinal locomotor centers (central pattern generators, CPGs) via the reticulospinal tract. A spinal cord injury (SCI) disrupts this regulating motor input to lumbosacral CPGs, impairing the ability to induce stepping and limiting the efficacy of gait training. However, the majority of SCI is anatomically incomplete, sparing reticulospinal fibers that cross the lesion site. Preclinical studies showed that this impaired motor drive can be enhanced with electrical deep brain stimulation (DBS) of the MLR, in particular its cuneiform nucleus (CNF), after incomplete SCI in rodents. Given the phylogenetic conservation of the CNF-reticulospinal system, we hypothesize that CNF-DBS can also augment training and improve gait in patients with incomplete SCI above the lumbosacral levels (clinicaltrials.gov, NCT03053791). So far, two non-ambulatory patients with chronic cervical SCI (five years after injury) underwent locomotor training supported by CNF-DBS at personalized stimulation settings for six months. They were followed-up regularly, performing motor and non-motor assessments without and with stimulation. Both patients tolerated CNF-DBS well and no serious adverse events occurred. They had a narrow therapeutic window with oscillopsia being the most frequently reported, intensity-dependent side effect upon suprathreshold stimulation. The walking distance covered during the 6-Minute Walking Test after 6 months compared to baseline served as primary study endpoint; it was reached by patient 1 in the off-condition, and by patient 2 in the off- and the on-condition. After study protocol modifications based on our lessons learnt, further patients can now be recruited.
Lennart STIEGLITZ, Lennart STIEGLITZ (Zurich, Switzerland), Anna-Sophie FAVRE-HOFER, Luca REGLI, Martin SCHWAB, Armin CURT
17:15 - 17:20
#46289 - OP107 Sound perception and sensory substitution through a spinal computer-brain interface.
OP107 Sound perception and sensory substitution through a spinal computer-brain interface.
Introduction
Sensory substituion offers a promissing tool for patients to restore function. Several preliminary studies investigated the possibility to use different devices to aid those who lost their sight or hearing. Spinal cord stimulation (SCS) provides a safe way to directly connect to the central nervous system. Our proposed spinal computer-brain interface might potentially serve as an auditory sensory substitution system through the spinal cord based on conventional SCS.
Methods
13 patients were enrolled in this study, who underwent SCS implantation suffering from chronic neuropathic pain due to persistent spinal pain syndrome. Everyday sound samples (such as ringing phone, vehicle engines, musical instruments) were translated to electrical signals and personalized stimulation patterns during the externalized trials.
Results
Participants (n = 8) achieved a mean accuracy of 72.8% using only SCS input in a sound identification task. Weak positive correlation between stimulation bitrate and identification accuracy was observed. A follow-up discrimination task (n = 5) confirmed that reduced bitrates significantly impaired participants’ ability to distinguish between consecutive SCS patterns, indicating effective processing of additional information at higher bitrates.
Discussion
Our preliminary results indicate that the use of a spinal computer-brain interface could be created and effectively used even with conventional SCS systems to provide auditory sensory substitution. Further research and evaulation of the proposed system is required to assess long-term use and feasibility for transmitting more complex sound samples or even live speech.
Halász LÁSZLÓ (Budapest, Hungary), Gabriella MIKLÓS, Maximilian HASSELBERGER, Emilia TÓTH, Ljubomir MANOLA, Saman HAGH GOOIE, Gijs VAN ELSWIJK, Bálint VÁRKUTI, Loránd ERŐSS
17:20 - 17:25
#45493 - OP108 Clinical applications of spinal and thalamic computer-brain interfaces: Functional outcomes across 28 patients and 5,400 interface trials.
OP108 Clinical applications of spinal and thalamic computer-brain interfaces: Functional outcomes across 28 patients and 5,400 interface trials.
This study reports outcomes from the largest dataset to date involving clinical applications of computer-brain interfaces (CBI) using implanted neuromodulation devices. Data from 28 patients (18 with spinal cord stimulation [SCS] implants and 10 with deep brain stimulation [DBS] electrodes) were collected across two medical centers, encompassing over 5,400 calibration and functional interface trials. Various Boston Scientific electrode leads (DB2202, Infinion CX, Artisan, CoverEdge32) were utilized in both percutaneous and surgically implanted configurations. Participants were evaluated through four distinct functional tasks designed to comprehensively assess performance in sensory encoding applications.
The results revealed significant functional capabilities across all tested sensory modalities. In rhythm discrimination tasks (n=13), participants achieved a mean accuracy of 97±5% following minimal training (<2 minutes), underscoring the practical potential of rhythmic cueing in therapeutic interventions for gait freezing in Parkinson’s disease. Symbolic association tasks (n=9) demonstrated participants' ability to interpret abstractly encoded information at an accuracy of 63±14%, significantly above chance levels (p<0.005), highlighting promise for basic communication interfaces. Tangibility assessment tasks (n=13) showed an accuracy of 79±9% in object characteristic recognition, thereby validating the utility of CBIs for providing effective sensory feedback in prosthetic applications.
Notably, spinal cord stimulation interfaces required considerably shorter median calibration times (79 minutes) compared to thalamic interfaces (94±46 minutes), despite achieving similar functional performance. Overall, task success rates were consistently high, with 90% of participants demonstrating above-chance performance across all tasks attempted.
Task-specific analyses indicated that neural interfaces optimized for direct sensory pathway access, such as those targeting dorsal columns or the ventral posterolateral (VPL) nucleus of the thalamus, outperformed those targeting less direct pathways (ventral intermediate nucleus [VIM]) in encoding precise tactile information. This novel comparative analysis of different neural interface modalities provides essential insights for clinical application strategies, suggesting that each modality may have specific advantages depending on temporal responsiveness, spatial resolution, and functional requirements. These findings facilitate evidence-based criteria for selecting appropriate interfaces for emerging therapeutic interventions aimed at sensory restoration and augmentation.
Bálint VÁRKUTI (Munich, Germany), László HALÁSZ, Bastian E.a. SAJONZ, Gabriella MIKLÓS, Saman HAGH-GOOIE, Emília TÓTH, Volker A. COENEN, Loránd ERŐSS
|
|
|
17:30 |
|
|
|
|
Friday 26 September |
Time |
ROOM A |
ROOM B |
ROOM C |
ROOM D |
BOARDROOM 949 |
|
08:30 |
08:30-10:00
Added to your list of favorites
Deleted from your list of favorites
A25
PLENARY SESSION 3
PLENARY SESSION 3
Chairpersons:
Jocelyne BLOCH (Médecin Cadre) (Chairperson, Lausanne, Switzerland), Joachim KRAUSS (Chairman and Director) (Chairperson, Hannover, Germany), Veerle VISSER-VANDEWALLE (Head of Dep. of Ster. and Funct. NS) (Chairperson, Cologne, Germany)
08:30 - 08:50
#45536 - PL02 DBS in 100 consecutive obsessive-compulsive disorder patients: do different targets really matter?
PL02 DBS in 100 consecutive obsessive-compulsive disorder patients: do different targets really matter?
Introduction:
There is evidence that deep brain stimulation (DBS) is effective in patients with treatment-refaractory obsessive-compulsive disorder (OCD). From 2005-2010, we reported significant decrease in OCD symptoms undergoing DBS target at the nucleus accumbens (NAc), with electrode trajectories following the anterior limb of the internal capsule (ALIC). Based on observations in the first 28 patients, we identified a theoretic DBS hotspot in the ventral part of the ALIC (vALIC), which was subsequently used from 2010-2017 in the following 43 patients. Then, magnetic resonance diffusion tensor imaging of ALIC allowed us to identfy the superolateral branch of the medial forebrain bundle (slMFB), which seemed helpful in further refinement of the OCD DBS hotspot. From 2018, DBS electrodes were targeted to slMFB within the ALIC in the next 29 patients. We have now sufficient long-term follow-up data available to allow for proper comparison of DBS effectivitiy among the abovementioned three targeting strategies.
Results:
In all three groups, roughly 60% of patients responded to DBS therapy at 6 months, one year and two years follow-up, without significant differences between groups. This is in contrast to our previous, preliminary results (that were presented at ESSFN meetings in Edinburgh, Marseille and Stockholm), that tended towards superiority of slMFB targeting over vALIC and NAc targeting. Moreover, reimplantation of DBS electrodes in non-responding NAc- and vALIC-targeted patients did in general only elicit a temporary DBS response, no sustained effect. Thus, the occurence of DBS response (or non-response) in OCD is not explained by different DBS targeting strategies within the ALIC/NAc complex. Instead, we found age of onset of clinically problematic OCD symptoms to be a strong predictor for DBS response, with 70% of adult-onset patients responding to DBS therapy versus only 38% of patient <18 years old. Age per se and disease duration did not correlate with chances of responding to DBS therapy.
Conclusion:
Although we longtime thought slMFB-targeting to be superior over NAc- and vALIC-targeting in OCD patients undergoing DBS, our current long-term follow-up data in 100 consecutive patients shows that the targeting strategy itself seems far less important for DBS response prediction than patient characteristics such as pre-adult onset of clinically problematic OCD symptoms. This observation adds an important nuance to our previously presented preliminary results at earlier ESSFN meetings.
Pepijn VAN DEN MUNCKHOF (Amsterdam, The Netherlands), Maarten BOT, Nienke VULINK, Pelle DE KONING, Roel MOCKING, Rick SCHUURMAN
08:50 - 09:10
#46169 - PL03 Patient-specific structural connectivity of nac/alic, mfb and amstn in treatment-resistant ocd patients.
PL03 Patient-specific structural connectivity of nac/alic, mfb and amstn in treatment-resistant ocd patients.
Introduction
Deep brain stimulation (DBS) is an effective intervention for treatment-resistant obsessive-compulsive disorder (trOCD), yet clinical outcomes vary by stimulation target. The most effective targets are thought to lie within the frontopontine-corticothalamic (Fp-Ct) and mesolimbic-orbitofrontal (Mes-OFC) networks. Key regions of interest (ROIs) such as the amygdala, insula, medial prefrontal cortex (mPFC), and dorsolateral prefrontal cortex (dlPFC) are implicated in symptom relief. Structural connectivity differences between DBS targets may underlie variable treatment responses. This study aimed to characterize patient-specific structural connectivity associated with three DBS targets: the nucleus accumbens/anterior limb of the internal capsule (NAc/ALIC), medial forebrain bundle (MFB), and anteromedial subthalamic nucleus (amSTN).
Methodology
We retrospectively analysed diffusion-weighted MRI data from 20 trOCD patients who received DBS at the University Hospital of Cologne between 2016 and 2024. Probabilistic tractography was performed using MRtrix3 and constrained spherical deconvolution. Structural connectivity matrices were generated using the HCP842 and CerebrA atlases in DSI-Studio. Structural metrics included streamline counts, fractional anisotropy (FA), and mean diffusivity (MD) across a priori ROIs. Statistical comparisons between targets were conducted using Kruskal–Wallis and post hoc tests. Ethical approval and patient consent were obtained.
Results
The cohort’s mean age was 42.9 ± 9 years, with a baseline Y-BOCS score of 30 ± 6. Each DBS target showed distinct connectivity patterns. NAc/ALIC demonstrated stronger connections to frontolimbic regions, including the orbitofrontal cortex, rostral anterior cingulate, insula, and nucleus accumbens (p < 0.001). MFB primarily connected with reward-related regions such as the pallidum and rostral middle frontal cortex (Brodmann areas 8BL, 9M, 9P) (p < 0.001). amSTN was linked to motor-inhibitory areas, including the precentral and paracentral gyri (p < 0.001). FA was higher in tracts associated with amSTN (0.48 ± 0.05) and NAc/ALIC (0.34 ± 0.04), suggesting greater fiber coherence. MD did not significantly differ among targets.
Conclusions
DBS targets engage distinct neural networks related to OCD symptom domains: frontolimbic-emotional regulation (NAc/ALIC), reward-processing (MFB), and motor-inhibition (amSTN). These findings support a connectivity-guided, symptom-specific approach to DBS planning. Patient-specific tractography may enhance targeting precision by accounting for individual microstructural variation. Future multicentric studies are needed to validate these structual connectivity patterns as predictors of clinical outcome andto refine DBS targeting based on symptom profiles.
Rene MARQUEZ FRANCO (Köln, Germany), Luis RUELAS, Ricardo LOUÇÃO, Veerle VISSER-VANDEWALLE, Jens KUHN, Pablo ANDRADE, Rabea SCHMAHL
09:10 - 09:30
#46319 - PL04 Alternative deep brain stimulation targets in the treatment of isolated dystonic syndromes: a multicenter experience-based survey.
PL04 Alternative deep brain stimulation targets in the treatment of isolated dystonic syndromes: a multicenter experience-based survey.
Background: The globus pallidus internus (GPi) is the traditional evidence-based deep brain stimulation (DBS) target for treating dystonia. Although patients with isolated "primary" dystonia respond best to GPi-DBS, some are primary or secondary nonresponders (improvement <25%), showing variability in clinical response.
Objective: The aim was to survey current practices regarding alternative DBS targets for isolated dystonia patients with focus on nonresponders to GPi-DBS.
Methods: A 42-question survey was emailed and distributed during a DBS conference to clinicians involved in DBS for dystonia. The survey covered (1) use of alternative DBS targets as primary or rescue options, (2) target selection based on dystonia phenomenology, (3) experience with secondary nonresponders to GPi-DBS, and (4) management of patients with additional DBS leads.
Results: The response rate was 53.8%, including neurologists and neurosurgeons from 28 DBS centers in 13 countries; 89% of neurologists and 86% of neurosurgeons used alternative DBS targets to GPi, with subthalamic nucleus being the most common initial or rescue alternative to GPi. Patients with additional tremor received DBS in the ventral intermediate nucleus or caudal zona incerta. Individual experience ranged from 5 to 25 patients. Most patients were still receiving dual target stimulation at the last follow-up.
Conclusions: We show that more than 85% of surveyed clinicians use alternative DBS targets, mostly in some isolated dystonia patients not adequately responsive to GPi-DBS. More knowledge is needed to evaluate outcomes in alternative targets and establish the best strategies for managing insufficient GPi-DBS response in dystonia patients with diverse phenomenology. Our article contributes to establishing a clearer time frame and criteria for defining nonresponders in dystonia patients undergoing DBS.
Laura CIF, Patricia LIMOUSIN, Zohra SOUEI (Paris), Marwan HARIZ, Joachim KRAUSS
09:30 - 09:50
State of the Art in Spasticity Surgery.
Patrick MERTENS (Head of the department) (Keynote Speaker, LYON, France)
09:50 - 10:00
Discussion.
|
|
|
|
|
|
10:00 - 10:30 |
COFFEE BREAK - FLASH POSTERS SESSION 3 - EXHIBITION
|
|
10:30 |
10:30-12:00
Added to your list of favorites
Deleted from your list of favorites
A31
PLENARY SESSION 4
PLENARY SESSION 4
Chairpersons:
Alexandre CAMPOS (Doctor) (Chairperson, São Paulo, Brazil), Vanessa MILANESE, Jean RÉGIS (PROFESSEUR) (Chairperson, Marseille, France)
10:30 - 11:00
Brain decoding and AI.
Henri LORACH (Assistant Prof.) (Faculty, Lausanne, Switzerland)
11:00 - 11:20
Best of 23-25 in Rehabilitation.
Grégoire COURTINE (Prof. Dr. Courtine) (Keynote Speaker, Geneve, Switzerland)
11:20 - 11:50
Visual prosthesis.
Pieter ROELFSEMA (Director) (Keynote Speaker, Amsterdam, The Netherlands)
10:30 - 12:00
Discussion.
|
|
|
|
|
|
12:00 |
|
|
|
|
|
|
13:30 |
13:30-15:30
Added to your list of favorites
Deleted from your list of favorites
A39
PARALLEL SESSION 10
Movement Disorder 4
PARALLEL SESSION 10
Movement Disorder 4
Chairpersons:
Kostiantyn KOSTIUK (Neurosurgeon) (Chairperson, KYIV, Ukraine), Ioannis PANOURIAS (DOCTOR) (Chairperson, ATHENS, Greece), Ali SAVAS (Prof Dr) (Chairperson, Ankara, Turkey)
13:30 - 13:40
#46115 - OP078 Dysgeusia following Vim thalamotomy: a systematic review and meta-analysis.
OP078 Dysgeusia following Vim thalamotomy: a systematic review and meta-analysis.
Background: Dysgeusia is increasingly recognized as a potential complication after ventral intermediate nucleus (Vim) thalamotomy for tremor. It may arise from unintended lesioning of gustatory pathways in the thalamus. This systematic review and meta-analysis synthesized recent evidence on the incidence, mechanisms, and clinical significance of post-thalamotomy dysgeusia across different lesioning techniques.
Methods: We searched peer-reviewed studies reporting taste disturbances after Vim thalamotomy, including radiofrequency (RF) ablation, focused ultrasound (FUS), and Gamma Knife radiosurgery. Key outcomes extracted were dysgeusia incidence, lesion location characteristics, severity/duration of taste disturbance, and any assessment or management approaches. Pooled incidence rates and qualitative comparisons across techniques were performed, and clinical impact measures (e.g. weight change, quality-of-life) were reviewed.
Results: 37 studies were included in this review from an initial search of 444 papers, representing a cohort of 2,445 patients. The description of dysgeusia was highly variable and non-specific. The pooled incidence of dysgeusia was found to be 10%, with a 95% confidence interval of 8 to 13%. There was moderate heterogeneity (I2 = 50.05%) which was found to be statistically significant. The subgroup analysis of surgical method could not explain this heterogeneity.
Focused ultrasound thalamotomy series reported taste disturbances in approximately 3–13% of cases, which were typically transient. By 3 months post-FUS, around 8% had persistent dysgeusia, declining to ~3% at 1 year. Dysgeusia after RF thalamotomy was less frequently documented, though cases have been noted, including mild persistent dysgeusia in bilateral procedures. It was rarely reported after Gamma Knife thalamotomy. Mechanistically, lesions inducing dysgeusia were associated with involvement of thalamic gustatory fibres. Tractography and lesion mapping studies showed that dysgeusia correlates with lesions extending medially into the ventral posteromedial nucleus region where the taste pathway runs. Partially disrupting these taste pathways can provoke dysgeusia, whereas complete disruption may abolish the aberrant taste signal. Consistently, more posterior or medial lesion locations were linked to higher dysgeusia risk. Bilateral thalamic lesions appeared to increase risk, with one trial noting a ~25% higher dysgeusia incidence after staged bilateral FUS thalamotomies compared to unilateral procedures.
Clinical Impact: Although usually mild, post-thalamotomy dysgeusia can significantly affect patients. Several reports describe reduced appetite and taste aversion leading to weight loss. In one case, a patient lost 20 kg over 18 months due to persistent dysgeusia-induced food aversion. Even mild taste disturbances were bothersome; patients commonly described metallic or bitter phantom tastes that diminished enjoyment of eating. Persistent dysgeusia has been associated with malnutrition and psychological effects such as anxiety and reduced mental health scores. Quality-of-life can be adversely impacted when normal taste is distorted for prolonged periods.
Conclusions: Dysgeusia is an uncommon but important complication of Vim thalamotomy. Awareness of this risk is crucial given its potential nutritional and psychosocial consequences. Lesioning techniques differ slightly in dysgeusia profile: incisionless methods like FUS may have a modestly higher incidence of taste side effects than radiosurgical or RF lesions, though typically resolving over time. There remains no standardized tool in routine use to characterize post-thalamotomy dysgeusia; studies have largely relied on patient self-report. We recommend that future thalamotomy protocols include systematic taste assessments at follow-up to detect and quantify dysgeusia. In the absence of established treatments for surgery-induced dysgeusia, management is supportive. Adjusting deep brain stimulation settings can ameliorate dysgeusia, but for lesion-induced dysgeusia emphasis is on symptomatic relief. Strategies such as dietary counselling, flavour enhancement, and zinc supplementation (extrapolated from oncology practices) may be offered. Research into more targeted interventions and preventive lesion targeting is needed. Improving our characterization and management of dysgeusia will enhance the overall safety profile and patient-catered outcomes of Vim thalamotomy for tremor control.
Vaasu BANSAL (London, United Kingdom), San San XU, Marie T. KRÜEGER, Tom FOLTYNIE, Patricia LIMOUSIN, Ludvic ZRINZO, Harith AKRAM
13:40 - 13:50
#46292 - OP079 Machine learning based modeling of sensory responses in thalamic deep brain stimulation.
OP079 Machine learning based modeling of sensory responses in thalamic deep brain stimulation.
Introduction
Undesirable stimulation-induced sensations such as persistent parestesia is considered as a side effect to be avoided in deep brain stimulation (DBS). Emerging applications of computer-brain interfaces might require such perceptions to be used as a tool to convay useful informaiton. Our study aims to streamline DBS parameter selection by employing
a machine learning model to predict the occurrence and somatic location of paresthesias.
Methods
10 patients, who underwent DBS lead implantation due to essential tremor (n=8) and chronic pain (n=2) in two clinical centers were enrolled in our study. 3,359 paresthetic sensations collected to create a dataset comprising from 18 thalamic DBS leads. For each stimulation, we modeled the Volume of Tissue Activation (VTA). We then used the stimulation parameters and the VTA information to train a machine learning (ML) model to predict the occurrence of sensations and their corresponding somatic areas.
Results
Our results indicate that the proposed ML model could effectively predict the presence and somatic location of DBS-evoked paresthesias, with Kappa values ranging from 0.31 to 0.72. We observed comparable performance in predicting the presence of paresthesias for both seen and unseen cases (Kappa 0.72 vs. 0.60). However, Kappa agreement for predicting specific somatic locations was significantly lower for unseen cases (0.53 vs. 0.31).
Conclusion
The results suggest that a sufficiently trained ML model can potentially be used to optimize DBS parameter selection awoke or avoid paraesthesia, leading to faster and more efficient postoperative management. Outcome predictions may be used to guide clinical DBS programming or tuning of DBS based computer-brain interfaces.
Halász LÁSZLÓ (Budapest, Hungary), Bastian E. A. SAJONZ, Gabriella MIKLÓS, Gijs VAN ELSWIJK, Saman HAGH GOOIE, Bálint VÁRKUTI, Gertrúd TAMÁS, Volker A. COENEN, Loránd ERŐSS
13:50 - 14:00
#45928 - OP080 Real-World Clinical Outcomes Using Radiofrequency Thermal Ablative Lesioning for Use in the Treatment of Movement Disorder Motor Symptoms.
OP080 Real-World Clinical Outcomes Using Radiofrequency Thermal Ablative Lesioning for Use in the Treatment of Movement Disorder Motor Symptoms.
Objective: In order to gain a better understanding of the associated outcomes following Radiofrequency (RF) thermal lesioning in the Central Nervous System (CNS), we have embarked on a real-world, observational evaluation of those who elected to use this therapeutic approach to help manage disease symptoms of movement disorders.
Background: Patients with movement disorders such as Essential Tremor, Parkinson’s disease, or Dystonia often undergo surgical implantation of a Deep Brain Stimulation device in order to neuromodulate specific stereotactic targets of interest to manage adverse motor signs and symptoms. However, not all patients may be suitable or desire to be implanted with these systems. With the advent of new imaging technologies used in the context of functional neurosurgery, ablative techniques such as thermal-based Radiofrequency (RF) offer a viable alternative with a satisfactory risk/benefit ratio.
Methods: This is an international, prospective, multi-center, observational outcomes assessment of up to 200 movement disorder patients treated using an RF thermal lesioning ablation system (Boston Scientific, Valencia, CA USA) as clinically applied at sites within the CNS. Criteria for study inclusion are treatment with an RF ablation system per locally applicable Instructions for Use (IFU) and prior completion of an approved consent form. Potential participants are excluded from inclusion if any contraindications for use of an RF ablation system are met per locally applicable IFU and/or currently exhibits any impairment or characteristic that would limit study candidate’s ability to complete study assessments. Key endpoints for assessment include (but are not limited to) the following: UPDRS or MDS-UPDRS III, change in tremor scores, and Global Impression of Change (clinician and patient). Participants will be examined at baseline and out to 1-, 3-, 6-, 12-, and 24-months post-procedure.
Results: This is an ongoing, active study. To date, 7 subjects (mean age: 72.3 ± 4.7 years) have been enrolled and received a unilateral thalamotomy. 4 subjects (all male) are diagnosed with Parkinson’s Disease while 3 subjects (2 female) have Essential Tremor. Global Impression of Change from both the subject and clinician at 6 months post-procedure report improvement compared to baseline. Follow-up data collection is ongoing and preliminary results will be reported.
Conclusions: Assessment of real-world outcomes in patients using an RF ablation system for treatment of movement disorder motor symptoms offers the opportunity to re-evaluate the clinical effectiveness of this approach amid the contemporary utilization of increasingly advanced imaging technologies and neurosurgical techniques.
Jan VESPER (Duesseldorf, Germany), Andrea DREYER, Erlick PEREIRA, Rajat SHIVACHARAN, Lilly CHEN, Edward GOLDBERG
14:00 - 14:05
#45146 - OP081 Magnetic resonance-guided focused ultrasound - thalamotomy for essential tremor: lesion location and clinical outcomes.
OP081 Magnetic resonance-guided focused ultrasound - thalamotomy for essential tremor: lesion location and clinical outcomes.
Background: Factors predicting clinical outcomes after MR-guided focused ultrasound (MRgFUS)-thalamotomy in patients with essential tremor (ET) are not well known.
Objective: To examine the clinical outcomes and their relationship with patients' baseline demographic and clinical features and lesion characteristics at 6-month follow-up in ET patients.
Methods: A total of 60 patients were prospectively evaluated at 6 months after MRgFUS-thalamotomy. Magnetic resonance imaging (MRI) was obtained at 6 months (n = 60). Primary outcomes included: (1) change in the Clinical Rating Scale of Tremor (CRST)-A+B score in the treated hand and (2) frequency and severity of adverse events (AEs) at 6 months. Secondary outcomes included changes in all subitems of the CRST scale in the treated hand, CRST-C, AEs, and correlation of primary outcomes at 6 months with lesion characteristics. Statistical analysis included linear mixed, standard, and logistic regression models.
Results: Scores for CRST-A+B, CRST-A, CRST-B in the treated hand, CRST-C and were improved at each evaluation (P < 0.001). Five patients had severe AEs at 1 month that became mild throughout the follow-up. Mild AEs occurred in 34% of patients at 6 months. Lesion volume was associated with the reduction in the CRST-A (P = 0.003) and its overlapping with the ventralis intermedius nucleus (Vim) nucleus with the reduction in CRST-A+B (P = 0.02) and CRST-B (P = 0.008) at 6 months.
Conclusions: MRgFUS-thalamotomy improves hand and axial tremor in ET patients. Transient and mild AEs are frequent. Lesion volume and location are associated with tremor reduction.
Alana ARCADI (Pamplona, Spain), Lain GONZALEZ-QUARANTE, Iciar AVILES, Antonio MARTIN, María Cruz RODRÍGUEZ
14:05 - 14:10
#46216 - OP082 Magnetic Resonance Guided Focused Ultrasound in Essential Tremor – A Scandinavian First.
OP082 Magnetic Resonance Guided Focused Ultrasound in Essential Tremor – A Scandinavian First.
Introduction: Essential Tremor (ET) is the most common hyperkinetic movement disorder. While most cases can be sufficiently treated pharmacologically, some patients do not respond to a sufficient degree. In these cases, advanced therapies such as surgical treatment is often considered. MRI guided Focuses Ultrasound (MRgFUS) has emerged as a newer such advanced therapy. Here, we report a single center experience of MRgFUS for treatment of ET.
Methods: Since May 2022 all patients treated with MRgFUS at Aarhus University Hospital have been systematically followed up regularly for no less than 12 months. Data entered in a regional clinical quality assurance database is collected on a rolling basis at the following timepoints baseline, three, six and twelve months. Treatment efficacy is evaluated systematically from both the Clinician- and patient perspectives by using the Fahn-Marin Tolosa (FMT) and Quality of Life in Essential Tremore (QUEST) scales, respectively. A further measure of patient-evaluated efficacy was the patient global impression of change (PGIC) and a baseline statement of a treatment goal to be evaluated at follow-up. Safety is evaluated as the incidence both adverse events in both the short- and long term. Additionally, in order to assess the wider impact of treatment, socioeconomic, overall health-related quality of life according to the Short Form 36, and the use of tremor-related medications is collected. At baseline, data of comorbidities are collected.
Results: To date, 181 persons with ET have been treated at our center and 110 of these have reached the 12 month assessment. Consistent with other centers, tremor is markedly improved following treatment at three months assessment (p<0.0001) and is sustained into 12 months follow-up (p<0.0001). According to the QUEST, patients experienced a marked reduction of daily hours with tremors (p<0.0001), and they reported that overall quality of life improved (p<0.005). More than 80 % reported their health to be much or very much improved compared to the year prior as well as a similar proportion having reached their treatment goal.
While the majority of patients experienced some side-effects, these where for the most part transient and self-limited. The most common in the short-term were feelings of disequilibrium and parasthesias, the former likewise being the most common, albeit infrequent, persistent side effect.
Conclusion: Our results are in line with experiences from similar centers. MRgFUS is a minimally invasive, effective and safe treatment of ET. Our results, furthermore, indicate opportunities of likely further improvement of long-term outcomes.
Victor HVINGELBY (Aarhus N, Denmark), Pernille KJELDSEN, Bo BERGHOLT, Gaston SCHECHTMANN, Erik DANIELSEN, Mette MØLLER, Erik JOHNSEN, Skirmante MARDOSIENE, Torben Ellegaard LUND, Dora GRAUBALLE, Michael GENESER, Tina Vincens SØRENSEN, Lisa Østergaard BAK, Martin ANDREASEN, Anne Sofie Møller ANDERSEN, Lone ANDERSEN, Kaare MEIER, Niels JUHL, Alp TANKISI, Bo JESPERSEN, Christian FENGER-ERIKSEN, Winnie ERIKSEN, Birgitte BARRUTIOA, Mette Sloth KROMANN, Ida BAANDRUP, Rie STJERNHOLM, Jette BJØRN, Charlotte BRÆMER-MADSEN, Signe Mygdal JØRGENSEN, Jens Christian Hedemann SØRENSEN, Andreas GLUD
14:10 - 14:15
#46240 - OP083 Staged bilateral MRgFUS thalamotomy for tremor: A technical analysis of 15 consecutive cases.
OP083 Staged bilateral MRgFUS thalamotomy for tremor: A technical analysis of 15 consecutive cases.
INTRODUCTION:
Staged bilateral thalamotomy for essential tremor (ET) using Magnetic Resonance guided Focused Ultrasound (MRgFUS) received regulatory approval in Europe in September 2023. A few case series and two clinical studies have been hitherto published. However, within these previous publications, little to no comparison of the technical aspects between the first and second (contralateral) thalamotomy have been reported.
OBJECTIVES:
To analyze the therapeutic technical parameters in staged bilateral thalamotomies with MRgFUS.
METHODS:
A restrospective, single-center consecutive cohort of 15 ET patients was reviewed and analyzed from a procedural and technical point of view. Skull Density Ratio (SDR) and SDR kurtosis were calculated with a new CT scan before the second treatment and compared to the first SDR. Key technical variables such as the Energy required to reach 50ºC (E50), number of sonications with average temperature ≥55ºC, number of target movements per treatment, initial target coordinates, inner and outer angle of each ultrasound beam per element and so on were calculated and analyzed.
RESULTS:
The interval between the first and second (contralateral) treatment ranged between 9 and 91 months. When comparing first and contralateral thalamotomies, a significant reduction in the number of sonications was observed for the second side (7 sonications in second side thalamotomies vs 10 sonications in first side; p=0.0090), along with a significantly decreased number of target movements or different sub-targets (2.1 targets in second side vs 2.9 targets in first side; p=0.0140). The analysis of coordinates yielded no significant changes in the X and Y axes, whereas a significant difference in the Z axis was obtained (2.3 mm above ACPC line in second side vs 1.7 mm above ACPC line in first side, p=0.0152). No significant differences were found for SDR values (average difference of 0.02 between the first calculation and the second one), SDR kurtosis and the E50. Inner and outer angles were also similar. From a tolerability point of view, of note is the fact that 2 out of the 15 patients did not tolerate well the second side treatment due to severe nausea and/or pain, while they tolerated very well the first treatment. Technical issues, including cavitations, beam misalignments, heat spread, and noisy thermography, were reduced by over 60% in the second (contralateral) treatment (15 events in the first side vs. 5 in the second).
CONCLUSIONS:
No significant differences in terms of energetic “efficiency” were observed between the first thalamotomy and the contralateral one. Seemingly, repeating a CT scan for SDR calculation before a second-side thalamotomy may not be necessary, as both the SDR and the E50 did not significantly change in our cohort of patients. A decrease in the number of sonications, intra-treatment movements and technical contretemps was observed although it may be due to factors such as the learning curve, changes in the treatment strategy (i.e: being more conservative in the second thalamotomy) and device-related improvements (hardware & software related).
Lain Hermes GONZALEZ-QUARANTE (Pamplona, Spain), Ayden FONSECA, Alana ARCADI, Carlos SANCHEZ-CATASUS, Iciar AVILES-OLMOS, Elena NATERA-VILLALBA, Antonio MARTIN-BASTIDA, Arantza GOROSPE, Tessa CASE, Giulia FRAZZETTA, Cristina HONORATO-CIA, Antonio MARTINEZ-SIMON, Maria Cruz RODRIGUEZ-OROZ, Jorge GURIDI
14:15 - 14:20
#46248 - OP084 Safety and Efficacy of Staged Bilateral MR-Guided Focused Ultrasound Pallidothalamic Tractotomy in Parkinson’s Disease.
OP084 Safety and Efficacy of Staged Bilateral MR-Guided Focused Ultrasound Pallidothalamic Tractotomy in Parkinson’s Disease.
Background:
Pallidothalamic tractotomy (PTT) has been performed using MR-guided focused ultrasound (MRgFUS) to treat Parkinson’s disease (PD) since 2011. We aimed to evaluate the safety and efficacy of staged bilateral PTT-MRgFUS in PD patients.
Methods:
Fourteen consecutive patients suffering from chronic (mean disease duration 9.0 years) and therapy-resistant PD were treated unilaterally with PTT-MRgFUS. Eleven received operation of the second side. The primary endpoints included the Unified Parkinson’s Disease Rating Scale (UPDRS) scores in on- and off-medication states, and adverse events at baseline, 1 week, 1 month, 3 months, and 6 months, 12 months after treatment.
Results :
The mean duration between baseline UPDRS score and 1 year after the second side was 13.5 months. The UPDRS III score on-medication at 1 year after the second PTT was reduced by 37% compared to that at baseline on-medication (p=0.001). The UPDRS off-medication postoperative score was compared to the baseline on-medication score and revealed percentage reductions of the mean of 68% for tremor, 65% for rigidity, and 77 % for distal hypobradykinesia, all values given for the treated side.
Conclusion:
Staged, bilateral focused ultrasound pallidothalamic tractotomy significantly reduced tremor severity and rigidity, distal hypobradykinesia scores. Adverse events for speech and ataxia were mostly mild and transient. Our results suggest PTT- MRgFUS was a safe and effective intervention for PD patients, in varying symptoms.
Longsheng PAN (Bejing, China)
14:20 - 14:25
#46360 - OP085 10 years of MRgFUS- summary and highlights from 300 treatments.
OP085 10 years of MRgFUS- summary and highlights from 300 treatments.
Background: MR Guided Focused Ultrasound (MRgFUS) was introduced for intracranial ablation in 2011. Since then, the platform has emerged worldwide with FDA clearance for treating Essential Tremor (ET) bilaterally and Parkinson's Disease (PD). About 15,000 ablative procedures around the globe have gained much experience, which influences real-world clinical. Rambam has been running MRgFUS practice since 2013 with more than 300 procedures, and is the first site in the world to explore and fully clinically treat with MRgFUS's new generation: the Exablate Prime. The MRgFUS practice has dramatically changed over the past ten years, from patient selection, indications, technical approach, system capabilities, ablative targets, patient and surgeon interface, and treatment outcomes.
Aim: to highlight the insights from Rambam and worldwide MRgFUS experience and their influence on daily practice, which enable expanded indications for treatments and improve clinical outcomes.
Methods: Analyze clinical data from the past ten years at Rambam and integrate insights from leading papers and case reports worldwide.
Results: Rambam has presented outstanding tremor control with a mild side effects profile in more than 300 treatments. However, based on the experience gained, clinical practice has changed significantly. Furthermore, the MRgFUS new generation -Exablate Prime, has significant technical and firmware improvements that were integrated into the clinical practice.
Conclusion: Integrating gained experience with technological improvements can dramatically enhance clinical practice, expand treatment indications, and improve patient experience, treatment safety, and outcomes. We will present our ten years of experience results, highlighting our clinical approach improvement and outcomes.
Lev-Tov LIOR (Haifa, Israel), Sinai ALON, Shalem NOAM, Sederova INNA, Nassar MARIA, Katson MARK, Eran AYELET, Schlesinger ILANA
14:25 - 14:30
#47702 - OP086 Efficacy and safety of thalamotomy in the treatment of tremor.
OP086 Efficacy and safety of thalamotomy in the treatment of tremor.
Thalamotomy remains an effective, safe treatment for drug-resistant tremor. Our experience includes 500+ procedures, with retrospective analysis of 100 cases confirming low complication rates (≤5% dysarthria, <1% hemorrhage) and sustained efficacy (85% tremor control at 5 years). Comparable to DBS in select patients, it offers a cost-effective, hardware-free alternative, particularly for unilateral symptoms or limited DBS access. Data support its relevance in modern functional neurosurgery.
Daniyar BAGAUTDINOV (Almaty, Kazakhstan)
14:30 - 14:35
#48014 - OP087 Brain Lesioning as a Cost-Effective Alternative to Deep Brain Stimulation: Clinical Outcomes in a Resource-Limited Setting.
OP087 Brain Lesioning as a Cost-Effective Alternative to Deep Brain Stimulation: Clinical Outcomes in a Resource-Limited Setting.
Introduction: While deep brain stimulation (DBS) has become the gold standard for advanced movement disorders, its high cost limits accessibility in resource-constrained healthcare systems. The author, with prior experience performing over 300 DBS procedures in Germany and Canada (2009–2019), transitioned to brain lesioning techniques upon relocating to Jordan. This shift was driven by financial limitations in public insurance coverage. Since performing the first radiofrequency lesioning procedure on July 21, 2022, 67 ablative surgeries have been completed, including pallidotomies for Parkinson’s disease (41 unilateral, 3 bilateral) and dystonia (8 unilateral, 3 bilateral). Gamma Knife Icon was additionally utilized for subthalamotomies (n=4), thalamotomy (n=8), cingulotomies for anxiety (n=2), and capsulotomies for refractory OCD (n=6).
Results: Median improvement in UPDRS-III scores post-intervention was 29.5%. Essential tremor resolved significantly in the treated case. Among OCD patients, 4 transitioned from severe to mild symptoms, while 2 showed no response. Dystonia patients achieved a mean 35% reduction in BFMDRS-M scores.
Conclusion: In settings where DBS is economically prohibitive, radiofrequency and Gamma Knife lesioning demonstrate clinically meaningful outcomes for movement and psychiatric disorders. These techniques offer a sustainable, lower-cost alternative without compromising therapeutic efficacy.
Mahmoud ABDALLAT (Amman/Jordan, Jordan)
14:35 - 14:40
#45695 - OP088 The eyes say it all! - Motor improvement and impulsivity after STN-DBS in Parkinson’s disease can be determined by activity of periocular facial muscles.
OP088 The eyes say it all! - Motor improvement and impulsivity after STN-DBS in Parkinson’s disease can be determined by activity of periocular facial muscles.
Objective: We anecdotally observed changes in lid fissure width related to motor improvement and impulsivity in patients after deep brain stimulation (DBS) in the subthalamic nucleus (STN) for Parkinson’s disease in clinical practice. Here we aim to analyze whether this phenomenon can be corroborated by analyzing the activity of Action Units (AU) of the face.
Methods: 12 patients who received STN DBS at our department and gave their informed consent were included. Each patient was examined at least twice in the timespan of a few days prior to surgery, to a year after surgery. Participants were filmed during an emotional imagination task with randomized topics of positive, neutral and negative valence (10 of each) in medication OFF state and at follow ups ≥ 3 months postoperatively in medication OFF state with stimulation ON.
We analyzed how activity of AUs surrounding the eyes correlated with simultaneously collected scores for the motor part of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS III), Self-Report Manic Inventory (SRMI) and the Barratt Impulsiveness Scale (BIS-11). The activity of facial AUs as defined by Ekman et al. (2002) was extracted with the FaceReader 9 software (Noldus Information Technology bv., Wageningen, The Netherlands) (Fig. 1).
Results: We found a significant correlation (p = 0.002) between the alleviation of motor symptoms (i.e. reduced UPDRS III scores) and the activity of the upper lid raising muscles (Fig. 2A). Furthermore, we found significant associations of SRMI score with activity of the inner brow raiser muscle (p = 0.025) and BIS-11 attentional subscore with the brow lowerer muscle (p = 0.0002) (Fig. 2B+C).
Conclusion: Especially the activity of AUs surrounding the eyes appear to be indicative of motor status and measures of impulsivity and might therefore serve as suitable markers that could be analyzed during intraoperative test stimulation , DBS programming and surveilance of motor improvement over time.
References: Ekman P. and W. V. Friesen (1978). Facial Action Coding System: A Technique
for the Measurement of Facial Movement. Consulting Psychologists Press,
Palo Alto.
Jan Justus GRITZMANN, Joana PEREIRA, Nadja JARC, Thomas PROKOP, Nils SCHRÖTER, Michel RIJNTJES, Juan Carlos BALDERMANN, Volker Arnd COENEN, Bastian Elmar Alexander SAJONZ (Freiburg, Germany)
14:40 - 14:45
#46254 - OP089 The Role of Preoperative Immunonutritional Scores in Predicting Complications After STN DBS in Parkinson’s Disease.
OP089 The Role of Preoperative Immunonutritional Scores in Predicting Complications After STN DBS in Parkinson’s Disease.
Introduction: Parkinson’s disease (PD) is a progressive neurodegenerative disorder associated with systemic inflammation, immune dysregulation, and malnutrition, all of which may influence surgical outcomes. Subthalamic nucleus deep brain stimulation (STN DBS) is a widely used treatment for advanced PD, yet postoperative complications remain a concern. This study evaluates the predictive value of preoperative immunonutritional markers—including the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score, Aggregate Index of Systemic Inflammation (AISI), Lymphocyte-to-Monocyte Ratio (LMR), and Systemic Inflammatory Response Syndrome (SIRS) - for the risk of extracranial complications following STN DBS.
Methods: A retrospective cohort study was conducted on 138 PD patients who underwent STN DBS. Clinical and laboratory data were analyzed to assess the association between preoperative immunonutritional markers and postoperative complications, including infections, wound healing disturbances, and surgical revisions. Logistic regression and receiver operating characteristic (ROC) analysis were performed to evaluate the predictive power of these markers.
Results: SIRS emerged as the strongest predictor of complications (aOR = 6.99, 95% CI = 1.844–26.509), emphasizing the critical role of systemic inflammation in surgical outcomes. HALP, AISI, and LMR also demonstrated significant predictive potential, with HALP (AUC = 0.69) and LMR (AUC = 0.73) being the most robust predictors of complications. While albumin alone was not a significant predictor, it correlated with inflammatory markers and comorbidities, underscoring its role in broader risk assessments.
Conclusion: This study underscores the value of preoperative immunonutritional markers in predicting complications following STN DBS in PD patients. Incorporating these markers into clinical risk stratification may enhance preoperative planning and personalized postoperative care, ultimately improving surgical outcomes. These findings, while promising, warrant validation through prospective, multicenter studies to refine predictive models and enhance patient outcomes.
Marina RAGUŽ (Zagreb, Croatia), Marko TARLE, Petar MARČINKOVIĆ, Darko ORESKOVIC, Vladimira VULETIC, Darko CHUDY
14:45 - 14:50
#46261 - OP090 Clinical prediction of bradykinesia kinematics during ramping subthalamic stimulation in parkinson’s disease.
OP090 Clinical prediction of bradykinesia kinematics during ramping subthalamic stimulation in parkinson’s disease.
Introduction:
Adaptive deep brain stimulation systems are under development; however, it has not been explored to what extent the bradykinesia parameters improve with raising subthalamic stimulation (STN-DBS) intensity and which clinical parameters predict its improvement slope.
Methods:
Thirty Parkinsonian patients treated chronically with bilateral STN-DBS were recruited for this study. Patients were asked to perform motor tasks (finger tapping/FT, hand grasping/HG, and pronation-supination/PS) with their more affected hand. Kinematic parameters were collected using a 3D gyroscope placed on the index finger. Stimulation was increased in 0.5V steps, and the immediate response was analyzed. Measurements were repeated on four previously selected stimulation levels (0: OFF, 1-3: improving bradykinesia), with a minimum of 10-minute resting periods in between, to observe the delayed response.
We calculated speed, amplitude, and rhythm for each motor task and analyzed their slope from their sequential values. We performed support-vector machine (SVM) prediction analysis to explore how clinical parameters and active contact location predict the slope of bradykinesia improvement.
Results:
The slope of speed improvement was significantly higher than the slope of amplitude or rhythm change (ANOVA for repeated measures, PARAMETER effect: F2,58=29.71, p<0.001; post hoc comparisons: pSPEED-AMP<0.001, pspeed-rhythm<0.001; pamp-rhythm=0.71). There was no difference between the prompt and delayed stimulation-induced alteration of speed, amplitude, and rhythm in the three tasks.
The 3D distance of active contact from the center of the dorsolateral STN, the preoperative Hoehn-Yahr stage, the postoperative UPDRS-III scores (on medication and on stimulation), and the postoperative L-DOPA dosage predicted the bradykinesia improvement (Shapley value>0.01).
Conclusion:
The reaction of speed was the greatest to ramping stimulation and was stable after a minimum of 10 minutes. The stage of Parkinson’s disease, the postoperative efficacy of STN-DBS, and the active contact location predicted the slope of bradykinesia improvement, emphasizing the importance of precise targeting during deep brain stimulation surgery.
Disclosures:
The authors declare no conflict of interest.
Marcell PALOTAI (Budapest, Hungary), Ádám József BERKI, László HALÁSZ, Loránd ERŐSS, Gábor FEKETE, László BOGNÁR, Muthuraman MUTHURAMAN, Hao DING, Péter BARSI, Andrea KELEMEN, Borbála JÁVOR-DURAY, Gertrúd TAMÁS
14:50 - 14:55
#46307 - OP091 Looking in the Mirror: Selfobject Needs Predict Satisfaction after DBS.
OP091 Looking in the Mirror: Selfobject Needs Predict Satisfaction after DBS.
Background:
Deep Brain Stimulation (DBS) is an established neurosurgical intervention for motor symptom management in Parkinson’s disease (PD), with demonstrated benefits in objective clinical metrics. However, subjective experiences of post-surgical success are highly variable. Selfobject needs refer to unconscious psychological needs for validation (mirroring), admiration of others (idealization), and a sense of belonging or likeness (twinship). These needs, when unmet, may reflect narcissistic vulnerability. While selfobject needs have been implicated in recovery and satisfaction following other medical interventions, their role in shaping perceived outcomes after DBS has not been previously established. This study examined whether mirroring, idealization, and twinship needs predict subjective versus objective responses following DBS.
Method:
Twenty-four PD patients PD patients (M_age = 58.5; M_disease duration = 9.0 years) undergoing DBS were assessed preoperatively and six months postoperatively. Objective outcomes included the Unified Parkinson’s Disease Rating Scale (UPDRS) and Levodopa Equivalent Daily Dose (LEDD). Subjective outcomes included the Parkinson’s Disease Questionnaire-8 (PDQ-8), WHOQOL-BREF, PHQ-9, GAD-7, and two Likert items assessing satisfaction and perceived success. Baseline narcissistic traits were measured using the Self- object Needs Inventory.
Results:
Higher baseline mirroring needs were significantly associated with improvement in psychological well-being (r = .46, p = .032), environmental QoL (r = .43, p = .044), postoperative satisfaction (r = .55, p = .015), and perceived success (r = .49, p = .035). Idealization needs predicted improvements in psychological (r = .46, p = .033), social (r = .53, p = .011), and environmental (r = .46, p = .031) domains. Interestingly, greater denial of twinship and idealization needs was associated with larger reductions in anxiety symptoms (r = –.49, p = .023), possibly reflecting a protective role of defensive mechanisms or reduced dependency on external validation. No significant correlations were observed between selfobject needs and objective outcomes (UPDRS, LEDD). Additionally, longer disease duration was negatively associated with postoperative improvement in disability (β = –.445, p = .038).
Conclusions:
In sum, selfobject needs, particularly mirroring and idealization, were consistently associated with perceived psychological and QoL improvements, but not with motor or pharmacological outcomes. These findings highlight the potential value of incorporating brief psychological assessments of selfobject related needs into preoperative evaluations. Accurate assessment of patients’ mirroring or idealization tendencies may help clinicians better align expectations, anticipate subjective responses, and tailor postoperative support to optimize satisfaction and emotional adjustment.
Anna ILIN, Shani BEN-VALID (Tel aviv, Israel), Amir BANNER, Genela MORRIS, Achinoam SOCHER, Vered LIVNEH, Yuval HANINOVICH, Firas FAHOUM, Ido STRAUSS
14:55 - 15:00
#48017 - OP092 Experimental videogrammetric evaluation of sagittal human gait in patients with freezing by Parkinson's disease versus healthy subject.
OP092 Experimental videogrammetric evaluation of sagittal human gait in patients with freezing by Parkinson's disease versus healthy subject.
Human gait is a complex set movement that involves the swinging of the body, and its understanding requires several areas of knowledge. People with Parkinson's disease (PD) represent a complexity due to the patient's characteristics, which also affects different people who suffer from it; the patients have tremors, lose balance, and freeze their limbs. The freezing of gait (FoG) usually occurs in people with advanced parkinsonism. This study aims to analyze the videogrammetry of sagittal balance to obtain the corridor behavior of healthy people compared to patients affected by FoG. The outcomes of this evaluation of both corridors are shown below. Leveraging the power of artificial intelligence, we propose an estimation of gait correction in people with Parkinson's, showcasing the cutting-edge nature of our research.
Emphasizing gait analysis, particularly through videogrammetry, is a valuable tool in understanding the movement about walking. this study confirms the potential of gait videogrammetry as a valuable tool in the assessment of PD. By providing detailed insights into gait abnormalities, this method offers promise in improving the diagnosis and treatment of Parkinson's disease. However, further studies are needed to optimize its use and explore its full potential in clinical practice .
For people with PD pathology analysis, is considered in two stages for gait, the OFF gait, which refers to the person not having taken their medication so the Parkinson's pathology becomes more evident as they reach the time of their next dose; and the ON gait which refers to the time when the patient already has their dose of medication and is acting within a range of 30 minutes to 1 hour to be able to perform the gait. We can observe the behavior of gait pattern in OFF gait, the walking is erratic and It takes a little longer to complete every gait cycle. We can evaluate the behavior of ON gait cycle, and we can observe a considerable improvement in gait can be noted.
This study provides important insights about gait cycle and how to understand in a sagittal balance only focused in the knee articulation, further research is needed to explore the full potential of this method in clinical settings. The conclusion also suggests that integrating this approach with other diagnostic tools could improve the management of Parkinson's disease, especially in its advanced stages where gait disturbances are more pronounced. But there is not enough data to validate patterns with Parkinson, this re-search cannot be determined but its an opportunity to find more subjects that can afford data.
Fiacro JIMENEZ (Mexico, Mexico), Jocabed MENDOZA-MARTÍNEZ, Karla C. PÉREZ-GONZÁLEZ, Cristopher R. TORRES-SANMIGUEL
15:00 - 15:05
#48037 - OP093 What is it like to experience deep brain stimulation surgery for Parkinson’s disease?
OP093 What is it like to experience deep brain stimulation surgery for Parkinson’s disease?
Background
Deep Brain Stimulation (DBS) for Parkinson’s Disease (PD) can be performed through either an awake or an asleep approach. While the clinical efficacy and motor outcomes of both techniques are well-documented, the subjective perioperative experiences of people with PD remain underexplored. Existing research on patient experience primarily relies on quantitative methods and questionnaires, which offer limited insight into the nuanced, lived experiences of patients. As surgical techniques continue to evolve and shared decision-making gains prominence in healthcare, it becomes increasingly important to understand how patients perceive and navigate the DBS journey. A qualitative, phenomenological approach can help address this gap by focusing on individual meaning-making and the patient’s perspective.
Objective
To explore the lived experiences of people with Parkinson’s disease undergoing DBS-surgery using a phenomenological approach.
Methods
A total of 15 semi-structured in-depth interviews were conducted with people with PD who underwent awake (n=7) or asleep (n=8) DBS surgery within the past six months at Radboud University Medical Center, Maastricht University Medical Center, or HagaHospital. Interviews were audio-recorded, transcribed verbatim, and analysed using ATLAS.ti. Coding and thematic analysis were independently performed by two researchers (CtDM, FJ), with bracketing employed to minimize bias. Themes were refined collaboratively within the research team.
Results
Data collection is nearing completion. We will finalise the interviews and analysis by June 2025. Key themes identified in the analysis will be presented at the congress.
Discussion
This study provides insight into how people with PD experience the DBS process before, during, and after surgery. By capturing what patients find most impactful and memorable, the findings aim to support clinicians in guiding patients more effectively through the DBS trajectory. Understanding the emotional and experiential aspects of both awake and asleep procedures can inform preoperative counselling, enhance shared decision-making, and improve overall patient-centred care in DBS.
C.a.j.m. TE DORSTHORST-MAAS (Nijmegen, The Netherlands), F.j.a. JOOSTEN, R. H. M. A. BARTELS, Maroeksa ROVERS, R. S. VINKE, R. A. J. ESSELINK
15:05 - 15:10
#46085 - OP094 Acute low-frequency globus pallidus internus deep brain stimulation in the treatment of dystonia: a double-blind cross-over study.
OP094 Acute low-frequency globus pallidus internus deep brain stimulation in the treatment of dystonia: a double-blind cross-over study.
Introduction
Globus pallidus internus deep brain stimulation (GPi-DBS) is an effective treatment for severe focal dystonia. However, the stimulation parameters are largely taken from protocols used in other movement disorders. High-frequency stimulation (≥100Hz), while effective, may induce parkinsonian motor side-effects. The aim of this study was to compare low- and high-frequency GPi-DBS in terms of their effects on dystonic symptoms and parkinsonian side effects in patients with focal dystonia.
Methods
This double-blinded randomized crossover trial included patients with focal dystonia (N=10), each undergoing three stimulation conditions: OFF, 80Hz, and 130Hz. After initial baseline measurements with the current stimulation settings, the stimulation was switched off, followed by a minimum one-hour washout period before the evaluation OFF stimulation conducted. Participants were then randomized to receive either 80Hz or 130Hz GPi-DBS, with a one-hour washout before assessment at the assigned frequency. Subsequently, they were switched to the alternate stimulation condition, followed by another one-hour washout before undergoing their final evaluation. Each evaluation assessed dystonic motor symptoms (BFMDRS and TWSTR), gait (APDM’s Mobility Lab system), and parkinsonian motor symptoms (MDS-UPDRS-III).
Results
Dystonic motor symptoms significantly improved with both low- and high-frequency GPi-DBS, as reflected in the motor subscale of the BFMDRS scores (Low: Z=-2.67, p=0.004; High: Z=-2.67, p=0.004) and the motor subscale of the TWSTR (Low: Z=-1.90, p=0.029; High: Z=-2.53, p=0.006). Gait speed also improved with both low- and high-frequency stimulation (Low: Z=-2.29, p=0.011; High: Z=-2.80, p=0.025), as did step length (Low: Z=-1.79, p=0.037; High: Z=-2.70, p=0.035). There were no significant differences between low- and high-frequency stimulation for dystonic motor symptoms (BFMDRS: Z=-1.70, p=0.433; TWSTR: Z=0.99, p=0.163), gait speed (Z=-0.05, p=0.480), and step length (Z=-0.71, p=0.238). Only the bradykinesia subscore of the MDS-UPDRS-III decreased OFF stimulation (χ²=6.46, p=0.040), with a significant difference observed compared to high-frequency stimulation (Z=-2.06, p=0.020), but not compared to low-frequency stimulation (Z=-1.52, p=0.064). There was no effect of frequency of stimulation on bradykinesia (Z=-1.10, p=0.140), or on other parkinsonian signs (all p>0.05).
Discussion
Both high- and low-frequency GPi-DBS effectively improved dystonic symptoms and gait performance. Bradykinesia improved OFF stimulation and there was no effect of frequency of stimulation on bradykinesia and the other parkinsonian signs. Further large-scale multicentric studies exploring the acute and chronic effect of parameter changes are needed to optimize DBS in dystonia.
Martijn HENDRIKS (Nijmegen, The Netherlands), Matic GREGORČIČ, Denis KORADY, Jure POTOČNIK, Matej LOKAR, Rok BERLOT, Maja TROŠT, Saman VINKE, Dejan GEORGIEV
15:10 - 15:15
#46282 - OP095 Treatment of refractory hiccups using globus pallidus internus stimulation: a case report.
OP095 Treatment of refractory hiccups using globus pallidus internus stimulation: a case report.
Objective:
Persistent intractable hiccups are a rare and disabling condition that can be managed with pharmacologic therapies and neuromodulation techniques, such as vagal nerve stimulation or phrenic nerve stimulation. This case report aims to evaluate the therapeutic effect of deep brain stimulation (DBS) of the globus pallidus internus (GPi) in the treatment of refractory hiccups.
Methods:
A 70-year-old woman presented with a 2-year history of persistent hiccups, occurring at a frequency of 5–15 episodes per minute. The symptoms significantly impaired her ability to speak and eat and were associated with chest and throat pain. The patient also experienced social isolation and had a history of abdominal hernia. Pharyngeal dystonia was excluded, and segmental thoracic, diaphragmatic dystonia was suspected. She underwent bilateral GPi DBS implantation with parameters of amplitude 1.5 mA, pulse width 90 μs, and frequency 130 Hz.
Results:
One week and three months postoperatively, the patient demonstrated complete resolution of dystonic symptoms, with Fahn-Marsden Dystonia Rating Scale scores decreasing from 13 to 0. Additionally, pain reduced from 8 to 1 in NRS, depressive symptoms improved, with the Patient Health Questionnaire-9 (PHQ-9) score decreasing from 16 to 4, and overall quality of life improved as reflected in the EQ-5D-3L assessment.
Conclusion:
This case suggests that in rare presentations of intractable hiccups potentially related to diaphragmatic dystonia, bilateral GPi DBS may offer an effective therapeutic option.
Paweł SOKAL (Bydgoszcz, Poland), Damian PALUS, Marcin RUDAŚ, Magdalena JABŁOŃSKA
15:15 - 15:20
#47973 - OP096 Long-term effect of bilateral Gpi-DBS in belly dancer's dyskinesia.
OP096 Long-term effect of bilateral Gpi-DBS in belly dancer's dyskinesia.
Background: Belly dancer’s dyskinesia (BDD) is a rare form of dystonia characterized by rhythmic, repetitive, and involuntary movements of the abdominal wall, often accompanied by diaphragmatic jerks or flutter, which may lead to chest or abdominal pain and dyspnoea. The etiology of BDD is heterogeneous, with idiopathic, psychogenic, and drug-induced cases reported in the literature.
Case Presentation: We report two cases of BDD with long-standing symptoms refractory to medical therapy.
Case 1: A 36-year-old woman presented with a 7-year history of daytime involuntary abdominal dyskinetic movements.
Case 2: A 70-year-old man exhibited disease onset three years prior to surgical intervention. In both cases, local botulinum toxin injections and pharmacological treatments yielded only transient and minimal improvements. Extensive diagnostic workup, including brain and spinal cord MRI and comprehensive laboratory testing (copper, ceruloplasmin, thyroid function, and peripheral blood smear), revealed no significant abnormalities.
Methods: Diaphragmatic contractions were confirmed by fluoroscopy. Involuntary abdominal movements were recorded pre- and postoperatively using an infrared video-based real-time passive marker motion analysis system (RTPAM) with a sampling rate of 50 frames per second. Retroreflective markers were placed bilaterally on the abdominal wall. Motion analysis and spectrogram evaluation were performed using MATLAB-based software (MathWorks, Sherborn, USA).
Bilateral deep brain stimulation (DBS) targeting the posteroventral lateral globus pallidus internus (GPi) was performed using a frameless MRI-to-frame-based CT fusion-guided stereotactic technique (MHT system, Bad Krozingen, Germany). Microelectrode recording (Neurospot, Neurostar, Germany) and intraoperative stimulation screening were used to optimize electrode placement. Quadripolar leads (model 6147, St. Jude Medical, USA) were implanted bilaterally in Case 1, and directional leads (Vercise Cartesia, Boston Scientific, USA) in Case 2. The DBS system was completed with a Brio (St. Jude Medical, USA) neurostimulator in Case 1 and a Vercise Gevia (Boston Scientific, USA) in Case 2. Postoperative CT confirmed accurate electrode positioning. No surgery- or stimulation-related complications were observed.
Results: At six months postoperatively, both patients demonstrated complete resolution of abdominal dyskinesia. Sustained clinical benefit was observed at 9 years in Case 1 and 5 years in Case 2. RTPAM analysis showed marked reduction in movement acceleration and disappearance of the dominant frequency characteristic of the dyskinetic movements.
Conclusions: Bilateral GPi-DBS is a safe and effective long-term treatment option for patients with refractory belly dancer’s dyskinesia. Additionally, RTPAM serves as a valuable tool for the objective quantification of involuntary abdominal movements and for assessing therapeutic efficacy.
István VALÁLIK (Budapest, Hungary), Ákos JOBBÁGY
15:20 - 15:25
#46235 - OP097 Intra-Operative Motor Stimulation During Asleep Subthalamic Nucleus Deep Brain Stimulation Predicts Post-Operative Motor Side Effects.
OP097 Intra-Operative Motor Stimulation During Asleep Subthalamic Nucleus Deep Brain Stimulation Predicts Post-Operative Motor Side Effects.
Rationale: Asleep subthalamic nucleus deep brain stimulation (STN-DBS) has shown therapeutic effects comparable to awake DBS for Parkinson's disease (PD). However, it doesn't typically utilize neurophysiological testing with microelectrode recordings, potentially leading to postoperative motor side effects at low thresholds, necessitating lead repositioning. Therefore, it is essential to identify predictive factors for postoperative motor side effects during asleep DBS. Since general anesthesia necessitates higher stimulation to obtain motor responses, we hypothesized higher pulse widths stimulation intraoperatively corelates with postoperative clinical pulse widths stimulation motor side effects. Furthermore, we aimed to investigate the anatomical substrates underlying these side effects.
Methods: We intraoperatively stimulated PD patients undergoing asleep STN-DBS below 4 mA amplitude, 130 Hz frequency, and pulse widths of 120 µsec at the bottom, second bottom, and top contacts while visually assessing for muscle contractions, or lack thereof, in peripheral or cranial muscles. Similarly, we postoperatively stimulated patients below 4 mA amplitude, 130 Hz frequency, and pulse widths of 60 µsec, which is clinically used. We used a Fisher’s exact test to analyze whether the occurrence of postoperative motor side effects was significantly associated with the occurrence of intraoperative motor activation. To assess the relationship between the breakdown of intraoperative motor activation and the anatomical substrates, we delineated corticobulbar tracts (CBT), corticospinal tracts (CST), and frontal eye fields (FEF) tract using tractography, and investigated the spatial relationship between STN-DBS contacts, CBT, CST, and FEF.
Results: A total of 19 patients were included. The threshold for intraoperative motor activation was significantly associated with the occurrence of postoperative motor side effects (p-value = 0.021). With tractography analysis, CBT and FEF were significantly closer to the STN-DBS contacts than CST (p < 0.001).
Conclusion: In PD patients undergoing asleep STN-DBS, intraoperative motor activation at a pulse width of 120 µsec below 4 mA is significantly associated with the occurrence of postoperative motor side effects below 4 mA.
Kazuki SAKAKURA, John PEARCE, Nathan PERTSCH, Vivekanudeep KARRI, Qianyi PU, Freya MEHTA, Neepa PATEL, Sepehr SANI (Chicago, USA)
15:25 - 15:30
#47977 - OP098 Image-guided asleep STN-DBS surgery for Parkinson’s disease at Oslo University Hospital – a prospective study.
OP098 Image-guided asleep STN-DBS surgery for Parkinson’s disease at Oslo University Hospital – a prospective study.
Aim: Image-guided and image-verified asleep deep brain stimulation (iDBS) surgery relies on high stereotactic accuracy to obtain good clinical outcome. Here, we report our surgical accuracy in a cohort of Parkinson's Disease (PD) patients with STN-DBS and their clinical outcome at 1-year follow-up.
Methods: All patients undergoing frame-based iDBS surgery (September 2020-January 2024) without microelectrode recording for PD at Oslo University Hospital were examined prospectively. Intracranial electrode trajectories were planned using dedicated 3T MRIs, and the electrode position was reviewed intraoperatively with CT. The Euclidean target point error was calculated, and the electrodes were replaced if the error was more than 2 mm and the electrode contacts did not reach the STN. The primary endpoints were to examine whether iDBS resulted in improvement of clinical outcomes in individual patients from pre-operative to 1 year of STN-DBS therapy, using the Med-off state Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III, and the 39-Item Parkinson's Disease Questionnaire (PDQ-39) scores. Secondary endpoints included the duration of surgery, surgical complications, DBS response ratio and reduction of levodopa equivalent daily dose (LEDD).
Results: Seventy-two consecutive PD patients who underwent bilateral STN-DBS surgery (mean age 59 ± 7 years; mean disease duration 9.8 ± 3.5 years) were included in the study. In our cohort, the mean stereotactic coordinates (target point) for STN were X: 11.4, Y: -3.1, and Z: -5.8. The mean Euclidean error from intended STN target to final electrode was 0.9 ± 0.4 mm, and 3/144 electrodes (2.1%) were replaced intraoperatively. Surgical site infection occurred in one patient (1.4%) and there was no intracerebral hemorrhage. The mean surgery time was 97 ± 23 minutes. There was a mean reduction of the MDS-UPDRS III off score from 40.2 ± 13.0 pre-operatively, to 18.2 ± 9.2 post-operatively (p = 0.001). The mean quality index was 0.93, and 34/66 (51.5%) patients had quality index > 1. The PDQ-39 scores improved (28.4 vs 24.1, p = 0.166), and the LEDD was reduced (1287 vs 591 mg, p = 0.001). The mean average current intensity was 2.2 ± 0.6 mA for both electrodes.
Conclusion: Our data show that we achieved high stereotactic accuracy of electrode implantation, low complication rates, and short surgery time in this cohort of PD patients undergoing iDBS surgery. Importantly, the patients had significantly improved MDS-UPDRS III scores, reduction of LEDD, and also improved quality of life at 1 year follow-up.
*Mughal A. and Jusufovic M. contributed equally to this work
Awais MUGHAL (Oslo, Norway), Mirza JUSUFOVIC, Jugoslav IVANOVIC, Silje BJERKNES, Ane KONGLUND
|
13:30-15:10
Added to your list of favorites
Deleted from your list of favorites
B39
PARALLEL SESSION 11
Imaging
PARALLEL SESSION 11
Imaging
Chairpersons:
Volker COENEN (Head of Department) (Chairperson, Freiburg, Germany), Marie KRUEGER (Consultant Neurosurgeon) (Chairperson, London, United Kingdom), Atilla YILMAZ (Nerosurgeon) (Chairperson, Istanbul, Turkey)
13:30 - 13:40
#46038 - OP034 The rubral wing and its connectome.
OP034 The rubral wing and its connectome.
Purpose: Magnetic resonance imaging developments for optimal targeting of stereotactic surgical approaches for tremor have yielded white matter attenuating sequences (FGATIR/FLAWS) directly showing a targetable hyperintensity in the subthalamic region (rubral wing, RW). The RW has been reported to coincide with the dentato-rubro-thalamic tract (DRT) without determining its exact portion (crossed, DRTx or uncrossed, DRTu). RW discernibility on the single subject level might be hampered due to low signal-to-noise ratio (SNR), potentially interfering with surgical outcomes.
Methods: We performed manual delineations of RW on FLAWS sequences in native space (n=77, 3 raters) and warped results into MNI 152. From this tractographic analyses of DRT (human connectome project body, n=1000) were carried out, using the red nuclei and RW as waypoints. In another approach, we investigated fiber tightness peaks of DRTX vs DRTu portions along their z-axis.
Results: Identification of RW was possible in all subjects. DICE coefficient for volumetric comparison was rather low with 0.54. Euclidean distance of the RW center of gravity (COG) between raters was <2mm. Tractographically, RW represents an optimal waypoint to define DRTx with optimal constraining fibers to the ipsilateral precentral gyrus (PCG). A peak for fibers descending from PCG (DRTx only) was found to coincide with RW.
Conclusions: COG can be determined with good accuracy, but full volumetric appreciation is difficult on the single subject level (SNR), potentially necessitating additional DRT tractography for surgical targeting. In the light of this connectomic study, the RW‘s role as a valid and individually visualizable tremor target for DBS and SLS is strengthened. In a way, the application of the FLAWS/FGATIR delineation of RW would potentially allow surgeons to rely on a more generic personalized MRI grey sequence based and geometrically accurate targeting for tremor without a cumbersome use of the more demanding DWI technology. However, the volumetric interpretation of the structure might not be unequivocal (especially in its anterior-posterior extensions) and care must be taken to readily identify the structure on a single case basis. This potentially necessitates the further use of adjunct imaging modalities (DWI) in cases of a low quality RW depiction with FLAWS/FGATIR to avoid detrimental side effects.
Volker Arnd COENEN (Freiburg, Germany), Alexander RAU, Horst URBACH, Bastian SAJONZ, Marco REISERT
13:40 - 13:50
#47966 - OP035 RegiNet: addressing key challenges in functional neurosurgery with robust, patient-specific deep brain nuclei segmentation.
OP035 RegiNet: addressing key challenges in functional neurosurgery with robust, patient-specific deep brain nuclei segmentation.
Millimetric precision is fundamental to functional stereotactic neurosurgery and research. This relies on accurate identification of deep brain targets, which in turn often requires time-intensive manual segmentation, machine learning generalisability, and atlas limitations. We introduce RegiNet, our novel deep learning framework, addressing three critical issues.
First, rapidly and robustly generating patient-specific deep brain nuclei segmentations across varied magnetic field strengths and MRI protocols. RegiNet, integrating subject-specific anatomical priors into a transformer-based model, demonstrates high fidelity for the subthalamic nucleus (STN) (Dice Similarity Coefficient (DSC) 0.94, 95th percentile Hausdorff Distance (HD95) 1.64 mm). This performance significantly outperformed three leading academic and industry segmentation algorithms by >28% on exclusively clinical STN-DBS scans (N=120). For thalamic nuclei—Ventral intermediate (Vim), Ventro-oral (Vo), and Ventro-posterior (Vp)—using multimodal inputs like fractional anisotropy maps, RegiNet achieved a mean DSC of 0.87. Crucially, HD95 values were consistently below the 2.0 mm surgical accuracy threshold (mean HD95: Vim ~1.36 mm, Vo ~1.60 mm, Vp ~1.62 mm).
Second, domain shift, which degrades segmentation model performance across imaging centers, slowing adoption and necessitating burdensome, site-specific retraining. RegiNet’s architecture demonstrates inherent cross-scanner/protocol robustness. In leave-one-out experiments testing adaptability to unseen field strengths (1.5T, 3T, 7T), RegiNet retained an average DSC performance of 82% and never produced null predictions, unlike baseline models which showed significant degradation and failures (e.g., SwinUNETR 72% retention with 10 nulls, DINTS 49% with 16 nulls). On completely unseen external data (N=476), RegiNet achieved 86% performance retention, starkly contrasting with SwinUNETR (48% retention, 26% failure rate). This was evidenced by successful segmentation from T1w/T2w and fractional anisotropy maps, maintaining performance across diverse scanner vendors. Our methods may offer rapid adaptation to site-specific protocols without extensive manual annotation, reducing retraining needs.
Third, the inadequacy of standard atlases (e.g., HCP-1065 from young healthy adults) for patients with disparate neuroanatomy, like older individuals with thalamic atrophy. Comparing RegiNet-derived Vim segmentations in our Parkinson's disease tremor (PDT) and Essential Tremor (ET) patients (N=45) against HCP-1065 templates (coordinates relative to AC-PC, Asymmetric MNI 2009b space) revealed substantial differences. RegiNet left Vim centroid (X=-13.62, Y=-18.43, Z=-2.38 mm) versus HCP-1065 (X=-14.36, Y=-18.20, Z=-1.58 mm) showed 1.11 mm displacement and 2.12 mm boundary disagreement (HD95). Right Vim showed 1.28 mm centroid displacement (RegiNet: X=13.12, Y=-17.56, Z=-2.56 mm; HCP-1065: X=14.14, Y=-17.40, Z=-1.80 mm) and 2.87 mm boundary disagreement. Our population-specific Vim locations were consistently more posterior/inferior, with >2 mm boundary disagreements, quantifying standard atlas mismatch. These results quantify potential systematic errors in normalised diffusion/quantitative MRI where patient-specific scans can be scarce.
RegiNet offers robust, precise, subject-specific analysis, pivotal for advancing large cohort studies where accurate individual segmentations are often infeasible.
Robert Tsi-Lok HO (London, Hong Kong), Francisca FERREIRA, Mikael BRUDFORS, Maarten BOT, John ASHBURNER, Harith AKRAM
13:50 - 14:00
#47974 - OP036 Accuracy and clinical effectiveness of CranioPass: a self-developed software for DBS planning in tremor treatment.
OP036 Accuracy and clinical effectiveness of CranioPass: a self-developed software for DBS planning in tremor treatment.
Objectives: To compare the performance of Brainlab’s commercially approved planning software with the newly developed CranioPass software in stereotactic neurosurgical planning for tremor treatment in patients unresponsive to medication and eligible for Deep Brain Stimulation (DBS).
Methods: Twelve patients (8 male, 4 female; mean age 62.8 ± 11.9 years) with a mean tremor duration of 7.5 ± 5.5 years (range: 4–22) were included. Diagnoses included secondary Parkinson’s syndrome (6), essential tremor (2), dystonic tremor (2), Parkinson’s disease (1), and post-thalamic hemorrhage (1). Nine patients underwent bilateral DBS lead implantation; three had right-sided implantation. Electrodes were implanted in GPi (1 patient), STN (1), and Vim-PSA (10). Six patients received the Infinity 7 system (Abbott, USA) and five received the Vercise Genus system (Boston Scientific, USA). Postoperative CT scans were performed one day after surgery and fused with preoperative stereotactic CT for target verification. Target coordinates were calculated using both Brainlab and CranioPass software and compared using the Riechert-Mundinger (RM) target point simulator. Lead tip positions on CT were compared with planned coordinates. Tremor was assessed using the Fahn-Tolosa-Marin Tremor Rating Scale (FTMTRS) at baseline, 4 weeks, and 16 weeks postoperatively.
Results: Among 21 implantations (12 left, 9 right), coordinate differences between the two software platforms were minimal. A 0.1 mm difference in the Z-axis was observed in one case. Arc settings were identical in 13 cases; A 0.1-degree difference has been observed in one parameter in 3 settings on the left and in 3 settings on the right side. In two values (0.2 and 0.1 degree) in 1 setting, and 0.1 and 0.1 degree in 1 setting. The average deviation between planned and actual lead tip positions was 0.7 ± 0.6 mm (left: 0.6 ± 0.7 mm; right: 0.8 ± 0.6 mm), which falls within the voxel size of the imaging datasets. FTMTRS scores showed an 87.5% improvement at 16 weeks, confirming clinical effectiveness.
Conclusions: CranioPass demonstrated high accuracy and consistency compared to Brainlab software in stereotactic planning for DBS. Surgeries based on CranioPass planning were successfully completed with no adverse events. These results suggest CranioPass is a reliable alternative for stereotactic DBS planning, supporting its potential for broader clinical use.
István VALÁLIK (Budapest, Hungary), Ferenc PONGRÁCZ
14:00 - 14:10
#46320 - OP037 The role of microcirculation as “vessel alarm” in stereotactic and functional neurosurgery.
OP037 The role of microcirculation as “vessel alarm” in stereotactic and functional neurosurgery.
Intact cerebral microcirculation is a key function for vital neural tissue. The cerebral microcirculation can be measured with laser Doppler flowmetry (LDF). Our research group has adapted an LDF system for use in relation to neurosurgical intervention that can investigate the microcirculation and act as a “vessel alarm” during stereotactic and functional neurosurgery. The aim is to give an overview of the system and give examples of applications already implemented and to suggest potential future applications.
The system comprises a LDF module (PF5010/PF6010, Perimed AB, Sweden) with an inhouse developed software (Labview/MatLab) for data collection, storage and real-time visualization of tissue Perfusion (microcirculation) and TLI (total light intensity, grey-whiteness). A set of optical probes have been designed. Probes are available for stereotactic guidance and creation of a trajectory in relation to deep brain stimulation (DBS) implantations, and stereotactic and neuronavigated brain tumor biopsies. In the latter set up the probes are adjusted to the inner cannula of a biopsy kit modified with an opening at the tip. The opening allows forward looking measurements in tissue not yet touched by the probe.
The system has been used in more than 130 DBS implantations and 50 brain tumor biopsies. As all probes are “forward looking” the microcirculation is recorded about 1 mm beyond the probe tip. Data is presented in real-time on a monitor during surgery. If necessary, e.g. due to very high Perfusion, the trajectory can be changed to avoid a hemorrhage. As the probe is securely fastened to the stereotactic device or neuronavigational system potential movement artifacts are reduced to a minimum. In addition, the TLI signal acts as an in-situ tracer of tissue grey-whiteness and can together with the Perfusion signal support in intraoperative guidance through brain structures during insertion of the probe. The system has a resolution of 0.5 mm, which makes it possible to detect changes in grey-whiteness between e.g. thin laminae in the pallidum and thalamus.
Additional applications not yet explored are cell line implantations, drug administration, RF-lesioning and guidance during LITT. In principle all types of stereotactic interventions are candidates for use of the LDF-system. In conclusion, micocirculation measurements can together with grey-white matter identification help the surgeon avoid vessels along a trajectory. It can also be used to study cerebral microcirculation in healthy and diseased tissue in relation to stereotactic and functional neurosurgery.
Karin WÅRDELL (Linköping, Sweden), Johan RICHTER, Peter ZSIGMOND
14:10 - 14:20
#45961 - OP038 Structural connectivity of the basal ganglia from patient-individual tractography for predicting therapeutic effects of deep brain stimulation in Parkinson’s Disease.
OP038 Structural connectivity of the basal ganglia from patient-individual tractography for predicting therapeutic effects of deep brain stimulation in Parkinson’s Disease.
Background
In Parkinson's disease (PD) patients, modulation of the fibre tracts of the cortico-basal ganglia-thalamo-cortical loop is the presumed mechanism of action of deep brain stimulation (DBS) of the subthalamic nucleus (STN). Therefore, we explored patient-individual cortical structural connectivity of the volume of tissue activated (VTA), as well as DBS-induced modulation of fibre tracts connecting the STN with cortical and sub-cortical nodes and their correlation with therapeutic effects.
Patients and Methods
A retrospective cohort of n = 69 PD patients treated with bilateral DBS of the STN was analysed. Clinical response was assessed from the DBS-induced change in the UPDRS-III motor scores (total and symptom-specific sub-scores for tremor, rigidity, and bradykinesia) under regular medication after a median follow-up of 9.0 (range 2.6 – 20.2) months. Tractography based on patient-individual diffusion-weighted MRI was employed in two ways. Firstly, whole brain tractography was used to identify the cortical connections of fibres passing the VTAs. Then, reconstruction of specific white matter pathways of the motor loop connecting the STN with the basal ganglia and cortex (informed by the regions obtained by the first analysis) were used to identify the proportion of fibres within these pathways which was modulated by STN-DBS. This proportion of pathway modulation was used in a correlative analysis with clinical outcomes.
Results
Streamlines traversing the VTAs were primarily connected to the supplementary motor area (SMA), pre-SMA and the premotor cortex. Streamlines from both primary motor (M1) and sensory (S1) cortices were also identified, but to a much lesser degree. Within the pathways connecting the STN with the cortical and subcortical nodes, on average 30-40% (range 10-80%) of the fibres were modulated by STN-DBS. This proportion correlated significantly with the percentage change in UPDRS motor score for fibres connecting the STN to cortical regions like the SMA (ρ=0.28), pre-SMA (ρ=0.26), and ventral and dorsal pre-motor cortices (ρ=0.26 and ρ=0.29, respectively). Interestingly, modulation of the pathways between the STN and the globus pallidus externus (GPe, ρ=0.26) and internus (GPi, ρ=0.29) also showed significant correlation to UPDRS motor improvement. Finally, good clinical responses for both tremor and rigidity were associated with a significantly (p < 0.05) higher proportion of modulated fibres for the same cortico- and sub-cortico-STN connections.
Conclusions
Patient-individual tractography reveals that, in PD, most of the cortical fibres traversing the VTA are connected to the SMA. In addition, clinical efficacy is related to the proportion of DBS-affected fibres connecting the STN with nodes of both the hyperdirect (cortex-STN) and the indirect pathways (STN-basal ganglia). As such, patient-specific tractography, in particular of the basal ganglia, could be used in a clinical context as a tool to guide therapy.
Funding:
Funds have been provided by the European Joint Programme Neurodegenerative Disease Research (JPND) 2020 call “Novel imaging and brain stimulation methods and technologies related to Neurodegenerative Diseases” for the Neuripides project ‘Neurofeedback for self-stImulation of the brain as therapy for ParkInson Disease’.
Ricardo LOUÇÃO (Cologne, Germany), Josef MANA, Pablo ANDRADE, Ondrej BEZDICEK, Robert JECH, David LINDEN, Veerle VISSER-VANDEWALLE, Martin KOCHER
14:20 - 14:25
#45976 - OP039 Segmentation and structural connectivity of the putamen for targeted convection-enhanced drug delivery in parkinson’s disease: a tractography-based approach.
OP039 Segmentation and structural connectivity of the putamen for targeted convection-enhanced drug delivery in parkinson’s disease: a tractography-based approach.
Background:
Convection-enhanced drug delivery (CED) for Parkinson's disease (PD) is costly, and current methods lack precision, often targeting the entire putamen, leading to the potentially inefficient use of resources. Our study addresses this by exploring a more targeted approach for drug delivery, which could reduce treatment costs by focusing therapy on specific regions of putamen. By optimizing drug delivery, we aim to make treatments more cost-effective without compromising efficacy.
Methods:
Twenty PD patients underwent diffusion-weighted imaging (DWI) to visualize the structural connectivity within the brain. A commercial subcortical auto-segmentation tool was used to define the putamen as well as the amygdala, the STN, and the cerebellum. Utilizing the Julich Brain Atlas, nine cortical regions (Brodmann areas 44, 45, 3a/b, 4a/p, pre-SMA, SMA, and insula) were semi-automatically segmented. Structural connectomes were analyzed through tractography, allowing for the parcellation of the putamen into four segments in relation to the anterior commissure. Two trajectories, occipital and frontal, were tested for segment coverage using stepwise injection of the therapeutic agent. A genetic algorithm was employed to simulate these injections and to compare the coverage of the target region.
Results:
Tractography revealed a significant projection of motor areas to the superior posterior segment of the putamen, suggesting this region as a more specific target for treating motor symptoms in PD via CED. Non-motor connections were most common in the inferior posterior segment for the amygdala and in the superior anterior segment for the insula. Both occipital and frontal trajectories were found to be equally feasible for targeting the putamen segments, with surgical feasibility varying by individual patient anatomy, and achieved comparable coverage, with no significant difference between them, highlighting the need for personalized surgical approaches.
Conclusions:
The application of DWI and tractography for the segmentation of the putamen by its cortical connections offers a pathway towards targeted gene therapy in PD. Identifying the posterior superior segment as the primary recipient of motor area projections and confirming the feasibility of using either the occipital or frontal trajectory underscores the flexibility in optimizing therapeutic efficacy while conserving resources. This precise targeting could potentially allow for reduced dosages and more focused treatment, minimizing exposure to non-motor segments of the putamen and associated risks.
Edgar TESSMANN (Heidelberg, Germany), Schell MARIANNE, Sandro KRIEG, Martin JAKOBS
14:25 - 14:30
#46195 - OP040 Homology between 3T FGATIR images and Klüver-Barrera stained human brain sections in the thalamus.
OP040 Homology between 3T FGATIR images and Klüver-Barrera stained human brain sections in the thalamus.
【Introduction】
In stereotactic thalamic surgery, accurate identification of the target subnuclei significantly affects therapeutic outcomes. However, the boundaries of these subnuclei are often ambiguous and challenging to visualize with conventional MRI. For tremor treatment targeting the ventral intermediate nucleus (Vim), tractography is frequently used to delineate the dentatorubrothalamic tract (DRTT) as a reference. Nonetheless, distinguishing the DRTT from the posteriorly located medial lemniscus (ML) remains difficult and reproducibility is limited. In this study, we investigated the utility of FGATIR MRI imaging as a tool to clearly differentiate the DRTT from the ML and compared the results with Klüver-Barrera-stained human brain sections.
【Methods】
We compared preoperative MRI images used for planning MRI-guided focused ultrasound (FUS) thalamotomy with previously prepared human brain specimens. MRI scans were acquired using a Siemens MAGNETOM Lumina scanner, including 3D T2 Cube, 3D SPGR, DTI, and FGATIR sequences. Human brain specimens were sectioned into continuous frozen slices at 50 μm thickness, with every 500 μm slice stained using the Klüver-Barrera method and digitized. FUS thalamotomy was then performed, and the validity of the preoperative MRI images was evaluated by postoperative MRI and clinical outcomes.
【Results】
Among the preoperative imaging modalities, FGATIR provided excellent visualization of intrathalamic fiber tracts. Postoperatively, tremor was completely resolved without any adverse events such as sensory disturbances. MRI confirmed the lesion localized to the Vim including the DRTT, while the ML remained identifiable and unaffected.
【Discussion】
In tremor treatments targeting the Vim, the therapeutic "sweet spot" often lies near the boundary with the posterior ML, increasing the risk of sensory side effects when seeking maximal efficacy. For FUS, where microelectrode recording cannot be performed, visualizing the ML boundary is particularly important. FGATIR imaging may provide more accurate visualization of the ML within the thalamus compared to tractography.
Takefumi HIGASHIJIMA (Yokohama, Japan), Takashi KAWASAKI, Katsuo KIMURA, Sujong PAK, Katsumi SAKATA, Ryosuke TAKAGI, Satoshi HORI, Chikashi AOYAGI, Wataru SHIMOHIGOSHI, Kenichi TANAKA, Yukiko IWAHASHI, Asami SAITO, Toshio YAMAGUCHI, Tetsuya YAMAMOTO
14:30 - 14:35
#46255 - OP041 Improving deep brain stimulation targeting accuracy using zero echo-time (zTE) MRI.
OP041 Improving deep brain stimulation targeting accuracy using zero echo-time (zTE) MRI.
Introduction:
Deep brain stimulation (DBS) is a therapy for neurological disorders, with accurate electrode placement being key to its success. Poor electrode placement accounts for up to 46% of treatment failures.[1]
Most DBS workflows use co-registration (‘fusion’) of preoperative MRI with perioperative CT for planning and evaluating electrode placement. However, inherent differences between CT and MRI present challenges to image registration algorithms. While CT provides excellent bone contrast, MRI renders bone tissues as nonspecific low signal structures in most sequences.[2] Moreover, while intraoperative CT has increased surgical efficiency, its lack of soft tissue contrast results in co-registration based exclusively on bone signal, compounding this problem.[3]
Zero echo-time (zTE) imaging, a novel MR technique, enables precise reconstruction of cortical bone.[4] zTE achieves this via efficient capture of short-lived bone signal and uniform soft-tissue response. Here, we present an optimised zTE sequence (with preserved brain tissue contrast), applied to our DBS surgical workflow.
Methods:
We optimised and implemented a brain zTE sequence in our preoperative DBS protocol (Figure 1). 25 consecutive patients who underwent DBS following the novel imaging protocol were included (targets: STN, GPi, VIM, PPN).
For initial validation, CT to T1-MPRAGE co-registration was performed in FSL-FLIRT[5] (6 degrees-of-freedom (DOF), normalised mutual information (nMI) cost function) with- and without the zTE image as an intermediate step i.e. CT-T1 and CT-(zTE)-T1, Figure 2.
To directly assess impact on our clinical workflow, two separate stereotactic plans were created per patient using Renishaw NeuroInspire™: with either T1-MPRAGE or zTE as the base sequence. This generated similar CT-T1 and CT-(zTE)-T1 co-registrations (6DOF, nMI).[6]
Registration accuracy was evaluated by:
a) Extraction and quantification of registration and cost function matrices (CT-T1 vs. CT-(zTE)-T1)
b) Calculation of Dice similarity coefficients of overlap between segmented skull structures (CT-T1 vs. CT-(zTE)-T1)
c) Blinded anatomical landmark-based assessment by an Attending Neurosurgeon
Results:
a) The root mean square difference between CT-T1 and CT-(zTE)-T1 registration matrices across the cohort was (i) 1.10mm (95% CI 0.88 – 1.32, p<0.0001, two-tailed t-test) in the clinical workflow (Renishaw NeuroInspire) and (ii) 0.77 mm (95% CI 0.64 – 0.91, p<0.0001, two-tailed t-test) in the FSL-FLIRT pipeline. Euclidean errors for electrode contacts tips on postoperative imaging were similar in magnitude (p<0.05).
b) Dice similarity coefficients for segmented skull structure overlap were greater for CT-(zTE)-T1 vs CT-T1 across the cohort (p<0.05).
c) In the blinded qualitative expert evaluation, CT-(zTE)-T1 outperformed CT-T1 in 15/23 patients, with no discernible difference in the remainder. There were no instances of CT-T1 outperforming CT-(zTE)-T1.
Discussion and Conclusions:
We optimized a novel MRI sequence with clear delineation of bony anatomy and neuraxial structures (Figure 1). The addition of zTE to our DBS surgical workflow has resulted in a statistically significant difference in CT-MR co-registration, with improvements in registration accuracy. The clinical significance of this difference is currently under prospective investigation. While <2mm accuracy is considered acceptable in the movement disorders literature,[7] optimising image co-registration is an important component of reducing planning error and more accurately evaluating DBS targeting postoperatively.
A limitation of this study is the lack of ground-truth structural information, leading to the use of Dice overlap coefficients and qualitative expert evaluations. An ongoing study with MR/CT fiducials and phantoms seeks to address this (to be discussed). Finally, we will discuss current development work on postoperative zTE, which can better localize DBS electrodes than existing MR methods (Figure 3). This could be utilised in postoperative MRI protocols.
References:
1. Okun MS et al. (2005) Arch Neurol. PMID: 15956104
2. Florkow MC et al. (2022) J Magn Reson Imaging. PMID: 35044717
3. Kremer NI et al. (2019) Neuromodulation. PMID: 30629330
4. Wiesinger F, Ho ML (2022) Br J Radiol. PMID: 35616709
5. Jenkinson M et al. (2012) Neuroimage. PMID: 21979382
6. Geevarghese R et al. (2016) Stereotact Funct Neurosurg. PMID: 27318464
7. Kremer NI et al. (2023) J Neurol Neurosurg Psychiatry. PMID: 36207065
Amir Puyan DIVANBEIGHI ZAND (Oxford, United Kingdom), John ERAIFEJ, James John FITZGERALD, James T GRIST, Alexander Laurence GREEN
14:35 - 14:40
#46374 - OP042 Spatial-oriented tractography analysis.
OP042 Spatial-oriented tractography analysis.
Background: Tractography is a non-invasive method for reconstructing and visualizing white matter tracts based on MRI imaging. The use of tractography as a clinical and research tool is increasingly growing, presenting promising results for targeting and improving neuromodulation procedures outcomes. Moreover, white matter characterization plays a key role in exploring and understanding normal populations and brain disorders, while multiple macroscopic and microscopic features of the tracts can be extracted. However, to date, while different tracts may contain thousands of fibers, the common approaches to tract parameters analysis are summarizing the tract with a single mean value or performing 1D along-tract analysis, which may result in loss-of-data and minimize its clinical value.
Methods: 10 MRI scans of healthy subjects from the Human Connectome Project database, and 4 from Rambam Health Care Campus were acquired. Utilizing the DTI sequence, a tractography analysis of six tracts was performed for each subject bilaterally. An algorithm written in Matlab™ was built for tract characterization and inter-subject comparison of the tracts. The algorithm performs a 3D analysis of a tract while using its spatial and geometrical information to gather and integrate data. It utilizes the anatomical position along the tract, its morphology, and the angle around it to calculate and highlight the tract characteristics in a 3D fashion. The algorithm was applied to various tracts (motor and limbic) that highly differ in morphology, and statistical analysis was performed.
Results: A method for 3D or 2D visualization of white matter tracts geometrical and microstructural features, generating 616 different maps. Utilizing the method for fractional anisotropy analysis yielded maps with a unique pattern for each of the six tracts, while preserving high inter-patient reproducibility. This method provides a comprehensive observation of a tract and its surrounding structures, an inter-subject comparison of different tracts through various parameters, and a tool for abnormalities detection, while projecting the results on the patient or MNI space anatomy.
Conclusions: We present an innovative tool for analyzing white matter tracts. This tool may contribute to the research of white matter tracts, the understanding of various disorders, the detection of biomarkers, targeting, and even diagnosis.
Noam SHALEM (Haifa, Israel), Alon SINAI, Haim AZHARI, Ilana SCHLESINGER, Lior LEV-TOV
14:40 - 14:45
#48008 - OP043 Modelling DBS leads, volumes of activated tissue and probabilistic sweet spots: how robust is the current image processing workflow?
OP043 Modelling DBS leads, volumes of activated tissue and probabilistic sweet spots: how robust is the current image processing workflow?
Deep brain stimulation (DBS) has become essential to treat movement disorders. As technology evolves for an ever-finer modulation of pathological networks, increasing numbers of lead contacts and directionality complexify manual programming. Therefore, automated algorithms are being evaluated to predict DBS parameters based on probabilistic sweet spots. As a preamble, such software requires accurate co-registration between pre- and postoperative images, reliable brain volume normalization, brain shift correction and precise electrode detection. This computational workflow is already embedded in tools dedicated to DBS research – such as Lead-DBS. However, its robustness between distinct postoperative CT scans at the individual level has not yet been assessed systematically.
To test the robustness of the image-processing workflow applied in Lead-DBS, we identified 34 retrospective patients (68 hemispheres) with Parkinson’s Disease (PD) or Essential Tremor who were implanted with DBS electrodes and received two distinct postoperative CT scans. Each of these two scans was processed independently in Lead-DBS (v3.1) for electrode reconstruction, using the same preoperative MRI as reference. At the individual level, the computed coordinates of the lead tip were compared between image sets, as well as the resulting volumes of tissue activated (VTA) based on patients’ effective stimulation parameters. At the group level for PD patients, we computed and compared probabilistic maps of clinical improvement, based on the first or second postoperative CT scan respectively, using the same clinical data.
Between image sets, lead tip coordinates in the normalized space showed a mean translation of 0.78mm (min 0.21mm, max 1.70mm). In our dataset, the robustness of lead reconstruction was not significantly influenced by pneumocephalus, as we compared subgroups with or without intracranial air on the first postoperative CT. No significant correlation could be drawn between the extent of lead translation and the pneumocephalus volume. To assess the relevance of up to 1.70mm lead tip translation, VTAs were computed and compared between postoperative image sets. The mean Dice index was 0.73 (min 0.33, max 0.94). In the twenty hemispheres with lead tip translation of 1mm or more, the Dice index was systematically below 0.75. At the group level of PD patients, the two computed probabilistic maps were overlapping without significant discrepancy.
From this robustness study, we conclude that brain shift correction algorithms are reliable, as no significant lead translation could be imputed to pneumocephalus. As VTA computation varies in a mean range of 27% at the individual level, the current co-registration, normalization and lead detection workflow still requires some improvement to serve as a robust base for automated DBS parameter prediction. However, the variability of lead reconstruction disappears at the group level and the current image processing workflow seems sufficient to compute probabilistic maps of clinical improvement – and therefore sweet spots. Future studies with postoperative MRI instead of CT may show better robustness of lead reconstruction at the individual level.
Sabry BARLATEY (Bern, Switzerland), Alexis TERRAPON, Claudio POLLO, Andreas NOWACKI
14:45 - 14:50
#45934 - OP044 Predictive factors for the target shift of subthalamic nucleus during implanting deep brain stimulation electrode.
OP044 Predictive factors for the target shift of subthalamic nucleus during implanting deep brain stimulation electrode.
Objective: Although brain shifts can occur during deep brain stimulation (DBS) electrode implantation in the subthalamic nucleus (STN), the underlying causes and predictive factors for these shifts remain unclear. In this study, we utilized an index derived from X-ray films and software analysis to quantify the degree and direction of changes in the implanted electrodes relative to the STN and investigated potential clinical factors associated with these shifts.
Methods: We analyzed 42 DBS electrodes implanted in the STN of 21 individuals with Parkinson’s disease. Electrode tip displacement was evaluated using Elements (BRAINLAB®️) software based on computed tomography (CT) scans obtained immediately after implantation (1st CT) and after complete dissipation of intracranial air (2nd CT), comparing the two images (2nd CT – 1st CT). We used “Angle A,” measured from the anterior and posterior commissure line and horizontal plane on X-ray films, along with intracranial air volume obtained from Elements software, as predictive factors for brain shifts.
Results: The x-coordinate of the electrode tip shifted significantly in the lateral direction (0.4 ± 1.12 mm, p = 0.025), while the y- and z-coordinates shifted significantly in the anterior (1.35 ± 0.84 mm, p < 0.0001) and caudal (0.54 ± 0.63 mm, p < 0.0001) directions, respectively. The displacement in the y-coordinate significantly correlated with both intracranial air volume (p = 0.001, R = 0.476) and Angle A (p = 0.047, R = -0.308). The z-coordinate displacement correlated with intracranial air volume (p = 0.049, R = 0.305), although this correlation had limited statistical power. The x-coordinate displacement did not correlate with any assessed factors.
Conclusion: Electrodes implanted in the STN shifted laterally, anteriorly, and caudally following the resolution of intracranial air. Minimizing intracranial air entry through burr holes and maintaining the head position closer to the horizontal plane may help mitigate brain shifts during STN DBS implantation.
Tomoyoshi OTA (Niigata, Japan), Yosuke ITO, Hiroshi MASUDA, Masafumi FUKUDA, Makoto OISHI
14:50 - 14:55
#46117 - OP045 Role of preoperative mapping with nTMS in surgical planning and intrasurgical navigation of pediatric supratentorial lesions and correlation with intraoperative neurophysiological mapping.
OP045 Role of preoperative mapping with nTMS in surgical planning and intrasurgical navigation of pediatric supratentorial lesions and correlation with intraoperative neurophysiological mapping.
INTRODUCTION
Preoperative and intraoperative identification of eloquent areas near supratentorial lesions is standard practice in pediatric patients, particularly for motor and language mapping. Non-invasive tools such as transcranial magnetic stimulation (TMS) and DTI-based fiber tracking enhance surgical planning, while intraoperative techniques like neuromonitoring, neuronavigation, and intraoperative MRI support safe resections. This abstract presents the role of motor mapping with navigated TMS (Nexstim®) at Hospital Sant Joan de Déu (Barcelona), with results integrated into the surgical planning platform and used intraoperatively (Fig. 1).
MATERIALS & METHODS
Patients with supratentorial lesions were prospectively recruited from the surgical program. All underwent a diagnostic 3T MRI, with additional studies (fMRI, DTI, and nTMS) ordered based on lesion location and clinical presentation. nTMS is a non-invasive technique using magnetic stimulation with image-guided navigation to map the motor cortex. Muscle responses or MEPs (Motor Evoked Potentials) were recorded via electromyography and saved as spatial coordinates. These data were imported into the Brainlab Node® platform for co-registration, segmentation, and tractography using anatomical and/or functional ROIs. The resulting 3D model was used for planning and transferred to the Brainlab Dual Curve® system for intraoperative navigation (Fig. 2). Intraoperative motor mapping was performed using direct cortical stimulation (DCS, Inomed®) over suspected motor areas. Preoperative and intraoperative data were correlated by registering intraoperative coordinates using the Brainlab® navigated pointer (Fig. 3).
RESULTS
Between March 2022 and January 2025, 29 pediatric patients (ages 3–18, mean age 9.87) with supratentorial lesions were prospectively enrolled. All underwent preoperative motor mapping with nTMS. 38% (n = 11) were male and 62% (n = 18) female. Most (90%) had drug-resistant epilepsy associated with structural or tumor-related lesions; 10% (n = 3) had tumor pathology without epilepsy. Lesions were in the left hemisphere in 72% (n = 21) and right in 28% (n = 8).
In 25 patients (86%), the motor cortex in the lesioned hemisphere was successfully localized. In 4 cases (13.7%), mapping failed due to poor cooperation—an inherent limitation in pediatric populations. 86% (n = 25) underwent surgery: 2 hemispherotomies, 10 tumor or epilepsy resections, and 11 laser ablations. Only hemispherotomies and resections were neuromonitored, so tractography and functional data were crucial for laser procedure planning.
Of the successful mappings, 76% (n = 19) were imported into Brainlab for functional CST tractography. Customized tracts were derived from 3D functional ROIs; anatomical CST tracts were also generated using anatomical motor ROIs. In 12 cases, both methods were combined. All cases with tractography were navigated intraoperatively.
Postoperative outcomes were consistent with planning: 64% had no motor deficits, and 36% had temporary, anticipated deficits (e.g., hemiparesis). In 3 cases, preoperative mapping was confirmed intraoperatively via DCS (Inomed®), validating functional localization.
DISCUSSION
Preoperative mapping is essential in pediatric epilepsy surgery, enabling precise localization of the motor cortex to avoid damaging eloquent areas. This reduces the risk of postoperative deficits such as paralysis or weakness. It also supports individualized surgical planning, accounting for age-dependent anatomical and functional variability. Functional maps guide tailored resections or ablations, minimizing the risk to non-epileptogenic motor areas. Correlating preoperative nTMS with intraoperative DCS provides an added layer of confidence, reinforcing a function-preserving, personalized surgical approach.
Laia BANYULS (Barcelona, Spain), Maria Alejandra CLIMENT PERIN, Santiago CANDELA CANTO, Javier APARICIO CALVO, Flores MARTA CECILIA
14:55 - 15:00
#46250 - OP046 Lead assist: an algorithm for semi-automated trajectory planning for subthalamic nucleus deep brain stimulation surgery.
OP046 Lead assist: an algorithm for semi-automated trajectory planning for subthalamic nucleus deep brain stimulation surgery.
Topic: Subthalamic Nucleus Deep Brain Stimulation
Communication preference: Poster or oral presentation
Key words: Deep brain stimulation – Trajectory planning – Automation
Introduction: Accurate electrode placement is essential to achieve good clinical outcomes in subthalamic nucleus deep brain stimulation (STN-DBS) for people with Parkinson’s disease. Electrode trajectory planning is based on the visual assessment of manually planned electrode trajectories on magnetic resonance imaging (MRI) scans. To our knowledge, there is currently no algorithm available that can present an automatically planned and analysed trajectory for patients undergoing STN-DBS surgery. Our aim is to develop an algorithm that can plan a safe trajectory for a given target point faster than it would take to manually plan the trajectory.
Method: The algorithm contains two parts: the selection of possible trajectories and trajectory analysis. The selection of possible trajectories is based on historical entry points (EPs) (n=231) corresponding to the T2-weighted MRI coordinate space. Historical EPs are transformed to patient-specific MRI space by a pipeline of image registration and point transformation using the ICBM 2009c nonlinear symmetric brain template. Historical EPs were first transformed to template space and after transformed to patient-specific MRI space. A cortical region of interest is defined based on the historical EPs. Samples are taken in the cortical region, and candidate EPs are adjusted to the patient’s anatomy. Four MRI features define an optimal trajectory (Fig.1): (1) T2-MRI voxel intensities, (2) contrast enhanced T1-MRI voxel intensities, (3) average distance to CSF, and (4) average T2-MRI voxel intensity along the first 7 mm from TP to EP. We hypothesize that an optimal trajectory maintains a safe margin relative to ventricles, sulci, blood vessels, and white matter hyperintensities by combining the first three features, while the fourth ensures maximal STN passage.
Results: The total time to output a top 5 semi-automatically planned trajectories is about 8 minutes, including all MRI pre-processing and computational steps. Preliminary results showed that a DBS experienced neurosurgeon chose the semi-automatically planned trajectory over their manual planned one in 50% of the cases. Further improvements were integrated in the algorithm. These improvements will be validated by two neurosurgeons and results will be available at the ESSFN congress.
Conclusion: We developed a novel semi-automatic algorithm by using historical surgical data, MRI-preprocessing steps and MRI analysis to obtain a set of potential trajectories for a new patient undergoing STN-DBS surgery. The algorithms output is obtained in a short timeframe which is suitable for clinical implementation. The algorithm offers a more standardized way of trajectory planning to guarantee safe patient-specific planning.
Wouter VAN DULLEMEN (Nijmegen, The Netherlands), Saman VINKE, Eva Marike DE RONDE
15:00 - 15:05
#46300 - OP047 Simultaneous bilateral deep brain stimulator implantation with intraoperative anatomical verification using the double NexFrame system in Parkinson's disease.
OP047 Simultaneous bilateral deep brain stimulator implantation with intraoperative anatomical verification using the double NexFrame system in Parkinson's disease.
Introduction: Deep brain stimulation (DBS) is an effective therapy for the treatment of Parkinson's disease (PD). It improves the symptoms by stimulating the motor part of the subthalamic nucleus (STN). Traditionally, DBS surgery is performed using a stereotaxic frame, which allows high precision. However, it is often uncomfortable for the patients and makes the several hours surgery a big strain for them. The navigation-based, frameless NexFrame targeting system provides more tolerable surgical conditions for the patients. The strain can be further reduced if the operating time could be significantly shortened and only the minimum requiered number of test electrodes are used for the electrophysiological registration.
Methods: Between October 2023 and February 2025, 6 patients underwent DBS implantation using a new surgical technique. During the procedure, bilateral electrodes were implanted simultaneously under real-time anatomical and electrophysiological control using a double NexFrame system and intraoperative 3D X-Ray (Siemens Pheno Artis). To assess the efficacy of the new technique, we determined the number of test electrodes used, duration of surgery, number of days in hospital and the reduction in levo-dopa dose and improvement in UPDRS III score six months after surgery.
Results: An average of 3 test electrodes (1.5 per side) were used per patient (5 in the first case, 3 in three patients and 2 in two cases). The average duration of surgery was 3 hours 29 minutes, which included the time for two 3D X-Ray scans (10 minutes per scan) and the time for anaesthesia and draping between the two phases of surgery. For comparison, the conventional single-sided technique uses 3 test electrodes per side and the surgery takes on an average of 4 hours 58 minutes. The final electrodes were implanted in an average of 2 hours and 12 minutes. Patients were discharged from the department on the third ostoperative day. Levodopa requirement decreased from 960.16 mg to 553 mg, while UPDRS III improved from 40.16 to 19.5 points (51.44%).
Dicussion: Based on our results, the simultaneous use of the double NexFrame system on both sides significantly reduces the operating time and the number of test electrodes required. Therefore it creates a safer, more comfortable and tolerable surgical situation for the patients and significantly improves the patients' symptoms.
David KIS (Szeged, Hungary), Balint DANCSO, Peter KLIVENYI, Adam VARGA, Denes ZADORI, Laszlo SZPISJAK, Bence LACZO, Norbert SZAPPANOS, Pal BARZO
|
13:30-15:10
Added to your list of favorites
Deleted from your list of favorites
C39
PARALLEL SESSION 12
Basics
PARALLEL SESSION 12
Basics
Chairpersons:
Juan Antonio BARCIA (Neurosurgeon) (Chairperson, Barcelona, Spain), Kerstin SCHWABE (Head of Experimental Neurosurgery) (Chairperson, Hannover, Germany), Kristen SCHEITLER (Neurosurgery Resident Physician) (Chairperson, Rochester, USA), Istvan ULBERT (director) (Chairperson, Budapest, Hungary)
13:30 - 13:40
#46363 - OP008 Probing laminar ensemble dynamics in the human neocortex using high-density intraoperative multielectrodes.
OP008 Probing laminar ensemble dynamics in the human neocortex using high-density intraoperative multielectrodes.
The layered architecture of the neocortex forms the fundamental basis for complex neural computations. However, identifying these layer-specific subcircuits and deciphering their functional contributions in the human brain remains challenging. Recent advances in high-resolution neural recording technologies now permit investigation of human cortical layers with unprecedented detail. We pioneered a rare opportunity to test state-of-the-art silicon probes (called Neuropixels) in the operating room setting during resection surgeries in the cases of tumors or epilepsy, or right before the implantation of a deep brain stimulator (DBS) in patients with Parkinson's disease. These probes feature hundreds of closely packed active contact sites, enabling high-density spatiotemporal sampling of extracellular single-unit activities. Spatiotemporally resolved morpho-electric properties of single units allow for sophisticated clustering of neural cell types. Using Neuropixels probes (N=21 participants) and histologically verified "thumbtack" laminar microelectrodes (N=7 patients) in human frontal and temporal cortex, we identified robust patterns of neurophysiological activity, including local field potential co-modulation and spectral features, that consistently segment the cortical column into its distinct layers. We found that neurons within these physiologically defined layers possess distinct electrophysiological profiles (waveforms, firing patterns, spatiotemporal dynamics), reflecting diverse underlying cell types. These cell types form layer-specific ensembles exhibiting characteristic oscillatory coupling patterns within and across laminae. Furthermore, these layer- and cell-type-specific subcircuits demonstrate distinct engagement profiles during baseline activity, across fluctuations in arousal state, and during task performance, including visual perception. This work provides a validated framework for mapping laminar circuits in vivo and reveals layer-specific cellular dynamics in the human cortex, offering new insights into the neural basis of cognition and neurological disorders.
Domokos MESZENA (Budapest, Hungary), William MUÑOZ, Richard HARDSTONE, Rishab JAIN, Mila HALGREN, Charlie WINDOLF, Douglas J. KELLAR, Brian COUGHLIN, Mohsen JAMALI, Irene CAPRARA, Lucia WITTNER, Reka BOD, Istvan ULBERT, Dániel FABO, Boglárka Zsófia HAJNAL, Johanna Petra SZABÓ, Loránd ERŐSS, Leigh R. HOCHBERG, Jeffrey S. SCHWEITZER, Ziv M. WILLIAMS, Sydney S. CASH, Angelique C. PAULK
13:40 - 13:50
#46343 - OP009 Absolute dopamine concentration recordings during opioid administration in a swine model of tractography-guided ventral tegmental area deep brain stimulation using a next-generation, multiplatform device (MAVEN).
OP009 Absolute dopamine concentration recordings during opioid administration in a swine model of tractography-guided ventral tegmental area deep brain stimulation using a next-generation, multiplatform device (MAVEN).
Background: Dysregulation of mesolimbic dopamine pathways contributes to the pathophysiology of opioid addiction, yet the neurochemical effects of opioids and neuromodulation therapies remain poorly understood in both large-animal models and humans. Real-time measurement of absolute dopamine concentrations during deep brain stimulation (DBS) has been limited previously by technical constraints in anatomically and physiologically relevant systems. To address this critical gap, we leveraged a next-generation technology, the Multifunctional Apparatus for Voltammetry, Electrophysiology, and Neuromodulation (MAVEN), to perform quantitative dopamine monitoring during mesolimbic-tractography-guided ventral tegmental area (VTA) DBS in a swine model during opioid administration. This platform enables integration of neurochemical sensing with clinical workflows to accelerate translational discovery in neuromodulation for addiction and other neuropsychiatric disorders.
Methods: An anesthetized swine model of frame-based, image-guided DBS was used. Optimized for dopamine detection, multiple cyclic square wave voltammetry (MCSWV) was applied using the MAVEN device to a stereotactically implanted carbon fiber microelectrode in the swine nucleus accumbens (NAc). The waveform parameters included an initial potential of -0.2 V, a staircase increment of +25 mV, a square wave amplitude of ±0.4 V, and a pulse duration of 1.0 ms. Five cyclic square waves were applied per scan at a repetition frequency of 0.1 Hz. Tonic dopamine concentrations were recorded from the swine NAc at baseline, after opioid (fentanyl) administration, and during high-frequency VTA DBS. Tractography-guided target planning (NAc, VTA) was performed using clinical planning software. Proof-of-principle testing included post-operative calibration via beaker setups, in-vivo stimulation-evoked phasic dopamine release, and pharmacological validation.
Results: In vitro tests confirmed reliable recording of dopamine by the carbon fiber microelectrode. In vivo recordings in the anesthetized swine detected increases in tonic dopamine concentrations following fentanyl administration. Pharmacologic confirmation of dopamine was obtained using a dopamine reuptake inhibitor.
Conclusions: This study demonstrates the feasibility of real-time, absolute dopamine concentration monitoring during tractography-guided VTA deep brain stimulation in a large-animal model of opioid administration. By integrating neurochemical sensing with human stereotactic and neuroimaging workflows, MAVEN allows real-time quantification of dopamine, suggesting the possibility of neurotransmitters as biomarkers in closed-loop neuromodulation for opioid addiction and other neuropsychiatric disorders.
Kristen SCHEITLER (Rochester, USA), Juan ROJAS-CABRARA, Sara VETTLESON-TRUTZA, Sheng-Ta TSAI, Marie REYES, Tyler OESTERLE, Charles BLAHA, Hojin SHIN, Yoonbae OH, Kendall LEE
13:50 - 14:00
#46114 - OP010 Frequency and characterization of lead revision and removal rates following DBS from the Product Surveillance Registry.
OP010 Frequency and characterization of lead revision and removal rates following DBS from the Product Surveillance Registry.
Background: Previous retrospective studies of DBS lead revision and removal rates have reported rates between 5-12% with up to 7 years follow-up. A recent retrospective report evaluating United States Medicare data, as well as from a smaller United States based patient cohort where data was collected at two sites, reported a revision and removal rate of 15.2% and 34.0%, respectively over a ten-year period (2006-2016)1. In order to characterize the rates and types of events that result in lead revisions or removals in a prospective study, information was analyzed from the Product Surveillance Registry (PSR).. It provides insights in how the therapy is utilized at DBS implanting centers while collecting product and safety information on DBS systems and patients.
Methods: Data was analyzed on 3590 DBS patients registered from 2009-2023 from 66 centers located in four continents. Lead survival was the primary endpoint, and analyses were performed to quantify the duration of time until a lead revision or removal occurs while adjusting for varying lengths of post-implant follow-up time.
Results: Of the 3,590 DBS patients enrolled overall, 2,574 had at least one lead implanted post enrollment;. This prospective analysis includes 5000 DBS leads implanted in the 2,574 patients, with a mean (±SD) follow-up duration of 42 (± 36) months.
Within the 2,574 patients, 60.4% were implanted for Parkinson’s disease (n=1555), 23.9% for Essential Tremor (n=615), 10.3% for Dystonia (n=264), and 5.4% for other indications (n=140). There were 184 leads that had at least one surgical modification. Based upon survival analyses for all indications, lead modification rates were 2.4% at 1 year and 6.4% at 10 years (Figure 1). There were no observed differences by indication; however, the study was not powered to evaluate that endpoint. Twenty-six percent (48/184) of the lead modifications were due to technical reasons (lead migration, lead impedance issues, or lead fracture) (Table 1); 71% (130/184) of the lead modifications were due to non-technical, adverse events such as medical device site infection (Table 2).
Conclusions: Results from this large, prospective global registry demonstrated lead revision and removal rates of 4.6% at approximately five years post-implant. Lead revision and removals were predominately due to non-technical issues such as infection versus technical issues. Further analyses of this registry over time will enable comparison across anatomical lead locations or other variables of interest.
Peter KONRAD, Stephane PALFI (PARIS), Danika PAULO, Joachim K. KRAUSS, Steven FALOWSKI
14:00 - 14:10
#46118 - OP011 Asleep vs. Awake DBS: Real-world Evidence from the Product Surveillance Registry.
OP011 Asleep vs. Awake DBS: Real-world Evidence from the Product Surveillance Registry.
Introduction:
Deep brain stimulation (DBS) has traditionally been performed on patients who are awake with local anesthesia, using microelectrode recording and intra-operative test stimulation for refinement of lead placement. Neuroimaging advancements have led to a trend toward image-based targeting under general anesthesia7, where patients are asleep during the procedure1.. Recent studies have shown similar outcomes between asleep and awake procedures2-5.This study compares safety and clinical outcomes of asleep versus awake DBS procedures in a long-term global registry of patients implanted with DBS.
Methods:
The Product Surveillance Registry (PSR) is a prospective global registry for DBS. This analysis includes 608 therapy-naïve Parkinson’s disease (PD) and 267 essential tremor (ET) patients at 50 centers from 2016- 2023. Anesthesia was determined by treating clinicians. Clinical outcomes are assessed using EQ-5D summary index score recorded at baseline and within one year of follow-up.
Summaries are presented as mean ± SD. Statistical tests of within-group changes in the EQ-5D were conducted using Wilcoxon signed rank tests, and between-group using Wilcoxon rank sum tests. Statistical tests comparing complication rates were conducted using Fisher’s Exact test.
Results:
Within PD patients, the asleep group was younger at enrollment (62±9 vs 64±9 years, p=0.003). Average years from disease onset was 9 in both groups. For ET patients, there was no statistically significant difference in age (66±10 in asleep and 66±12 years in awake, p>0.99) or years from disease onset (20±15 for both groups, p=0.93).
The EQ-5D assessment was available at baseline and within the first year of implant for 329 PD and 152 ET patients. The average months to the first follow-up was 7.1±3.2 months in asleep group and 7.2±3.1 months in awake group. The EQ-5D index scores significantly improved for both groups within PD patients (p<0.001, Table 1). For PD, serious adverse events rate within the first 6-months of implant appeared higher in the awake group than the asleep group, although not statistically different (6.5% and 3.6% respectively; Table 2). There were no disease specific rating scales available.
Conclusions:
Data from PD and ET patients were examined to compare asleep versus awake DBS procedures in clinical outcomes (EQ-5D) and safety (SAE). No statistically significant differences were found by type of DBS procedure. Asleep technique may be considered as an alternative of DBS awake procedures. As more patients are followed in the registry, further analyses will enable comparisons between these sub-group of patients.
Peter KONRAD, Alfonso ARELLANO-REYNOSO, Jean-Philippe AZULAY, Emmanuel CUNY, Joachim K. KRAUSS (Hannover, Germany), Adriana L. LOPEZ RIOS, Soledad NAVARRO, George M. PLOTKIN, Mya SCHIESS, Thomas C. WITT
14:10 - 14:15
#48027 - OP012 Ultra-long polymer-based flexible electrode arrays for deep brain recording.
OP012 Ultra-long polymer-based flexible electrode arrays for deep brain recording.
Neural probes fabricated from flexible and compliant materials typically exhibit limited shank lengths, constraining access to deeper regions within the brain. In this investigation, we engineered various configurations of single-shank polyimide-based neural probes featuring ultra-long implantable shanks capable of reaching depths of several centimeters. These devices, fabricated on 6-inch silicon wafers, consist of multiple discrete components assembled via gold-gold thermocompression bonding post wafer-level processing. When assembled from three components, the total device length exceeds 300 mm. The tapered shank, designed for insertion into neural tissue, measures approximately 200 µm in width and 15 µm in thickness, and incorporates 32 iridium-oxide microelectrodes arranged linearly with a diameter of 30 µm and spacing of either 100 µm or 150 µm center-to-center. Variations in probe architecture were achieved through different fabrication strategies, including single- or dual-metal layer structures encapsulated within polyimide layers, as well as diverse microelectrode arrangements (edge versus center configurations). We present preliminary functional validation of these devices through in vitro and in vivo experiments. Impedance characterization in physiological saline revealed that the microelectrodes exhibited an average impedance of 200.45 ± 95.52 kΩ at 1 kHz (n=68 sites). The acute electrophysiological performance was assessed in the neocortex and hippocampus of anesthetized rats, following removal of the dura and pia mater over the targeted regions to facilitate probe insertion. Successful recordings of high-quality local field potentials—including cortical slow waves and hippocampal gamma oscillations—as well as single- and multi-unit activity, were obtained. Spike waveforms exceeding 100 µV in amplitude were detected across multiple sites, with the simultaneous isolation of multiple single units. Concurrent efforts are underway to refine implantation techniques and develop brain tissue-mimicking phantoms to enhance insertion reliability and repeatability.
Istvan ULBERT (Budapest, Hungary), Marc KELLER, Richárd FIÁTH, Patrick RUTHER
14:15 - 14:20
#48006 - OP013 Juvenile lesions of the cerebellar fastigial nucleus cause lasting cognitive deficits and prefrontal cortex dysfunction in adult rats: implications for the cerebellar cognitive affective syndrome.
OP013 Juvenile lesions of the cerebellar fastigial nucleus cause lasting cognitive deficits and prefrontal cortex dysfunction in adult rats: implications for the cerebellar cognitive affective syndrome.
The cerebellar cognitive affective syndrome has been reported following the resection of pediatric brain tumors affecting cerebellar midline structures, with particular emphasis on the involvement of the fastigial nucleus. Previous research demonstrated that juvenile fastigial lesions in rats lead to persistent behavioral impairments and altered neural oscillatory activity in the medial prefrontal cortex (mPFC) in adulthood. The present study investigates how early-life fastigial damage affects neural information processing in the adult mPFC during a behavioral oddball paradigm designed to assess learning and attentional performance.
Lesions of the fastigial nucleus were induced in 23-day-old male Sprague Dawley rats (n = 9). Age-matched naïve controls (n = 9) and sham-lesioned animals (n = 6) served as comparison groups. In adulthood, all rats were trained on an auditory oddball paradigm requiring a response to a rare Target tone, while ignoring both a rare Distractor and a frequent Standard tone, with a criterion of at least 70% correct responses for each category. Following successful training, local field potentials were recorded from electrodes implanted in the mPFC during task performance.
Rats with fastigial lesions required more training sessions to reach the ≥70% performance criterion, indicating delayed acquisition of the task. However, once the task was learned, their behavioral performance was only mildly impaired. Event-related potentials (ERPs) recorded from the medial prefrontal cortex revealed reduced amplitudes in response to all stimulus types, along with prolonged latencies of the late ERP component following Target stimuli. Reaction times did not differ significantly between groups, suggesting that the observed effects were not attributable to motor deficits.
The observed behavioral and electrophysiological abnormalities following fastigial lesions underscore the critical role of these cerebellar midline nuclei in sensory information processing and higher-order cognitive functions. This rodent model offers a valuable experimental framework for elucidating the neurobiological mechanisms underlying the cerebellar cognitive affective syndrome in greater detail.
Franziska M. DECKER, Jonas JELINEK, Mesbah ALAM, Joachim K. KRAUSS, Elvis J. HERMANN, Kerstin SCHWABE (Hannover, Germany)
14:20 - 14:25
#46197 - OP014 Implantable epidural focused ultrasound for neuromodulation: technical validation and biomarker exploration in a rodent model of depression.
OP014 Implantable epidural focused ultrasound for neuromodulation: technical validation and biomarker exploration in a rodent model of depression.
Depression is one of the most prevalent psychiatric disorders, with approximately one-third of patients classified as treatment-resistant. Neuromodulation approaches, such as deep brain stimulation (DBS) targeting the superolateral medial forebrain bundle (slMFB), have demonstrated sustained efficacy in these patients. Transcranial focused ultrasound (FUS) at low intensities has recently emerged as a non-invasive alternative. However, its clinical utility faces two key limitations: (1) transient neuromodulatory effects from acute sessions and (2) skull-induced ultrasound attenuation, which forces the use of lower frequencies-a trade-off that reduces spatial resolution
To address these limitations, this study aims to develop and validate an implantable epidural focused ultrasound (eFUS) device in rodents. Meanwhile, an innovative electrocorticography (ECoG) electrode array was designed to identify model-specific biomarkers in the Flinders Sensitive Line (FSL) rat-a validated rodent model of depression exhibiting neurochemical and behavioral parallels to human depression. This work is part of the UPSIDE project, an EU funded initiative developing a closed-loop eFUS system for neuromodulation in treatment-resistant depression and other psychiatric disorders.
We successfully developed the first-generation eFUS chip, capable of generating pressures up to 1 MPa at 8 mm depth in the rat brain. Unlike DBS, this approach achieves comparable precision with reduced invasiveness by leveraging a steerable, focused ultrasound beam for targeted neuromodulation with enhanced spatial resolution and broad network coverage. We validated targeting accuracy in vivo by inducing localized blood-brain barrier opening via microbubble-enhanced focused ultrasound at the target site. Current investigations include assessing auditory side effects and preliminary parameter optimization for mfb stimulation using eFUS, with fiber photometry in healthy controls monitoring calcium dynamics across both anesthetized and awake states.
Additionally, we recorded prefrontal ECoG signals in FSL rats and healthy controls under resting and stress conditions, with the goal of identifying candidate electrophysiological biomarkers relevant to the depression model, and guiding the development of future closed-loop applications.
This study establishes proof-of-concept for an eFUS neuromodulation platform, demonstrating its potential as a precise, minimally invasive, and chronically implantable tool for targeted brain stimulation. By integrating the identification of potential biomarkers in a rodent model of depression, this work advances the UPSIDE project’s translational roadmap to develop closed-loop eFUS systems for treatment-resistant depression, combining stimulation with real-time electrophysiological feedback.
Lisa RATZ (Freiburg, Germany), Hassan RIVANDI, Eshani SARKAR, Gandhika K. WARDHANA, Sofia DRAKOPOULOU, Linta SOHAIL, Vanessa ALOIA, Mattia ARLOTTI, Georgios D. SPYROPOULOS, Tiago L. COSTA, Volker Arnd COENEN, Máté D. DÖBRÖSSY
14:25 - 14:30
#46221 - OP015 Input-output relation of midbrain connectomics in a rodent model of depression.
OP015 Input-output relation of midbrain connectomics in a rodent model of depression.
Introduction. Major depressive disorder (MDD) impacts over 300 million people globally, with approximately 30% developing treatment-resistant depression (TRD). Deep brain stimulation (DBS) of the superolateral medial forebrain bundle (slMFB) shows promise for TRD by modulating mood-reward circuits, but its therapeutic mechanisms remain unclear. The ventral tegmental area (VTA)-a hub for dopamine signaling-projects to the nucleus accumbens (NAc; core/shell) and prefrontal cortex (PFC) via MFB pathways critical for reward processing and emotional regulation. This study maps monosynaptic inputs to these VTA-NAc/PFC projections in a rodent model of depression, identifying circuit-level alterations that may underlie the antidepressant effects of slMFB-DBS.
Methods. Flinders Sensitive Line (FSL) rats were employed as a rodent model of depression and aged and sex matched Sprague-Dawleys (SD) were used as controls. FSL and SD rats (n = 10 each) were assigned into 3 groups: “VTA-NAc core”, “VTA-NAc shell” and “VTA-PFC”. Animals in each group received a helper virus (AAV-TVA-oG-GFP) into the VTA, followed by a genetical-modified rabies virus (EnvA-RbdG-mCherry) injected into one of the output areas (NAc core, NAc shell or PFC). The modified rabies virus expressed monosynaptically and labelled direct inputs to the VTA-output projecting neurons. The whole brain input mapping between FSL and SDs were compared.
Results. Direct input towards VTA ascending neurons were found in 31 brain areas in the FSL and SD rats. Importantly, significant higher afferents from dorsal raphe towards VTA-NAc core projecting neurons and significant lower inputs from the cortex, zona incerta, pretectal area and thalamus towards VTA-NAc shell neurons were identified in FSL rats compared with SDs. No significant afferents difference was found in VTA-PFC group. Furthermore, it has been found that VTA-NAc shell neurons play a more critical role in both FSL and SD rats. In FSL rats, afferents from the striatum to the VTA-NAc shell neurons are significantly higher than in other VTA-output neurons; while in SD rats, afferents from the septum and thalamus are significantly higher to the VTA-NAc shell neurons. Overall, differences in connectivity between FSLs and SDs were observed in several neuronal circuits associated with depression.
Conclusion. This study reveals depression-associated alterations in whole-brain inputs to VTA mesocortical/mesolimbic pathways (projecting via MFB) in a rodent model of depression. FSL rats showed distinct innervation patterns from cortico-thalamic, limbic-striatal, and stress-modulatory regions (zona incerta, pretectal nuclei, dorsal raphe) compared to controls. These circuit-level dysregulations provide a neuroanatomical basis for understanding how slMFB-DBS may restore mood by modulating MFB-embedded VTA efferents.
Yixin TONG (Freiburg, Germany), Seonghee CHO, Volker COENEN, Mate DÖBRÖSSY
14:30 - 14:35
#46341 - OP016 A 3D metric for measuring electrode placement accuracy in sEEG and DBS procedures.
OP016 A 3D metric for measuring electrode placement accuracy in sEEG and DBS procedures.
Stereotactic electroencephalography (sEEG) and deep brain stimulation (DBS) are critical neurosurgical procedures that rely on the precise insertion of electrodes into specific brain targets. Accurate electrode placement is essential for both diagnostic and therapeutic efficacy, as even small deviations from the planned trajectory can significantly impact clinical outcomes. The process of electrode implantation involves meticulous preoperative planning based on neuroimaging data, followed by the actual surgical procedure, during which inherent technical and anatomical factors introduce placement errors.
Traditionally, the accuracy of electrode placement has been assessed using relatively straightforward metrics derived from postoperative imaging. Commonly employed measures include the Euclidean distance between the planned and actual entry points on the cortical surface, the distance between planned and actual target endpoints within deep brain structures, and angular deviations between planned and achieved trajectories. While these metrics are simple to calculate and provide a basic quantification of placement error, they fall short in capturing the full complexity of electrode deviations in three-dimensional space.
One critical limitation of conventional metrics is that they consider individual error components in isolation without integrating their spatial relationships. For example, two electrodes with identical entry point and target point errors may have entirely different spatial orientations or curvatures, leading to divergent clinical implications such as altered stimulation fields or inaccurate localization of epileptogenic zones. Moreover, these metrics do not account for the cumulative effect of combined translational and rotational deviations along the entire electrode trajectory, which can influence both safety and efficacy.
To address these limitations, we propose a novel, comprehensive metric designed to quantify electrode placement accuracy in a holistic three-dimensional manner. This metric synthesizes all significant forms of deviation, translational, angular, and trajectory-base into a single scalar value that reflects the overall fidelity of electrode implantation relative to the surgical plan. By incorporating the full 3D spatial characteristics of electrode placement, our metric provides a more nuanced and clinically relevant assessment of implantation accuracy.
The calculation of this metric is not possible by manual calculation due to its complexity and the multidimensional nature of the data involved. Instead, we have developed a numerical algorithm that requires input data extracted from standard postoperative imaging modalities, such as CT or MRI scans co-registered with preoperative plans. This algorithm computes the metric by analyzing the spatial coordinates of the planned and actual electrode trajectories, integrating deviations along the entire length of the electrode.
To facilitate widespread adoption and practical application, we have implemented this algorithm in a publicly available software tool. This tool automates the computation of the proposed accuracy metric, and generates detailed reports that can be used for clinical evaluation, surgical quality control, and research purposes. The software is designed to seamlessly integrate into existing neurosurgical workflows, providing surgeons and clinical teams with actionable insights into electrode placement precision.
Moreover, given partial information about the operational situation, the tool can optimize remaining parameters for best end results. If interoperative trajectory can be recorded given the entry point and orientation of the screw, the tool can provide suggestions on the optimal length of the electrode.
Sándor KOLUMBÁN, Dávid MOLNÁR (Cluj-Napoca, Romania), Bálint KOLUMBÁN
14:35 - 14:40
#46345 - OP017 Comparing electrode implantation accuracy in frame based SEEG and DBS surgeries using a novel three-dimensional accuracy measure.
OP017 Comparing electrode implantation accuracy in frame based SEEG and DBS surgeries using a novel three-dimensional accuracy measure.
High accuracy is essential in stereotactic procedures, where the precise placement of electrodes is critical to achieving optimal therapeutic outcomes, and avoiding complications. However, measuring and evaluating this accuracy can be challenging due to the inherent complexities of neurosurgical techniques. While various methods exist to ensure the desired level of accuracy. The existing literature provides numerous insights into the precision of electrode positioning, often utilizing postoperative imaging to quantify parameters such as end point distance, entry point distance, Euclidean distance, and angles. However, these metrics typically rely on two-dimensional data, which may not fully capture the intricacies of three-dimensional relationships. In this study, we aim to present the utility of a novel three-dimensional measurement method that enhances the evaluation of electrode placement accuracy in stereotactic electroencephalography (sEEG) and deep brain stimulation (DBS) procedures, providing a more comprehensive understanding of spatial relationships between the surgical plan and the postoperative elctrode positions.
A retrospective analysis was conducted on a cohort of patients who underwent sEEG and DBS procedures between 2018 and 2024. Electrode placements were assessed using postoperative images (CT or MRI) uploaded to the preoperatively used planning software, where the electrodes were outlined to determine the spatial accuracy of electrode positioning relative to the planned trajectory. Surgical technique and intraoperative validation factors influencing accuracy were analyzed.
Our results confirmed the usability of the novel accuracy measurment method. Based on these calculations the accuracy evaluation of a clinical center or surgical technique is facile, and objective. This metric offers more comprehensive comparison of different working groups.
In guiding screw based electrode implantations our method can give the opportunity of intraoperative predicting electrode position before even entering the brain tissue, and also providing optimal electrode length.
Balint KOLUMBAN (Pécs, Hungary), Sandor KOLUMBAN, David MOLNAR, Marton TOTH, Eszter BACSA, Tamas DOCZI, Zsolt HORVATH
14:40 - 14:45
#46125 - OP018 Variable light exposure differentially alters midbrain dopamine expression, brain morphology and behaviors in a rodent model of depression.
OP018 Variable light exposure differentially alters midbrain dopamine expression, brain morphology and behaviors in a rodent model of depression.
Background: Depression is a major global health issue. There have been decades of research investigating the underlying role of specific neurotransmitter systems (such as the dopaminergic system), changes in the brain morphology (such as hippocampal atrophy observed in MDD patients) and the way neuroplasticity influences both. Light exposure plays a crucial role in regulating mood and circadian rhythms. While appropriate light exposure can alleviate symptoms of certain types of depression, such as seasonal affective disorder, disrupted light cycles may contribute to mood disorders by interfering with circadian regulation. The ventral tegmental area (VTA) contains tyrosine hydroxylase (TH)-expressing neurons, primarily dopaminergic (DA), which are central to the brain’s reward system and closely linked to mood regulation. Therefore, we investigated how altered light exposure influences DA neuron identity in the VTA using a rodent model of depression. We hypothesized that i.) DA expression will be sensitive to changes in the light exposure with reduced light also reducing DA expression and increasing the depressive-like phenotype and vice-versa; and ii.) that exposure to different light conditions will have structural effects on different brain areas such as the hippocampus, striatum and ventricle system and detectable influence on the phenotype. To detect sexual dimorphisms, both males and females were used in the study.
Method: Flinders Sensitive Line (FSL, n=95; ♂=47 ♀=48) rats were used as a depression model, with Sprague-Dawley (SD, n=104; ♂=52, ♀=52) rats as controls. All animals were phenotyped on the Forced Swim Test (FST). Additional baseline behavioral assessments included the locomotion, open field test (OF), elevated plus maze (EPM), and sucrose consumption test (SCT). Based on their FST performance, all animals were then assigned to one of three light conditions: Light+ (19 hours of light, 5 hours of darkness), control (12 hours of light, 12 hours of darkness), and Light- (5 hours of light, 19 hours of darkness), forming 12 total groups.
Next, in a purpose built light-control cabinet, the rats were kept under the assigned light condition for 2 weeks, during which their locomotor activity, and body weight were continuously recorded. After the 2-week period, OFT, EPM, and SCT were repeated. Rats were sacrificed and either prepared for in-situ hybridization (ISH) or perfused with paraformaldehyde (PFA), and processed for immunohistochemical staining. Tissue sections stained with Tyrosine-Hydroxylase (TH) were used to analyze TH neuron density and TH nuclei counting in the VTA. Tissue stained with NeuN, identifying neurons and macro-structures, was used to measure lateral ventricles, hippocampi and striatal volumes. To exclude apoptosis, tissue from 4-5 rats per group was stained following a TUNEL protocol. In-situ-hybridization (ISH) was also performed with dopaminergic, GABAergic and glutamergic markers in order to investigate up- or downregulations in the neurotransmitter expressions.
Results:
Light conditions influenced weight and locomotor activities in the animals. In males, SD rats exhibited greater exploratory behavior in the OF and EPM after extended light exposure (Light+), while FSL rats showed similar effects. In females, significant differences were observed only in EPM, where FSL rats exposed to reduced light (Light-) showed lower anxiety than both SD rats and FSL rats under normal (Control) or extended light (Light+) conditions. All groups exhibited reduced TH neuron density in the VTA following reduced light exposure (Light-), with an additional decline in SD males after extended light condition (Light+). Morphological changes occurred mainly in the lateral ventricles ( increase in volume from the male L+ and L- SD rats) and the hippocampi. Apoptosis was not detected in any of the experimental groups, or conditions. Additional results, including from the ISH analysis will be presented at the conference.
Conclusion: Altering light exposure conditions can modify the characteristics of dopamine neurons in the VTA, lead to structural changes in the brain morphology and cause adaptations in rat behavior.
Sandrine RAHMOUNE (Freiburg, Germany), Xionpeng WENG, Yixin TONG, Volker Arnold COENEN, Máté DÖBRÖSSY
14:45 - 14:50
#46291 - OP019 Apomorphine and MK801 have different effects on processing of auditory information in the three-tone oddball paradigm in rats.
OP019 Apomorphine and MK801 have different effects on processing of auditory information in the three-tone oddball paradigm in rats.
In our environment only few of the sensory stimuli are behaviorally relevant. The distinction between relevant and irrelevant information is impaired in certain neuropsychiatric disorders characterized by disturbed information processing (e.g., in schizophrenia). Injections of the dopamine receptor agonist apomorphine and the glutamate NMDA receptor antagonist MK801 are used in rat models. In this study, we investigated the effect of apomorphine and MK801 on behavior in the auditory oddball paradigm, which allows to investigate the processing of behaviorally relevant auditory events.
Male Sprague-Dawley rats (n=11) were trained in the auditory three-tone oddball paradigm, in which they had to respond by nose poking to a rare target tone (5000 Hz, rewarded with a casein pellet), while ignoring a rare distractor (1500 Hz) and frequent standard tone (3000 Hz). After reaching a pre-defined success criterion of correct response to the target tone and correct rejection of the standard and distractor tones (80%, each), rats were injected with different doses of either apomorphine (vehicle, 0.0625, 0.125 and 0.250 mg/kg) or MK801 (vehicle, 0.05, 0.1, and 0.15, and 0.2mg/kg) and then behaviorally tested in the oddball paradigm.
Both, apomorphine and MK801 impaired performance in a dose-dependent manner. After apomorphine, rats gradually stopped responding to all stimuli, resulting in a reduced hit rate to the target tone, combined with ignoring both standard and distractor tones (p<0.05). In contrast, rats injected with low doses of MK801 still responded correctly to the target tone but also made more false responses to the distractor and standard tones, which was combined with more impulsive hits in the inter-trial intervals (p<0.05).
Both neuroactive compounds impair performance in the oddball paradigm. However, low doses of dopamine receptor agonists reduce responses to all stimuli, whereas NMDA receptor antagonists enhance false responses to standard and distractor tones. Together, apomorphine and MK801 address different aspects of disturbed information processing seen in certain neuropsychiatric disorders.
Marcel M. OELERICH, Franziska M. DECKER, Joachim K. KRAUSS, Kerstin SCHWABE (Hannover, Germany)
|
|
|
15:10 |
|
|
|
|
|
15:30 - 16:00 |
COFFEE BREAK - FLASH POSTERS SESSION 4 - EXHIBITION
|
|
16:00 |
16:00-17:00
Added to your list of favorites
Deleted from your list of favorites
A38
PARALLEL SESSION 13
Radiosurgery
PARALLEL SESSION 13
Radiosurgery
Chairpersons:
Imre FEDORCSAK, Andrea FRANZINI (Assistant Neurosurgeon) (Chairperson, Milan, Italy), Brigitte GATTERBAUER (Gamma Knife) (Chairperson, Vienna, Austria), Marcell NAGY (Resident) (Chairperson, Miskolc, Hungary)
16:00 - 16:10
#46123 - OP151 Study of predictive factors of hyper-response after gamma knife radiosurgery for essential tremor.
OP151 Study of predictive factors of hyper-response after gamma knife radiosurgery for essential tremor.
Gamma Knife Radiosurgery (GKRS) is a recognized therapeutic option for treating various neurological disorders, including essential tremor. Over 80% of patients report a significant reduction in tremor following this radiosurgical procedure. However, the variability in individual post-treatment responses remains a major challenge, as some patients may develop a hyper-response leading to serious complications that can compromise functional outcomes and, in rare cases, be life-threatening.The aim of this study is to identify predictive factors of post-radiation response variability, particularly hyper-responsiveness following GKRS thalamotomy. This involves a retrospective study of 73 patients (69 with essential tremor, and 4 treated for pain), who underwent GKRS thalamotomy between 2007 and 2024.The methodology includes collecting pre- and post-treatment MRI scans, followed by manual and then automated segmentation of radionecrosis lesions using an artificial intelligence model. This will allow the development of a dynamic volumetric profile of these lesions over time and the categorization of patients as hypo-responders, normo-responders, or hyper-responders.Patients’ data (clinical, pre-treatment radiological, and technical parameters) will then be correlated with these three categories to identify the factors and parameters involved in the variability of therapeutic responses for each patient group.The results of this study will contribute to a better understanding of the factors involved in the variability of therapeutic responses to radiation, particularly hyper-responsiveness, and will help enable more personalized and optimized treatment decisions for patients.
Sonia DJERROUD, Sonia DJERROUD (Sherbrooke, Canada), David Jacob SIGAL, Omar ALJUBAIRI, Christian IORIO-MORIN, Kevin WHITTINGSTALL
16:10 - 16:20
#46321 - OP152 Seizure outcomes in patients with large AVMs following GKRS.
OP152 Seizure outcomes in patients with large AVMs following GKRS.
Introduction. Seizure-associated large AVMs represent a life-threatening condition, which optimal treatment should provide both vessel obliteration and seizure control.
Methods. We analyzed seizure frequency and type in patients with large AVMs before and after Gamma Knife radiosurgery (GKRS) in junction with radiological outcomes. Patients with neurological and radiological follow-ups were selected from a our prospectively-maintained database and their clinical, neurological, radiological and radiosurgery-related data were collected. Overall, 30 patients with large AVMs associated with seizures were identified. The Spetzler-Martin grade was 3 for 8 AVMs, 4 for 17 AVMs and 5 for 5 AVMs. GKRS was done with a prescription dose of 20-24 Gy. Volume-staged radiosurgery was performed for 18 patients with a year interval between stages. After GKRS patients were followed-up regularly.
Results. Seizure frequency following GKRS significantly reduced (paired t-test p-value < 0.001). At the time of GKRS seizure frequency was as follow: 4 patients had weekly seizures, 10 patients – monthly, 13 patients had seizures several times per year, but not every month and 3 patients - less than once per year. After GKRS 16 patients became free of seizures, 1 patient had seizures less than once per year, 7 patient – at least once per year and 5 patients – monthly. Seizure type distribution also significantly changed following GKRS (p-value = 0.002). Before GKRS most patients were presented with generalized seizures (19 patients), 5 patients had both focal and generalized seizures and 6 patients only focal seizures. After GKRS 5 patients had generalized seizures, 3 both focal and generalized seizures and 6 only focal seizures. Overall, most of the patients improved in seizures following GKRS, 4 patients unchanged and had the same frequency and seizure types before and after GKRS, 2 patients had a reduction in seizure frequency but experienced in addition to focal seizures also generalized ones after GKRS.
Conclusion. GKRS can be served as a viable treatment for patients with large AVMs associated with seizures, as it offers favourable seizure outcomes as well as AVM obliteration.
Pavel IVANOV (Saint-Petersburg, Russia), Alyona KISELYOVA, Irina ZUBATKINA
16:20 - 16:30
#46337 - OP153 Gamma Knife Radiosurgery for Tumor-related Trigeminal Neuralgia: A Single-center Retrospective Study.
OP153 Gamma Knife Radiosurgery for Tumor-related Trigeminal Neuralgia: A Single-center Retrospective Study.
Background: Tumor-related trigeminal neuralgia (TN) is a challenging condition to manage that can be treated by Gamma Knife Radiosurgery (GKRS). The tumor, the trigeminal nerve, or a combination of both have been targeted using GKRS; however, the outcomes have only been investigated in a few patient series. This study aims to report the outcomes of patients with TN caused by a meningioma or schwannoma compressing or encasing the trigeminal nerve, who underwent GKRS targeting the trigeminal nerve, the tumor, or a combination of both targets.
Methods: 41 patients underwent GKRS for tumor related TN. A retrospective database review was conducted to determine background medical history, dosimetric data, and outcomes of the procedures. Facial pain and sensory function were evaluated using the Barrow Neurological Institute (BNI) scales.
Results: Tumor-related TN was caused by a meningioma or a schwannoma in, respectively, 30 and 11 patients. The tumor, the trigeminal nerve alone, or a combination of both were targeted in, respectively, 28, 7, and 6 patients, for a total of 47 GKRS procedures. In all patients except 1, the trigeminal nerve was targeted following a tumor-targeted radiation treatment which failed in reducing trigeminal neuralgia. Thirty (88%) and 11(85%) patients had pain control (BNI I-IIIa) after undergoing GKRS targeting the tumor or the trigeminal nerve, respectively. Pain recurred in 8 and 3 patients, respectively. After GKRS targeting the tumor, percentages of patients with pain control at 1, 4, 7 and 10 years were 82%, 69%, 56%, and 56%, respectively. After GKRS targeting the trigeminal nerve, percentages of patients with pain control at 1, 4, 7 and 10 years were 77%, 67%, 50%, and 50%, respectively. When GKRS targeting the tumor and subsequently the trigeminal nerve are considered as part of the same treatment, pain control rates at 1, 4, 7 and 10 years were 83%, 75%, 71%, and 71%, respectively. After GKRS targeting the nerve, 2 patients developed facial hypesthesia. After GKRS targeting the tumor, 6 patients developed facial sensory disturbances, which were transiently bothersome in 2.
Conclusions: GKRS targeting the tumor is an effective treatment for tumor-related TN in many patients. Second stage GKRS targeting the trigeminal nerve may increase the fraction of patients who achieve sustained pain reduction. Facial sensory disturbances occur in some patients and may be bothersome.
Stefano TOMATIS, Andrea FRANZINI (Milan, Italy), Piero PICOZZI, Pierina NAVARRIA, Elena CLERICI, Pessina FEDERICO
16:30 - 16:40
#46362 - OP154 Outcomes of Stereotactic Radiosurgical treatment for Glomus Jugulare Tumors: a single center study of 49 cases.
OP154 Outcomes of Stereotactic Radiosurgical treatment for Glomus Jugulare Tumors: a single center study of 49 cases.
Object: Glomus tumors are rare benign skull base neoplasms that arise from chemo¬receptor paraganglionic cells, involving crucial structures such as cerebrovascular structures and lower cranial nerves. stereotactic radiosurgery has an increasing role in the management of glomus tumors as surgeries are complex and have a higher rate of morbidity and complication rates. The authors of this study examine the outcomes of radiosurgery treatment in a single centre patient population.
Method: All treatment of glumos tumors at the Gamma-Knife Centre in Debrecen were gathered retrospectively. Forty-nine procedures were included in this study. In thirty eight of them gamma-knife surgery was the primary treatment. The patients’ median age was 53 years. Leading symptoms were pulstile tinnitus and hypacusis as 44% had them at the time of treatment. The median dose to the tumor margin was 15 Gy. The median duration of the follow up was 49,8 months (range 3 month to 131 month)
Results: At last follow up tumor controll was achieved in 92,8%. Symptoms improved in 46,5% of patients. New cranial nerve deficits were noted in 4,5% and preexisting cranial nerve deficits progressed in 2,3%. No patient died as a result of treatment or tumor progression.
Conclusion: Gamma Knife surgery is a well-suitable treatment that provides great tumor and symptom controll as well as less complications compared to surgery. Patients also spend less time in the hospital. Leading symptoms improved in almost half of the treated patients.
Marcell NAGY (Miskolc, Hungary)
16:40 - 16:45
#46121 - OP155 Detection of additional brain metastases on same-day MRI prior to gamma knife treatment: A single-institution review.
OP155 Detection of additional brain metastases on same-day MRI prior to gamma knife treatment: A single-institution review.
Purpose/Objective(s): Linear accelerator based stereotactic radiosurgery (SRS) for brain metastases is a common practice in the United States. Typically, due to the workflow associated with this modality, a diagnostic MRI is obtained for treatment planning purposes several days prior to treatment delivery. In contrast, the typical Gamma Knife (GK) SRS workflow calls for a repeat MRI on the actual day of treatment. This study reports the incidence of additional brain metastases identified on the day of GK SRS, compared with the immediate pre-treatment diagnostic MRI. The objective is therefore to provide insight into the likelihood of missed metastases when a same-day MRI is not incorporated into an SRS workflow.
Materials/Methods: This is a retrospective analysis of data collected at a single institution’s GK treatment facility from June 1st, 2019 through December 31st, 2020 under an IRB approved study. Patient demographics, primary site diagnoses, number of metastases on initial MRI, time from initial MRI to the day of GK treatment, and number of metastases at GK were recorded. A high-resolution magnetization prepared rapid gradient-echo (MP RAGE) T1-weighted MRI was obtained the day of GK. Fisher’s exact test was used to determine the effect of time (between the 2 MRIs) on the appearance of additional metastases.
Results: During the study period, 134 patients were treated for metastatic disease. Demographics, primary disease site, number of metastases, and the incidence of additional metastases at time of treatment are reported in Table 1.
Conclusion: In this study, the overall incidence of additional metastases identified for treatment at the time of GK SRS was 44%. The likelihood of additional metastases when the diagnostic MRI is ≤7 days vs. ≤14 days old was statistically significant (p-value = 0.02) increased with increasing time to treatment. When using MRIs obtained the same week as treatment, the incidence of additional metastases on day of treatment was 6.7%. This jumped to 16.4% when the preceding MRI was up to 14 days old. Further time-to-event analyses will be evaluated on the 5-year data set which will include additional consecutive patients.
Phillip JENKINS, Cole SABINASH, Gregory DYSON, Michael DOMINELLO (Detroit, USA)
16:45 - 16:50
#47768 - OP156 Gamma knife radiosurgery for falcotentorial meningiomas: a series of 33 consecutive patients.
OP156 Gamma knife radiosurgery for falcotentorial meningiomas: a series of 33 consecutive patients.
Introduction:
Falcotentorial meningiomas (FTMs) arise at the junction of the tentorium and falx cerebri, however may develop anywhere along the falcotentorial junction between the vein of Galen, the straight sinus, and the torcular herophili. These rare tumors are located near critical neurovascular structures, rendering surgical resection particularly challenging. Although Gamma Knife radiosurgery (GKRS) is an established and effective treatment for meningiomas, data specific to FTMs remain limited. This study aims to evaluate the long-term efficacy and safety of GKRS for FTMs by assessing tumor control, complications, neurological outcomes, and quality of life, as well as identifying factors that influence treatment outcomes to optimize patient management.
Materials and Methods:
The study involved FTM patients treated with GKRS between 2008 and 2022. The inclusion criteria included meningioma at the falcotentorial junction, single-session or hypofractionated GKRS, and a minimum follow-up period of 36 months. The multidisciplinary team planned dosing, with follow-up magnetic resonance images every six months and annually. Progression was defined as a volume increase of ≥20%, regression as ≤20% decrease, and stability as within ±20%. Karnofsky Performance Scale, neurological status, and hydrocephalus were also assessed at GKRS and follow-up.
Results:
Thirty-three FTM patients underwent GKRS with a median follow-up of 90 months (range, 36-180). The mean age was 52 (range, 33-78), and the mean tumor volume was 6.9 cm3 (range, 0.7-17.7). GKRS was primary treatment in 76% of cases, adjuvant in 21%, and for recurrence in 3%. The median marginal dose was 13.3 Gy (range, 11-25) and the mean V12 was 8.0 cm3 (range, 0.97-20.2). At the last follow-up, tumor shrinkage was 42%, stability in 55%, and progression in 3% (1 patient). A second GKRS procedure was performed for the patient who experienced tumor progression. There were no significant correlations between tumor volume, marginal dose, V12, surgical history, treatment indication, sinus invasion, or peritumoral edema. The estimated 5-year OS and PFS exceeded 95%.
Discussion:
GKRS is a safe and effective treatment for FTMs, providing long-term tumor control and preserving neurological function. 97% of patients achieved radiological control, with only one case of progression over a 90-month follow-up. GKRS resulted in minimal morbidity, with no neurological decline, hydrocephalus, or significant toxicity. The Karnofsky Performance Status remained stable or improved in all cases. Tumor volume, marginal dose, V12, surgical history, treatment indication, peritumoral edema, and sinus invasion were not significantly linked to tumor progression or toxicity. These findings support GKRS as an effective first-line or adjunctive treatment for FTMs.
Conclusion:
GKRS is a noninvasive treatment for FTMs, providing reliable tumor control and neurological function preservation, especially in challenging cases. Despite limited sample size, consistent tumor control and functional stability support its continued use.
Dogu Cihan YILDIRIM (Istanbul, Turkey), Ali Haluk DUZKALIR, Mehmet Orbay ASKEROGLU, Selcuk PEKER
16:50 - 16:55
#47828 - OP157 Factors Associated with Peritumoral Edema Following Gamma Knife Radiosurgery for Intracranial Meningiomas.
OP157 Factors Associated with Peritumoral Edema Following Gamma Knife Radiosurgery for Intracranial Meningiomas.
Purpose:
The objective of this study is to identify the dosimetric and clinical factors associated with increased post-treatment edema in patients treated with single-fraction Gamma Knife radiosurgery (GKRS) for intracranial meningiomas.
Methods:
A retrospective analysis was conducted on 29 patients with meningiomas treated with single-fraction GKRS. A total of 20 variables were collected for each patient, including demographic data (age, sex, diabetes status), tumor characteristics (location, post-treatment tumor volume), dosimetric parameters [prescription dose (Gy), isodose percentage, BED (α/β = 2), maximum dose, V5, V12, mean dose, integral dose], and treatment-related factors (fractionation, control time in months). The primary outcome was peritumoral edema, assessed by the ratio of pre-treatment to post-treatment edema volume.
Correlation analyses were performed to evaluate the relationship between potential predictors and edema increase. Variables with moderate or strong correlation were identified as candidates for further investigation.
Results:
The analysis revealed that several dosimetric parameters demonstrated a moderate positive correlation with post-treatment edema increase. Among them, the most significant factors were:
- Pre-edema V12 (cc): r = 0.44
- Pre-edema V5 (cc): r = 0.41
- Whole brain V5 and V12 (cc): r = 0.40 and r = 0.36, respectively
- BED (α/β=2): r = 0.32
- Mean dose to peritumoral region: r = 0.31
- Pre-treatment tumor volume: r = 0.28
- Pre-edema maximum dose (0.1cc): r = 0.22
These findings indicate that low-dose volume exposure (V5 and V12) and biologically effective dose (BED) are among the most relevant predictors of edema development. Clinical factors such as age, sex, and diabetes status showed no significant correlation in preliminary analysis.
Conclusion:
This study suggests that increased peritumoral edema following Gamma Knife treatment of meningiomas is most strongly associated with higher low-dose volume exposure and higher BED values. Dosimetric parameters such as V5, V12, and mean dose to surrounding brain tissue should be carefully considered during treatment planning to minimize the risk of symptomatic edema. The use of more conformal plans that limit unnecessary low-dose spillage may help improve patient outcomes and reduce post-treatment complications. Further multivariate analysis and validation in larger cohorts are warranted to confirm these findings and develop predictive models for edema risk stratification.
Mehmet Orbay ASKEROĞLU (İstanbul, Turkey), Damla POYRAZ, Doğu Cihan YILDIRIM, Ali Haluk DÜZKALIR, Ömer YAZICI, Mustafa ÇAĞLAR, Selçuk PEKER
16:55 - 17:00
#48030 - OP158 Delayed thalamic cysts or chronic incapsulated expanding hematomas after radiosurgical thalamotomy in Parkinson’s disease.
OP158 Delayed thalamic cysts or chronic incapsulated expanding hematomas after radiosurgical thalamotomy in Parkinson’s disease.
Introduction
Gamma Knife stereotactic radiosurgery (GK-SRS) is used in various movement disorders to treat disabling medically refractory tremor. Staged bilateral radiosurgical thalamotomy is proposed for bilateral tremor in patients who are not eligible or not willing invasive procedures. Possible adverse events include dysarthria, dysphagia, ataxia, gait instability, paresis, and sensory loss. Delayed cysts formation after GK-SRS has been occasionally observed in patients with arteriovenous malformations, brain tumors and metastasis, reaching up to 10%. Rare cases of cyst formation have been described after bilateral capsulotomy for obsessive-compulsive disorder. Single description of a cyst after thalamotomy in patient with essential tremor was presented as a chronic incapsulated expanding hematoma. We describe two patients with Parkinson’s disease (PD) who developed this complication in the long-term period after GK-SRS thalamotomy.
Patients and methods
The first patient is a 67-year-old man who sought consultation due to progressive deterioration in his condition over the past 2 years. He was diagnosed with PD at the age of 53 upon the appearance of tremor in his right hand. Despite the treatment, patient was hampered by significant hand tremor. At the age of 58, left-sided radiosurgical thalamotomy was performed. After treatment, he experienced pronounced tremor reduction in the dominant hand. 8 months after the first procedure, right-sided GK-SRS thalamotomy was conducted. Radiation dose for each procedure comprised 130Gy. Patient’s condition remained relatively stable for 7 years with efficient control of parkinsonian symptoms, when unexpected gait, balance, speech and swallowing disorders, right-sided motor and sensory deficits appeared.
The other patient is a 50-year-old woman who had deterioration in her condition over the course of six months. She was diagnosed with PD at the age of 38 (young onset with right hand tremor). At the age of 42, left-sided GK-SRS thalamotomy was conducted to manage disabling tremor of the right hand (radiation dose 130Gy). Despite good result for tremor, over the years, bradykinesia has increased and diskinesia has appeared, disrupting daily activity. 7 years after GK-SRS thalamotomy, patient underwent bilateral implantation of electrodes for subthalamic deep brain stimulation. In early postoperative period, she experienced improvement in motor symptoms and disability. In half a year after DBS-surgery, worsening in walking and balance, falls, right leg paresis and dystonia, and swallowing disorders appeared which forced her to contact our center.
Results
In the first patient, MRI revealed bilateral large thalamic cystic formations causing compression of neighboring structures, more pronounced on the left. 18F-FET PET/CT was performed to exclude neoplastic origin. Ommaya reservoir was implanted in the left cyst and its content was evacuated. Thereafter, patient’s condition progrediently ameliorated with regression of hemiparesis, improvement in gait, balance, speech, and swallowing. CT scan showed reduction in left cyst size. However, a month after the procedure, patient’s condition worsened again. Control CT revealed expansion of the left thalamic cyst. In the subsequent period, patient’s symptoms fluctuated depending on increase in the cyst volume, which required repeated frequent punctures of Ommaya reservoir and a course of bevacizumab. Despite this, patient continued to experience balance, gait, speech and swallowing problems, which necessitated the implantation of Ommaya reservoir into the right thalamic cyst. At present, both cyst size decreased significantly, but patient continues to have balance and gait disturbances, and slight paresis of the right arm.
In the second patient, MRI conducted found a left thalamic cyst, compressing the surrounding structures and the electrode. Ommaya reservoir was implanted into the left cyst and the content was drained. Six months after procedure the thalamic cyst is emptied. At the same time, patient retains gait disorders associated with paresis and dystonia of the right leg and balance impairment.
Conclusions
GK-SRS may cause delayed formation of cysts, including after thalamotomy. In PD patients, this might lead to significant disability, despite a considerable and sustained decrease in tremor. Dynamic monitoring in the long-term follow-up is required, especially when unexpected symptoms appear that differ from the clinical picture of PD.
Alexey TOMSKIY, Anna GAMALEYA (Moscow, Russia), Svetlana ASRIANTS, Anna PODDUBSKAIA, Andrey GOLANOV
|
16:00-17:00
Added to your list of favorites
Deleted from your list of favorites
B38
PARALLEL SESSION 14
Epilepsy Surgery 2
PARALLEL SESSION 14
Epilepsy Surgery 2
Chairpersons:
Stéphan CHABARDES (head of the department) (Chairperson, GRENOBLE, France), Kai LEHTIMÄKI (Associate Professor in Neurosurgery) (Chairperson, Tampere, Finland), Ash MEHTA
16:00 - 16:10
#46376 - OP028 Thalamic centromedian closed-loop stimulation in pediatric and adult patients with refractory epilepsy.
OP028 Thalamic centromedian closed-loop stimulation in pediatric and adult patients with refractory epilepsy.
Objectives: Responsive neurostimulation (RNS) targeting the centromedian (CM) thalamic nucleus has shown promising results for refractory epilepsy in both adult and pediatric populations. These treatment populations may have substantial differences in clinical presentation, but the relationship between these and variability in treatment response or programming strategies has not yet been addressed.
Methods: We retrospectively reviewed 14 pediatric and 21 adult patients with refractory epilepsy, who underwent bilateral CM RNS implantation at Massachusetts General Hospital (MGH). Seizure burden was quantified using long episode (LE) counts, which represents presumed electrographic epileptiform activity lasting longer than 30 seconds, as detected by the device. Programming parameters were analyzed across programming epochs for up to 3 years post-stimulation initiation, using last observation carried forward (mean follow-up adults=1.7 years; peds=3.7 years). LE counts were Z-scored within periods of static detection settings in each patient. Baseline seizure burden was calculated as the average LE count over the first 21 days post-implantation. Relative reduction in seizure burden from baseline was calculated at 6, 12, 18, 24 months. Differences in relative reduction of Z-scored LE counts at each timepoint between pediatric and adult cohorts were assessed, using Welch's t-tests.
Results: There was no significant difference in epilepsy syndrome distribution between pediatric and adult cohorts (FBTCS, GTC, JAE, JME, LGS/Dravet; p=0.84). However, developmental delay was more prevalent among pediatric patients compared to adults (86% vs 43%; p=0.03). Pediatric patients received higher charge density at 12 months post-stimulation initiation (2.0 uC/cm2 vs 1.2 uC/cm2; p<0.01) and had a greater relative reduction in LE counts in the first 6 months (46% vs 13%; p=0.13).
Conclusion: Bilateral closed-loop stimulation of the CM region is an effective treatment option for both adult and pediatric patients with refractory epilepsy. Baseline clinical differences may influence treatment trajectories, underscoring the need for age-specific programming strategies to optimize clinical response. The significance of reduction in LE count may correlate with clinical improvement, but requires further investigation.
Mira HASNER (Boston, USA), Nathaniel D SISTERSON, Catherine CHU, Sydney CASH, Marike BROEKMAN, R. Mark RICHARDSON
16:10 - 16:20
#46249 - OP029 Unveiling the basal temporal language area in epilepsy surgery: resection outcomes, connectivity, and voxel-lesion-symptom-mapping insights.
OP029 Unveiling the basal temporal language area in epilepsy surgery: resection outcomes, connectivity, and voxel-lesion-symptom-mapping insights.
Over multiple studies, our team has expanded and refined our understanding of the basal temporal language area (BTLA) in patients with drug-resistant temporal lobe epilepsy. By integrating stereoelectroencephalography (SEEG) language mapping, lesion-symptom correlation techniques (e.g., voxel-based lesion-symptom mapping), and postoperative neuropsychological assessments, we have characterized how specific ventral temporal regions contribute to naming and memory functions.
Our findings indicate that BTLA resection leads to a specific and early decline in naming, which, although partially transient, often remains below baseline levels over time. Similarly, postoperative verbal memory performance declines when the BTLA is involved in the surgical resection.
Further, using cortico-cortical evoked potentials (CCEP), we revealed a robust and distributed basal temporal language network in the ventral temporal cortex supporting visual naming. Within this network, posterior ventral temporal regions behaved as “projectors,” whereas the fusiform gyrus functioned predominantly as an “integrator.” In contrast, for non-eloquent sites, the anterior fusiform gyrus demonstrated an opposite pattern, acting as a strong projector rather than an integrator.
We also explored the surgical limits and localization of the BTLA in light of recent VLSM (voxel lesion-symptom mapping) studies, noting that maintaining a resection cavity anterior to the VLSM-defined critical region does not necessarily prevent postoperative naming decline. Lastly, our investigations extended to functionnectomes, enhancing our knowledge of BTLA connectivity and further emphasizing the importance of precise identification and preservation of language-critical regions to optimize postoperative outcomes.
Insafe MEZJAN (NANCY), Olivier ARON, Fabien RECH, Mickaël FERRAND, Hélène BRISSART, Natacha FORTHOFFER, Louis MAILLARD, Sophie COLNAT-COULBOIS
16:20 - 16:30
#46306 - OP030 The white matter connections of anterior thalamic nucleus subregions revealed by probabilistic multi shell multi tissue constrained spherical deconvolution tractography: The correlation to treatment outcomes.
OP030 The white matter connections of anterior thalamic nucleus subregions revealed by probabilistic multi shell multi tissue constrained spherical deconvolution tractography: The correlation to treatment outcomes.
Background: Deep brain stimulation of the anterior nucleus of thalamus (ANT-DBS) is a treatment option in refractory epilepsy, with a proven short and long -term efficacy. European registry -based data suggests significant differences in treatment outcomes. Different subregions of the ANT have been suggested as the most optimal targets, potentially explaining variable treatment outcomes. In addition to the existing histological data regarding the anatomical connections of ANT, a large number of white matter pathways have been described in humans using diffusion weighted imaging and tractography methods. Objective: Here we have studied the white matter pathways of different anterior thalamic nucleus subregions using probabilistic multi shell multi tissue (MSMT) constrained spherical deconvolution (CSD) tractography. Materials and methods: Thirteen healthy volunteers underwent MRI with T1 and DW images which were further processed for tractography using Mrtrix3 software. The centre, anterior, posterior and inferior aspects of the ANT were used as 2 mm spherical regions of interest (Roi) for fiber tracking. The location of responding (n=25; ≥ 50% seizure reduction) and non-responding contacts (n=37, <50% seizure reduction) in the stereotactic space from a group of 15 patients with ANT-DBS was compared to calculated fiber tracts. Results: Three main white matter pathways were identified in accordance with previous data: 1) inferior thalamic peduncle with fiber connections to amygdaloid complex; 2) anterior thalamic radiation with orbitofrontal, prefrontal and occasionally cingulate connections; and 3) posterior fiber pathway with terminations in the hippocampus, occipital cortex and parietal cortex. The connectivity pattern was similar in the anterior, centre and posterior ANT Rois, but the inferior part of ANT differed markedly with stronger connections to frontal cortical areas but with lesser connections to the inferior of posterior main fiber streams. The location of responding contacts matched with the fiber streams calculated from the anterior, centre and posterior aspects of the ANT while non-responding contacts located along the fiber stream between the inferior part of ANT and frontal cortical areas. Discussion: The differences in connectivity patterns of different ANT subregions together with existing outcome data suggest that the stimulation of all three main white matter pathways, namely inferior, anterior and posterior pathways is essential for optimal treatment outcomes.
Ruhunur ÖZDEMIR, Kai LEHTIMÄKI (Tampere, Finland), Eetu SIITAMA, Timo MÖTTÖNEN, Joonas HAAPASALO, Soila JÄRVENPÄÄ, Hannu ESKOLA, Jukka PELTOLA
16:30 - 16:35
#46259 - OP031 Interaction between sleep spindles and interictal epileptic discharges in human thalamic nuclei.
OP031 Interaction between sleep spindles and interictal epileptic discharges in human thalamic nuclei.
Sleep spindles are oscillatory events specific to Non-Rapid Eye Movement (NREM) sleep, characterized by waxing and waning waveforms in the 10–16 Hz frequency range. They are generated in the thalamic reticular nucleus and propagated to other brain regions via thalamo-cortical circuits. Sleep spindles have been associated with cognitive functions and general intellectual ability. In addition to their role in physiological neural plasticity, spindles have also been linked to pathological off-line plasticity in both epileptic models and patients with epilepsy. Several studies suggest a connection between sleep spindles and interictal epileptic discharges (IEDs), which are considered markers of pathological neural plasticity in the central nervous system.
We investigated the relationship between thalamic sleep spindles and thalamic IEDs in the anterior (ANT) and mediodorsal (MD) thalamic nuclei of epilepsy patients. Whole-night local field potentials (LFPs) from the ANT and MD were co-registered with scalp EEG/polysomnography using externalized leads in 15 pharmacoresistant, surgically non-treatable epilepsy patients undergoing deep brain stimulation protocols. DBS electrodes were localized in the ANT for 15 patients, and in the MD for 10 patients. Sleep spindles and IEDs were detected during all-night non-artifactual NREM sleep (stage 2 and 3). Both slow (~12 Hz) and fast (~14 Hz) sleep spindles were detected in the thalamic nuclei. Approximately 10% of the detected sleep spindles co-occurred with IEDs. These IED-associated spindles exhibited significantly longer durations and a broadband increase in thalamic and cortical activity, both below and above the spindle frequency range, compared to typical spindles. Additionally, the density of IEDs in the MD showed a positive correlation with the number of years since epilepsy onset.
These findings suggest a role for the human ANT and MD in both physiological and pathological sleep spindle-related neural plasticity.
Orsolya SZALÁRDY (Budapest, Hungary), Péter SIMOR, Zsófia JORDÁN, László HALÁSZ, Loránd ERŐSS, Dániel FABÓ, Róbert BÓDIZS
16:35 - 16:40
#46310 - OP032 Cenobamate increases responder rates and the possibility of seizure freedom in patients receiving ANT-DBS treatment.
OP032 Cenobamate increases responder rates and the possibility of seizure freedom in patients receiving ANT-DBS treatment.
Objective: Drug-resistant epilepsy (DRE) remains a significant clinical challenge, with approximately 30% of patients failing to achieve seizure control with anti-seizure medications (ASMs). Deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) has emerged as an effective neuromodulatory treatment for DRE, yet a subset of patients remains refractory, with only a small portion achieving seizure freedom. Cenobamate (CNB), a novel ASM with GABA-A receptor modulation and persistent sodium current inhibition, has demonstrated promising efficacy in seizure control even in ultra-resistant epilepsy. This study evaluates the potential synergy between cenobamate and ANT-DBS in patients with ultra-refractory focal epilepsy.
Methods: A retrospective analysis was conducted on 44 patients who underwent ANT-DBS for drug-resistant focal epilepsy at Tampere University Hospital, Finland. Among these, 29 patients were initiated on cenobamate therapy, with 27 continuing treatment for a median follow-up time of 18 months. Treatment responses (≥50%-74% and 75%-99% seizure reduction and seizure freedom rates) were analyzed in the total cohort, as well as in the CNB and non-CNB subgroups. Safety and tolerability of cenobamate in ANT-DBS patients were also assessed.
Results: Before cenobamate initiation, 61% of all included patients were responders to ANT-DBS, with only 7% achieving seizure freedom. Following cenobamate addition, seizure freedom rates significantly increased to 27% in the total cohort. The overall responder rate rose from 61% to 75%. In the CNB subgroup, the responder rate increased from 63% to 85%, with seizure freedom rates rising from 0% to 33%.
Patients who were initial ANT-DBS responders exhibited the highest benefit, with 94% achieving seizure reduction and 47% reaching seizure freedom. In contrast, initial ANT-DBS non-responders had a lower response rate of 70%, with 10% achieving seizure freedom. In the non-CNB subgroup, both the responder and seizure freedom rates remained unchanged during the observation period.
Discussion:
The combination of cenobamate and ANT-DBS has the potential to significantly enhance seizure control in patients with ultra-refractory focal epilepsy. The observed synergy may be attributed to overlapping mechanisms involving GABAergic enhancement, sodium channel modulation, and network-level reorganization. These findings suggest that cenobamate is a promising adjunctive therapy in ANT-DBS patients, potentially increasing the likelihood of seizure freedom. Future prospective studies are warranted to validate these results and further explore the mechanistic interactions between cenobamate and ANT-DBS.
Kristina ZAITSEVA, Kai LEHTIMÄKI (Tampere, Finland), Niina LÄHDE, Soila JÄRVENPÄÄ, Timo MÖTTÖNEN, Joonas HAAPASALO, Jukka PELTOLA
16:40 - 16:45
#47849 - OP033 Subcortical tract-based language mapping in pediatric SEEG: insights from two case studies.
OP033 Subcortical tract-based language mapping in pediatric SEEG: insights from two case studies.
Background:
Recent findings highlight the critical role of subcortical white matter tracts (WMTs) in supporting language processing. This report focuses on WMT monitoring using invasive stereo-electroencephalography (SEEG). We present two case studies: MN, a 17-year-old adolescent, and CO, a 10-year-old child, both with non-lesional, drug-resistant focal epilepsy originating from the left frontal lobe with rapid frontal propagation. Both patients underwent invasive intracranial monitoring to identify the epileptogenic zone and preserve eloquent functional areas. Electrodes were implanted along presumed dorsal language WMTs, as identified by preoperative MRI-DTI imaging.
Method:
A comprehensive language assessment battery was administered before, during, and after the monitoring procedure, evaluating naming, sentence repetition, comprehension and production of syntactically complex sentences, and reading of words and pseudowords.
Results:
MN demonstrated intact preoperative language functions. However, during SEEG monitoring, stimulation of electrodes located along the arcuate fasciculus (AF, figure 1 in the attached appendix) produced language interference resembling a phonological loop deficit, primarily manifested as sentence repetition failures. Stimulation of electrodes along the frontal aslant tract (FAT, figure 2 in the attached appendix) resulted in speech initiation difficulties (e.g., speech arrest or prolonged hesitations) and impaired production of syntactically complex sentences—particularly object-relative clauses.
In contrast, CO exhibited preoperative language impairment. Nevertheless, monitoring of the AF using a word span repetition task was feasible. Importantly, in both cases, stimulation of electrode contacts placed outside the targeted tracts resulted in negative language mapping. Similarly, stimulation of electrodes not traversing known language pathways also yielded no interference.
Conclusions:
These cases underscore the value of subcortical language mapping using targeted language paradigms. Addressing tracts such as the AF and FAT enhances the precision of functional mapping, helping preserve critical cognitive functions—even in children with premorbid language difficulties—while optimizing surgical outcomes.
Monitoring language in pediatric patients, particularly those with premorbid intellectual impairments, presents unique challenges. These are further complicated by the nature of SEEG, which does not fully cover the cortical surface but instead samples subcortical structures. Nevertheless, our findings demonstrate that stimulation along subcortical language tracts enables effective monitoring of both the tracts and their cortical terminations. This approach allows for indirect yet reliable identification of eloquent cortical language areas, offering a valuable tool for surgical planning when conventional surface-based mapping is limited.
The full presentation will include video clips and imaging data illustrating the stimulated subcortical contacts and their spatial relationship to functional areas, providing a detailed visualization of the mapping process.
Naomi KAHANA-LEVY (Tel Aviv, Israel), Naama FRIEDMANN, Guy GUREVITCH, Romi MICHAEL, Jonathan ROTH, Ido STRAUSS, Shimirit ULLIEL-SIBONY
|
16:00-17:00
Added to your list of favorites
Deleted from your list of favorites
C38
PARALLEL SESSION 15
Others
PARALLEL SESSION 15
Others
Chairpersons:
Giuseppe CINALLI (Chairperson, Naples, Italy), Michel LEFRANC (MEDECIN) (Chairperson, AMIENS, France), Krasimir MINKIN (Head of Center of Functional Neurosrgery) (Chairperson, Sofia, Bulgaria), Pawel SOKAL (head of department) (Chairperson, Bydgoszcz, Poland)
16:00 - 16:10
#47825 - OP109 Selective syntactic impairment following dominant premotor tumor resection: preliminary results and Aslant tract preservation in awake craniotomy.
OP109 Selective syntactic impairment following dominant premotor tumor resection: preliminary results and Aslant tract preservation in awake craniotomy.
Background:
The Frontal Aslant Tract (FAT) connects the superior frontal gyrus with the ventromedial premotor cortex, including the supplementary motor area (SMA, Brodmann area [BA] 6) and the inferior frontal gyrus (BA 44, 45). Tumors involving the FAT or SMA cortex have been associated with severe transcortical aphasia, typically characterized by impaired spontaneous speech initiation despite preserved comprehension, phonology, and repetition. Although these prominent deficits often resolve within weeks following tumor resection, many patients report persistent subjective speech difficulties. We hypothesize that subtle, undetected syntactic impairments may underlie this discrepancy. This study investigates syntactic processing before, during, and after glioma resection involving the FAT, and proposes an intraoperative syntactic monitoring approach to support FAT preservation.
Method:
From an initial cohort of 116 patients with frontal lesions, 27 patients who met the inclusion criteria were included in the final study sample. All participants had lesions in the dominant hemisphere and underwent comprehensive language assessments preoperatively, intraoperatively (when possible), and 3 to 6 months postoperatively. In 15 of these patients, the lesion overlapped with the frontal aslant tract (FAT) region; in the remaining 12, the lesion was located remotely from the FAT. The language assessments included tasks of naming, repetition, fluency, reading, and a detailed evaluation of syntactic abilities.
Results:
Preoperatively, both groups exhibited similar impairments in fluency and syntax. Postoperative evaluations revealed that patients with lesions involving the FAT exhibited significantly greater syntactic generation impairments compared to patients with other frontal lesions. Syntax comprehension and other language domains remained largely intact and comparable between groups. Intraoperative syntactic mapping was successfully implemented in 6 patients, demonstrating its feasibility near the FAT region.
Conclusions:
Our findings suggest that the FAT region plays a role not only in speech initiation but also in syntactic processing. The observed pattern of selective syntactic impairments, both intraoperatively and postoperatively, supports its involvement in syntactic structure construction. Intraoperative syntactic assessment may aid in preserving FAT integrity, potentially improving language outcomes following tumor resection. The full presentation will include video clips and imaging data illustrating aslant subcortical stimulation, providing a detailed visualization of the mapping process.
Naomi KAHANA-LEVY (Tel Aviv, Israel), Ashraf SHARBOOK, Naama FRIEDMANN, Akiva KORN, Guy GUREVITCH, Moran ARTZI, Neomi SINGER, Tal SHAHAR
16:10 - 16:15
#45937 - OP110 Magnetic Resonance guided Laser Interstitial Thermal Therapy for paediatric intracranial cavernous malformations.
OP110 Magnetic Resonance guided Laser Interstitial Thermal Therapy for paediatric intracranial cavernous malformations.
Introduction: Microsurgical resection is the standard for treating intracranial cavernous malformations (CMs), but minimally invasive approaches are gaining popularity, particularly for deep-seated lesions and pediatric patients. Magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) has emerged as a potential alternative to open surgery. This study aims to evaluate the safety and efficacy of MRgLITT for pediatric cavernomas and review existing literature.
Methods: A systematic search of MEDLINE (PubMed), Scopus, Embase, and Cochrane databases using terms related to MRgLITT and cavernomas identified studies reporting MRgLITT outcomes in pediatric patients. Data on demographics, symptoms, lesion characteristics, and outcomes were extracted. A combined database included cases from literature and four treated at our institution, Santobono-Pausilipon Children’s Hospital of Naples.
Results: Three studies with eight pediatric cases and four additional institutional cases were analyzed, totaling 12 patients. Outcomes for epilepsy were favorable: two patients achieved Engel class IA, one class IC, and one class II. No recurrences or hemorrhages occurred. Two patients experienced permanent complications—one with partial right superior quadrantanopia and another with unilateral hearing loss.
Conclusion: MRgLITT offers comparable outcomes to open surgery with reduced invasiveness, particularly for deep-seated lesions. Advances in thermal monitoring, neurophysiological monitoring, and functional MRI integration could further refine this approach, expanding its applications while minimizing complications in pediatric CMs.
Giuseppe MIRONE (NAPOLI, Italy), Giulia MECCARIELLO, Francesco TENGATTINI, Domenico CICALA, Nicola ONORINI, Claudio RUGGIERO, Giuseppe CINALLI
16:15 - 16:20
#46305 - OP111 Robot-Assisted Interstitial Laser Thermotherapy: A Minimally Invasive and Effective Approach for Treating Brainstem Cavernomas.
OP111 Robot-Assisted Interstitial Laser Thermotherapy: A Minimally Invasive and Effective Approach for Treating Brainstem Cavernomas.
Introduction:
Brainstem cavernomas are rare lesions associated with significant morbidity and mortality in the event of hemorrhage. There is currently no consensus regarding their optimal therapeutic management. Surgical treatment carries a substantial risk of morbidity—and in some published series—even mortality. Radiosurgery may reduce the risk of rebleeding, but does not completely eliminate it. Robot-assisted interstitial laser thermotherapy (LITT), guided by the ROSA® robot, is a minimally invasive technique increasingly used in neurosurgery. We report a case series conducted at Amiens University Hospital for cavernomas located in surgically challenging areas of the brainstem.
Methods:
Three patients were retrospectively included in 2024. The mean age at the time of surgery was 54 years. All patients underwent surgical management of their brainstem cavernoma via LITT. Two had experienced two prior hemorrhagic episodes, and one had a single hemorrhage. A single laser probe was introduced using the ROSA® robot, allowing for precise and optimal placement within the lesion while minimizing the risk of clinical deterioration.
Thermal ablation was controlled using the VISUALASE® system (Medtronic), which allows real-time monitoring of temperature to preserve surrounding healthy brainstem tissue. Complete ablation was confirmed intraoperatively using MRI sequences including FLAIR, diffusion, gadolinium-enhanced T1, and spectroscopy.
Results :
None of the patients had undergone prior treatment for their cavernoma. Preoperative oculomotor deficits were present in two patients as a result of prior hemorrhages. One patient experienced a transient worsening of pre-existing symptoms (alternating syndrome), which improved with corticosteroid therapy. The other two patients showed no postoperative clinical worsening; their pre-existing oculomotor deficits remained stable.
No patient experienced a loss of autonomy following the procedure. The average postoperative follow-up duration was six months, and no cases of hemorrhagic recurrence were reported.
Conclusion:
LITT, in combination with robotic guidance and low-temperature ablation, appears to be a promising, minimally invasive, and low-morbidity technique for the complete ablation of brainstem cavernomas, with no observed impact on patients' quality of life. Further studies and longer-term follow-up are necessary to confirm these encouraging results.
Pauline CARLIER (amiens), Jean-Marc CONSTANS, Michel LEFRANC
16:20 - 16:25
#46241 - OP112 Modern laser technology applications in neurosurgery: advances in bone ablation and vessel coagulation.
OP112 Modern laser technology applications in neurosurgery: advances in bone ablation and vessel coagulation.
Objective
To investigate modern laser technology for neurosurgical procedures, focusing on bone ablation using ultra-short pulsed lasers and optimization of blood vessel coagulation parameters.
Methods
For bone ablation, a picosecond laser (200W, 200 kHz) performed plasma-induced cold ablation. Real-time monitoring used an 80 kHz OCT system. We conducted 138 experiments on bovine bones.
For vessel coagulation, we compared four laser systems: Nd (28W, 1064 nm), two ytterbium YAG fiber lasers (120W and 200W, 1070 nm), and a frequency-doubled Nd (18W, 532 nm). We performed 561 coagulations on swine coronary arteries and 337 coagulations in 20 Sprague-Dawley rats through air and under saline. Success was determined by vessel closure after cutting.
Results
In bone ablation, infrared laser light achieved a removal rate of 2.5 mm³/s at 130W without carbonization. The handpiece with galvanometer scanner and OCT sensor allowed voxel-based cutting of predefined 3D geometries with continuous real-time monitoring.
In vessel coagulation through air, the ytterbium YAG fiber laser showed successful coagulation at 12W (94%) and 14W (98%) in the animal model. Under saline solution, infrared wavelengths failed even at high powers. However, the 532 nm system successfully coagulated 100% of vessels (n=50) at only 6W.
Discussion
Ultra-short pulsed laser technology addresses limitations of conventional instruments. The absence of vibration, heat, and noise benefits patients undergoing awake deep brain stimulation procedures, where drilling is particularly challenging for patient comfort.
The integration of OCT guidance transforms precision by providing submillimeter accuracy with real-time residual thickness control, significantly reducing risk to critical neural structures. For vessel coagulation, wavelength selection is crucial, with infrared lasers optimal for microsurgical environments and green wavelength lasers superior for underwater endoscopic applications.
Conclusion
This study establishes technical foundations for implementing advanced laser systems in neurosurgery. These technologies enable high-precision bone removal with OCT guidance for residual thickness control, while optimal parameters for vessel coagulation have been determined for both microsurgical and endoscopic applications, promising improvements in surgical precision and patient experience.
Peter Christoph REINACHER (Freiburg im Breisgau, Germany), Lazar BOCHVAROV, Christina GIESEN, Leo MUELLER, Cristian TULEA, Roland ROELZ, Achim LENENBACH
16:25 - 16:30
#46204 - OP113 Evaluation of the Preventive Effect of Flat Position Surgery on Postoperative Pneumocephalus.
OP113 Evaluation of the Preventive Effect of Flat Position Surgery on Postoperative Pneumocephalus.
Introduction
In deep brain stimulation (DBS) surgery, elevating the upper body is a common practice to prevent brain shift caused by intraoperative pneumocephalus, which can impede accurate electrode placement. In this study, we performed DBS surgeries in the flat position and evaluated the relationship between pneumocephalus and patient positioning.
Methods
We analyzed 65 consecutive patients who underwent bilateral DBS implantation at our institution between September 2020 and October 2023. The first 30 patients (up to June 2022) underwent surgery in the conventional semi-seated position, while subsequent cases were operated on in the flat position. Image analysis was performed using Elements software (BrainLab). The volume of intracranial air was measured from immediate postoperative CT scans. Axial CT images were manually traced to create 3D objects for volumetric analysis. The degree of brain atrophy was assessed by automatic segmentation of preoperative MRI, calculating the ratio of cerebrospinal fluid spaces to total brain volume.
Results
The cohort included 36 males and 29 females with a mean age of 61.11 ± 10.11 years. Forty-seven procedures were performed under local anesthesia, and 18 under general anesthesia with simultaneous implantable pulse generator placement. Forty-four patients underwent subthalamic nucleus targeting, and 21 underwent globus pallidus internus targeting. The mean intracranial air volume was significantly lower in the flat position group (9.43 ± 13.58 cm³) compared to the semi-seated group (19.42 ± 15.31 cm³; p < 0.01). Multivariate analysis showed no significant association between intracranial air volume and operative time (p = 0.98), number of recording tracks (p = 0.24), or brain atrophy (p = 0.51); only patient positioning was significantly related (p < 0.01).
Conclusion
Contrary to previous assumptions, factors such as operative time, number of recording tracks, and brain atrophy were not significantly associated with cerebrospinal fluid loss. Only intraoperative positioning was significantly correlated. In the flat position, the brain surface likely maintained closer contact with the burr hole, reducing the ingress of air.
Sujong PAK (Yokosuka, Japan), Takefumi HIGASHIJIMA, Takashi KAWASAKI, Katsuo KIMURA, Hitaru KISHIDA, Katsuya ABE, Kaori KUSAMA, Katsumi SAKATA, Ryosuke TAKAGI, Satoshi HORI, Chikashi AOYAGI, Wataru SHIMOHIGOSHI
16:30 - 16:35
#48012 - OP114 LITT in patients with gliomas, preliminary experience.
OP114 LITT in patients with gliomas, preliminary experience.
INTRODUCTION
Laser interstitial thermal therapy (LITT) is a minimally invasive surgical technique that can achieve tissue ablation in deep seated gliomas when exeresis is unfeasible.
Preliminary studies have shown that a higher Extent of Ablation (EOA) allows higher local control. In patients with small tumor volume (< 4 cm3) if the EOA is gross total the OS is similar to patients submitted to surgery.
Though there is little evidence and the true effect of LITT on OS remains unclear.
Other studies suggest that LITT may enable faster recovery and earlier chemoradiation compared to surgery, while temporarily increasing BBB permeability 1–2 weeks after LITT with resolution by 4–6 weeks, providing a potential window for additional treatments.
METHODS
We retrospectively analysed a series of 6 patients treated with LITT for deep seated lesions from April 2022 to February 2025. Demographic, clinical and radiographic characteristics were collected from electronic medical records to describe patient selection, the outcomes and complications.
All the LITT procedures where performed in our hospital with Visualase MRI-Guided Laser Ablation System
RESULTS
We analysed 6 patients, mean age at diagnosis was 45 (range 30-56), there were 2 males and 4 females. Median KPF was 85 at the time of surgery. Histological diagnosis was obtained before LITT in all patients by stereotactic biopsy or craniotomy (2 Glioblastoma IDH wildtype, 2 diffuse low-grade gliomas, 1 glioneuronal tumor; 1 pineoblastoma). Lesion sites were thalamic in 3 cases, thalamo-mesencefalic in 2 cases and pineal region in one.
Lesion volume was <3 cc in 2 patients; between 3 cc and 8 cc in 2 patients and > 8 cc in the last 2 patients. LITT ablation was achieved in all cases with 1 fiber. After LITT 2 patients needed a ventricular peritoneal shunt (VPS), one patient a VPS revision, one patient suffered a hematoma in the ablated tissue that did not require surgery.
Average hospital stay was 18 days in patients until discharged home after the procedure and 79 days in patients needing discharge to a higher level of care.
Three patients (50%) experienced a post operative paresis, gaze palsy or other neurological deficit, that slightly improved during follow up.
At last follow up (mean 6,9 months, range 2,8-14,6) all patients were alive, KPF was lower compared to pre-operative status in 3 cases and stable in the other 3 (with a median KPF of 65). One patient with thalamic glioblastoma received chemo-radiotherapy 2 months after LITT while the others started chemotherapy as late as 5 months after LITT. Low grade lesions were treated in tertiary referral centers.
CONCLUSIONS
LITT can be a valid option to treat deep seated lesions in selected patients that are not amenable for surgery. Complications’ rate is however considerable at the moment and must be taken into account upon patient consultation. Further data are needed to understand the true benefit of treatment and to improve patient selection.
Cristiano PARISI, Fabio RANERI, Valerio VITALE, Piacentino MASSIMO (Vicenza, Italy)
16:35 - 16:40
#46317 - OP115 Full mono-bipolar cortical-subcortical stimulation-mapping.
OP115 Full mono-bipolar cortical-subcortical stimulation-mapping.
Introduction
It has always been an issue for neurosurgeons and neurophysiologists to overcome the dichotomy between monopolar stimulation, most reliable in CorticoSpinal Tract motor evaluation, and bipolar stimulation, the only possible to evaluate cognitive faculties. Switching between boths modes has till now been the only alternative.
Methods
We developed a combined method where continuous High Frequent monopolar stimulation (Taniguchi, train of 5) is alternated with intermittent Low Frequent bipolar 4 sec. stimuli (Penfield) .
At cortical level, both stimulation modes can be applied consequently, i.e. first monopolar HF in the vicinity of the precentral gyrus, afterwards bipolar allover the exposed cortex, with one single switch.
At subcortical level, CST and cognitive fasicles can be encountered at frontal, parietal an deep temporal sites.
At these areas, fast and ergonomic switches are mandatory.
Continuous monopolar HF mapping is regularly practiced since years with an insulated suction tip.
When the CUSA tip is connected to the IONM device, bipolar LF stimulation is possible between both tips, without need for other tools to be brought in and out the operative cavity.
Pressing the Nose Cone key activates the bipolar stimulation, which can be synchronised with the task presentation if desired.
A simple splitting of the suction probe connection cable to the IONM is sufficient, so the method is vitually costless.
Results
The methodology being recently introduced, results are preliminary.
Particularly in the SMA, at the posterior frontal and anterior parietal areas, and in deep temporal regions, the mono-bipolar switching method reveals reliable and ergonomic.
Conclusion
A novel concept of switching between continuous monopolar HF and intermittent bipolar LF mapping is presented, using current on suction tip and CUSA tip.The method is safe, ergonomic and almost costless.
David COLLE (Gent, Belgium), Peter MULLER, Kristel VANCHAZE, Bonny NOENS, Tybault HOLLANDERS, Henry COLLE
16:40 - 16:45
#46269 - OP116 Frame-based stereotactic biopsy of intracerebral lesions - a retrospective analysis of 622 consecutive cases at a large tertiary care hospital in Germany.
OP116 Frame-based stereotactic biopsy of intracerebral lesions - a retrospective analysis of 622 consecutive cases at a large tertiary care hospital in Germany.
Frame-based stereotactic brain biopsy is a reliable technique for obtaining tissue samples from intracranial lesions, essential for integrated molecular and histopathological diagnoses, particularly in cases unsuitable for resection. Despite advances in imaging, significant discrepancies between radiological and histopathological diagnoses persist. Although generally safe, rare but serious complications may occur. This study evaluates the safety, diagnostic accuracy, and complications of frame-based stereotactic brain biopsy, focusing on lesion location and radiological features.
A retrospective analysis of our stereotactic database was conducted for the period 2015–2023. N= 622 patients who underwent stereotactic biopsy for unclear brain lesions were included. Neuropathological, surgical, radiological, and clinical follow-up data was analyzed regarding diagnostic yield and complications.
The overall diagnostic yield was 91.6%, with glioblastoma (45.7%) and lymphoma (16.2%) being the most common diagnoses. A concordance rate of 76 % was found between the suspected diagnoses and the final molecular and histological diagnoses. Diagnostic yield was positively associated with the presence of necrosis and contrast enhancement in presurgical imaging. Negative associations were observed for the suspected entities "inflammatory processes", "unclear lesion" and non-enhancing lesions. Surgical associated complications were identified in 60 cases (9.6%), predominantly presenting as neurological deterioration (47 cases, 7.6%), which was temporary in 25 cases (4.0%) and permanent in 22 cases (3.5%). New Neurological deterioration was associated with post-surgical hemorrhage in 40 % of the cases (n=24, 32.0 % temporary deterioration, 72.7 % permanent deterioration). Other complications were surgical site infections and wound healing disorders (n=8, 1.3 %), and seizures (n=6, 1.0 %). 30-day mortality rate was 3.4%, a direct relation with surgery-was found in 3 cases (0.5%). Multivariate analyses showed the following risk factors for complications: frontal localization, estimated glioma and presurgical NIHSS.
Frame-based stereotactic brain biopsy for unclear CNS lesions is a reliable neurosurgical procedure with a high diagnostic yield. The diagnostic outcome is influenced by the suspected diagnosis and radiological features, underscoring the importance of precise clinical questions. Although complications are rare, neurological deterioration is the most common adverse event, warranting careful risk-benefit evaluation in clinical decision-making.
Manuel KAES (Heidelberg, Germany), Vincenzo RONDINELLI, Paul NASER, Jan-Oliver NEUMANN, Sandro M. KRIEG, Martin JAKOBS
16:45 - 16:50
#46267 - OP117 The LITTability Study - Evaluation of the Applicability of LITT in a Real-World Cohort of Glioma Patients.
OP117 The LITTability Study - Evaluation of the Applicability of LITT in a Real-World Cohort of Glioma Patients.
Objective
Laser-interstitial thermal therapy (LITT) is a minimally invasive technique used in neurosurgery for ablation of epileptic foci and malignant lesions, especially for glioma located in regions that pose high surgical risk. Current research mainly focuses on maximizing the safety on the procedure and proofing the non-inferiority compared to open resection of glioma. However, data regarding the current applicability in real-time cohorts are lacking. The goal of this study is to evaluate the real-world applicability of LITT in glioma patients, specifically focusing on those who had undergone stereotactic biopsy, and to define limiting factors.
Methods
For this retrospective study, we analyzed n=207 glioma patients from a monocentric stereotactic surgery database over a 5-year period (2018 – 2022). Clinical, histopathological and radiological data was assessed. To define a lesion suitable for LITT a two-step approach was used. In a first step, predefined selection criteria were applied consisting of a Karnofsky Performance Score of 70 or higher, an ASA Score of 3 or less, MRI compatibility, and glioma presenting as a single or bifocal lesion. In a second step, the LITT simulation was performed with additional criteria consisting of at least 90% possible ablation volume, a safe trajectory with avoidance of vessels, and optimal lesion accessibility without brainstem involvement.
Results
Out of 207 patients, 137 cases met initial preselection criteria, while 36 cases (17.4%) were ultimately deemed suitable for LITT post-simulation. Common exclusion factors included multifocal lesions, irregular lesion shape, and size constraints. Among suitable cases, 94.4% had unifocal lesions. For 44.4% of cases, only a single catheter was needed, with the number of ablation points varying from one to twelve per trajectory. The average lesion diameter for LITT-suitable cases was 26.4 mm.
Conclusion
Even though LITT offers a promising alternative for glioma not suitable for open resection, the current application is limited. Main reasons were due to lesion morphology and size. Enhancing LITT applicability could involve addressing constraints posed by lesion geometry and volume. Prospective studies comparing LITT with conventional resection could better define the subset of glioma patients who may benefit most, advancing the potential for LITT in clinical neurosurgical practice.
Manuel KAES (Heidelberg, Germany), Vincenzo RONDINELLI, Sandro M. KRIEG, Martin JAKOBS
16:50 - 16:55
#46173 - OP118 Hi-SMILE: Stereotactic Laser Interstitial Thermal Therapy (LITT) and preclinical tumororganoid-based drug screening in recurrent high-grade glioma. Results from 24 patients.
OP118 Hi-SMILE: Stereotactic Laser Interstitial Thermal Therapy (LITT) and preclinical tumororganoid-based drug screening in recurrent high-grade glioma. Results from 24 patients.
Introduction:
Recurrent high-grade glioma (glioblastoma & astrocytoma WHO 4°) require innovative locoregional and systemic treatment options. Laser Interstitital thermal therapy (LITT) is a stereotactic, minimally invasive surgical approach to target small and difficult to resect tumors under MR-thermometric guidance. Tumororganoids are representative tumor avatars that enable ex-vivo drug testing even from small tissue samples provided by stereotactic biopsies. The Hi-SMILE study is an ongoing trial to evaluate safety and efficacy of LITT and feasibility of preclinical tumororganoid-based drug screening in n=30 patients with recurrent high-grade glioma.
Material and Methods:
Patients are prospectively enrolled in a registry. Fot LITT tumor volume and ablation coverage, as well as accuracy of laser catheter placement are assessed. OR time, length of hospital stay and surgical complications are documented. Stereotactic frame-based biospsy and laser catheter placement are performed before laser ablation is carried out in an intraoperative MRI setting.biopsy samples taken during LITT surgery are used for tumororganoid formation. After tumororganoid formation, ex-vivo high-throughput drug testing of up to 9 selected drugs is performed. Responses are classified as „sensitive“ „intermediate“ or „resistant“.
Results:
So far, n=24 patients (12 females, 12 males; mean age 58.8 years (+/- 10.4 years) have been enrolled. Final histological diagnoses was glioblastoma (n=18), astrocytoma WHO 4° (n=4) and radiation necrosis (n=2). N=11 patients required 2 laser catheters to cover the desired mean tumor volume of 4.6 (+/- 4.5) ml. Mean operative time was 166 minutes (+/- 46) of which a mean 93 minutes (+/- 29) were spent in the intraoperative MRI scanner. Ablation coverage was on average 194% and took on average 14min 36s per catheter. Laser catheters could be placed with a Euclidian distance of 1.0 mm (+/- 0.7) and a mean radial error of 1.0 mm (+/- 0.7). Treatment-related complications were two epileptic seizures and two deteriorations of a preexisting neurological deficit. It was always possible to test at least 2 drugs. Most tumors revealed a high level of drug resistance with only 2 cases revealing drug sensivitivy more than 1 drug.
Conclusions:
In the first patients surgical accuracy an ablation coverage was high. LITT seems to be a safe and well-tolerated procedure. Progression free and overall survival need to be evaluated at the end of the trial. Tumororganoid-based drug screening is feasible with tissue from stereotactic biopsies, however its impact on clinical decision-making is yet unclear.
Martin JAKOBS (Heidelberg, Germany)
16:55 - 17:00
#46348 - OP119 Diagnostic yield and complication rate in 280 stereotactic biopsies.
OP119 Diagnostic yield and complication rate in 280 stereotactic biopsies.
Diagnostic yield and complication rate in 280 stereotactic biopsies
Abstract
Background: Stereotactic brain biopsies are a well-established technique used to obtain tissue samples from brain lesions for pathological analysis, enabling more tailored and effective treatments. Despite being considered minimally invasive, the biopsies still carry risks, including neurological damage, haemorrhage, and the sampling of non-tumour tissue, leading to inconclusive results. Complication rates, severity, and outcomes can vary, and at the same time, new technologies, such as optical guidance using fluorescence, have the potential to improve the precision and safety of biopsies. To provide a comprehensive assessment of these biopsies and their associated risks, this study seeks to analyse the results of conventional stereotactic biopsies, i.e., without optical guidance.
Method: This retrospective study analysed data from patients who underwent conventional stereotactic brain biopsies at the Department of Neurosurgery at Linköping University Hospital between 2008 and 2024. Data were extracted from electronic patient records and operation reports, excluding cases involving optical guidance or additional concurrent procedures. Data on patient demographics, biopsy indication, imaging, methods, complications, trajectories, number of biopsies, lesion size and localisation, procedural timeframe, and pathology results were collected. Ethics approval number 2024-07218-01.
Results: A total of 280 biopsies from 267 patients (146 males and 121 females) were reviewed, with an overall diagnostic yield of 87.5%. The rate of inconclusive biopsies was higher in second biopsies (38.5% vs 11.2%), where gliosis was the most common finding. Symptomatic complications occurred in 16% of the cases, defined as epilepsy, infection, neurological deficits, or symptomatic haemorrhage, while asymptomatic haemorrhages were observed in 19.3% during the procedure or in postoperative radiographs. Clinical bleeding did not affect the diagnostic yield, nor did factors such as age, sex, or biopsy method. Furthermore, no correlation was found between complications and age, sex, number of biopsies, operative time, biopsy method, or conclusiveness.
Conclusion: Inconclusive results and complications remain key challenges in stereotactic brain biopsies. Brain shift, lesion characteristics, and preoperative corticosteroid use may be factors that can influence diagnostic yield. Second biopsies showed a higher likelihood of being inconclusive, and symptomatic complications were more frequent than previously reported. The clinical significance of asymptomatic haemorrhages remains unclear, and 35% of patients with post-biopsy neurological deficits showed no evidence of haemorrhage, suggesting that other factors may contribute to brain damage. Future research should focus on newer techniques, such as 5-aminolevulinic acid (5-ALA) fluorescence techniques, to enhance biopsy accuracy and reduce complications.
Evelina FROM, Karin WÅRDELL, Johan RICHTER (Linköping, Sweden)
|
|
|
|
17:00 |
|
|
|
|
|
Saturday 27 September |
Time |
ROOM A |
ROOM B |
ROOM C |
ROOM D |
BOARDROOM 949 |
|
08:30 |
08:30-10:30
Added to your list of favorites
Deleted from your list of favorites
A33
PLENARY SESSION 5
PLENARY SESSION 5
Chairpersons:
Linda ACKERMANS (Neurosurgeon) (Chairperson, Maastricht, The Netherlands), Ruby MAHESPARAN (Neurosurgeon) (Chairperson, Bergen, Norway), Claudio POLLO (Chief Deputy) (Chairperson, Bern, Switzerland)
08:30 - 09:00
Can Ultrasound be used for deep brain stimulation.
Andres LOZANO (Alan & Susan Hudson Cornerstone Chair in Neurosurgery, University Health Network) (Keynote Speaker, Toronto, Canada)
09:00 - 09:20
Mechanisms underlying gait and balance impairment in Parkinson’s disease.
Viviana AURELI (Neurosurgeon) (Keynote Speaker, Lausanne, Switzerland)
09:20 - 09:40
#46271 - PL05 Long-term follow-up in Tourette syndrome patients treated with deep brain stimulation.
PL05 Long-term follow-up in Tourette syndrome patients treated with deep brain stimulation.
Background: Tourette syndrome (TS) is a chronic neuropsychiatric disorder that presents with a combination of vocal and motor tics. Since 1999, deep brain stimulation (DBS) can be considered a therapeutic option for patients with treatment-refractory TS. The aim of this study is to evaluate long-term (>5 years) follow-up in TS patient treated with DBS.
Methods: We retrospectively assessed all TS patients treated with DBS within a 10-year time period between 2009 and 2019. Demographic data, stimulation parameters, response of tics to chronic DBS and quality of life were evaluated. Clinical outcome was assessed using self-assessment scales (i.e.YGTSS).
Results: A total of 22 TS patients (5 female, 17 male) were implanted for the treatment of severe tics. One patient received GPi DBS, while the targets for all remaining patients were located in the thalamus, predominantly in the centromedian nucleus/nucleus ventro-oralis internus (CM/V oi). The average age at the time of the initial implantation was 31.9 (SD = 11.2). 21 patients (95%) were available for long-term follow-up. The mean time interval since the initial implantation was 9.9 years (SD = 3.0). Of the 21 patients, 17 (81%) were responders with active stimulation. Three patients turned off the stimulation – one patient did not benefit, one patient's tics improved significantly even without stimulation and one patient's vocal tics disappeared completely, while motor tics showed little response to stimulation. In self-assessment, tics decreased on average by 73% under stimulation compared to the preoperative condition, while the premonitory urge diminished by 57%, and the quality of life improved by 77%.The Yale Global Tic Severity Scale (YGTSS), a gold standard for assessing tics in TS, was available for twelve patients during the long-term follow-up. The average YGTSS score decreased from 79.7 (SD = 16.4) preoperatively to 36.0 (SD = 24.3) after 12 months, and 24.2 (SD = 14.5) in the long-term follow-up, demonstrating persistent and even increasing significant improvement (p < 0.001). Complications leading to surgical revisions occurred in five patients. There were two instances of a short circuit due to a defect in the extension, one case of electrode dislocation following a fall during an epileptic seizure, and two cases of infection, each requiring the explantation of the entire DBS system, with reimplantation done in one instance.
Conclusions: DBS for TS patients remains a highly effective therapy over many years after the implantation with a further tendency for improvement in the long-term.
Petra HEIDEN (Cologne, Germany), Rastislav PJONTEK, Laura WEHMEYER, Ricardo LOUÇÃO, Veerle VISSER-VANDEWALLE, Pablo ANDRADE
09:40 - 10:00
#45617 - PL05 Stereotactic laser ablation for mesial temporal lobe epilepsy (SLATE): Summary of safety, effectiveness, and cognitive outcomes at 1 year of follow-up.
PL05 Stereotactic laser ablation for mesial temporal lobe epilepsy (SLATE): Summary of safety, effectiveness, and cognitive outcomes at 1 year of follow-up.
Introduction:
Over the past decade there has been increased use of laser interstitial thermal therapy (LITT) for stereotactic laser ablation (SLA) as an alternative to open resective procedures including anterior temporal lobectomy (ATL). Retrospective studies evaluating SLA for the treatment of mesial temporal lobe epilepsy (MTLE) have been promising, demonstrating slightly lower seizure freedom rates but fewer side effects and improved patient recovery. Here we report primary results from the SLATE trial, the first large prospective study to evaluate the safety and efficacy of the Visualase System in subjects with MTLE due to mesial temporal sclerosis (MTS).
Methods:
Prospective, single-arm, observational, multicenter study with outcomes compared against known effects of ATL. Pre-surgical evaluation consisted of a central review of each subject’s epilepsy history, MRI, EEG and any additional testing results available (e.g., PET, SPECT, invasive EEG or MEG) to confirm study qualification for treatment of their MTLE. Eligible subjects underwent unilateral MRI-guided SLA of their amygdala and hippocampus with the Visualase System (fig. 1) and were followed for 12 months.
Results:
In this study, 167 subjects were enrolled across 21 sites in the United States. 114 subjects received treatment across 18 sites and 107 subjects successfully completed the study (without a retreatment). One subject was retreated in the study between 3 and 6 months. The mean age of treated subjects was 44.2 ± 13.9 years (58.8% female). The average years from epilepsy diagnosis was 24.0 ± 17.2 years, and the average monthly seizure frequency of all seizure types over the 12 months prior to enrollment was 11.5 ± 15.4 seizures (median 4.5 seizures). Five subjects (4.4%) had a vagus nerve stimulator. Seventy-four patients (64.9%) had left sided SLA.
At 12 months, 56.0% (95% LCI: 46.2%) of subjects had an Engel I outcome and were free of disabling seizures (Engel IA/IB). No subjects reported generalized convulsions with ASM discontinuation (Engel ID). The average change from baseline in the QOLIE-31 overall score was 9.4 ± 9.8 (N=93), with 38 (40.9%) subjects experiencing a clinically significant increase (≥ 11.8). The greatest improvement in quality of life (QOL) was in Engel I subjects. Performance on neuropsychological measures related to cognition and language, verbal learning and memory, and visual reproduction appeared stable between baseline and 1-year post-surgical evaluation at the group level, with none of the tests showing changes that would indicate a clinically meaningful decline. Mood assessments at 1-year showed mean reductions in depression (Beck Depression Inventory) and anxiety (Beck Anxiety Inventory) of -4.4 ± 7.9 (37.6%) and -4.7 ± 9.1 (43.4%), respectively.
There were 157 adverse events (AEs) reported in 73 (64%) treated subjects through 12 months post-enrollment. For the primary safety endpoint, the incidence of qualifying device, procedure, or anesthesia related AEs through 12 months was 10 events in 9 treated subjects (7.9%) (95% UCI: 14.5%) and included the following: postoperative wound infection (1), soft tissue infection (1), upper respiratory tract infection (1), cognitive disorder (1), headache (3), partial seizures with secondary generalization (1), quadrantanopia (1), and confusional state (1). The most commonly reported visually related AEs post enrollment were quadrantanopia (21 subjects, 18.4%) and visual field defects (5 subjects, 4.4%), and were either mild (24) or moderate (2) in severity. One quadrantanopia event was classified as moderate and permanent, qualifying for the primary safety endpoint. No deaths or unanticipated adverse events were observed.
Conclusions:
The SLATE study passed both its primary safety and efficacy endpoints. The Engel I rate at 1 year was 56%, which is consistent with prior studies evaluating SLA in patients with MTS, but lower than an historical benchmark for open surgical resection (Engel I 64%). Notable clinical improvements in QOL were observed with no reports of SUDEP. Neuropsychological outcomes appeared to be superior to that of open resection procedures, which are known to result in significant post-surgical declines in language and memory for a large proportion of patients even when MTS is present. The results from the SLATE study demonstrate that SLA is an effective and well-tolerated therapy that may be used in place of open resective procedures for MTLE.
Robert GROSS (Atlanta, USA), Daniel DRANE, Guy MCKHANN, Vicenta SALANOVA, Jamie VAN GOMPEL, Jonathan JAGID, Brian CABANISS, Nitin TANDON, Jon WILLIE, Robert KNOWLTON, Kristie WALLACE, Alejandra GRACIA, Ashwini SHARAN, Jonathon GIFTAKIS, Michael SPERLING
10:00 - 10:20
Best of 23-25 in Epilepsy Surgery.
Ash MEHTA
|
|
|
|
|
|
10:30 - 11:00 |
COFFEE BREAK & VISIT OF POSTERS AND EXHIBITION
|
|
11:00 |
11:00-12:00
Added to your list of favorites
Deleted from your list of favorites
A43
PLENARY SESSION 6
PLENARY SESSION 6
Chairpersons:
Patric BLOMSTEDT (Neurosurgeon) (Chairperson, Umeå, Sweden), Brigitte GATTERBAUER (Gamma Knife) (Chairperson, Vienna, Austria), Ludvic ZRINZO (Professor of Neurosurgery) (Chairperson, London, UK, United Kingdom)
11:00 - 11:20
#46150 - PL06 Elevated rates of patient-reported adverse effects after bilateral MRgFUS thalamotomy for essential tremor: a single center experience of 30 patients.
PL06 Elevated rates of patient-reported adverse effects after bilateral MRgFUS thalamotomy for essential tremor: a single center experience of 30 patients.
Essential tremor (ET) can be extremely disabling, may not respond to conservative therapy, and is often bilateral. Other than the phase three clinical trial data, experience with outcomes following bilateral MRgFUS thalamotomy is limited. We report on a single-institution cohort of ET patients who underwent staged bilateral MRgFUS thalamotomy from 2020 to 2024, with minimum three-months of follow-up after bilateral treatment. Follow-up occurred at three, six, 12, and 24+ months post-treatment. Upper extremity tremor was assessed using the Clinical Rating Scale for Tremor Part B (CRST-B) and normalized based on maximum score for dominant and non-dominant arms (nCRST-B). Patients were asked directly about six adverse effects (speech changes, sensory changes, gait disturbance, dysphagia, dysgeusia, and upper extremity ataxia) and their satisfaction with the decision to undergo bilateral treatment. Thirty patients underwent staged bilateral MRgFUS thalamotomy, mostly to treat their non-dominant arm (86.7%). Of the 30 patients, 25 (83%) have 6-month follow-up, 19 (63%) have 12-month follow-up, and 10 (33%) have 24+ months of follow-up. The median time between unilateral and staged-bilateral treatment was 11.6 months (IQR 9.7 – 13.8; Range 6.0 – 21.6). Tremor severity at baseline for the unilateral and bilateral sides was similar (nCRST-B 63.5% and 67.7% respectively), and was significantly improved bilaterally after MRgFUS, but not as greatly on the second treated side (nCRST-B of 17.0% for unilateral and 33.1% for bilateral sides at combined last follow up for patients with minimum six-months of data). Most patients reported at least one new adverse effect after bilateral treatment (86.7%), although these were largely mild (Figure 1). Notably, 70% reported speech changes at three-months, improving to 53% at 12-months; 50% reported sensory changes at three-months, improving to 26% at 12-months; 40% reported gait disturbance, improving to 21% at 12-months; 30% reported dysphagia at three-months, improving to 16% at 12-months; 23% reported dysgeusia at three-months, improving to 11% at 12-months; and 7% reported upper extremity ataxia at three-months, improving to 5% at 12-months. When asked whether they considered bilateral treatment worthwhile in retrospect, 83% patients reported “yes” at three- and six-months, but this declined to 71% at 12-months, and 60% at 24+ months. In this series, rates of patient-reported adverse effects were higher than expected after staged bilateral MRgFUS thalamotomy for ET. In combination with less complete tremor control, adverse effects appeared to contribute to lower patient satisfaction at 12-months and 24+ months after bilateral treatment.
Nathan PERTSCH (Chicago, IL, USA), Kazuki SAKAKURA, Yoo Jin AHN, Julia MUELLER, Dustin KIM, Jesus VARELA, Shama PATEL, John PEARCE, Lucinda CHIU, Neepa PATEL, Sepehr SANI
11:20 - 11:40
High-Intensity Focused Ultrasound.
Jeff ELIAS (Professor) (Keynote Speaker, Charlottesville, USA)
11:40 - 12:00
HIFU in the "Real World".
Patric BLOMSTEDT (Neurosurgeon) (Keynote Speaker, Umeå, Sweden)
|
|
|
|
|
|
12:00 |
12:00-12:30
Added to your list of favorites
Deleted from your list of favorites
A44
ESSFN SEARCH GRANT AND AWARDS 2025
ESSFN SEARCH GRANT AND AWARDS 2025
Chairpersons:
Jocelyne BLOCH (Médecin Cadre) (Chairperson, Lausanne, Switzerland), Lorand ERÖSS (Chairperson, Budapest, Hungary), Rick SCHUURMAN (neurosurgeon) (Chairperson, Amsterdam, The Netherlands)
|
|
|
|
|